NCT01975389,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT02451137,Sanofi,FALSE,AL,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT01101035,Takeda,TRUE,AL,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT01991795,AstraZeneca,FALSE,AL,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT02164513,GlaxoSmithKline,FALSE,AL,https://ClinicalTrials.gov/show/NCT02164513,TRUE,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],4-Feb-16,40,9999,Both,FALSE,8NCT01966107,AstraZeneca,FALSE,AL,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT02182830,Boehringer Ingelheim,FALSE,AL,https://ClinicalTrials.gov/show/NCT02182830,TRUE,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],26-Jan-16,18,9999,Both,FALSE,75NCT02019264,Eisai Inc.,FALSE,AL,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT02528253,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT02528253,TRUE,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],1-Feb-16,18,9999,Both,FALSE,10NCT02504216,Bayer,FALSE,AL,https://ClinicalTrials.gov/show/NCT02504216,TRUE,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],1-Feb-16,50,9999,Both,FALSE,23NCT02406677,AstraZeneca,FALSE,AL,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02387359,Synergy Pharmaceuticals Inc.,FALSE,AL,https://ClinicalTrials.gov/show/NCT02387359,TRUE,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],10-Dec-15,18,85,Both,FALSE,183NCT02111564,"Janssen Research & Development, LLC",FALSE,AL,https://ClinicalTrials.gov/show/NCT02111564,TRUE,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],26-Jan-16,40,9999,Both,FALSE,132NCT01920711,Novartis Pharmaceuticals,FALSE,AL,https://ClinicalTrials.gov/show/NCT01920711,TRUE,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],14-Oct-15,50,9999,Both,FALSE,156NCT01663402,Sanofi,FALSE,AL,https://ClinicalTrials.gov/show/NCT01663402,TRUE,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],3-Feb-16,40,9999,Both,FALSE,12NCT01652872,Amgen,FALSE,AL,https://ClinicalTrials.gov/show/NCT01652872,TRUE,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],9-Dec-15,18,9999,Both,FALSE,16NCT01492361,Amarin Pharma Inc.,FALSE,AL,https://ClinicalTrials.gov/show/NCT01492361,TRUE,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],14-Jul-15,45,9999,Both,FALSE,62NCT02573311,Boehringer Ingelheim,FALSE,AL,https://ClinicalTrials.gov/show/NCT02573311,TRUE,Actual Use Study of Tamsulosin in Men,Urological Manifestations,Drug:tamsulosin hydrochloride,[],25-Jan-16,18,9999,Male,FALSE,75NCT02526524,"Elcelyx Therapeutics, Inc.",FALSE,AL,https://ClinicalTrials.gov/show/NCT02526524,TRUE,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],7-Jan-16,25,9999,Both,FALSE,103NCT02487446,Novartis Pharmaceuticals,FALSE,AL,https://ClinicalTrials.gov/show/NCT02487446,TRUE,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol); Drug:Placebo (QVA149),[],29-Jun-15,40,9999,Both,FALSE,156NCT02465567,"Pearl Therapeutics, Inc.",FALSE,AL,https://ClinicalTrials.gov/show/NCT02465567,TRUE,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],22-Dec-15,40,80,Both,FALSE,163NCT02342249,Vertex Pharmaceuticals Incorporated,FALSE,AL,https://ClinicalTrials.gov/show/NCT02342249,TRUE,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],28-Jul-15,18,64,Both,FALSE,218NCT02336685,"Janssen Research & Development, LLC",FALSE,AL,https://ClinicalTrials.gov/show/NCT02336685,TRUE,"Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],20-Jan-16,18,99,Both,FALSE,132NCT01968967,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT01968967,TRUE,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],25-Jan-16,18,9999,Both,FALSE,10NCT01877915,"Janssen Research & Development, LLC",FALSE,AL,https://ClinicalTrials.gov/show/NCT01877915,TRUE,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],26-Jan-16,18,95,Both,FALSE,132NCT01272037,National Cancer Institute (NCI),FALSE,AL,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02590432,Forest Laboratories,FALSE,AL,https://ClinicalTrials.gov/show/NCT02590432,TRUE,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],23-Dec-15,18,9999,Both,FALSE,110NCT02388165,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT02388165,TRUE,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],25-Jan-16,18,85,Both,FALSE,10NCT02386072,"Astellas Scientific & Medical Affairs, Inc.",FALSE,AL,https://ClinicalTrials.gov/show/NCT02386072,TRUE,"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",Overactive Bladder; Urinary Bladder Overactive; Urinary Bladder Diseases; Urologic Diseases,Drug:mirabegron; Drug:antimuscarinic medication,[],16-Dec-15,18,9999,Both,FALSE,69NCT02367456,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT02367456,TRUE,"A Combination Study of PF-04449913 and Azacitidine In 1st Line MDS, AML and CMML Patients",Myelodysplastic Syndrome,Drug:PF-04449913; Drug:Azacitidine; Drug:PF-04449913 Placebo,[],5-Jan-16,18,9999,Both,FALSE,10NCT02343458,"Pearl Therapeutics, Inc.",FALSE,AL,https://ClinicalTrials.gov/show/NCT02343458,TRUE,"Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD",COPD,Drug:GFF MDI (PT003); Drug:FF MDI (PT005); Drug:GP MDI (PT001); Drug:Placebo MDI,[],28-Sep-15,40,80,Both,FALSE,163NCT02258542,AstraZeneca,FALSE,AL,https://ClinicalTrials.gov/show/NCT02258542,TRUE,A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA,Asthma,Biological:Benralizumab; Biological:Benralizumab,[],12-Jan-16,12,75,Both,FALSE,13NCT02194699,AstraZeneca,FALSE,AL,https://ClinicalTrials.gov/show/NCT02194699,TRUE,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Experimental: Tralokinumab; Other:Placebo,[],29-Jan-16,12,75,Both,FALSE,13NCT02092467,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT02092467,TRUE,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],15-Jan-16,50,9999,Both,FALSE,10NCT01997333,Celldex Therapeutics,FALSE,AL,https://ClinicalTrials.gov/show/NCT01997333,TRUE,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.,Drug:CDX-011; Drug:Capecitabine,[],5-Nov-15,18,9999,Both,FALSE,87NCT01919697,Synergy Pharmaceuticals Inc.,FALSE,AL,https://ClinicalTrials.gov/show/NCT01919697,TRUE,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],10-Dec-15,18,81,Both,FALSE,183NCT01751906,Abbott Vascular,FALSE,AL,https://ClinicalTrials.gov/show/NCT01751906,TRUE,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],11-Oct-15,18,9999,Both,FALSE,50NCT01701817,"Janssen Scientific Affairs, LLC",FALSE,AL,https://ClinicalTrials.gov/show/NCT01701817,TRUE,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],7-Jan-16,21,9999,Both,FALSE,133NCT01594333,Brigham and Women's Hospital,FALSE,AL,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01546038,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT01546038,TRUE,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,Acute Myeloid Leukemia,Drug:PF-04449913; Drug:Low dose ARA-C (LDAC); Drug:PF-04449913; Drug:Decitabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Low dose ARA-C (LDAC),[],20-Jan-16,18,9999,Both,FALSE,10NCT01120249,Southwest Oncology Group,FALSE,AL,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT00547469,Dynogen Pharmaceuticals,FALSE,AL,https://ClinicalTrials.gov/show/NCT00547469,TRUE,A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females,Irritable Bowel Syndrome,Drug:DDP733,[],7-Apr-08,18,65,Female,FALSE,100NCT02674386,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT02674386,TRUE,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],1-Feb-16,18,9999,Both,FALSE,10NCT02640612,Boehringer Ingelheim,FALSE,AL,https://ClinicalTrials.gov/show/NCT02640612,TRUE,Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:BI 695501,[],2-Feb-16,18,80,Both,FALSE,75NCT02488967,NRG Oncology,FALSE,AK,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02311933,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02194738,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02375204,Alliance for Clinical Trials in Oncology,FALSE,AK,https://ClinicalTrials.gov/show/NCT02375204,TRUE,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],8-Dec-15,14,9999,Male,FALSE,1NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,AK,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02003222,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT02003222,TRUE,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],28-Jan-16,30,70,Both,FALSE,9NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,AK,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT00887146,Alliance for Clinical Trials in Oncology,FALSE,AK,https://ClinicalTrials.gov/show/NCT00887146,TRUE,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],18-Dec-15,18,9999,Both,FALSE,1NCT00565851,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01674140,Southwest Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,AK,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,AK,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01101451,Gynecologic Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,AK,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01856192,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01835145,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT01835145,TRUE,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],1-Feb-16,18,9999,Both,FALSE,9NCT01781468,Alliance for Clinical Trials in Oncology,FALSE,AK,https://ClinicalTrials.gov/show/NCT01781468,TRUE,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],13-Nov-15,18,9999,Both,FALSE,1NCT01668719,Southwest Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT01415752,Eastern Cooperative Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01169337,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02059265,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT02059265,TRUE,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Female,FALSE,9NCT01013649,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01620190,University of Washington,FALSE,AK,https://ClinicalTrials.gov/show/NCT01620190,TRUE,Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation,"[u'Anchorage Oncology Centre', u'Katmai Oncology Group', u'Providence Alaska Medical Center', u'Bozeman Deaconess Hospital', u'Kadlec Clinic Hematology and Oncology', u'Skagit Valley Hospital', u'Olympic Medical Center', u'Group Health Cooperative', u'Fred Hutch/University of Washington Cancer Consortium', u'Spokane Valley Cancer Center-Mission', u'Multicare Health System', u'Wenatchee Valley Hospital and Clinics']",29-Jan-16,18,9999,Both,FALSE,212NCT01274338,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT02673190,Radiation Therapy Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02152982,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT02152982,TRUE,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,AK,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01908101,University of Washington,FALSE,AK,https://ClinicalTrials.gov/show/NCT01908101,TRUE,Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer,Recurrent Breast Carcinoma; Stage IV Breast Cancer,Drug:Eribulin Mesylate; Other:Laboratory Biomarker Analysis,"[u'Katmai Oncology Group', u'Providence Alaska Medical Center', u'The University of Arizona Medical Center-University Campus', u'Bozeman Deaconess Hospital', u'Bend Memorial Clinic', u'Kadlec Clinic Hematology and Oncology', u'Skagit Valley Hospital', u'Olympic Medical Center', u'Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium', u'Group Health Cooperative-Seattle', u'Multicare Health System', u'Wenatchee Valley Hospital and Clinics']",12-Nov-15,18,9999,Both,FALSE,212NCT01414608,Gynecologic Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT01414608,TRUE,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],16-Jul-15,18,9999,Female,FALSE,14NCT01349881,Southwest Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT00430183,Alliance for Clinical Trials in Oncology,FALSE,AK,https://ClinicalTrials.gov/show/NCT00430183,TRUE,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],13-Mar-15,18,9999,Male,FALSE,1NCT02663908,Ferring Pharmaceuticals,FALSE,AK,https://ClinicalTrials.gov/show/NCT02663908,TRUE,A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease,Prostate Cancer,Drug:Degarelix; Drug:Leuprolide,[],22-Jan-16,0,9999,Male,FALSE,108NCT02614183,Eli Lilly and Company,FALSE,AK,https://ClinicalTrials.gov/show/NCT02614183,TRUE,Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Migraine,Drug:LY2951742; Drug:Placebo,[],28-Jan-16,18,65,Both,FALSE,104NCT02589236,"Nivalis Therapeutics, Inc.",FALSE,AK,https://ClinicalTrials.gov/show/NCT02589236,TRUE,Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation,Cystic Fibrosis,Drug:N91115; Drug:Placebo,[],1-Feb-16,18,9999,Both,FALSE,154NCT02477020,Takeda,FALSE,AK,https://ClinicalTrials.gov/show/NCT02477020,TRUE,A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia,Schizophrenia,Drug:TAK-063 20 mg; Drug:Placebo,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']",18-Jan-16,18,65,Both,FALSE,5NCT02470585,AbbVie,FALSE,AK,https://ClinicalTrials.gov/show/NCT02470585,TRUE,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer; Ovarian Neoplasm,Other:Placebo; Drug:Veliparib; Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel,[],13-Jan-16,18,99,Female,FALSE,51NCT02451137,Sanofi,FALSE,AK,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02443688,"Celtaxsys, Inc.",FALSE,AK,https://ClinicalTrials.gov/show/NCT02443688,TRUE,"EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult CF Patients",Cystic Fibrosis,Drug:CTX-4430; Drug:Placebo,"[u'University of Alabama', u'Providence Health and Services', u'Banner University of Arizona Medical Center', u'Pediatric Pulmonary and Cystic Fibrosis Clinic, Stanford University', u'University of California Davis Medical Center', u'National Jewish Health', u'University of Florida', u'Central Florida Pulmonary Group', u'Emory University', u'University of Chicago', u'Massachusetts General Hospital', u'University of Michigan', u'Spectrum Health Butterworth Campus', u'University of New Mexico', u'Hershey Medical Center', u""Children's Hospital of Pittsburgh of UPMC"", u'Universiy of Tennessee Medical Center UHS']",1-Feb-16,18,30,Both,FALSE,88NCT02431611,Mayo Clinic,FALSE,AK,https://ClinicalTrials.gov/show/NCT02431611,TRUE,Biomarker Feedback to Motivate Cessation in Pregnancy,Nicotine Dependence; Pregnancy,Behavioral:Biomarker feedback (phone based smoking cessation counseling); Behavioral:Control condition (phone based smoking cessation counseling),[u'Alaska Native Tribal Health Consortium'],12-Jan-16,18,45,Female,TRUE,142NCT02406677,AstraZeneca,FALSE,AK,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02365818,"Cold Genesys, Inc.",FALSE,AK,https://ClinicalTrials.gov/show/NCT02365818,TRUE,Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure,Bladder Cancer,Drug:CG0070,"[u'Alaska Clinical Research Center', u'BCG Oncology', u'Tower Urology', u'Institute of Urologic Oncology at UCLA', u'UC Irvine Medical Center', u'UF Health Cancer Center', u'University of Chicago', u'Michigan Institute of Urology, P.C.', u'Adult Pediatric Urology and Urogynecology, PC', u'Premier Urology Group, LLC.', u'Premier Medical Group of the Hudson Valley', u'Wake Forest University School of Medicine', u'The Urology Group', u'Erlanger Institute for Clinical Research', u'Vanderbilt University Medical Center, Dept. of Urologic Surgery']",1-Feb-16,18,9999,Both,FALSE,90NCT02326454,Light Sciences Oncology,FALSE,AK,https://ClinicalTrials.gov/show/NCT02326454,TRUE,A Placebo Controlled Study of MR901 for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Drug:talaporfin sodium; Drug:Saline; Device:Drug Activator 100 J/cm; Device:Drug Activator 200 J/cm,[],1-Feb-16,40,9999,Male,FALSE,137NCT02319837,"Medivation, Inc.",FALSE,AK,https://ClinicalTrials.gov/show/NCT02319837,TRUE,Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK),Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate,Drug:Enzalutamide; Drug:Placebo; Drug:Leuprolide,[],1-Dec-15,18,9999,Male,FALSE,144NCT02315469,NRG Oncology,FALSE,AK,https://ClinicalTrials.gov/show/NCT02315469,TRUE,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],13-Jul-15,70,9999,Female,FALSE,159NCT02439320,CoLucid Pharmaceuticals,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02439320,TRUE,Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:,Acute Migraine,Drug:Lasmiditan 100 mg; Drug:Lasmiditan 200 mg; Drug:Placebo (matches lasmiditan doses),[],13-Nov-15,18,9999,Both,FALSE,91NCT02104817,AstraZeneca,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02104817,TRUE,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],21-Dec-15,18,99,Both,FALSE,13NCT01966107,AstraZeneca,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01594333,Brigham and Women's Hospital,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01101035,Takeda,TRUE,AZ,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT02164513,GlaxoSmithKline,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02164513,TRUE,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],4-Feb-16,40,9999,Both,FALSE,8NCT01975376,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01845025,Novartis Pharmaceuticals,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01845025,TRUE,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],3-Feb-16,12,9999,Both,FALSE,156NCT01991795,AstraZeneca,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01975389,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01968967,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01968967,TRUE,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],25-Jan-16,18,9999,Both,FALSE,10NCT02638129,Takeda,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02638129,TRUE,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],28-Jan-16,18,9999,Both,FALSE,5NCT02526524,"Elcelyx Therapeutics, Inc.",FALSE,AZ,https://ClinicalTrials.gov/show/NCT02526524,TRUE,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],7-Jan-16,25,9999,Both,FALSE,103NCT02301234,"Janssen Research & Development, LLC",FALSE,AZ,https://ClinicalTrials.gov/show/NCT02301234,TRUE,"Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg; Drug:Celecoxib 100 mg; Drug:Celecoxib 100 mg Matching Placebo,[],20-Jan-16,18,99,Both,FALSE,132NCT02019264,Eisai Inc.,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT02674386,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02674386,TRUE,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],1-Feb-16,18,9999,Both,FALSE,10NCT02590432,Forest Laboratories,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02590432,TRUE,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],23-Dec-15,18,9999,Both,FALSE,110NCT02528188,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02528188,TRUE,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],19-Jan-16,18,9999,Both,FALSE,10NCT02336698,"Janssen Research & Development, LLC",FALSE,AZ,https://ClinicalTrials.gov/show/NCT02336698,TRUE,"Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],20-Jan-16,18,99,Both,FALSE,132NCT02111564,"Janssen Research & Development, LLC",FALSE,AZ,https://ClinicalTrials.gov/show/NCT02111564,TRUE,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],26-Jan-16,40,9999,Both,FALSE,132NCT02065687,Gynecologic Oncology Group,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01701817,"Janssen Scientific Affairs, LLC",FALSE,AZ,https://ClinicalTrials.gov/show/NCT01701817,TRUE,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],7-Jan-16,21,9999,Both,FALSE,133NCT01652872,Amgen,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01652872,TRUE,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],9-Dec-15,18,9999,Both,FALSE,16NCT00936390,Radiation Therapy Oncology Group,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT02673190,Radiation Therapy Oncology Group,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02504268,Bristol-Myers Squibb,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02504268,TRUE,Effects of Abatacept in Patients With Early Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Abatacept; Drug:Methotrexate; Other:Abatacept Placebo; Other:Methotrexate Placebo,[],28-Jan-16,18,9999,Both,FALSE,80NCT02504216,Bayer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02504216,TRUE,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],1-Feb-16,50,9999,Both,FALSE,23NCT02465515,GlaxoSmithKline,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02465515,TRUE,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Diabetes Mellitus,Biological:Albiglutide 30 mg; Biological:Albiglutide 50 mg; Biological:Albiglutide matching placebo,[],4-Feb-16,40,9999,Both,FALSE,8NCT02451137,Sanofi,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02412917,"ContraVir Pharmaceuticals, Inc.",FALSE,AZ,https://ClinicalTrials.gov/show/NCT02412917,TRUE,A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia,Shingles; Herpes Zoster; Postherpetic Neuralgia,Drug:FV-100; Drug:valacyclovir,[],1-Sep-15,50,9999,Both,FALSE,92NCT02386072,"Astellas Scientific & Medical Affairs, Inc.",FALSE,AZ,https://ClinicalTrials.gov/show/NCT02386072,TRUE,"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",Overactive Bladder; Urinary Bladder Overactive; Urinary Bladder Diseases; Urologic Diseases,Drug:mirabegron; Drug:antimuscarinic medication,[],16-Dec-15,18,9999,Both,FALSE,69NCT02164864,Boehringer Ingelheim,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02164864,TRUE,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],26-Jan-16,18,9999,Both,FALSE,75NCT02047097,Biogen,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02047097,TRUE,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],31-Jul-15,18,9999,Both,FALSE,73NCT01997333,Celldex Therapeutics,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01997333,TRUE,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.,Drug:CDX-011; Drug:Capecitabine,[],5-Nov-15,18,9999,Both,FALSE,87NCT01953601,Merck Sharp & Dohme Corp.,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01953601,TRUE,Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019),Amnestic Mild Cognitive Impairment; Alzheimer's Disease; Prodromal Alzheimer's Disease,Drug:Verubecestat (Part I and Part II); Drug:Verubecestat (Part I and Part II); Drug:Placebo (Part I); Drug:Verubecestat (Part II),[],31-Dec-15,50,85,Both,FALSE,145NCT01919697,Synergy Pharmaceuticals Inc.,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01919697,TRUE,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],10-Dec-15,18,81,Both,FALSE,183NCT01901900,Novartis Pharmaceuticals,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01901900,TRUE,Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.,Rheumatoid Arthritis,Biological:Secukinumab (AIN457),[],12-Jan-15,18,9999,Both,FALSE,156NCT01885078,Eli Lilly and Company,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01885078,TRUE,An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Baricitinib; Drug:Placebo,[],27-Jan-16,18,9999,Both,FALSE,104NCT01858532,AbbVie,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01858532,TRUE,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],20-Jan-16,18,85,Both,FALSE,51NCT01808573,"Puma Biotechnology, Inc.",FALSE,AZ,https://ClinicalTrials.gov/show/NCT01808573,TRUE,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],26-Jan-16,18,9999,Both,FALSE,166NCT01729455,"Human Genome Sciences Inc., a GSK Company",FALSE,AZ,https://ClinicalTrials.gov/show/NCT01729455,TRUE,Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry,Systemic Lupus Erythematosus,Biological:BENLYSTA; Other:SLE treatment,[],4-Feb-16,18,9999,Both,FALSE,122NCT01674140,Southwest Oncology Group,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01633112,Novartis Pharmaceuticals,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01633112,TRUE,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Relapsing-remitting Multiple Sclerosis (RRMS),Drug:fingolimod; Drug:copaxone,[],9-Dec-15,18,65,Both,FALSE,156NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT02671981,Radiation Therapy Oncology Group,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02671981,TRUE,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],2-Feb-16,18,9999,Both,FALSE,4NCT02640612,Boehringer Ingelheim,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02640612,TRUE,Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:BI 695501,[],2-Feb-16,18,80,Both,FALSE,75NCT02629159,AbbVie,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02629159,TRUE,A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE),Rheumatoid Arthritis,Drug:ABT-494; Drug:Placebo for ABT-494; Drug:Adalimumab; Drug:Placebo for Adalimumab,[],10-Dec-15,18,99,Both,FALSE,51NCT00351611,Pfizer,FALSE,AR,https://ClinicalTrials.gov/show/NCT00351611,TRUE,Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo,"Epilepsies, Partial",Drug:Lyrica (pregabalin); Drug:placebo,[],19-Jan-16,18,65,Both,FALSE,10NCT02150577,University of Arkansas,TRUE,AR,https://ClinicalTrials.gov/show/NCT02150577,TRUE,Implementation Trial of Evidence Based Practices for Mood Disorders,Bipolar Disorder; Treatment Resistant Depression,Behavioral:Evidence Based Quality Improvement,"[u'Mainline Health Systems Inc.', u'Boston Mountain Rural Health Center', u'Lee County Cooperative Clinic', u'ARcare', u'Jefferson Comprehensive Care System', u'East Arkansas Family Health Center']",14-Oct-15,18,100,Both,FALSE,42NCT01274338,National Cancer Institute (NCI),FALSE,AR,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT00858364,Amgen,FALSE,AR,https://ClinicalTrials.gov/show/NCT00858364,TRUE,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],27-Jan-16,18,9999,Both,FALSE,16NCT02674386,Pfizer,FALSE,AR,https://ClinicalTrials.gov/show/NCT02674386,TRUE,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],1-Feb-16,18,9999,Both,FALSE,10NCT02528188,Pfizer,FALSE,AR,https://ClinicalTrials.gov/show/NCT02528188,TRUE,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],19-Jan-16,18,9999,Both,FALSE,10NCT02451137,Sanofi,FALSE,AR,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02427802,Innocoll,FALSE,AR,https://ClinicalTrials.gov/show/NCT02427802,TRUE,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,"Foot Ulcer, Diabetic; Infection",Drug:Gentamicin collagen sponge; Other:Placebo,[],4-Jan-16,18,85,Both,FALSE,127NCT02406677,AstraZeneca,FALSE,AR,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02164864,Boehringer Ingelheim,FALSE,AR,https://ClinicalTrials.gov/show/NCT02164864,TRUE,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],26-Jan-16,18,9999,Both,FALSE,75NCT02019264,Eisai Inc.,FALSE,AR,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01966107,AstraZeneca,FALSE,AR,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01888120,Jazz Pharmaceuticals,FALSE,AR,https://ClinicalTrials.gov/show/NCT01888120,TRUE,Patient Registry of Intrathecal Ziconotide Management(PRIZM),Patients With Severe Chronic Pain,Drug:Ziconotide,[],18-Jun-15,18,9999,Both,FALSE,134NCT01272037,National Cancer Institute (NCI),FALSE,AR,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02528253,Pfizer,FALSE,AR,https://ClinicalTrials.gov/show/NCT02528253,TRUE,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],1-Feb-16,18,9999,Both,FALSE,10NCT02526524,"Elcelyx Therapeutics, Inc.",FALSE,AR,https://ClinicalTrials.gov/show/NCT02526524,TRUE,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],7-Jan-16,25,9999,Both,FALSE,103NCT02431806,Forest Laboratories,FALSE,AR,https://ClinicalTrials.gov/show/NCT02431806,TRUE,Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder,Major Depressive Disorder (MDD),Drug:Placebo; Drug:Levomilnacipran ER; Drug:Fluoxetine,[],23-Dec-15,12,17,Both,FALSE,110NCT02357420,"Rhythm Pharmaceuticals, Inc.",FALSE,AR,https://ClinicalTrials.gov/show/NCT02357420,TRUE,A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis,Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis,Drug:RM-131; Drug:Placebo,[],2-Dec-15,18,75,Both,FALSE,169NCT02240121,"Valeant Pharmaceuticals International, Inc.",FALSE,AR,https://ClinicalTrials.gov/show/NCT02240121,TRUE,One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease,Crohn's Disease,Drug:Rifaximin DR; Drug:Placebo,[],11-Jun-15,18,9999,Both,FALSE,47NCT02182830,Boehringer Ingelheim,FALSE,AR,https://ClinicalTrials.gov/show/NCT02182830,TRUE,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],26-Jan-16,18,9999,Both,FALSE,75NCT02164916,Southwest Oncology Group,FALSE,AR,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02111564,"Janssen Research & Development, LLC",FALSE,AR,https://ClinicalTrials.gov/show/NCT02111564,TRUE,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],26-Jan-16,40,9999,Both,FALSE,132NCT02075047,Pfizer,FALSE,AR,https://ClinicalTrials.gov/show/NCT02075047,TRUE,Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder,Bipolar Disorder,Drug:placebo oral capsules; Drug:ziprasidone oral capsules,[],16-Jan-16,10,17,Both,FALSE,10NCT02048813,National Cancer Institute (NCI),FALSE,AR,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01970865,Pfizer,FALSE,AR,https://ClinicalTrials.gov/show/NCT01970865,TRUE,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,Drug:PF-06463922; Drug:Crizotinib,[],20-Jan-16,18,9999,Both,FALSE,10NCT01968876,University of Arkansas,FALSE,AR,https://ClinicalTrials.gov/show/NCT01968876,TRUE,Is a Smartphone Application Effective as an Oral Medication Adherence Aid,Hypertension; Diabetes; Dyslipidemia,Other:Medication Adherence Smartphone App,"[u'Internal Medicine Clinic North; University of Arkansas for Medical Sciences', u'Remedy Drug', u'Internal Medicine Clinic West; University of Arkansas for Medical Sciences']",12-Nov-15,18,9999,Both,FALSE,42NCT01897532,Boehringer Ingelheim,FALSE,AR,https://ClinicalTrials.gov/show/NCT01897532,TRUE,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],26-Jan-16,18,9999,Both,FALSE,75NCT01828112,Novartis Pharmaceuticals,FALSE,AR,https://ClinicalTrials.gov/show/NCT01828112,TRUE,LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,Non-Small Cell Lung Cancer,Drug:LDK378; Drug:pemetrexed; Drug:docetaxel,[],24-Jan-16,18,9999,Both,FALSE,156NCT01594333,Brigham and Women's Hospital,FALSE,AR,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01546571,Polynoma LLC,FALSE,AR,https://ClinicalTrials.gov/show/NCT01546571,TRUE,"Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients",Melanoma,Biological:POL-103A; Biological:POL-103A without API,[],8-Dec-15,18,80,Both,FALSE,165NCT01120249,Southwest Oncology Group,FALSE,AR,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01101035,Takeda,TRUE,AR,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT02638129,Takeda,FALSE,AR,https://ClinicalTrials.gov/show/NCT02638129,TRUE,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],28-Jan-16,18,9999,Both,FALSE,5NCT02592434,Pfizer,FALSE,AR,https://ClinicalTrials.gov/show/NCT02592434,TRUE,Efficacy Study Of Tofacitinib In Pediatric JIA Population,Juvenile Idiopathic Arthritis,"Drug:CP-690,550 (tofacitinib); Other:placebo","[u""Arkansas Children's Hospital - Attention: Billy Furgerson (IP Shipment Address)"", u""Arkansas Children's Hospital"", u'Tufts Medical Center, Inc.', u'Tufts Medical Center', u'Montefiore Medical Center (Drug Shipment)', u'Montefiore Medical Center', u""Cohen Children's Medical Center of NY"", u""Cohen Children's Medical Center of New York (Drug Shipment Address)"", u""Randall Children's Hospital at Legacy Emanuel""]",11-Jan-16,2,17,Both,FALSE,10NCT02590432,Forest Laboratories,FALSE,AR,https://ClinicalTrials.gov/show/NCT02590432,TRUE,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],23-Dec-15,18,9999,Both,FALSE,110NCT02580305,Suven Life Sciences Limited,FALSE,AR,https://ClinicalTrials.gov/show/NCT02580305,TRUE,SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study,Alzheimer's Disease,Drug:SUVN-502; Drug:Placebo,"[u'Woodland International Research Group, LLC', u'Woodland Research Northwest', u'ATP Clinical Research, Inc.', u'Neuro-Pain Medical Center Inc', u'Senior Clinical Trials, Inc.', u'Jacksonville Center for Clinical Research', u'Premier Clinical Research Institute Inc', u'Miami Research Associates, LLC', u'The Roskamp Institute, Inc.', u'Neurology Clinical Research, Inc.', u'Axiom Clinical Research of Florida', u'Stedman Clinical Trials', u'Radiant Research', u'Sheppard Pratt Health System', u'AdvanceMed Research', u'Biobehavioral Health', u'Advanced Memory Research Institute', u'Integrative Clinical Trials, LLC', u'Eastside Comprehensive Medical Center, LLC', u'Valley Medical Research', u'IPS Research Company', u'Tulsa Clinical Research, LLC', u'Radiant Research, Inc.', u'Universal Research Group, LLC']",18-Jan-16,50,85,Both,FALSE,182NCT02580058,Pfizer,FALSE,AR,https://ClinicalTrials.gov/show/NCT02580058,TRUE,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),Ovarian Cancer,Biological:avelumab; Drug:PLD,"[u'Highlands Oncology Group', u'Highlands Oncology Group', u'Cabrini Health Limited', u'Cabrini Health Limited']",13-Jan-16,18,9999,Female,FALSE,10NCT02544152,Sucampo AG,FALSE,AR,https://ClinicalTrials.gov/show/NCT02544152,TRUE,Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome,Irritable Bowel Syndrome,Drug:Lubiprostone; Drug:Placebo,"[u'Gastroenterology Associates,P.A.', u'Arkansas Gastroenterology', u'GW Research Inc.', u'Therapeutic Research Institute of Orange County', u'The Regents of the University of California / Los Angeles Campus', u'Advanced Gastroenterology Associates, LLC', u'Digestive Care Physicians', u'Meritus Center for Clinical Research', u'Mayo Clinic', u'Cumberland Research Associates, LLC', u'Wake Research Associates, LLC', u'Clinical Research Solutions', u'Nashville Medical Research Institute', u'Houston Endoscopy Research Center']",4-Jan-16,18,9999,Both,FALSE,178NCT02504268,Bristol-Myers Squibb,FALSE,AR,https://ClinicalTrials.gov/show/NCT02504268,TRUE,Effects of Abatacept in Patients With Early Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Abatacept; Drug:Methotrexate; Other:Abatacept Placebo; Other:Methotrexate Placebo,[],28-Jan-16,18,9999,Both,FALSE,80NCT02504216,Bayer,FALSE,AR,https://ClinicalTrials.gov/show/NCT02504216,TRUE,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],1-Feb-16,50,9999,Both,FALSE,23NCT02488967,NRG Oncology,FALSE,AR,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02486718,Hoffmann-La Roche,FALSE,AR,https://ClinicalTrials.gov/show/NCT02486718,TRUE,Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Other:Best Supportive Care (BSC),[],1-Feb-16,18,9999,Both,FALSE,119NCT02674386,Pfizer,FALSE,CA,https://ClinicalTrials.gov/show/NCT02674386,TRUE,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],1-Feb-16,18,9999,Both,FALSE,10NCT02673190,Radiation Therapy Oncology Group,FALSE,CA,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02601209,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02601209,TRUE,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02562716,Southwest Oncology Group,FALSE,CA,https://ClinicalTrials.gov/show/NCT02562716,TRUE,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],26-Jan-16,18,75,Both,FALSE,3NCT02540993,Bayer,FALSE,CA,https://ClinicalTrials.gov/show/NCT02540993,TRUE,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],21-Jan-16,18,9999,Both,FALSE,23NCT02528188,Pfizer,FALSE,CA,https://ClinicalTrials.gov/show/NCT02528188,TRUE,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],19-Jan-16,18,9999,Both,FALSE,10NCT02506153,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02506153,TRUE,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,18,9999,Both,FALSE,9NCT02488967,NRG Oncology,FALSE,CA,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02451137,Sanofi,FALSE,CA,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02342249,Vertex Pharmaceuticals Incorporated,FALSE,CA,https://ClinicalTrials.gov/show/NCT02342249,TRUE,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],28-Jul-15,18,64,Both,FALSE,218NCT02315469,NRG Oncology,FALSE,CA,https://ClinicalTrials.gov/show/NCT02315469,TRUE,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],13-Jul-15,70,9999,Female,FALSE,159NCT02311933,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02194738,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02180867,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02180867,TRUE,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],1-Feb-16,2,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,CA,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02164513,GlaxoSmithKline,FALSE,CA,https://ClinicalTrials.gov/show/NCT02164513,TRUE,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],4-Feb-16,40,9999,Both,FALSE,8NCT02154490,Southwest Oncology Group,FALSE,CA,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02152982,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02152982,TRUE,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02135042,NRG Oncology,FALSE,CA,https://ClinicalTrials.gov/show/NCT02135042,TRUE,Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA,Epstein-Barr Virus Infection; Stage II Nasopharyngeal Carcinoma; Stage III Nasopharyngeal Carcinoma; Stage IVA Nasopharyngeal Carcinoma; Stage IVB Nasopharyngeal Carcinoma,Drug:Cisplatin; Other:Clinical Observation; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],29-Jan-16,18,9999,Both,FALSE,159NCT02111564,"Janssen Research & Development, LLC",FALSE,CA,https://ClinicalTrials.gov/show/NCT02111564,TRUE,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],26-Jan-16,40,9999,Both,FALSE,132NCT02101788,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT02092467,Pfizer,FALSE,CA,https://ClinicalTrials.gov/show/NCT02092467,TRUE,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],15-Jan-16,50,9999,Both,FALSE,10NCT02065791,"Janssen Research & Development, LLC",FALSE,CA,https://ClinicalTrials.gov/show/NCT02065791,TRUE,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],5-Jan-16,30,9999,Both,FALSE,132NCT02065687,Gynecologic Oncology Group,FALSE,CA,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02059265,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02059265,TRUE,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Female,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,CA,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT02019264,Eisai Inc.,FALSE,CA,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT02003209,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01991795,AstraZeneca,FALSE,CA,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01975389,Pfizer,FALSE,CA,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,CA,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01966107,AstraZeneca,FALSE,CA,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,CA,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,CA,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01919697,Synergy Pharmaceuticals Inc.,FALSE,CA,https://ClinicalTrials.gov/show/NCT01919697,TRUE,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],10-Dec-15,18,81,Both,FALSE,183NCT01903811,Southwest Oncology Group,FALSE,CA,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,CA,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT01877915,"Janssen Research & Development, LLC",FALSE,CA,https://ClinicalTrials.gov/show/NCT01877915,TRUE,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],26-Jan-16,18,95,Both,FALSE,132NCT01872975,NSABP Foundation Inc,FALSE,CA,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01870778,Novartis Pharmaceuticals,FALSE,CA,https://ClinicalTrials.gov/show/NCT01870778,TRUE,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],16-Sep-15,18,9999,Both,FALSE,156NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,CA,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01858532,AbbVie,FALSE,CA,https://ClinicalTrials.gov/show/NCT01858532,TRUE,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],20-Jan-16,18,85,Both,FALSE,51NCT01856192,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01824875,Eastern Cooperative Oncology Group,FALSE,CA,https://ClinicalTrials.gov/show/NCT01824875,TRUE,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],7-May-15,18,9999,Both,FALSE,17NCT01814813,Alliance for Clinical Trials in Oncology,FALSE,CA,https://ClinicalTrials.gov/show/NCT01814813,TRUE,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],26-Jan-16,18,9999,Both,FALSE,1NCT01809691,Southwest Oncology Group,FALSE,CA,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01808573,"Puma Biotechnology, Inc.",FALSE,CA,https://ClinicalTrials.gov/show/NCT01808573,TRUE,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],26-Jan-16,18,9999,Both,FALSE,166NCT02488967,NRG Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02194738,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02115282,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02101788,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01856192,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01809691,Southwest Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01674140,Southwest Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01573442,Alliance for Clinical Trials in Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT01573442,TRUE,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],3-Nov-15,18,9999,Female,FALSE,1NCT01533207,Gynecologic Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01533207,TRUE,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],23-Dec-14,18,9999,Female,FALSE,14NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01415752,Eastern Cooperative Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01414608,Gynecologic Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01414608,TRUE,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],16-Jul-15,18,9999,Female,FALSE,14NCT01359592,Southwest Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01359592,TRUE,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],17-Nov-15,18,9999,Both,FALSE,3NCT01349881,Southwest Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01216683,Eastern Cooperative Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01216683,TRUE,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,18,9999,Both,FALSE,17NCT01169337,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01124695,Eastern Cooperative Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01124695,TRUE,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],6-Dec-12,18,9999,Both,FALSE,17NCT01120249,Southwest Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01107626,Eastern Cooperative Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT01101451,Gynecologic Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01079780,Pam Cogliano,FALSE,CO,https://ClinicalTrials.gov/show/NCT01079780,TRUE,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],19-Sep-14,18,9999,Both,FALSE,161NCT01013649,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00897767,Eastern Cooperative Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT00897767,TRUE,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],5-Dec-12,0,9999,Both,FALSE,17NCT00887146,Alliance for Clinical Trials in Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT00887146,TRUE,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],18-Dec-15,18,9999,Both,FALSE,1NCT00843882,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT00807768,Gynecologic Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT00719303,Gynecologic Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT00565851,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02085408,Eastern Cooperative Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT02085408,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],16-Sep-14,60,9999,Both,FALSE,17NCT01242800,Eastern Cooperative Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT01041703,Eastern Cooperative Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01041703,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],24-Jul-14,60,9999,Both,FALSE,17NCT00074282,Eastern Cooperative Oncology Group,TRUE,CO,https://ClinicalTrials.gov/show/NCT00074282,TRUE,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],9-Nov-12,18,9999,Both,FALSE,17NCT00632853,Alliance for Clinical Trials in Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT00632853,TRUE,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],10-Aug-15,18,9999,Both,FALSE,1NCT02154490,Southwest Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02301156,"TG Therapeutics, Inc.",FALSE,CO,https://ClinicalTrials.gov/show/NCT02301156,TRUE,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],2-Feb-16,18,9999,Both,FALSE,188NCT02152982,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT02152982,TRUE,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT01272037,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02194738,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02488967,NRG Oncology,FALSE,CT,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT01674140,Southwest Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT02048813,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,CT,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT01668719,Southwest Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT01349881,Southwest Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01470612,Pfizer,FALSE,CT,https://ClinicalTrials.gov/show/NCT01470612,TRUE,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug:CP-690,550; Drug:CP-690,550",[],11-Jan-16,18,9999,Both,FALSE,10NCT02019264,Eisai Inc.,FALSE,CT,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01120249,Southwest Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT00807768,Gynecologic Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT00719303,Gynecologic Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01274338,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01169337,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02164513,GlaxoSmithKline,FALSE,CT,https://ClinicalTrials.gov/show/NCT02164513,TRUE,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],4-Feb-16,40,9999,Both,FALSE,8NCT02111564,"Janssen Research & Development, LLC",FALSE,CT,https://ClinicalTrials.gov/show/NCT02111564,TRUE,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],26-Jan-16,40,9999,Both,FALSE,132NCT01975389,Pfizer,FALSE,CT,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,CT,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,CT,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01458574,Pfizer,FALSE,CT,https://ClinicalTrials.gov/show/NCT01458574,TRUE,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",Ulcerative Colitis,"Drug:Placebo; Drug:CP690,550; Drug:CP-690,550",[],15-Jan-16,18,9999,Both,FALSE,10NCT01013649,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00936390,Radiation Therapy Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT00565851,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02406677,AstraZeneca,FALSE,CT,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT01991795,AstraZeneca,FALSE,CT,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,CT,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,CT,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT00430183,Alliance for Clinical Trials in Oncology,FALSE,CT,https://ClinicalTrials.gov/show/NCT00430183,TRUE,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],13-Mar-15,18,9999,Male,FALSE,1NCT00351611,Pfizer,FALSE,CT,https://ClinicalTrials.gov/show/NCT00351611,TRUE,Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo,"Epilepsies, Partial",Drug:Lyrica (pregabalin); Drug:placebo,[],19-Jan-16,18,65,Both,FALSE,10NCT02459925,Yale University,FALSE,CT,https://ClinicalTrials.gov/show/NCT02459925,TRUE,MOMS Hubs- CT Dept of Social Services Block Grant,Depression,Behavioral:CBT- Mental Health Program; Behavioral:MOMS GROW,"[u'Boys & Girls Club of New Haven', u'Center for Wellbeing of Women and Mothers, Dept. of Psychiatry, Yale University', u'Stop & Shop', u""West Rock Author's Academy""]",1-Feb-16,18,9999,Female,FALSE,48NCT02358031,Merck Sharp & Dohme Corp.,FALSE,CT,https://ClinicalTrials.gov/show/NCT02358031,TRUE,A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),Recurrent Head and Neck Cancer; Metastatic Head and Neck Cancer,Biological:Pembrolizumab; Drug:Cisplatin; Drug:Carboplatin; Drug:5-FU; Biological:Cetuximab,[],2-Feb-16,18,9999,Both,FALSE,145NCT02352883,ECOG-ACRIN Cancer Research Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT02352883,TRUE,MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ,Ductal Breast Carcinoma In Situ,Procedure:Magnetic Resonance Imaging; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Surgical Procedure; Radiation:Radiation Therapy; Drug:Endocrine Therapy; Other:Quality-of-Life Assessment; Other:Laboratory Biomarker Analysis; Other:Cytology Specimen Collection Procedure,[],22-Sep-15,18,9999,Female,FALSE,101NCT02271217,Acorda Therapeutics,FALSE,CT,https://ClinicalTrials.gov/show/NCT02271217,TRUE,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke,Post-Ischemic Stroke,Drug:Placebo; Drug:dalfampridine-ER 7.5mg; Drug:dalfampridine-ER 10mg,[],18-Nov-15,18,9999,Both,FALSE,54NCT02115282,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02065687,Gynecologic Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01920711,Novartis Pharmaceuticals,FALSE,CT,https://ClinicalTrials.gov/show/NCT01920711,TRUE,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],14-Oct-15,50,9999,Both,FALSE,156NCT01872975,NSABP Foundation Inc,FALSE,CT,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01771809,Pfizer,FALSE,CT,https://ClinicalTrials.gov/show/NCT01771809,TRUE,Long-Term Safety Of PF-00547659 In Ulcerative Colitis,Ulcerative Colitis,Drug:PF-00547659; Drug:PF-00547659; Drug:PF-00547659,[],16-Jan-16,18,65,Both,FALSE,10NCT01414608,Gynecologic Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT01414608,TRUE,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],16-Jul-15,18,9999,Female,FALSE,14NCT01107626,Eastern Cooperative Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT01101451,Gynecologic Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01101035,Takeda,TRUE,CT,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT01674140,Southwest Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01272037,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02601209,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT02601209,TRUE,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02488967,NRG Oncology,FALSE,DE,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02412670,ECOG-ACRIN Cancer Research Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT02412670,TRUE,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,Localized Urothelial Carcinoma of the Renal Pelvis and Ureter; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter,Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin Hydrochloride; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Drug:Carboplatin; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,[],19-Aug-15,18,9999,Both,FALSE,101NCT02194738,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02048813,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01950390,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01903811,Southwest Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01835145,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01835145,TRUE,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],1-Feb-16,18,9999,Both,FALSE,9NCT01824875,Eastern Cooperative Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT01824875,TRUE,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],7-May-15,18,9999,Both,FALSE,17NCT01668719,Southwest Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT01622868,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01622868,TRUE,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],4-Feb-16,18,9999,Both,FALSE,9NCT01595061,Gynecologic Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT01595061,TRUE,"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva",Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVA Vulvar Cancer; Vulvar Squamous Cell Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Gemcitabine Hydrochloride; Drug:Cisplatin; Procedure:Therapeutic Conventional Surgery,[],23-Dec-14,18,9999,Female,FALSE,14NCT01575548,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01573442,Alliance for Clinical Trials in Oncology,FALSE,DE,https://ClinicalTrials.gov/show/NCT01573442,TRUE,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],3-Nov-15,18,9999,Female,FALSE,1NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,DE,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT01533207,Gynecologic Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT01533207,TRUE,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],23-Dec-14,18,9999,Female,FALSE,14NCT01415752,Eastern Cooperative Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01349881,Southwest Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01169337,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,DE,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01120249,Southwest Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01013649,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00719303,Gynecologic Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT00565851,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00492778,Gynecologic Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT00492778,TRUE,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],13-Jul-15,0,9999,Female,FALSE,14NCT02152137,Alliance for Clinical Trials in Oncology,FALSE,DE,https://ClinicalTrials.gov/show/NCT02152137,TRUE,Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer; Recurrent Thyroid Cancer,Drug:efatutazone; Drug:paclitaxel,[],12-Aug-15,18,9999,Both,FALSE,1NCT02115282,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01856192,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT02154490,Southwest Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT01236547,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01236547,TRUE,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00843882,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,DE,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,DE,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT02474160,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT02474160,TRUE,Collection and Storage of Tissue and Blood Samples From Patients With Cancer,Malignant Neoplasm,Other:Cytology Specimen Collection Procedure,[],22-Jan-16,18,9999,Both,FALSE,9NCT01439711,Alliance for Clinical Trials in Oncology,FALSE,DE,https://ClinicalTrials.gov/show/NCT01439711,TRUE,Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ,Breast Cancer,Drug:letrozole; Procedure:MRI; Procedure:conventional surgery,[],18-Sep-15,18,9999,Female,FALSE,1NCT02352883,ECOG-ACRIN Cancer Research Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT02352883,TRUE,MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ,Ductal Breast Carcinoma In Situ,Procedure:Magnetic Resonance Imaging; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Surgical Procedure; Radiation:Radiation Therapy; Drug:Endocrine Therapy; Other:Quality-of-Life Assessment; Other:Laboratory Biomarker Analysis; Other:Cytology Specimen Collection Procedure,[],22-Sep-15,18,9999,Female,FALSE,101NCT01781468,Alliance for Clinical Trials in Oncology,FALSE,DE,https://ClinicalTrials.gov/show/NCT01781468,TRUE,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],13-Nov-15,18,9999,Both,FALSE,1NCT02019264,Eisai Inc.,FALSE,DE,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01959581,University of Delaware,FALSE,DE,https://ClinicalTrials.gov/show/NCT01959581,TRUE,Movement Enhancing Device for Children,Upper Extremity Dysfunction,Device:Movement Enhancing Device,"[u'Christiana Care Health Services', u'University of Delaware', u'Nemours Foundation']",11-Dec-14,1,6,Both,TRUE,200NCT01809691,Southwest Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT02673190,Radiation Therapy Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02336685,"Janssen Research & Development, LLC",FALSE,DE,https://ClinicalTrials.gov/show/NCT02336685,TRUE,"Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],20-Jan-16,18,99,Both,FALSE,132NCT02085408,Eastern Cooperative Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT02085408,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],16-Sep-14,60,9999,Both,FALSE,17NCT02674386,Pfizer,FALSE,FL,https://ClinicalTrials.gov/show/NCT02674386,TRUE,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],1-Feb-16,18,9999,Both,FALSE,10NCT02545049,Bayer,FALSE,FL,https://ClinicalTrials.gov/show/NCT02545049,TRUE,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],21-Jan-16,18,9999,Both,FALSE,23NCT02540993,Bayer,FALSE,FL,https://ClinicalTrials.gov/show/NCT02540993,TRUE,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],21-Jan-16,18,9999,Both,FALSE,23NCT02528188,Pfizer,FALSE,FL,https://ClinicalTrials.gov/show/NCT02528188,TRUE,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],19-Jan-16,18,9999,Both,FALSE,10NCT02451137,Sanofi,FALSE,FL,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02427802,Innocoll,FALSE,FL,https://ClinicalTrials.gov/show/NCT02427802,TRUE,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,"Foot Ulcer, Diabetic; Infection",Drug:Gentamicin collagen sponge; Other:Placebo,[],4-Jan-16,18,85,Both,FALSE,127NCT02406677,AstraZeneca,FALSE,FL,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02342249,Vertex Pharmaceuticals Incorporated,FALSE,FL,https://ClinicalTrials.gov/show/NCT02342249,TRUE,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],28-Jul-15,18,64,Both,FALSE,218NCT02336698,"Janssen Research & Development, LLC",FALSE,FL,https://ClinicalTrials.gov/show/NCT02336698,TRUE,"Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],20-Jan-16,18,99,Both,FALSE,132NCT02301156,"TG Therapeutics, Inc.",FALSE,FL,https://ClinicalTrials.gov/show/NCT02301156,TRUE,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],2-Feb-16,18,9999,Both,FALSE,188NCT02291679,"Ironwood Pharmaceuticals, Inc.",FALSE,FL,https://ClinicalTrials.gov/show/NCT02291679,TRUE,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],24-Mar-15,18,9999,Both,FALSE,130NCT02234583,Daiichi Sankyo Inc.,FALSE,FL,https://ClinicalTrials.gov/show/NCT02234583,TRUE,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],4-Nov-15,18,9999,Both,FALSE,95NCT02164513,GlaxoSmithKline,FALSE,FL,https://ClinicalTrials.gov/show/NCT02164513,TRUE,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],4-Feb-16,40,9999,Both,FALSE,8NCT02155660,AstraZeneca,FALSE,FL,https://ClinicalTrials.gov/show/NCT02155660,TRUE,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],7-Jan-16,40,85,Both,FALSE,13NCT02138916,AstraZeneca,FALSE,FL,https://ClinicalTrials.gov/show/NCT02138916,TRUE,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Placebo,[],29-Jan-16,40,85,Both,FALSE,13NCT02111564,"Janssen Research & Development, LLC",FALSE,FL,https://ClinicalTrials.gov/show/NCT02111564,TRUE,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],26-Jan-16,40,9999,Both,FALSE,132NCT02104817,AstraZeneca,FALSE,FL,https://ClinicalTrials.gov/show/NCT02104817,TRUE,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],21-Dec-15,18,99,Both,FALSE,13NCT02100514,Pfizer,FALSE,FL,https://ClinicalTrials.gov/show/NCT02100514,TRUE,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],3-Feb-16,18,9999,Both,FALSE,10NCT02092467,Pfizer,FALSE,FL,https://ClinicalTrials.gov/show/NCT02092467,TRUE,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],15-Jan-16,50,9999,Both,FALSE,10NCT02049515,"Infinity Pharmaceuticals, Inc.",FALSE,FL,https://ClinicalTrials.gov/show/NCT02049515,TRUE,A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07,Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,Drug:IPI-145 (duvelisib); Drug:Ofatumumab,[],16-Nov-15,18,9999,Both,FALSE,126NCT02019264,Eisai Inc.,FALSE,FL,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01991795,AstraZeneca,FALSE,FL,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01975389,Pfizer,FALSE,FL,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,FL,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01968967,Pfizer,FALSE,FL,https://ClinicalTrials.gov/show/NCT01968967,TRUE,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],25-Jan-16,18,9999,Both,FALSE,10NCT01966107,AstraZeneca,FALSE,FL,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01919697,Synergy Pharmaceuticals Inc.,FALSE,FL,https://ClinicalTrials.gov/show/NCT01919697,TRUE,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],10-Dec-15,18,81,Both,FALSE,183NCT01897532,Boehringer Ingelheim,FALSE,FL,https://ClinicalTrials.gov/show/NCT01897532,TRUE,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],26-Jan-16,18,9999,Both,FALSE,75NCT01887912,"Sanofi Pasteur, a Sanofi Company",FALSE,FL,https://ClinicalTrials.gov/show/NCT01887912,TRUE,Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection,Clostridium Difficile Infection,Biological:C. difficile Toxoid Vaccine; Biological:Placebo: 0.9% normal saline,[],11-Dec-15,50,9999,Both,TRUE,38NCT01858532,AbbVie,FALSE,FL,https://ClinicalTrials.gov/show/NCT01858532,TRUE,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],20-Jan-16,18,85,Both,FALSE,51NCT01674140,Southwest Oncology Group,FALSE,FL,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01663402,Sanofi,FALSE,FL,https://ClinicalTrials.gov/show/NCT01663402,TRUE,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],3-Feb-16,40,9999,Both,FALSE,12NCT01652872,Amgen,FALSE,FL,https://ClinicalTrials.gov/show/NCT01652872,TRUE,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],9-Dec-15,18,9999,Both,FALSE,16NCT01594333,Brigham and Women's Hospital,FALSE,FL,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01492361,Amarin Pharma Inc.,FALSE,FL,https://ClinicalTrials.gov/show/NCT01492361,TRUE,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],14-Jul-15,45,9999,Both,FALSE,62NCT01274338,National Cancer Institute (NCI),FALSE,FL,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,FL,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01101035,Takeda,TRUE,FL,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT00867815,Bayer,FALSE,FL,https://ClinicalTrials.gov/show/NCT00867815,TRUE,PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION),Anterior Ischemic Optic Neuropathy,Drug:Diagnostic procedures,[],25-Jan-16,40,9999,Male,FALSE,23NCT00858364,Amgen,FALSE,FL,https://ClinicalTrials.gov/show/NCT00858364,TRUE,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],27-Jan-16,18,9999,Both,FALSE,16NCT02465567,"Pearl Therapeutics, Inc.",FALSE,FL,https://ClinicalTrials.gov/show/NCT02465567,TRUE,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],22-Dec-15,40,80,Both,FALSE,163NCT01767311,Eisai Inc.,FALSE,FL,https://ClinicalTrials.gov/show/NCT01767311,TRUE,"A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease",Alzheimer's Disease,Drug:BAN2401 2.5 mg/kg; Drug:BAN2401 5.0 mg/kg; Drug:BAN2401 10 mg/kg; Drug:BAN2401 5.0 mg/kg; Drug:BAN2401 10 mg/kg,[],29-Nov-15,50,90,Both,FALSE,102NCT01406756,Children's Oncology Group,FALSE,FL,https://ClinicalTrials.gov/show/NCT01406756,TRUE,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],3-Feb-16,1,30,Both,FALSE,17NCT01190930,Children's Oncology Group,FALSE,FL,https://ClinicalTrials.gov/show/NCT01190930,TRUE,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],6-Aug-15,1,30,Both,FALSE,17NCT02601703,Glenmark Pharmaceuticals Ltd. India,FALSE,FL,https://ClinicalTrials.gov/show/NCT02601703,TRUE,"To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)",Atopic Dermatitis,"Drug:Tacrolimus Ointment 0.1%; Drug:Protopic ointment, 0.1%; Drug:Placebo of Tacrolimus Ointment",[],11-Dec-15,18,9999,Both,FALSE,115NCT02451137,Sanofi,FALSE,GA,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT01272037,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01966107,AstraZeneca,FALSE,GA,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT02194738,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT01975389,Pfizer,FALSE,GA,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT02085408,Eastern Cooperative Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT02085408,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],16-Sep-14,60,9999,Both,FALSE,17NCT01975376,Pfizer,FALSE,GA,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01594333,Brigham and Women's Hospital,FALSE,GA,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01101451,Gynecologic Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01101035,Takeda,TRUE,GA,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT01041703,Eastern Cooperative Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT01041703,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],24-Jul-14,60,9999,Both,FALSE,17NCT01359592,Southwest Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT01359592,TRUE,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],17-Nov-15,18,9999,Both,FALSE,3NCT02182830,Boehringer Ingelheim,FALSE,GA,https://ClinicalTrials.gov/show/NCT02182830,TRUE,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],26-Jan-16,18,9999,Both,FALSE,75NCT02164513,GlaxoSmithKline,FALSE,GA,https://ClinicalTrials.gov/show/NCT02164513,TRUE,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],4-Feb-16,40,9999,Both,FALSE,8NCT02154490,Southwest Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT01991795,AstraZeneca,FALSE,GA,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01274338,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01242800,Eastern Cooperative Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT00936390,Radiation Therapy Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT02003209,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT02674386,Pfizer,FALSE,GA,https://ClinicalTrials.gov/show/NCT02674386,TRUE,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],1-Feb-16,18,9999,Both,FALSE,10NCT02673190,Radiation Therapy Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02528188,Pfizer,FALSE,GA,https://ClinicalTrials.gov/show/NCT02528188,TRUE,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],19-Jan-16,18,9999,Both,FALSE,10NCT02406677,AstraZeneca,FALSE,GA,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02187003,Pfizer,FALSE,GA,https://ClinicalTrials.gov/show/NCT02187003,TRUE,Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease,"Anemia, Sickle Cell",Drug:Rivipansel; Other:Placebo,[],8-Jan-16,6,9999,Both,FALSE,10NCT02019264,Eisai Inc.,FALSE,GA,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01919697,Synergy Pharmaceuticals Inc.,FALSE,GA,https://ClinicalTrials.gov/show/NCT01919697,TRUE,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],10-Dec-15,18,81,Both,FALSE,183NCT01877915,"Janssen Research & Development, LLC",FALSE,GA,https://ClinicalTrials.gov/show/NCT01877915,TRUE,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],26-Jan-16,18,95,Both,FALSE,132NCT01701817,"Janssen Scientific Affairs, LLC",FALSE,GA,https://ClinicalTrials.gov/show/NCT01701817,TRUE,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],7-Jan-16,21,9999,Both,FALSE,133NCT01535053,Gynecologic Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT01535053,TRUE,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT02528253,Pfizer,FALSE,GA,https://ClinicalTrials.gov/show/NCT02528253,TRUE,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],1-Feb-16,18,9999,Both,FALSE,10NCT01872975,NSABP Foundation Inc,FALSE,GA,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01845025,Novartis Pharmaceuticals,FALSE,GA,https://ClinicalTrials.gov/show/NCT01845025,TRUE,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],3-Feb-16,12,9999,Both,FALSE,156NCT01751906,Abbott Vascular,FALSE,GA,https://ClinicalTrials.gov/show/NCT01751906,TRUE,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],11-Oct-15,18,9999,Both,FALSE,50NCT01169337,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00719303,Gynecologic Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02465567,"Pearl Therapeutics, Inc.",FALSE,GA,https://ClinicalTrials.gov/show/NCT02465567,TRUE,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],22-Dec-15,40,80,Both,FALSE,163NCT02138916,AstraZeneca,FALSE,GA,https://ClinicalTrials.gov/show/NCT02138916,TRUE,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Placebo,[],29-Jan-16,40,85,Both,FALSE,13NCT02066636,Bristol-Myers Squibb,FALSE,GA,https://ClinicalTrials.gov/show/NCT02066636,TRUE,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],26-Jan-16,18,9999,Both,FALSE,80NCT01897532,Boehringer Ingelheim,FALSE,GA,https://ClinicalTrials.gov/show/NCT01897532,TRUE,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],26-Jan-16,18,9999,Both,FALSE,75NCT01870778,Novartis Pharmaceuticals,FALSE,GA,https://ClinicalTrials.gov/show/NCT01870778,TRUE,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],16-Sep-15,18,9999,Both,FALSE,156NCT01858532,AbbVie,FALSE,GA,https://ClinicalTrials.gov/show/NCT01858532,TRUE,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],20-Jan-16,18,85,Both,FALSE,51NCT01674140,Southwest Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01672892,Radiation Therapy Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT01672892,TRUE,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],14-Nov-15,18,9999,Female,FALSE,4NCT01632241,"Human Genome Sciences Inc., a GSK Company",FALSE,GA,https://ClinicalTrials.gov/show/NCT01632241,TRUE,Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Biological:Placebo plus standard therapy; Biological:Belimumab 10 mg/kg plus standard therapy; Drug:Standard therapy,[],4-Feb-16,18,9999,Both,FALSE,122NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,GA,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT02488967,NRG Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02311933,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT01349881,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01272037,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT02194738,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02003209,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT02177695,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT02177695,TRUE,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",Bladder Cancer,Drug:Gemcitabine; Drug:Cisplatin; Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin; Drug:Filgrastim,[],8-Dec-15,18,9999,Both,FALSE,3NCT02065687,Gynecologic Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02059265,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT02059265,TRUE,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Female,FALSE,9NCT01950390,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01674140,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT01359592,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01359592,TRUE,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],17-Nov-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01064648,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01064648,TRUE,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],1-Feb-16,18,9999,Both,FALSE,9NCT02085408,Eastern Cooperative Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT02085408,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],16-Sep-14,60,9999,Both,FALSE,17NCT01903811,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01415752,Eastern Cooperative Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT02152137,Alliance for Clinical Trials in Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT02152137,TRUE,Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer; Recurrent Thyroid Cancer,Drug:efatutazone; Drug:paclitaxel,[],12-Aug-15,18,9999,Both,FALSE,1NCT02032823,AstraZeneca,FALSE,HI,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01824875,Eastern Cooperative Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01824875,TRUE,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],7-May-15,18,9999,Both,FALSE,17NCT01668719,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT01124695,Eastern Cooperative Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01124695,TRUE,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],6-Dec-12,18,9999,Both,FALSE,17NCT01041703,Eastern Cooperative Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01041703,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],24-Jul-14,60,9999,Both,FALSE,17NCT00700882,Eastern Cooperative Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT00700882,TRUE,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],16-Sep-14,18,9999,Both,FALSE,17NCT00430183,Alliance for Clinical Trials in Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT00430183,TRUE,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],13-Mar-15,18,9999,Male,FALSE,1NCT01781468,Alliance for Clinical Trials in Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT01781468,TRUE,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],13-Nov-15,18,9999,Both,FALSE,1NCT01286272,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01286272,TRUE,Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,Grade 3a Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma,Drug:Bendamustine Hydrochloride; Drug:Bortezomib; Radiation:Fludeoxyglucose F-18; Other:Laboratory Biomarker Analysis; Biological:Ofatumumab; Procedure:Positron Emission Tomography with Radiolabeled Targeting Agent,[],3-Feb-16,18,9999,Both,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT02154490,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02115282,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01809691,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT01242800,Eastern Cooperative Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT01856192,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01533207,Gynecologic Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01533207,TRUE,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],23-Dec-14,18,9999,Female,FALSE,14NCT01595061,Gynecologic Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01595061,TRUE,"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva",Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVA Vulvar Cancer; Vulvar Squamous Cell Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Gemcitabine Hydrochloride; Drug:Cisplatin; Procedure:Therapeutic Conventional Surgery,[],23-Dec-14,18,9999,Female,FALSE,14NCT01013649,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01808573,"Puma Biotechnology, Inc.",FALSE,HI,https://ClinicalTrials.gov/show/NCT01808573,TRUE,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],26-Jan-16,18,9999,Both,FALSE,166NCT01672892,Radiation Therapy Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01672892,TRUE,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],14-Nov-15,18,9999,Female,FALSE,4NCT01414608,Gynecologic Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01414608,TRUE,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],16-Jul-15,18,9999,Female,FALSE,14NCT00719303,Gynecologic Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02186847,NRG Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT02186847,TRUE,Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,Adenosquamous Lung Carcinoma; Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Non-Small Cell Lung Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Squamous Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Radiation:Volume Modulated Arc Therapy,[],29-Jan-16,18,9999,Both,FALSE,159NCT02152982,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT02152982,TRUE,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01872975,NSABP Foundation Inc,FALSE,HI,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01120249,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01272037,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02488967,NRG Oncology,FALSE,ID,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02311933,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02194738,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02003222,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT02003222,TRUE,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],28-Jan-16,30,70,Both,FALSE,9NCT01674140,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01169337,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00887146,Alliance for Clinical Trials in Oncology,FALSE,ID,https://ClinicalTrials.gov/show/NCT00887146,TRUE,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],18-Dec-15,18,9999,Both,FALSE,1NCT00719303,Gynecologic Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01966107,AstraZeneca,FALSE,ID,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,ID,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01107626,Eastern Cooperative Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT01013649,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00843882,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,ID,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT01575548,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01242800,Eastern Cooperative Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT00565851,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02375204,Alliance for Clinical Trials in Oncology,FALSE,ID,https://ClinicalTrials.gov/show/NCT02375204,TRUE,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],8-Dec-15,14,9999,Male,FALSE,1NCT02003209,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01853748,Dana-Farber Cancer Institute,FALSE,ID,https://ClinicalTrials.gov/show/NCT01853748,TRUE,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),Breast Cancer,Drug:Trastuzumab; Drug:Paclitaxel; Drug:Trastuzumab emtansine,[],3-Feb-16,18,9999,Both,FALSE,96NCT01516216,Dana-Farber Cancer Institute,FALSE,ID,https://ClinicalTrials.gov/show/NCT01516216,TRUE,Study of Vitamin D in Untreated Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug:FOLFOX + bevacizumab; Dietary Supplement:Vitamin D; Dietary Supplement:Vitamin D,"[u""Mountain States Tumor Institute at St. Luke's Regional Medical Center"", u'Mountain States Tumor Institute- Fruitland', u'Mountain States Tumor Institute - Meridian', u'Mountain States Tumor Institute- Nampa', u'Mountain States Tumor Institute- Twin Falls', u'The Robert H. Lurie Comprehensive Cancer Center of Northwestern University', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'Lowell General Hospital', u""Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center"", u'Newton-Wellesley Hospital', u""Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital"", u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'Dana-Farber/New Hampshire Oncology-Hematology', u'Vanderbilt-Ingram Cancer Center']",10-Jan-16,18,9999,Both,FALSE,96NCT01349881,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02134912,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT02134912,TRUE,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Drug:crizotinib; Drug:pemetrexed disodium; Other:laboratory biomarker analysis; Other:pharmacological study,[],5-Feb-15,18,9999,Both,FALSE,3NCT02115282,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01991795,AstraZeneca,FALSE,ID,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01975389,Pfizer,FALSE,ID,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,ID,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,ID,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01950390,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01903811,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01814813,Alliance for Clinical Trials in Oncology,FALSE,ID,https://ClinicalTrials.gov/show/NCT01814813,TRUE,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],26-Jan-16,18,9999,Both,FALSE,1NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,ID,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,ID,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01415752,Eastern Cooperative Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01064648,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01064648,TRUE,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],1-Feb-16,18,9999,Both,FALSE,9NCT02673190,Radiation Therapy Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02601209,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT02601209,TRUE,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02562716,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT02562716,TRUE,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],26-Jan-16,18,75,Both,FALSE,3NCT02388165,Pfizer,FALSE,ID,https://ClinicalTrials.gov/show/NCT02388165,TRUE,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],25-Jan-16,18,85,Both,FALSE,10NCT02315469,NRG Oncology,FALSE,ID,https://ClinicalTrials.gov/show/NCT02315469,TRUE,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],13-Jul-15,70,9999,Female,FALSE,159NCT01968967,Pfizer,FALSE,ID,https://ClinicalTrials.gov/show/NCT01968967,TRUE,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],25-Jan-16,18,9999,Both,FALSE,10NCT01839864,Family Medicine Residency of Idaho,FALSE,ID,https://ClinicalTrials.gov/show/NCT01839864,TRUE,Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical Trial,Metabolic Syndrome,"Behavioral:Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count","[u'Saint Alphonsus Medical Group Caldwell Clinic', u'Saint Lukes Clinic Jerome', u'St Alphonsus Medical Group Nampa Clinic']",22-Apr-13,18,9999,Both,FALSE,107NCT01835145,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01835145,TRUE,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],1-Feb-16,18,9999,Both,FALSE,9NCT02562716,Southwest Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT02562716,TRUE,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],26-Jan-16,18,75,Both,FALSE,3NCT02523014,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT02523014,TRUE,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],8-Dec-15,18,9999,Both,FALSE,1NCT02488967,NRG Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02474160,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02474160,TRUE,Collection and Storage of Tissue and Blood Samples From Patients With Cancer,Malignant Neoplasm,Other:Cytology Specimen Collection Procedure,[],22-Jan-16,18,9999,Both,FALSE,9NCT02438722,Southwest Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT02438722,TRUE,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],1-Sep-15,0,9999,Both,FALSE,3NCT02412670,ECOG-ACRIN Cancer Research Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT02412670,TRUE,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,Localized Urothelial Carcinoma of the Renal Pelvis and Ureter; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter,Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin Hydrochloride; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Drug:Carboplatin; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,[],19-Aug-15,18,9999,Both,FALSE,101NCT02315469,NRG Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT02315469,TRUE,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],13-Jul-15,70,9999,Female,FALSE,159NCT02311933,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02249949,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT02249949,TRUE,"Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients With Previously Treated, Unresectable Myxoid Liposarcoma",Liposarcoma,Drug:efatutazone; Drug:placebo,[],12-Jun-15,18,9999,Both,FALSE,1NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02194738,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02143414,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02143414,TRUE,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],15-Jan-16,65,9999,Both,FALSE,9NCT02115282,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02085408,Eastern Cooperative Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT02085408,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],16-Sep-14,60,9999,Both,FALSE,17NCT02065687,Gynecologic Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02059265,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02059265,TRUE,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Female,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,IL,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT02003222,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02003222,TRUE,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],28-Jan-16,30,70,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01950390,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01903811,Southwest Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01856192,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01824875,Eastern Cooperative Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01824875,TRUE,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],7-May-15,18,9999,Both,FALSE,17NCT01814813,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT01814813,TRUE,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],26-Jan-16,18,9999,Both,FALSE,1NCT01809691,Southwest Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01781468,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT01781468,TRUE,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],13-Nov-15,18,9999,Both,FALSE,1NCT01674140,Southwest Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01668719,Southwest Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT01575548,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01416688,Southwest Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01416688,TRUE,"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride",Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity,Procedure:assessment of therapy complications; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],15-Oct-15,18,120,Both,FALSE,3NCT01415752,Eastern Cooperative Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01414608,Gynecologic Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01414608,TRUE,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],16-Jul-15,18,9999,Female,FALSE,14NCT01359592,Southwest Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01359592,TRUE,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],17-Nov-15,18,9999,Both,FALSE,3NCT01349881,Southwest Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01242800,Eastern Cooperative Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT01216683,Eastern Cooperative Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01216683,TRUE,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,18,9999,Both,FALSE,17NCT01169337,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01164228,Eastern Cooperative Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01164228,TRUE,Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,Kidney Cancer,Drug:gemcitabine hydrochloride; Drug:sunitinib malate,[],24-Jul-14,18,9999,Both,FALSE,17NCT02101788,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT01349881,Southwest Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT00565851,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,IN,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT00843882,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,IN,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01013649,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00807768,Gynecologic Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT02194738,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT01856192,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01535053,Gynecologic Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT01535053,TRUE,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,IN,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT00719303,Gynecologic Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02115282,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02019264,Eisai Inc.,FALSE,IN,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01622868,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01622868,TRUE,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],4-Feb-16,18,9999,Both,FALSE,9NCT01124695,Eastern Cooperative Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT01124695,TRUE,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],6-Dec-12,18,9999,Both,FALSE,17NCT02154490,Southwest Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02032823,AstraZeneca,FALSE,IN,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT02164916,Southwest Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,IN,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT00892866,Gynecologic Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT00892866,TRUE,"CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells",Atypical Endocervical Glandular Cell of Undetermined Significance; Atypical Endometrial Hyperplasia; Human Papillomavirus Infection; Stage 0 Cervical Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],13-Jul-15,18,9999,Female,FALSE,14NCT02406677,AstraZeneca,FALSE,IN,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02065687,Gynecologic Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01991795,AstraZeneca,FALSE,IN,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01975389,Pfizer,FALSE,IN,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,IN,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01674140,Southwest Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01242800,Eastern Cooperative Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT00936390,Radiation Therapy Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT02451137,Sanofi,FALSE,IN,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01808573,"Puma Biotechnology, Inc.",FALSE,IN,https://ClinicalTrials.gov/show/NCT01808573,TRUE,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],26-Jan-16,18,9999,Both,FALSE,166NCT01085630,Alliance for Clinical Trials in Oncology,FALSE,IN,https://ClinicalTrials.gov/show/NCT01085630,TRUE,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],3-Aug-15,18,9999,Both,FALSE,1NCT00430183,Alliance for Clinical Trials in Oncology,FALSE,IN,https://ClinicalTrials.gov/show/NCT00430183,TRUE,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],13-Mar-15,18,9999,Male,FALSE,1NCT01810913,Radiation Therapy Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT01810913,TRUE,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],14-Nov-15,18,9999,Both,FALSE,4NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,IN,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT00978458,Eastern Cooperative Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT00978458,TRUE,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],4-Dec-12,18,9999,Both,FALSE,17NCT02111564,"Janssen Research & Development, LLC",FALSE,IN,https://ClinicalTrials.gov/show/NCT02111564,TRUE,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],26-Jan-16,40,9999,Both,FALSE,132NCT02104817,AstraZeneca,FALSE,IN,https://ClinicalTrials.gov/show/NCT02104817,TRUE,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],21-Dec-15,18,99,Both,FALSE,13NCT01872975,NSABP Foundation Inc,FALSE,IN,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01781468,Alliance for Clinical Trials in Oncology,FALSE,IN,https://ClinicalTrials.gov/show/NCT01781468,TRUE,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],13-Nov-15,18,9999,Both,FALSE,1NCT02488967,NRG Oncology,FALSE,IN,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02488967,NRG Oncology,FALSE,IA,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02194738,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02115282,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01903811,Southwest Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01674140,Southwest Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01533207,Gynecologic Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01533207,TRUE,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],23-Dec-14,18,9999,Female,FALSE,14NCT01349881,Southwest Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,IA,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01120249,Southwest Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01107626,Eastern Cooperative Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT01101451,Gynecologic Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT02048813,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01950390,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01824875,Eastern Cooperative Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01824875,TRUE,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],7-May-15,18,9999,Both,FALSE,17NCT01575548,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,IA,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT01013649,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00887146,Alliance for Clinical Trials in Oncology,FALSE,IA,https://ClinicalTrials.gov/show/NCT00887146,TRUE,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],18-Dec-15,18,9999,Both,FALSE,1NCT00843882,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02311933,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02154490,Southwest Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT01079780,Pam Cogliano,FALSE,IA,https://ClinicalTrials.gov/show/NCT01079780,TRUE,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],19-Sep-14,18,9999,Both,FALSE,161NCT00492778,Gynecologic Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT00492778,TRUE,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],13-Jul-15,0,9999,Female,FALSE,14NCT02003209,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,IA,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT00565851,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02032823,AstraZeneca,FALSE,IA,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT01573442,Alliance for Clinical Trials in Oncology,FALSE,IA,https://ClinicalTrials.gov/show/NCT01573442,TRUE,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],3-Nov-15,18,9999,Female,FALSE,1NCT01415752,Eastern Cooperative Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01169337,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01124695,Eastern Cooperative Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01124695,TRUE,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],6-Dec-12,18,9999,Both,FALSE,17NCT02065687,Gynecologic Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,IA,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01242800,Eastern Cooperative Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT02101788,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT01835145,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01835145,TRUE,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],1-Feb-16,18,9999,Both,FALSE,9NCT01781468,Alliance for Clinical Trials in Oncology,FALSE,IA,https://ClinicalTrials.gov/show/NCT01781468,TRUE,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],13-Nov-15,18,9999,Both,FALSE,1NCT00828009,Eastern Cooperative Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT00828009,TRUE,BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,Lung Cancer,Biological:bevacizumab; Biological:emepepimut-S; Drug:carboplatin; Drug:cyclophosphamide; Drug:paclitaxel; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT01856192,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01668719,Southwest Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT00897767,Eastern Cooperative Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT00897767,TRUE,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],5-Dec-12,0,9999,Both,FALSE,17NCT00897442,Gynecologic Oncology Group,TRUE,IA,https://ClinicalTrials.gov/show/NCT00897442,TRUE,Collecting Tumor Samples From Patients With Gynecological Tumors,Cancer,Other:biologic sample preservation procedure,[],30-Aug-12,0,9999,Female,FALSE,14NCT00807768,Gynecologic Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,IA,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT02488967,NRG Oncology,FALSE,KS,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02194738,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02115282,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,KS,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT02003222,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT02003222,TRUE,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],28-Jan-16,30,70,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01950390,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,KS,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01903811,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01824875,Eastern Cooperative Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01824875,TRUE,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],7-May-15,18,9999,Both,FALSE,17NCT01809691,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01674140,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01649089,Gynecologic Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01649089,TRUE,Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Lymphedema; Sexual Dysfunction and Infertility; Stage IA Cervical Cancer; Stage IB Cervical Cancer,Procedure:Conization; Procedure:Loop Electrosurgical Excision; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01575548,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01533207,Gynecologic Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01533207,TRUE,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],23-Dec-14,18,9999,Female,FALSE,14NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,KS,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01416688,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01416688,TRUE,"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride",Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity,Procedure:assessment of therapy complications; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],15-Oct-15,18,120,Both,FALSE,3NCT01372787,Gynecologic Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01372787,TRUE,"Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:assessment of therapy complications; Procedure:cognitive assessment; Procedure:fatigue assessment and management; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],8-May-13,18,9999,Female,FALSE,14NCT01359592,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01359592,TRUE,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],17-Nov-15,18,9999,Both,FALSE,3NCT01349881,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01242800,Eastern Cooperative Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT01169337,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01164228,Eastern Cooperative Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01164228,TRUE,Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,Kidney Cancer,Drug:gemcitabine hydrochloride; Drug:sunitinib malate,[],24-Jul-14,18,9999,Both,FALSE,17NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,KS,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01124695,Eastern Cooperative Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01124695,TRUE,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],6-Dec-12,18,9999,Both,FALSE,17NCT01120249,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01085630,Alliance for Clinical Trials in Oncology,FALSE,KS,https://ClinicalTrials.gov/show/NCT01085630,TRUE,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],3-Aug-15,18,9999,Both,FALSE,1NCT01079780,Pam Cogliano,FALSE,KS,https://ClinicalTrials.gov/show/NCT01079780,TRUE,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],19-Sep-14,18,9999,Both,FALSE,161NCT01013649,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00897767,Eastern Cooperative Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT00897767,TRUE,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],5-Dec-12,0,9999,Both,FALSE,17NCT00807768,Gynecologic Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT00719303,Gynecologic Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT00700882,Eastern Cooperative Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT00700882,TRUE,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],16-Sep-14,18,9999,Both,FALSE,17NCT00565851,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00492778,Gynecologic Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT00492778,TRUE,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],13-Jul-15,0,9999,Female,FALSE,14NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,KS,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02154490,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02143414,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT02143414,TRUE,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],15-Jan-16,65,9999,Both,FALSE,9NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,KS,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT01668719,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT00840177,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT00840177,TRUE,"S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia",Leukemia,Drug:cytarabine; Drug:idarubicin; Drug:pravastatin sodium,[],25-Sep-15,18,9999,Both,FALSE,3NCT00316888,Eastern Cooperative Oncology Group,TRUE,KS,https://ClinicalTrials.gov/show/NCT00316888,TRUE,"Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",Anal Cancer,Biological:cetuximab; Drug:cisplatin; Drug:fluorouracil; Radiation:radiation therapy,[],22-Aug-12,18,9999,Both,FALSE,17NCT00074282,Eastern Cooperative Oncology Group,TRUE,KS,https://ClinicalTrials.gov/show/NCT00074282,TRUE,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],9-Nov-12,18,9999,Both,FALSE,17NCT02562716,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT02562716,TRUE,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],26-Jan-16,18,75,Both,FALSE,3NCT01272037,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02488967,NRG Oncology,FALSE,KY,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02194738,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01674140,Southwest Oncology Group,FALSE,KY,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,KY,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT02315469,NRG Oncology,FALSE,KY,https://ClinicalTrials.gov/show/NCT02315469,TRUE,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],13-Jul-15,70,9999,Female,FALSE,159NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,KY,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT02115282,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01781468,Alliance for Clinical Trials in Oncology,FALSE,KY,https://ClinicalTrials.gov/show/NCT01781468,TRUE,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],13-Nov-15,18,9999,Both,FALSE,1NCT01573442,Alliance for Clinical Trials in Oncology,FALSE,KY,https://ClinicalTrials.gov/show/NCT01573442,TRUE,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],3-Nov-15,18,9999,Female,FALSE,1NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,KY,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT01120249,Southwest Oncology Group,FALSE,KY,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,KY,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT01814813,Alliance for Clinical Trials in Oncology,FALSE,KY,https://ClinicalTrials.gov/show/NCT01814813,TRUE,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],26-Jan-16,18,9999,Both,FALSE,1NCT01349881,Southwest Oncology Group,FALSE,KY,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT00565851,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02451137,Sanofi,FALSE,KY,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02438722,Southwest Oncology Group,FALSE,KY,https://ClinicalTrials.gov/show/NCT02438722,TRUE,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],1-Sep-15,0,9999,Both,FALSE,3NCT02311933,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,KY,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02048813,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,KY,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01575548,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT00887146,Alliance for Clinical Trials in Oncology,FALSE,KY,https://ClinicalTrials.gov/show/NCT00887146,TRUE,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],18-Dec-15,18,9999,Both,FALSE,1NCT02601209,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT02601209,TRUE,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02101788,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT01872975,NSABP Foundation Inc,FALSE,KY,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01808573,"Puma Biotechnology, Inc.",FALSE,KY,https://ClinicalTrials.gov/show/NCT01808573,TRUE,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],26-Jan-16,18,9999,Both,FALSE,166NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,KY,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT00858364,Amgen,FALSE,KY,https://ClinicalTrials.gov/show/NCT00858364,TRUE,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],27-Jan-16,18,9999,Both,FALSE,16NCT02048917,University of Kentucky,FALSE,KY,https://ClinicalTrials.gov/show/NCT02048917,TRUE,Smoking Cessation Strategies in Community Cancer Programs for Lung and Head and Neck Cancer Patients,Lung Cancer; Head and Neck Cancer,Drug:High Intensity Counseling + Long Acting NRT + PRN NRT; Drug:High Intensity Counseling + bupropion + PRN NRT; Drug:High Intensity Counseling + varenicline + PRN NRT; Drug:High Intensity Counseling + Long Acting NRT; Drug:High Intensity Counseling + bupropion; Drug:High Intensity Counseling + varenicline; Drug:Low Intensity Counseling + Long Acting NRT + PRN NRT; Drug:Low Intensity Counseling + bupropion + PRN NRT; Drug:Low Intensity Counseling + varenicline + PRN NRT; Drug:Low Intensity Counseling + Long Acting NRT; Drug:Low Intensity Counseling + bupropion; Drug:Low Intensity Counseling + varenicline,"[u""King's Daughters Medical Center"", u'Hardin Memorial Health Cancer Care Center', u'ARH Cancer Center', u'Kentucky Cancer Clinic', u'University Of Kentucky, Markey Cancer Center', u'University of Louisville, James Graham Brown Cancer Center', u'St. Claire Regional Medical Center']",6-Jan-16,18,9999,Both,FALSE,202NCT01966107,AstraZeneca,FALSE,KY,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01845025,Novartis Pharmaceuticals,FALSE,KY,https://ClinicalTrials.gov/show/NCT01845025,TRUE,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],3-Feb-16,12,9999,Both,FALSE,156NCT01389596,Pfizer,FALSE,KY,https://ClinicalTrials.gov/show/NCT01389596,TRUE,A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years,"Epilepsy, Partial Seizures",Drug:Pregabalin add-on therapy; Drug:Pregabalin add-on therapy; Drug:Pregabalin add-on therapy,[],8-Jan-16,4,16,Both,FALSE,10NCT02072226,"Genentech, Inc.",FALSE,KY,https://ClinicalTrials.gov/show/NCT02072226,TRUE,A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS),Brain Ischemia,Drug:alteplase [Activase]; Drug:alteplase placebo; Drug:aspirin; Drug:aspirin placebo,[],1-Feb-16,18,9999,Both,FALSE,113NCT01991795,AstraZeneca,FALSE,KY,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01877915,"Janssen Research & Development, LLC",FALSE,KY,https://ClinicalTrials.gov/show/NCT01877915,TRUE,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],26-Jan-16,18,95,Both,FALSE,132NCT01663402,Sanofi,FALSE,KY,https://ClinicalTrials.gov/show/NCT01663402,TRUE,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],3-Feb-16,40,9999,Both,FALSE,12NCT01649089,Gynecologic Oncology Group,FALSE,KY,https://ClinicalTrials.gov/show/NCT01649089,TRUE,Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Lymphedema; Sexual Dysfunction and Infertility; Stage IA Cervical Cancer; Stage IB Cervical Cancer,Procedure:Conization; Procedure:Loop Electrosurgical Excision; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01594333,Brigham and Women's Hospital,FALSE,KY,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01463306,Pfizer,FALSE,KY,https://ClinicalTrials.gov/show/NCT01463306,TRUE,A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures,"Epilepsy, Partial Seizures; Epilepsy, Primary Generalized Tonic-Clonic Seizures",Drug:Pregabalin,[],20-Jan-16,1,65,Both,FALSE,10NCT01312909,Pfizer,FALSE,KY,https://ClinicalTrials.gov/show/NCT01312909,TRUE,Smoking Cessation Study In Healthy Adolescent Smokers,Smoking Cessation,Drug:Varenicline 1mg BID; Drug:Varenicline 0.5mg BID; Drug:Placebo,[],3-Feb-16,12,19,Both,FALSE,10NCT01274338,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT00807768,Gynecologic Oncology Group,FALSE,KY,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT02671981,Radiation Therapy Oncology Group,FALSE,KY,https://ClinicalTrials.gov/show/NCT02671981,TRUE,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],2-Feb-16,18,9999,Both,FALSE,4NCT01272037,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01674140,Southwest Oncology Group,FALSE,LA,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,LA,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02488967,NRG Oncology,FALSE,LA,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02111564,"Janssen Research & Development, LLC",FALSE,LA,https://ClinicalTrials.gov/show/NCT02111564,TRUE,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],26-Jan-16,40,9999,Both,FALSE,132NCT01991795,AstraZeneca,FALSE,LA,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01966107,AstraZeneca,FALSE,LA,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,LA,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT02451137,Sanofi,FALSE,LA,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02194738,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT01349881,Southwest Oncology Group,FALSE,LA,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01975389,Pfizer,FALSE,LA,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,LA,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01107626,Eastern Cooperative Oncology Group,FALSE,LA,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT02115282,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01274338,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,LA,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01594333,Brigham and Women's Hospital,FALSE,LA,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT02406677,AstraZeneca,FALSE,LA,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02387359,Synergy Pharmaceuticals Inc.,FALSE,LA,https://ClinicalTrials.gov/show/NCT02387359,TRUE,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],10-Dec-15,18,85,Both,FALSE,183NCT02164513,GlaxoSmithKline,FALSE,LA,https://ClinicalTrials.gov/show/NCT02164513,TRUE,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],4-Feb-16,40,9999,Both,FALSE,8NCT01920711,Novartis Pharmaceuticals,FALSE,LA,https://ClinicalTrials.gov/show/NCT01920711,TRUE,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],14-Oct-15,50,9999,Both,FALSE,156NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,LA,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01858532,AbbVie,FALSE,LA,https://ClinicalTrials.gov/show/NCT01858532,TRUE,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],20-Jan-16,18,85,Both,FALSE,51NCT01845025,Novartis Pharmaceuticals,FALSE,LA,https://ClinicalTrials.gov/show/NCT01845025,TRUE,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],3-Feb-16,12,9999,Both,FALSE,156NCT01809691,Southwest Oncology Group,FALSE,LA,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01652872,Amgen,FALSE,LA,https://ClinicalTrials.gov/show/NCT01652872,TRUE,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],9-Dec-15,18,9999,Both,FALSE,16NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,LA,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01169337,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02504216,Bayer,FALSE,LA,https://ClinicalTrials.gov/show/NCT02504216,TRUE,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],1-Feb-16,50,9999,Both,FALSE,23NCT02239120,Boehringer Ingelheim,FALSE,LA,https://ClinicalTrials.gov/show/NCT02239120,TRUE,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],26-Jan-16,18,150,Both,FALSE,75NCT02164916,Southwest Oncology Group,FALSE,LA,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT01950390,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01919697,Synergy Pharmaceuticals Inc.,FALSE,LA,https://ClinicalTrials.gov/show/NCT01919697,TRUE,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],10-Dec-15,18,81,Both,FALSE,183NCT01663402,Sanofi,FALSE,LA,https://ClinicalTrials.gov/show/NCT01663402,TRUE,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],3-Feb-16,40,9999,Both,FALSE,12NCT01079780,Pam Cogliano,FALSE,LA,https://ClinicalTrials.gov/show/NCT01079780,TRUE,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],19-Sep-14,18,9999,Both,FALSE,161NCT00858364,Amgen,FALSE,LA,https://ClinicalTrials.gov/show/NCT00858364,TRUE,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],27-Jan-16,18,9999,Both,FALSE,16NCT00807768,Gynecologic Oncology Group,FALSE,LA,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT02528188,Pfizer,FALSE,LA,https://ClinicalTrials.gov/show/NCT02528188,TRUE,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],19-Jan-16,18,9999,Both,FALSE,10NCT02182830,Boehringer Ingelheim,FALSE,LA,https://ClinicalTrials.gov/show/NCT02182830,TRUE,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],26-Jan-16,18,9999,Both,FALSE,75NCT02048813,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,LA,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01877915,"Janssen Research & Development, LLC",FALSE,LA,https://ClinicalTrials.gov/show/NCT01877915,TRUE,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],26-Jan-16,18,95,Both,FALSE,132NCT01870778,Novartis Pharmaceuticals,FALSE,LA,https://ClinicalTrials.gov/show/NCT01870778,TRUE,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],16-Sep-15,18,9999,Both,FALSE,156NCT01701817,"Janssen Scientific Affairs, LLC",FALSE,LA,https://ClinicalTrials.gov/show/NCT01701817,TRUE,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],7-Jan-16,21,9999,Both,FALSE,133NCT01085630,Alliance for Clinical Trials in Oncology,FALSE,LA,https://ClinicalTrials.gov/show/NCT01085630,TRUE,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],3-Aug-15,18,9999,Both,FALSE,1NCT00632853,Alliance for Clinical Trials in Oncology,FALSE,LA,https://ClinicalTrials.gov/show/NCT00632853,TRUE,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],10-Aug-15,18,9999,Both,FALSE,1NCT00565851,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02155296,RAND,FALSE,ME,https://ClinicalTrials.gov/show/NCT02155296,TRUE,RCT of the Restorative Practices Intervention,Intervention Schools (Schools Receiving RPI); Control Schools (Schools Not Receiving RPI),Behavioral:Restorative Practices Intervention,"[u'Bath Middle School', u'Boothbay school', u'Bucksport school', u'Bonny Eagle school', u'Ridge View school', u'Hall-Dale school', u'Molly Ockett', u'Gorham school', u'Hope school', u'Jefferson Village school', u'Mt. Jefferson school', u'Libby school', u'Maranacook school', u'Oak Hill school', u'Skowhegan school', u'Windham school']",27-Oct-15,12,9999,Both,TRUE,167NCT02194738,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02154490,Southwest Oncology Group,FALSE,ME,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02032823,AstraZeneca,FALSE,ME,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,ME,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01674140,Southwest Oncology Group,FALSE,ME,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02115282,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02019264,Eisai Inc.,FALSE,ME,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01663402,Sanofi,FALSE,ME,https://ClinicalTrials.gov/show/NCT01663402,TRUE,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],3-Feb-16,40,9999,Both,FALSE,12NCT01594333,Brigham and Women's Hospital,FALSE,ME,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,ME,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01120249,Southwest Oncology Group,FALSE,ME,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT02488967,NRG Oncology,FALSE,ME,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02048813,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01950390,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,ME,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT02562716,Southwest Oncology Group,FALSE,ME,https://ClinicalTrials.gov/show/NCT02562716,TRUE,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],26-Jan-16,18,75,Both,FALSE,3NCT02438722,Southwest Oncology Group,FALSE,ME,https://ClinicalTrials.gov/show/NCT02438722,TRUE,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],1-Sep-15,0,9999,Both,FALSE,3NCT02311933,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,ME,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02152982,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT02152982,TRUE,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01991795,AstraZeneca,FALSE,ME,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01975389,Pfizer,FALSE,ME,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,ME,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,ME,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01903811,Southwest Oncology Group,FALSE,ME,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,ME,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT01809691,Southwest Oncology Group,FALSE,ME,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01772472,Hoffmann-La Roche,FALSE,ME,https://ClinicalTrials.gov/show/NCT01772472,TRUE,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),Breast Cancer,Drug:trastuzumab; Drug:trastuzumab emtansine,[],1-Feb-16,18,9999,Both,FALSE,119NCT01415752,Eastern Cooperative Oncology Group,FALSE,ME,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01311336,University of Vermont,FALSE,ME,https://ClinicalTrials.gov/show/NCT01311336,TRUE,Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain,Pegfilgrastim-induced Back and Leg Pain,Drug:Loratadine; Drug:placebo,"[u'Cancer Care of Maine', u'Maine Center for Cancer Medicine', u'York Hospital', u'CR Wood Cancer Center', u'Mountainview Medical Center', u'Vermont Cancer Center', u'Vermont Center for Cancer Medicine']",23-Jan-13,18,9999,Both,FALSE,45NCT01286272,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT01286272,TRUE,Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,Grade 3a Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma,Drug:Bendamustine Hydrochloride; Drug:Bortezomib; Radiation:Fludeoxyglucose F-18; Other:Laboratory Biomarker Analysis; Biological:Ofatumumab; Procedure:Positron Emission Tomography with Radiolabeled Targeting Agent,[],3-Feb-16,18,9999,Both,FALSE,9NCT00048958,Alliance for Clinical Trials in Oncology,TRUE,ME,https://ClinicalTrials.gov/show/NCT00048958,TRUE,Cytogenetic Studies in Acute Leukemia and Multiple Myeloma,Acute Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Multiple Myeloma,Genetic:cytogenetic analysis,[],6-Aug-15,18,9999,Both,FALSE,1NCT02670083,Hoffmann-La Roche,FALSE,ME,https://ClinicalTrials.gov/show/NCT02670083,TRUE,"CREAD Study"" A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)",Alzheimer's Disease,Drug:Crenezumab; Drug:Placebo,[],3-Feb-16,50,85,Both,FALSE,119NCT02406677,AstraZeneca,FALSE,ME,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02180867,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT02180867,TRUE,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],1-Feb-16,2,9999,Both,FALSE,9NCT02173379,Abbott Vascular,FALSE,ME,https://ClinicalTrials.gov/show/NCT02173379,TRUE,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],17-Jul-15,18,9999,Both,FALSE,50NCT02112916,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT02112916,TRUE,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],28-Jan-16,2,30,Both,FALSE,9NCT02085408,Eastern Cooperative Oncology Group,FALSE,ME,https://ClinicalTrials.gov/show/NCT02085408,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],16-Sep-14,60,9999,Both,FALSE,17NCT02065791,"Janssen Research & Development, LLC",FALSE,ME,https://ClinicalTrials.gov/show/NCT02065791,TRUE,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],5-Jan-16,30,9999,Both,FALSE,132NCT02027428,Celgene Corporation,FALSE,ME,https://ClinicalTrials.gov/show/NCT02027428,TRUE,Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer,"Squamous Cell Carcinoma, Non-Small-Cell Lung",Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Drug:Abraxane (Maintenance); Other:Best Supportive Care (Maintenance); Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Other:Best Supportive Care (Maintenance),[],8-Dec-15,18,9999,Both,FALSE,86NCT02003209,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01966107,AstraZeneca,FALSE,ME,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01877915,"Janssen Research & Development, LLC",FALSE,ME,https://ClinicalTrials.gov/show/NCT01877915,TRUE,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],26-Jan-16,18,95,Both,FALSE,132NCT01858532,AbbVie,FALSE,ME,https://ClinicalTrials.gov/show/NCT01858532,TRUE,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],20-Jan-16,18,85,Both,FALSE,51NCT01674140,Southwest Oncology Group,FALSE,MD,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01272037,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02194738,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02488967,NRG Oncology,FALSE,MD,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT01594333,Brigham and Women's Hospital,FALSE,MD,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT02019264,Eisai Inc.,FALSE,MD,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT02406677,AstraZeneca,FALSE,MD,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT01991795,AstraZeneca,FALSE,MD,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01975389,Pfizer,FALSE,MD,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,MD,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT00858364,Amgen,FALSE,MD,https://ClinicalTrials.gov/show/NCT00858364,TRUE,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],27-Jan-16,18,9999,Both,FALSE,16NCT02154490,Southwest Oncology Group,FALSE,MD,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,MD,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT00936390,Radiation Therapy Oncology Group,FALSE,MD,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT02115282,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,MD,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01107626,Eastern Cooperative Oncology Group,FALSE,MD,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT02673190,Radiation Therapy Oncology Group,FALSE,MD,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02364999,Pfizer,FALSE,MD,https://ClinicalTrials.gov/show/NCT02364999,TRUE,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,Non-small Cell Lung Cancer (NSCLC),Drug:Bevacizumab-Pfizer; Drug:Bevacizumab-EU; Drug:Paclitaxel; Drug:Carboplatin,[],5-Jan-16,18,9999,Both,FALSE,10NCT02254577,Shady Grove Fertility Reproductive Science Center,TRUE,MD,https://ClinicalTrials.gov/show/NCT02254577,TRUE,Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer,Infertility,Drug:Endometrin Only; Drug:Endometrin plus Progesterone in Oil (PIO); Drug:Progesterone in Oil (PIO) Only,"[u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center']",17-Nov-15,18,48,Female,FALSE,39NCT02032823,AstraZeneca,FALSE,MD,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,MD,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01872975,NSABP Foundation Inc,FALSE,MD,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01242800,Eastern Cooperative Oncology Group,FALSE,MD,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT00807768,Gynecologic Oncology Group,FALSE,MD,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT02111564,"Janssen Research & Development, LLC",FALSE,MD,https://ClinicalTrials.gov/show/NCT02111564,TRUE,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],26-Jan-16,40,9999,Both,FALSE,132NCT02075047,Pfizer,FALSE,MD,https://ClinicalTrials.gov/show/NCT02075047,TRUE,Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder,Bipolar Disorder,Drug:placebo oral capsules; Drug:ziprasidone oral capsules,[],16-Jan-16,10,17,Both,FALSE,10NCT01663402,Sanofi,FALSE,MD,https://ClinicalTrials.gov/show/NCT01663402,TRUE,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],3-Feb-16,40,9999,Both,FALSE,12NCT01101035,Takeda,TRUE,MD,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT00843882,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT00565851,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00351611,Pfizer,FALSE,MD,https://ClinicalTrials.gov/show/NCT00351611,TRUE,Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo,"Epilepsies, Partial",Drug:Lyrica (pregabalin); Drug:placebo,[],19-Jan-16,18,65,Both,FALSE,10NCT02251366,Johns Hopkins University,FALSE,MD,https://ClinicalTrials.gov/show/NCT02251366,TRUE,NVAMD Satellite Study,Neovascular Age Related Macular Degeneration,Procedure:Physician-guided diagnostic,"[u'Wilmer Eye Institute', u'Wilmer Eye Institute', u'Wilmer Eye Institute', u'Wilmer Eye Institute', u'Wilmer Eye Institute']",7-Sep-15,18,9999,Both,TRUE,135NCT02187003,Pfizer,FALSE,MD,https://ClinicalTrials.gov/show/NCT02187003,TRUE,Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease,"Anemia, Sickle Cell",Drug:Rivipansel; Other:Placebo,[],8-Jan-16,6,9999,Both,FALSE,10NCT02164916,Southwest Oncology Group,FALSE,MD,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02125461,AstraZeneca,FALSE,MD,https://ClinicalTrials.gov/show/NCT02125461,TRUE,A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Drug:MEDI4736; Other:PLACEBO,[],11-Jan-16,18,130,Both,FALSE,13NCT02114203,Pfizer,FALSE,MD,https://ClinicalTrials.gov/show/NCT02114203,TRUE,"Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease",Phase 1 Sickle Cell,Drug:PDE9i; Drug:PDE9i; Drug:placebo for PDE9i; Drug:PDE9i,[],1-Feb-16,18,65,Both,FALSE,10NCT02066636,Bristol-Myers Squibb,FALSE,MD,https://ClinicalTrials.gov/show/NCT02066636,TRUE,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],26-Jan-16,18,9999,Both,FALSE,80NCT02047097,Biogen,FALSE,MD,https://ClinicalTrials.gov/show/NCT02047097,TRUE,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],31-Jul-15,18,9999,Both,FALSE,73NCT01997333,Celldex Therapeutics,FALSE,MD,https://ClinicalTrials.gov/show/NCT01997333,TRUE,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.,Drug:CDX-011; Drug:Capecitabine,[],5-Nov-15,18,9999,Both,FALSE,87NCT01966107,AstraZeneca,FALSE,MD,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01946204,"Aragon Pharmaceuticals, Inc.",FALSE,MD,https://ClinicalTrials.gov/show/NCT01946204,TRUE,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],19-Jan-16,18,9999,Male,FALSE,64NCT01855750,"Janssen Research & Development, LLC",FALSE,MD,https://ClinicalTrials.gov/show/NCT01855750,TRUE,"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",Lymphoma,Drug:Ibrutinib; Drug:Placebo; Drug:Rituximab; Drug:Cyclophosphamide; Drug:Doxorubicin; Drug:Vincristine; Drug:Prednisone (or equivalent),[],19-Jan-16,18,9999,Both,FALSE,132NCT01272037,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02194738,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,MA,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01674140,Southwest Oncology Group,FALSE,MA,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01594333,Brigham and Women's Hospital,FALSE,MA,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,MA,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01274338,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,MA,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT00936390,Radiation Therapy Oncology Group,FALSE,MA,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT02154490,Southwest Oncology Group,FALSE,MA,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT01238588,Brigham and Women's Hospital,FALSE,MA,https://ClinicalTrials.gov/show/NCT01238588,TRUE,The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan,Dialysis; Cardiovascular Disease; Atherosclerosis; Inflammation; Hyperphosphatemia,Drug:Sevelamer Carbonate (Renvela),"[u""Brigham and Women's Hospital"", u'BWH/FH/DCI Outpatient Dialysis Unit', u'Fresenius Boston-TKC', u'Fresenius Framingham (#1109)', u'Fresenius Marlborough (#3448)', u'Fresenius Medford Dialysis (#1246)', u'Fresenius Quincy (#1610)', u'Fresenius Roxbury (#1630)', u'DCI Dialysis Unit-Somerville', u'Fresenius QCDC-Weymouth (#9144)']",5-Oct-15,50,9999,Both,FALSE,79NCT00251875,Agency for Healthcare Research and Quality (AHRQ),FALSE,MA,https://ClinicalTrials.gov/show/NCT00251875,TRUE,Shared Online Health Records for Patient Safety and Care,Diabetes,Device:online health information journal,"[u'Beacon Hill/Downtown Primary Care', u'Bulfinch Medical Group', u""Massachusetts General Hospital Women's Health Associates"", u'Charlestown Health Center', u""Brigham & Women's Physicians Group"", u""Brigham & Women's Hospital Women's Health Center"", u'Brigham Primary Physicians at Faulkner', u'Southern Jamaica Plain Health Center', u""Brigham & Women's Hospital at Norwood"", u'Revere Health Center']",9-Nov-05,18,9999,Both,TRUE,56NCT02060630,New England Research Institutes,FALSE,MA,https://ClinicalTrials.gov/show/NCT02060630,TRUE,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],7-Dec-15,18,9999,Both,FALSE,33NCT02048813,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01817660,Boston University,FALSE,MA,https://ClinicalTrials.gov/show/NCT01817660,TRUE,Open Versus Endovascular Repair of Popliteal Artery Aneurysm Trial,Popliteal Artery Aneurysm.,Procedure:Open repair of popliteal artery; Procedure:Endovascular repair of popliteal artery,"[u'Danbury Hospital', u'Hartford Hospital', u'Yale-New Haven Hospital', u'Indiana University Medical Center', u'LSU Medical Center', u'Maine Medical Center', u""Brigham and Women's Hospital"", u'BI-Deaconess Hospital', u'Boston Medical Center', u'Massachusetts General Hospital', u'Tufts Medical Center', u'St. Elizabeth Hospital', u'Charlton Memorial Hospital/St. Anne', u'Bay State Medical Center', u'Henry Ford Hospital', u'Dartmouth Medical Center', u'Cardiothoracic Surgical Associates, PA', u'Albany Medical Center', u'Rhode Island Hospital', u'Fletcher Allen Healthcare', u'University of Virginia Health Center']",28-Mar-13,35,9999,Both,FALSE,78NCT02671981,Radiation Therapy Oncology Group,FALSE,MA,https://ClinicalTrials.gov/show/NCT02671981,TRUE,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],2-Feb-16,18,9999,Both,FALSE,4NCT02359084,Boston University,FALSE,MA,https://ClinicalTrials.gov/show/NCT02359084,TRUE,"Project EARLY: Engagement, Assessment, Referral, & Linkage for Young Children",Autism; Developmental Delay Disorders,Behavioral:Family Navigation; Behavioral:Conventional Care Management,"[u'Yale University School of Medicine', u'Boston University School of Public Health', u'South End Community Health Center', u'Dorchester House Multi-Service Center', u'Codman Square Health Center', u'East Boston Neighborhood Health Center', u'Boston Medical Center', u'MGH Chelsea', u""Children's Hospital of Philadelphia""]",28-Jul-15,15,27,Both,FALSE,78NCT02019264,Eisai Inc.,FALSE,MA,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01947283,Cambridge Health Alliance,FALSE,MA,https://ClinicalTrials.gov/show/NCT01947283,TRUE,"Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation",Mental Disorders,Behavioral:DECIDE-PA; Behavioral:DECIDE-PC,"[u'South Cove Community Health Center', u""Children's Hospital Boston (Martha Elliot Health Center)"", u'Beth Israel Deaconess Medical Center (Ambulatory Psychiatry Unit)', u'Beth Israel Deaconess Medical Center (Latino Mental Health)', u'Cambridge Health Alliance (Windsor Clinic, Macht Building, Central Street, Malden Primary Care Mental Health)', u'Harbor Health Services, Inc. (Geiger Gibson Community Health Center and Neponset Health Center)', u'Edward M Kennedy Health Center (Great Brook Valley Health Center)']",4-May-15,18,80,Both,FALSE,83NCT01853748,Dana-Farber Cancer Institute,FALSE,MA,https://ClinicalTrials.gov/show/NCT01853748,TRUE,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),Breast Cancer,Drug:Trastuzumab; Drug:Paclitaxel; Drug:Trastuzumab emtansine,[],3-Feb-16,18,9999,Both,FALSE,96NCT01809691,Southwest Oncology Group,FALSE,MA,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01672892,Radiation Therapy Oncology Group,FALSE,MA,https://ClinicalTrials.gov/show/NCT01672892,TRUE,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],14-Nov-15,18,9999,Female,FALSE,4NCT01516216,Dana-Farber Cancer Institute,FALSE,MA,https://ClinicalTrials.gov/show/NCT01516216,TRUE,Study of Vitamin D in Untreated Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug:FOLFOX + bevacizumab; Dietary Supplement:Vitamin D; Dietary Supplement:Vitamin D,"[u""Mountain States Tumor Institute at St. Luke's Regional Medical Center"", u'Mountain States Tumor Institute- Fruitland', u'Mountain States Tumor Institute - Meridian', u'Mountain States Tumor Institute- Nampa', u'Mountain States Tumor Institute- Twin Falls', u'The Robert H. Lurie Comprehensive Cancer Center of Northwestern University', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'Lowell General Hospital', u""Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center"", u'Newton-Wellesley Hospital', u""Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital"", u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'Dana-Farber/New Hampshire Oncology-Hematology', u'Vanderbilt-Ingram Cancer Center']",10-Jan-16,18,9999,Both,FALSE,96NCT01013649,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02509078,Massachusetts General Hospital,FALSE,MA,https://ClinicalTrials.gov/show/NCT02509078,TRUE,Reevaluation Of Systemic Early Neuromuscular Blockade,Acute Respiratory Distress Syndrome,Drug:cisastracurium besylate,[],19-Jan-16,18,9999,Both,FALSE,140NCT02488967,NRG Oncology,FALSE,MA,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT01991795,AstraZeneca,FALSE,MA,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01975389,Pfizer,FALSE,MA,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,MA,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01920711,Novartis Pharmaceuticals,FALSE,MA,https://ClinicalTrials.gov/show/NCT01920711,TRUE,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],14-Oct-15,50,9999,Both,FALSE,156NCT01858532,AbbVie,FALSE,MA,https://ClinicalTrials.gov/show/NCT01858532,TRUE,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],20-Jan-16,18,85,Both,FALSE,51NCT00858364,Amgen,FALSE,MA,https://ClinicalTrials.gov/show/NCT00858364,TRUE,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],27-Jan-16,18,9999,Both,FALSE,16NCT00042289,National Institute of Allergy and Infectious Diseases (NIAID),TRUE,MA,https://ClinicalTrials.gov/show/NCT00042289,TRUE,Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy,HIV Infections,Drug:Current ARV medications; Drug:Current TB medications; Drug:Current hormonal contraceptive medications,[],2-Sep-15,0,9999,Female,FALSE,7NCT02673190,Radiation Therapy Oncology Group,FALSE,MA,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02477618,Sage Therapeutics,FALSE,MA,https://ClinicalTrials.gov/show/NCT02477618,TRUE,A Study With SAGE-547 for Super-Refractory Status Epilepticus,Super-Refractory Status Epilepticus,Drug:SAGE-547; Drug:Placebo,[],28-Jan-16,2,9999,Both,FALSE,172NCT02239120,Boehringer Ingelheim,FALSE,MA,https://ClinicalTrials.gov/show/NCT02239120,TRUE,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],26-Jan-16,18,150,Both,FALSE,75NCT02233946,Children's Hospital Boston,TRUE,MA,https://ClinicalTrials.gov/show/NCT02233946,TRUE,Computerized Alcohol Screening for Children and Adolescents (cASCA) in Primary Care,Prevention Harmful Effects,Behavioral:computer-facilitated brief intervention,"[u'Tufts Medical Center', u'Boston Childrens Primary Care Center', u'Longwood Pediatrics', u'East Boston Neighborhood Health Center', u'Lexington Pediatrics']",5-Feb-15,9,18,Both,TRUE,25NCT02065687,Gynecologic Oncology Group,FALSE,MA,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02047097,Biogen,FALSE,MA,https://ClinicalTrials.gov/show/NCT02047097,TRUE,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],31-Jul-15,18,9999,Both,FALSE,73NCT01950390,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01870778,Novartis Pharmaceuticals,FALSE,MA,https://ClinicalTrials.gov/show/NCT01870778,TRUE,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],16-Sep-15,18,9999,Both,FALSE,156NCT01827787,Dana-Farber Cancer Institute,FALSE,MA,https://ClinicalTrials.gov/show/NCT01827787,TRUE,Eribulin in HER2 Negative Metastatic BrCa,Breast Cancer,Drug:Eribulin,"[u'Eastern Maine Medical Center', u'Dana-Farber Cancer Institute at Faulkner Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'DF/BWCC at Milford Regional Cancer Center', u'South Shore Hospital', u'Dana-Farber/New Hampshire Oncology-Hematology']",26-Jan-16,18,9999,Both,FALSE,96NCT01751906,Abbott Vascular,FALSE,MA,https://ClinicalTrials.gov/show/NCT01751906,TRUE,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],11-Oct-15,18,9999,Both,FALSE,50NCT01674842,Dana-Farber Cancer Institute,FALSE,MA,https://ClinicalTrials.gov/show/NCT01674842,TRUE,Cisplatin + RT for Triple Negative Breast Cancer,Breast Cancer,Radiation:Radiation Therapy; Drug:Cisplatin,"[u'Massachusetts General Hospital', u""Brigham and Women's Hospital"", u'Dana-Farber Cancer Institute', u'Dana-Farber at Milford', u'Dana Farber at South Shore Hospital']",19-Jan-16,18,9999,Both,FALSE,96NCT02673190,Radiation Therapy Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02488967,NRG Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02311933,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02194738,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02115282,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02101788,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT02085408,Eastern Cooperative Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT02085408,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],16-Sep-14,60,9999,Both,FALSE,17NCT02065687,Gynecologic Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02048813,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,MI,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT02003222,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT02003222,TRUE,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],28-Jan-16,30,70,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01950390,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01903811,Southwest Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01856192,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01824875,Eastern Cooperative Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01824875,TRUE,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],7-May-15,18,9999,Both,FALSE,17NCT01809691,Southwest Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01674140,Southwest Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01668719,Southwest Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT01622868,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01622868,TRUE,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],4-Feb-16,18,9999,Both,FALSE,9NCT01575548,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01415752,Eastern Cooperative Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01349881,Southwest Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01242800,Eastern Cooperative Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT01169337,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01120249,Southwest Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01107626,Eastern Cooperative Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT01041703,Eastern Cooperative Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01041703,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],24-Jul-14,60,9999,Both,FALSE,17NCT01013649,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00936390,Radiation Therapy Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT00843882,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT00719303,Gynecologic Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT00565851,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00492778,Gynecologic Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT00492778,TRUE,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],13-Jul-15,0,9999,Female,FALSE,14NCT00430183,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT00430183,TRUE,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],13-Mar-15,18,9999,Male,FALSE,1NCT01101451,Gynecologic Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01079780,Pam Cogliano,FALSE,MI,https://ClinicalTrials.gov/show/NCT01079780,TRUE,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],19-Sep-14,18,9999,Both,FALSE,161NCT00897767,Eastern Cooperative Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT00897767,TRUE,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],5-Dec-12,0,9999,Both,FALSE,17NCT02406677,AstraZeneca,FALSE,MI,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02488967,NRG Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02315469,NRG Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT02315469,TRUE,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],13-Jul-15,70,9999,Female,FALSE,159NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02194738,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02059265,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT02059265,TRUE,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Female,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,MN,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT02003209,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01903811,Southwest Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01856192,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01835145,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01835145,TRUE,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],1-Feb-16,18,9999,Both,FALSE,9NCT01824875,Eastern Cooperative Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01824875,TRUE,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],7-May-15,18,9999,Both,FALSE,17NCT01814813,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT01814813,TRUE,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],26-Jan-16,18,9999,Both,FALSE,1NCT01674140,Southwest Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01668719,Southwest Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT01649089,Gynecologic Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01649089,TRUE,Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Lymphedema; Sexual Dysfunction and Infertility; Stage IA Cervical Cancer; Stage IB Cervical Cancer,Procedure:Conization; Procedure:Loop Electrosurgical Excision; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT01535053,Gynecologic Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01535053,TRUE,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01415752,Eastern Cooperative Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01372787,Gynecologic Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01372787,TRUE,"Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:assessment of therapy complications; Procedure:cognitive assessment; Procedure:fatigue assessment and management; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],8-May-13,18,9999,Female,FALSE,14NCT01359592,Southwest Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01359592,TRUE,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],17-Nov-15,18,9999,Both,FALSE,3NCT01349881,Southwest Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01242800,Eastern Cooperative Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT01216683,Eastern Cooperative Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01216683,TRUE,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,18,9999,Both,FALSE,17NCT01169337,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01124695,Eastern Cooperative Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01124695,TRUE,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],6-Dec-12,18,9999,Both,FALSE,17NCT01120249,Southwest Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01107626,Eastern Cooperative Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT01101451,Gynecologic Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01079780,Pam Cogliano,FALSE,MN,https://ClinicalTrials.gov/show/NCT01079780,TRUE,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],19-Sep-14,18,9999,Both,FALSE,161NCT00978458,Eastern Cooperative Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT00978458,TRUE,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],4-Dec-12,18,9999,Both,FALSE,17NCT00897767,Eastern Cooperative Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT00897767,TRUE,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],5-Dec-12,0,9999,Both,FALSE,17NCT00887146,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT00887146,TRUE,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],18-Dec-15,18,9999,Both,FALSE,1NCT00843882,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT00807768,Gynecologic Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT00719303,Gynecologic Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT00700882,Eastern Cooperative Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT00700882,TRUE,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],16-Sep-14,18,9999,Both,FALSE,17NCT00565851,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00492778,Gynecologic Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT00492778,TRUE,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],13-Jul-15,0,9999,Female,FALSE,14NCT00430183,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT00430183,TRUE,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],13-Mar-15,18,9999,Male,FALSE,1NCT01991795,AstraZeneca,FALSE,MS,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,MS,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT02142868,Pfizer,FALSE,MS,https://ClinicalTrials.gov/show/NCT02142868,TRUE,"Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate",Advanced Breast Cancer (Female),Drug:Palbociclib; Drug:Letrozole,[],20-Jan-16,18,9999,Female,FALSE,10NCT01594333,Brigham and Women's Hospital,FALSE,MS,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01272037,National Cancer Institute (NCI),FALSE,MS,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02273726,FibroGen,FALSE,MS,https://ClinicalTrials.gov/show/NCT02273726,TRUE,Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects,CKD Anemia in Stable Dialysis Patients,Drug:Epoetin Alfa; Drug:FG-4592,[],9-Dec-15,18,9999,Both,FALSE,109NCT02052310,FibroGen,FALSE,MS,https://ClinicalTrials.gov/show/NCT02052310,TRUE,Safety and Efficacy Study for Treatment of Anemia in ESRD Newly Initiated Dialysis Patients,Anemia in Incident Dialysis Patients,Drug:FG-4592 (roxadustat); Drug:Epoetin Alfa,[],24-Mar-15,18,9999,Both,FALSE,109NCT01920711,Novartis Pharmaceuticals,FALSE,MS,https://ClinicalTrials.gov/show/NCT01920711,TRUE,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],14-Oct-15,50,9999,Both,FALSE,156NCT00858364,Amgen,FALSE,MS,https://ClinicalTrials.gov/show/NCT00858364,TRUE,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],27-Jan-16,18,9999,Both,FALSE,16NCT02528253,Pfizer,FALSE,MS,https://ClinicalTrials.gov/show/NCT02528253,TRUE,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],1-Feb-16,18,9999,Both,FALSE,10NCT02528188,Pfizer,FALSE,MS,https://ClinicalTrials.gov/show/NCT02528188,TRUE,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],19-Jan-16,18,9999,Both,FALSE,10NCT02164916,Southwest Oncology Group,FALSE,MS,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,MS,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02115282,National Cancer Institute (NCI),FALSE,MS,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02066636,Bristol-Myers Squibb,FALSE,MS,https://ClinicalTrials.gov/show/NCT02066636,TRUE,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],26-Jan-16,18,9999,Both,FALSE,80NCT02019264,Eisai Inc.,FALSE,MS,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01975389,Pfizer,FALSE,MS,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,MS,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01845025,Novartis Pharmaceuticals,FALSE,MS,https://ClinicalTrials.gov/show/NCT01845025,TRUE,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],3-Feb-16,12,9999,Both,FALSE,156NCT01808573,"Puma Biotechnology, Inc.",FALSE,MS,https://ClinicalTrials.gov/show/NCT01808573,TRUE,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],26-Jan-16,18,9999,Both,FALSE,166NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,MS,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01101035,Takeda,TRUE,MS,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT00565851,National Cancer Institute (NCI),FALSE,MS,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02674386,Pfizer,FALSE,MS,https://ClinicalTrials.gov/show/NCT02674386,TRUE,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],1-Feb-16,18,9999,Both,FALSE,10NCT02673190,Radiation Therapy Oncology Group,FALSE,MS,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02615002,Neurim Pharmaceuticals Ltd.,FALSE,MS,https://ClinicalTrials.gov/show/NCT02615002,TRUE,Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION),Alzheimer's Disease,Drug:Piromelatine; Drug:Placebo,[],26-Jan-16,60,85,Both,FALSE,152NCT02574078,Bristol-Myers Squibb,FALSE,MS,https://ClinicalTrials.gov/show/NCT02574078,TRUE,A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),Non-Small Cell Lung Cancer,Drug:Nivolumab; Drug:Bevacizumab; Drug:Pemetrexed; Other:Palliative radiation; Drug:nab-Paclitaxel; Drug:Paclitaxel; Drug:Docetaxel; Drug:Gemcitabine; Drug:Erlotinib; Drug:Crizotinib; Drug:Carboplatin,[],26-Jan-16,18,9999,Both,FALSE,80NCT02542384,"Cara Therapeutics, Inc.",FALSE,MS,https://ClinicalTrials.gov/show/NCT02542384,TRUE,A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery,Post Abdominal Surgery Pain,Drug:CR845 IV 1 mcg/kg; Drug:CR845 IV 2 mcg/kg; Drug:CR845 IV 5 mcg/kg; Drug:Placebo IV,[],3-Feb-16,21,9999,Both,FALSE,85NCT02504294,"Hospira, Inc.",FALSE,MS,https://ClinicalTrials.gov/show/NCT02504294,TRUE,A Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis,Chronic Kidney Disease (CKD),Drug:Epoetin Hospira Arm; Other:Standard of Care Arm,"[u'CA Institute of Renal Research', u'CA Institute of Renal Research', u'Genesis Clinical Research, Inc', u'Boise Kidney and Hypertension Institute', u'Nephrology Center, PC', u'South Mississippi Medical Research, LLC', u'Southern Renal Research Group, LLC', u'Metrolina Nephrology Associates, PA', u'Durham Nephrology Associates', u'Delaware Valley Nephrology and Hypertension Associates, PC', u'Rhode Island Hospital', u'Knoxville Kidney Center, PLLC', u'Nephrology Associates, PC', u'Research Management Inc', u'Gamma Medical Research, Inc', u'Southwest Houston Research, Ltd', u'Eugenia M. Galindo-Ramos', u'Jose L. Cangiano-Rivera']",25-Nov-15,18,9999,Both,FALSE,120NCT02422615,Novartis Pharmaceuticals,FALSE,MS,https://ClinicalTrials.gov/show/NCT02422615,TRUE,Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.,"Breast Neoplasms; Breast Diseases; Neoplasms; Neoplasms by Site; Fulvestrant; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Estrogen Receptor Antagonists; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Therapeutic Use",Drug:Ribociclib; Drug:fulvestrant; Drug:Ribociclib placebo,[],14-Sep-15,18,9999,Female,FALSE,156NCT02415400,Bristol-Myers Squibb,FALSE,MS,https://ClinicalTrials.gov/show/NCT02415400,TRUE,Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention,Acute Coronary Syndromes,Drug:Apixaban; Drug:vitamin K antagonist; Drug:Acetylsalicylic acid; Other:Acetylsalicylic acid placebo,[],11-Jan-16,18,95,Both,FALSE,80NCT02406677,AstraZeneca,FALSE,MS,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02367794,Hoffmann-La Roche,FALSE,MS,https://ClinicalTrials.gov/show/NCT02367794,TRUE,A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel; Drug:Paclitaxel,[],1-Feb-16,18,9999,Both,FALSE,119NCT02311933,National Cancer Institute (NCI),FALSE,MS,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02240108,"Valeant Pharmaceuticals International, Inc.",FALSE,MS,https://ClinicalTrials.gov/show/NCT02240108,TRUE,One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease,Crohn's Disease,Drug:Rifaximin DR; Drug:Placebo,[],11-Jun-15,18,9999,Both,FALSE,47NCT02235545,St. Jude Medical,FALSE,MS,https://ClinicalTrials.gov/show/NCT02235545,TRUE,Optisure Lead Post Approval Study,"Heart Failure; Tachycardia, Ventricular",Device:St. Jude Medical Optisure Lead,[],17-Nov-15,18,9999,Both,FALSE,177NCT02228681,Gynecologic Oncology Group,FALSE,MS,https://ClinicalTrials.gov/show/NCT02228681,TRUE,Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,"Advanced, Persistent, or Recurrent Endometrial Cancer",Drug:Everolimus; Drug:Tamoxifen; Drug:Letrozole; Drug:Medroxyprogesterone Acetate,[],18-Nov-15,18,9999,Female,FALSE,14NCT02155660,AstraZeneca,FALSE,MS,https://ClinicalTrials.gov/show/NCT02155660,TRUE,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],7-Jan-16,40,85,Both,FALSE,13NCT02065687,Gynecologic Oncology Group,FALSE,MS,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01946204,"Aragon Pharmaceuticals, Inc.",FALSE,MS,https://ClinicalTrials.gov/show/NCT01946204,TRUE,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],19-Jan-16,18,9999,Male,FALSE,64NCT01919697,Synergy Pharmaceuticals Inc.,FALSE,MS,https://ClinicalTrials.gov/show/NCT01919697,TRUE,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],10-Dec-15,18,81,Both,FALSE,183NCT01870778,Novartis Pharmaceuticals,FALSE,MS,https://ClinicalTrials.gov/show/NCT01870778,TRUE,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],16-Sep-15,18,9999,Both,FALSE,156NCT01729455,"Human Genome Sciences Inc., a GSK Company",FALSE,MS,https://ClinicalTrials.gov/show/NCT01729455,TRUE,Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry,Systemic Lupus Erythematosus,Biological:BENLYSTA; Other:SLE treatment,[],4-Feb-16,18,9999,Both,FALSE,122NCT01705977,"Human Genome Sciences Inc., a GSK Company",FALSE,MS,https://ClinicalTrials.gov/show/NCT01705977,TRUE,Belimumab Assessment of Safety in SLE,Systemic Lupus Erythematosus,Biological:Placebo plus standard therapy; Biological:Belimumab 10 mg/kg plus standard therapy; Other:Standard therapy,[],4-Feb-16,18,9999,Both,FALSE,122NCT01674140,Southwest Oncology Group,FALSE,MS,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01652872,Amgen,FALSE,MS,https://ClinicalTrials.gov/show/NCT01652872,TRUE,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],9-Dec-15,18,9999,Both,FALSE,16NCT02562716,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT02562716,TRUE,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],26-Jan-16,18,75,Both,FALSE,3NCT02488967,NRG Oncology,FALSE,MO,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02311933,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,MO,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02194738,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02115282,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,MO,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT02003222,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT02003222,TRUE,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],28-Jan-16,30,70,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,MO,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01674140,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01668719,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT01622868,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01622868,TRUE,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],4-Feb-16,18,9999,Both,FALSE,9NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,MO,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01415752,Eastern Cooperative Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01349881,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01169337,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,MO,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01120249,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01107626,Eastern Cooperative Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT01101451,Gynecologic Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01013649,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00843882,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT00719303,Gynecologic Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT00565851,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02474160,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT02474160,TRUE,Collection and Storage of Tissue and Blood Samples From Patients With Cancer,Malignant Neoplasm,Other:Cytology Specimen Collection Procedure,[],22-Jan-16,18,9999,Both,FALSE,9NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01533207,Gynecologic Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT01533207,TRUE,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],23-Dec-14,18,9999,Female,FALSE,14NCT00892866,Gynecologic Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT00892866,TRUE,"CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells",Atypical Endocervical Glandular Cell of Undetermined Significance; Atypical Endometrial Hyperplasia; Human Papillomavirus Infection; Stage 0 Cervical Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],13-Jul-15,18,9999,Female,FALSE,14NCT02438722,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT02438722,TRUE,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],1-Sep-15,0,9999,Both,FALSE,3NCT02412670,ECOG-ACRIN Cancer Research Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT02412670,TRUE,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,Localized Urothelial Carcinoma of the Renal Pelvis and Ureter; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter,Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin Hydrochloride; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Drug:Carboplatin; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,[],19-Aug-15,18,9999,Both,FALSE,101NCT02143414,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT02143414,TRUE,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],15-Jan-16,65,9999,Both,FALSE,9NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,MO,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01903811,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01575548,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01950390,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,MO,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT01835145,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01835145,TRUE,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],1-Feb-16,18,9999,Both,FALSE,9NCT01814813,Alliance for Clinical Trials in Oncology,FALSE,MO,https://ClinicalTrials.gov/show/NCT01814813,TRUE,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],26-Jan-16,18,9999,Both,FALSE,1NCT00936390,Radiation Therapy Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT00807768,Gynecologic Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT02059265,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT02059265,TRUE,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Female,FALSE,9NCT01810913,Radiation Therapy Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT01810913,TRUE,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],14-Nov-15,18,9999,Both,FALSE,4NCT01809691,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT00843882,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01415752,Eastern Cooperative Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT02085408,Eastern Cooperative Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT02085408,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],16-Sep-14,60,9999,Both,FALSE,17NCT01533207,Gynecologic Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT01533207,TRUE,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],23-Dec-14,18,9999,Female,FALSE,14NCT01169337,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01064648,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT01064648,TRUE,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],1-Feb-16,18,9999,Both,FALSE,9NCT01575548,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01359592,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT01359592,TRUE,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],17-Nov-15,18,9999,Both,FALSE,3NCT01107626,Eastern Cooperative Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT01041703,Eastern Cooperative Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT01041703,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],24-Jul-14,60,9999,Both,FALSE,17NCT01013649,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00700882,Eastern Cooperative Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT00700882,TRUE,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],16-Sep-14,18,9999,Both,FALSE,17NCT01349881,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01124695,Eastern Cooperative Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT01124695,TRUE,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],6-Dec-12,18,9999,Both,FALSE,17NCT02048813,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01814813,Alliance for Clinical Trials in Oncology,FALSE,MT,https://ClinicalTrials.gov/show/NCT01814813,TRUE,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],26-Jan-16,18,9999,Both,FALSE,1NCT01674140,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT00840177,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT00840177,TRUE,"S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia",Leukemia,Drug:cytarabine; Drug:idarubicin; Drug:pravastatin sodium,[],25-Sep-15,18,9999,Both,FALSE,3NCT00430183,Alliance for Clinical Trials in Oncology,FALSE,MT,https://ClinicalTrials.gov/show/NCT00430183,TRUE,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],13-Mar-15,18,9999,Male,FALSE,1NCT02601209,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT02601209,TRUE,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01535053,Gynecologic Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT01535053,TRUE,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT02523014,Alliance for Clinical Trials in Oncology,FALSE,MT,https://ClinicalTrials.gov/show/NCT02523014,TRUE,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],8-Dec-15,18,9999,Both,FALSE,1NCT02194738,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02134912,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT02134912,TRUE,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Drug:crizotinib; Drug:pemetrexed disodium; Other:laboratory biomarker analysis; Other:pharmacological study,[],5-Feb-15,18,9999,Both,FALSE,3NCT02003222,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT02003222,TRUE,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],28-Jan-16,30,70,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,MT,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01950390,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01903811,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01835145,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT01835145,TRUE,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],1-Feb-16,18,9999,Both,FALSE,9NCT01573442,Alliance for Clinical Trials in Oncology,FALSE,MT,https://ClinicalTrials.gov/show/NCT01573442,TRUE,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],3-Nov-15,18,9999,Female,FALSE,1NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,MT,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT00887146,Alliance for Clinical Trials in Oncology,FALSE,MT,https://ClinicalTrials.gov/show/NCT00887146,TRUE,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],18-Dec-15,18,9999,Both,FALSE,1NCT00719303,Gynecologic Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT00492778,Gynecologic Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT00492778,TRUE,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],13-Jul-15,0,9999,Female,FALSE,14NCT02562716,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT02562716,TRUE,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],26-Jan-16,18,75,Both,FALSE,3NCT02488967,NRG Oncology,FALSE,MT,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02315469,NRG Oncology,FALSE,MT,https://ClinicalTrials.gov/show/NCT02315469,TRUE,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],13-Jul-15,70,9999,Female,FALSE,159NCT02311933,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02177695,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT02177695,TRUE,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",Bladder Cancer,Drug:Gemcitabine; Drug:Cisplatin; Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin; Drug:Filgrastim,[],8-Dec-15,18,9999,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,MT,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01274338,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,MT,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01414608,Gynecologic Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT01414608,TRUE,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],16-Jul-15,18,9999,Female,FALSE,14NCT02115282,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02194738,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01674140,Southwest Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01272037,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02488967,NRG Oncology,FALSE,NE,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02164916,Southwest Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT01349881,Southwest Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT02438722,Southwest Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT02438722,TRUE,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],1-Sep-15,0,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT00887146,Alliance for Clinical Trials in Oncology,FALSE,NE,https://ClinicalTrials.gov/show/NCT00887146,TRUE,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],18-Dec-15,18,9999,Both,FALSE,1NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,NE,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT02154490,Southwest Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT01950390,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01668719,Southwest Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT02315469,NRG Oncology,FALSE,NE,https://ClinicalTrials.gov/show/NCT02315469,TRUE,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],13-Jul-15,70,9999,Female,FALSE,159NCT02311933,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02101788,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT01814813,Alliance for Clinical Trials in Oncology,FALSE,NE,https://ClinicalTrials.gov/show/NCT01814813,TRUE,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],26-Jan-16,18,9999,Both,FALSE,1NCT01781468,Alliance for Clinical Trials in Oncology,FALSE,NE,https://ClinicalTrials.gov/show/NCT01781468,TRUE,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],13-Nov-15,18,9999,Both,FALSE,1NCT01575548,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01573442,Alliance for Clinical Trials in Oncology,FALSE,NE,https://ClinicalTrials.gov/show/NCT01573442,TRUE,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],3-Nov-15,18,9999,Female,FALSE,1NCT00565851,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02601209,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02601209,TRUE,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,NE,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,NE,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT01120249,Southwest Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01013649,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00936390,Radiation Therapy Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT01966107,AstraZeneca,FALSE,NE,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01169337,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02152982,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02152982,TRUE,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT00843882,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT00666731,University of Nebraska,FALSE,NE,https://ClinicalTrials.gov/show/NCT00666731,TRUE,A Breast Cancer Information Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer,Breast Cancer; Precancerous Condition,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:Excess human biological tissue; Procedure:quality-of-life assessment,[],30-Nov-15,19,120,Both,FALSE,206NCT02134912,Southwest Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT02134912,TRUE,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Drug:crizotinib; Drug:pemetrexed disodium; Other:laboratory biomarker analysis; Other:pharmacological study,[],5-Feb-15,18,9999,Both,FALSE,3NCT02106546,AbbVie,FALSE,NE,https://ClinicalTrials.gov/show/NCT02106546,TRUE,"Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",Squamous Non-Small Cell Lung Cancer,Drug:veliparib; Drug:carboplatin; Drug:paclitaxel; Drug:placebo,[],13-Jan-16,18,99,Both,FALSE,51NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,NE,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01124695,Eastern Cooperative Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT01124695,TRUE,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],6-Dec-12,18,9999,Both,FALSE,17NCT01107626,Eastern Cooperative Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT02115282,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,NE,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,NE,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT01242800,Eastern Cooperative Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT01079780,Pam Cogliano,FALSE,NE,https://ClinicalTrials.gov/show/NCT01079780,TRUE,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],19-Sep-14,18,9999,Both,FALSE,161NCT00828009,Eastern Cooperative Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT00828009,TRUE,BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,Lung Cancer,Biological:bevacizumab; Biological:emepepimut-S; Drug:carboplatin; Drug:cyclophosphamide; Drug:paclitaxel; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT00316888,Eastern Cooperative Oncology Group,TRUE,NE,https://ClinicalTrials.gov/show/NCT00316888,TRUE,"Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",Anal Cancer,Biological:cetuximab; Drug:cisplatin; Drug:fluorouracil; Radiation:radiation therapy,[],22-Aug-12,18,9999,Both,FALSE,17NCT02524275,University of Nebraska,FALSE,NE,https://ClinicalTrials.gov/show/NCT02524275,TRUE,Docetaxel and Capecitabine in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,Head and Neck Squamous Cell Carcinoma,Drug:Capecitabine; Drug:Docetaxel; Other:Quality-of-Life Assessment,"[u'Saint Francis Medical Center', u'Faith Regional Medical Offices West', u'Great Plains Regional Medical Center', u'Omaha Veterans Administration Medical Center', u'University of Nebraska Medical Center', u'Bellevue Hospital Center', u'Avera Cancer Institute', u'Veterans Affairs Medical Center - Memphis']",12-Aug-15,18,9999,Both,FALSE,206NCT02601209,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02601209,TRUE,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02488967,NRG Oncology,FALSE,NV,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,NV,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02194738,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02177695,Southwest Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT02177695,TRUE,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",Bladder Cancer,Drug:Gemcitabine; Drug:Cisplatin; Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin; Drug:Filgrastim,[],8-Dec-15,18,9999,Both,FALSE,3NCT02164916,Southwest Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02048813,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02003222,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02003222,TRUE,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],28-Jan-16,30,70,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01950390,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01903811,Southwest Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01835145,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01835145,TRUE,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],1-Feb-16,18,9999,Both,FALSE,9NCT01674140,Southwest Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01668719,Southwest Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT01575548,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01573442,Alliance for Clinical Trials in Oncology,FALSE,NV,https://ClinicalTrials.gov/show/NCT01573442,TRUE,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],3-Nov-15,18,9999,Female,FALSE,1NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,NV,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT01349881,Southwest Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01169337,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01013649,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00887146,Alliance for Clinical Trials in Oncology,FALSE,NV,https://ClinicalTrials.gov/show/NCT00887146,TRUE,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],18-Dec-15,18,9999,Both,FALSE,1NCT00492778,Gynecologic Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT00492778,TRUE,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],13-Jul-15,0,9999,Female,FALSE,14NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,NV,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT02474160,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02474160,TRUE,Collection and Storage of Tissue and Blood Samples From Patients With Cancer,Malignant Neoplasm,Other:Cytology Specimen Collection Procedure,[],22-Jan-16,18,9999,Both,FALSE,9NCT02451137,Sanofi,FALSE,NV,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02671981,Radiation Therapy Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT02671981,TRUE,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],2-Feb-16,18,9999,Both,FALSE,4NCT02526524,"Elcelyx Therapeutics, Inc.",FALSE,NV,https://ClinicalTrials.gov/show/NCT02526524,TRUE,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],7-Jan-16,25,9999,Both,FALSE,103NCT02439320,CoLucid Pharmaceuticals,FALSE,NV,https://ClinicalTrials.gov/show/NCT02439320,TRUE,Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:,Acute Migraine,Drug:Lasmiditan 100 mg; Drug:Lasmiditan 200 mg; Drug:Placebo (matches lasmiditan doses),[],13-Nov-15,18,9999,Both,FALSE,91NCT02180867,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02180867,TRUE,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],1-Feb-16,2,9999,Both,FALSE,9NCT01919697,Synergy Pharmaceuticals Inc.,FALSE,NV,https://ClinicalTrials.gov/show/NCT01919697,TRUE,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],10-Dec-15,18,81,Both,FALSE,183NCT01808573,"Puma Biotechnology, Inc.",FALSE,NV,https://ClinicalTrials.gov/show/NCT01808573,TRUE,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],26-Jan-16,18,9999,Both,FALSE,166NCT01594333,Brigham and Women's Hospital,FALSE,NV,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,NV,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01406756,Children's Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT01406756,TRUE,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],3-Feb-16,1,30,Both,FALSE,17NCT01190930,Children's Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT01190930,TRUE,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],6-Aug-15,1,30,Both,FALSE,17NCT02674386,Pfizer,FALSE,NV,https://ClinicalTrials.gov/show/NCT02674386,TRUE,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],1-Feb-16,18,9999,Both,FALSE,10NCT02528188,Pfizer,FALSE,NV,https://ClinicalTrials.gov/show/NCT02528188,TRUE,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],19-Jan-16,18,9999,Both,FALSE,10NCT02112916,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02112916,TRUE,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],28-Jan-16,2,30,Both,FALSE,9NCT02059265,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02059265,TRUE,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Female,FALSE,9NCT01966107,AstraZeneca,FALSE,NV,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01272037,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,NH,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT02194738,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT01674140,Southwest Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,NH,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT02115282,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01856192,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT00936390,Radiation Therapy Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT02390401,Dartmouth-Hitchcock Medical Center,FALSE,NH,https://ClinicalTrials.gov/show/NCT02390401,TRUE,Vacuum Assisted Closure for Cesarean Section,Surgical Wound Infection,Device:Vacuum-assisted closure; Device:Standard sterile dressing,"[u'Dartmouth-Hitchcock Medical Center', u""Women's Care of Nashua"", u'Dartmouth-Hitchcock Nashua', u'Southern New Hampshire Medical Center']",20-Jan-16,18,9999,Female,TRUE,26NCT02154490,Southwest Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02152982,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT02152982,TRUE,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,NH,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01853748,Dana-Farber Cancer Institute,FALSE,NH,https://ClinicalTrials.gov/show/NCT01853748,TRUE,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),Breast Cancer,Drug:Trastuzumab; Drug:Paclitaxel; Drug:Trastuzumab emtansine,[],3-Feb-16,18,9999,Both,FALSE,96NCT01781468,Alliance for Clinical Trials in Oncology,FALSE,NH,https://ClinicalTrials.gov/show/NCT01781468,TRUE,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],13-Nov-15,18,9999,Both,FALSE,1NCT01516216,Dana-Farber Cancer Institute,FALSE,NH,https://ClinicalTrials.gov/show/NCT01516216,TRUE,Study of Vitamin D in Untreated Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug:FOLFOX + bevacizumab; Dietary Supplement:Vitamin D; Dietary Supplement:Vitamin D,"[u""Mountain States Tumor Institute at St. Luke's Regional Medical Center"", u'Mountain States Tumor Institute- Fruitland', u'Mountain States Tumor Institute - Meridian', u'Mountain States Tumor Institute- Nampa', u'Mountain States Tumor Institute- Twin Falls', u'The Robert H. Lurie Comprehensive Cancer Center of Northwestern University', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'Lowell General Hospital', u""Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center"", u'Newton-Wellesley Hospital', u""Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital"", u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'Dana-Farber/New Hampshire Oncology-Hematology', u'Vanderbilt-Ingram Cancer Center']",10-Jan-16,18,9999,Both,FALSE,96NCT02311933,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02032277,AbbVie,FALSE,NH,https://ClinicalTrials.gov/show/NCT02032277,TRUE,A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,Triple Negative Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Placebo; Drug:Placebo,[],9-Oct-15,18,99,Female,FALSE,51NCT01950390,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01872975,NSABP Foundation Inc,FALSE,NH,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01809691,Southwest Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01349881,Southwest Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01208662,"Paul G. Richardson, MD",FALSE,NH,https://ClinicalTrials.gov/show/NCT01208662,TRUE,"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65",Multiple Myeloma,Drug:Lenalidomide; Drug:Bortezomib; Drug:Dexamethasone; Procedure:Autologous Stem Cell Transplant,[],21-Jan-16,18,65,Both,FALSE,162NCT00922974,Radiation Therapy Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT00922974,TRUE,Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis,Metastatic Cancer; Pain,Radiation:external beam radiation therapy; Radiation:image-guided radiation therapy; Radiation:radiosurgery; Radiation:stereotactic body radiation therapy,[],19-Nov-15,18,120,Both,FALSE,4NCT00430183,Alliance for Clinical Trials in Oncology,FALSE,NH,https://ClinicalTrials.gov/show/NCT00430183,TRUE,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],13-Mar-15,18,9999,Male,FALSE,1NCT02673190,Radiation Therapy Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02513394,"Alliance Foundation Trials, LLC.",FALSE,NH,https://ClinicalTrials.gov/show/NCT02513394,TRUE,PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer,Breast Cancer,Drug:Palbociclib; Drug:Standard Adjuvant Endocrine Therapy,"[u'', u'', u'']",10-Dec-15,18,9999,Both,FALSE,61NCT02360319,Vanguard Research Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT02360319,TRUE,Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics,Schizophrenia,Drug:Any FDA approved antipsychotic agent; Drug:aripiprazole long acting injectable formulation,[],7-Dec-15,18,35,Both,FALSE,216NCT02315469,NRG Oncology,FALSE,NH,https://ClinicalTrials.gov/show/NCT02315469,TRUE,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],13-Jul-15,70,9999,Female,FALSE,159NCT02277665,Dartmouth-Hitchcock Medical Center,FALSE,NH,https://ClinicalTrials.gov/show/NCT02277665,TRUE,Clinical Trial Tobacco Marijuana,Cannabis Use Disorder; Tobacco Use Disorder,Behavioral:CUD Treatment; Behavioral:Tobacco Treatment,"[u'Geisel School of Medicine at Dartmouth; State Building Site', u'Geisel School of Medicine at Dartmouth; Rivermill Complex Site', u'University of Washington School of Social Work']",3-Aug-15,18,9999,Both,TRUE,26NCT02254278,NRG Oncology,FALSE,NH,https://ClinicalTrials.gov/show/NCT02254278,TRUE,Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer,Stage III Oropharyngeal Squamous Cell Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma,Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],29-Jan-16,18,9999,Both,FALSE,159NCT02188745,Dartmouth-Hitchcock Medical Center,FALSE,NH,https://ClinicalTrials.gov/show/NCT02188745,TRUE,ER Reactivation Therapy for Breast Cancer,Metastatic Breast Cancer,Drug:17B-estradiol; Drug:Letrozole; Drug:Anastrozole; Drug:Exemestane,"[u'Dartmouth Hitchcock Medical Center', u'Dartmouth Hitchcock Medical Center']",7-Dec-15,18,90,Female,FALSE,26NCT02178956,"Boston Biomedical, Inc",FALSE,NH,https://ClinicalTrials.gov/show/NCT02178956,TRUE,A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer,Gastric Cancer; Gastroesophageal Junction Cancer,Drug:BBI608; Drug:Paclitaxel; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,76NCT02161718,"Alkermes, Inc.",FALSE,NH,https://ClinicalTrials.gov/show/NCT02161718,TRUE,A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder,Schizophrenia; Alcohol Use Disorder,Drug:Samidorphan + olanzapine (ALKS 3831); Drug:Placebo,[],3-Feb-16,18,65,Both,FALSE,60NCT02065687,Gynecologic Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02037529,Academic and Community Cancer Research United,FALSE,NH,https://ClinicalTrials.gov/show/NCT02037529,TRUE,A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer,Metastatic Breast Cancer; Locally Recurrent Breast Cancer,Drug:Eribulin; Drug:Paclitaxel,[],26-Jan-16,18,9999,Both,FALSE,53NCT01984268,Dartmouth-Hitchcock Medical Center,FALSE,NH,https://ClinicalTrials.gov/show/NCT01984268,TRUE,ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate,Rheumatoid Arthritis,Drug:ACTHAR; Drug:NSAID,"[u'Dartmouth-Hitchcock Medical Center', u'Dartmouth-Hitchcock Medical Center']",13-Nov-13,18,70,Both,TRUE,26NCT01822496,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT01822496,TRUE,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Feb-16,18,9999,Both,FALSE,9NCT01817660,Boston University,FALSE,NH,https://ClinicalTrials.gov/show/NCT01817660,TRUE,Open Versus Endovascular Repair of Popliteal Artery Aneurysm Trial,Popliteal Artery Aneurysm.,Procedure:Open repair of popliteal artery; Procedure:Endovascular repair of popliteal artery,"[u'Danbury Hospital', u'Hartford Hospital', u'Yale-New Haven Hospital', u'Indiana University Medical Center', u'LSU Medical Center', u'Maine Medical Center', u'BI-Deaconess Hospital', u""Brigham and Women's Hospital"", u'Boston Medical Center', u'Massachusetts General Hospital', u'Tufts Medical Center', u'St. Elizabeth Hospital', u'Charlton Memorial Hospital/St. Anne', u'Bay State Medical Center', u'Henry Ford Hospital', u'Dartmouth Medical Center', u'Cardiothoracic Surgical Associates, PA', u'Albany Medical Center', u'Rhode Island Hospital', u'Fletcher Allen Healthcare', u'University of Virginia Health Center']",28-Mar-13,35,9999,Both,FALSE,78NCT01415752,Eastern Cooperative Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01274338,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01242800,Eastern Cooperative Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT01107626,Eastern Cooperative Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT00956007,Radiation Therapy Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT00956007,TRUE,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Both,FALSE,4NCT00492778,Gynecologic Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT00492778,TRUE,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],13-Jul-15,0,9999,Female,FALSE,14NCT02675244,Icahn School of Medicine at Mount Sinai,FALSE,NH,https://ClinicalTrials.gov/show/NCT02675244,TRUE,Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery,Mild Tricuspid Regurgitation; Moderate Tricuspid Regurgitation; Tricuspid Regurgitation,Procedure:TV Annuloplasty; Procedure:MVS Alone,[],3-Feb-16,18,9999,Both,FALSE,124NCT02666664,Esperion Therapeutics,TRUE,NH,https://ClinicalTrials.gov/show/NCT02666664,TRUE,Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk,Hypercholesterolemia; Atherosclerotic Cardiovascular Diseases,Drug:ETC-1002; Drug:Placebo,"[u'', u'', u'', u'', u'', u'']",25-Jan-16,18,9999,Both,FALSE,28NCT01674140,Southwest Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01272037,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02194738,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT00936390,Radiation Therapy Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT02193282,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT02406677,AstraZeneca,FALSE,NJ,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT01975389,Pfizer,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01966107,AstraZeneca,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01872975,NSABP Foundation Inc,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01594333,Brigham and Women's Hospital,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01274338,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01101451,Gynecologic Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01013649,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02019264,Eisai Inc.,FALSE,NJ,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01701817,"Janssen Scientific Affairs, LLC",FALSE,NJ,https://ClinicalTrials.gov/show/NCT01701817,TRUE,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],7-Jan-16,21,9999,Both,FALSE,133NCT01663402,Sanofi,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01663402,TRUE,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],3-Feb-16,40,9999,Both,FALSE,12NCT02488967,NRG Oncology,FALSE,NJ,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02164916,Southwest Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT01991795,AstraZeneca,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01107626,Eastern Cooperative Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT00843882,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT00565851,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00492778,Gynecologic Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00492778,TRUE,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],13-Jul-15,0,9999,Female,FALSE,14NCT02301156,"TG Therapeutics, Inc.",FALSE,NJ,https://ClinicalTrials.gov/show/NCT02301156,TRUE,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],2-Feb-16,18,9999,Both,FALSE,188NCT02111564,"Janssen Research & Development, LLC",FALSE,NJ,https://ClinicalTrials.gov/show/NCT02111564,TRUE,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],26-Jan-16,40,9999,Both,FALSE,132NCT02104817,AstraZeneca,FALSE,NJ,https://ClinicalTrials.gov/show/NCT02104817,TRUE,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],21-Dec-15,18,99,Both,FALSE,13NCT02003209,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01877915,"Janssen Research & Development, LLC",FALSE,NJ,https://ClinicalTrials.gov/show/NCT01877915,TRUE,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],26-Jan-16,18,95,Both,FALSE,132NCT01856192,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT02504216,Bayer,FALSE,NJ,https://ClinicalTrials.gov/show/NCT02504216,TRUE,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],1-Feb-16,50,9999,Both,FALSE,23NCT02115282,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,NJ,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT01951534,"Rutgers, The State University of New Jersey",FALSE,NJ,https://ClinicalTrials.gov/show/NCT01951534,TRUE,Decisional Aid Intervention for Women Considering Breast Reconstruction,Breast Cancer,Behavioral:Breast Reconstruction Decisional Aid (BRDA); Behavioral:Usual Care,"[u'Ocean Medical Center', u'Cooper Hospital/University Medical Center', u'Bayshore Community Hospital', u'Southern Ocean Medical Center', u'Jersey Shore University Medical Center', u'Rutgers Cancer Institute of New Jersey', u'Riverview Medical Center', u'Somerset Medical Center', u'Fox Chase Cancer Center']",10-Jun-15,18,9999,Female,FALSE,171NCT01406756,Children's Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01406756,TRUE,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],3-Feb-16,1,30,Both,FALSE,17NCT01307579,Children's Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01307579,TRUE,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],18-Aug-15,3,30,Both,FALSE,17NCT01190930,Children's Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01190930,TRUE,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],6-Aug-15,1,30,Both,FALSE,17NCT00807768,Gynecologic Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT01674140,Southwest Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT02115282,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT00936390,Radiation Therapy Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT02003209,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,NM,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01101451,Gynecologic Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01079780,Pam Cogliano,FALSE,NM,https://ClinicalTrials.gov/show/NCT01079780,TRUE,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],19-Sep-14,18,9999,Both,FALSE,161NCT00565851,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02629159,AbbVie,FALSE,NM,https://ClinicalTrials.gov/show/NCT02629159,TRUE,A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE),Rheumatoid Arthritis,Drug:ABT-494; Drug:Placebo for ABT-494; Drug:Adalimumab; Drug:Placebo for Adalimumab,[],10-Dec-15,18,99,Both,FALSE,51NCT02163694,AbbVie,FALSE,NM,https://ClinicalTrials.gov/show/NCT02163694,TRUE,"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",Metastatic Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Other:Placebo,[],26-Jan-16,18,99,Both,FALSE,51NCT02101788,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,NM,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,NM,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01856192,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01850524,"Millennium Pharmaceuticals, Inc.",FALSE,NM,https://ClinicalTrials.gov/show/NCT01850524,TRUE,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug:IXAZOMIB + Lenalidomide + Dexamethasone; Drug:Placebo + Lenalidomide + Dexamethasone,[],23-Feb-15,18,9999,Both,FALSE,146NCT01809691,Southwest Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01607554,New Mexico Cancer Care Alliance,FALSE,NM,https://ClinicalTrials.gov/show/NCT01607554,TRUE,"Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer",Non-small Cell Lung Cancer,Drug:Irinotecan,"[u'Hematology Oncology Associates', u'University of New Mexico Cancer Center', u'New Mexico Cancer Care Associates']",6-Jan-16,18,9999,Both,FALSE,153NCT01414608,Gynecologic Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT01414608,TRUE,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],16-Jul-15,18,9999,Female,FALSE,14NCT01242800,Eastern Cooperative Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT01124695,Eastern Cooperative Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT01124695,TRUE,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],6-Dec-12,18,9999,Both,FALSE,17NCT01120249,Southwest Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01042522,Gynecologic Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT01042522,TRUE,"Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",Malignant Ovarian Surface Epithelial-Stromal Tumor,Drug:Paclitaxel; Drug:Carboplatin; Biological:Bleomycin Sulfate; Drug:Etoposide Phosphate; Drug:Cisplatin,[],23-Dec-14,18,9999,Female,FALSE,14NCT00807768,Gynecologic Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT00492778,Gynecologic Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT00492778,TRUE,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],13-Jul-15,0,9999,Female,FALSE,14NCT00430183,Alliance for Clinical Trials in Oncology,FALSE,NM,https://ClinicalTrials.gov/show/NCT00430183,TRUE,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],13-Mar-15,18,9999,Male,FALSE,1NCT02674386,Pfizer,FALSE,NM,https://ClinicalTrials.gov/show/NCT02674386,TRUE,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],1-Feb-16,18,9999,Both,FALSE,10NCT02590432,Forest Laboratories,FALSE,NM,https://ClinicalTrials.gov/show/NCT02590432,TRUE,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],23-Dec-15,18,9999,Both,FALSE,110NCT02573311,Boehringer Ingelheim,FALSE,NM,https://ClinicalTrials.gov/show/NCT02573311,TRUE,Actual Use Study of Tamsulosin in Men,Urological Manifestations,Drug:tamsulosin hydrochloride,[],25-Jan-16,18,9999,Male,FALSE,75NCT02551822,University of New Mexico,FALSE,NM,https://ClinicalTrials.gov/show/NCT02551822,TRUE,Cycling Versus Continuous Mode in Neuromodulator Programming,"Urinary Incontinence, Urge",Device:sacral neuromodulator,"[u'University of New Mexico Hospital', u'University of New Mexico Health Science Center']",15-Sep-15,21,9999,Female,FALSE,207NCT02548858,University of New Mexico,FALSE,NM,https://ClinicalTrials.gov/show/NCT02548858,TRUE,Perineorrhaphy Outcomes Related to Body Imagery,Pelvic Organ Prolapse,Procedure:Perineorrhaphy; Procedure:No Perineorrhaphy,"[u'University of New Mexico', u'Sandoval Regional Medical Center']",10-Sep-15,18,9999,Female,TRUE,207NCT02528253,Pfizer,FALSE,NM,https://ClinicalTrials.gov/show/NCT02528253,TRUE,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],1-Feb-16,18,9999,Both,FALSE,10NCT02528188,Pfizer,FALSE,NM,https://ClinicalTrials.gov/show/NCT02528188,TRUE,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],19-Jan-16,18,9999,Both,FALSE,10NCT02526524,"Elcelyx Therapeutics, Inc.",FALSE,NM,https://ClinicalTrials.gov/show/NCT02526524,TRUE,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],7-Jan-16,25,9999,Both,FALSE,103NCT02504268,Bristol-Myers Squibb,FALSE,NM,https://ClinicalTrials.gov/show/NCT02504268,TRUE,Effects of Abatacept in Patients With Early Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Abatacept; Drug:Methotrexate; Other:Abatacept Placebo; Other:Methotrexate Placebo,[],28-Jan-16,18,9999,Both,FALSE,80NCT02470585,AbbVie,FALSE,NM,https://ClinicalTrials.gov/show/NCT02470585,TRUE,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer; Ovarian Neoplasm,Other:Placebo; Drug:Veliparib; Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel,[],13-Jan-16,18,99,Female,FALSE,51NCT02365636,"Teva Branded Pharmaceutical Products, R&D Inc.",FALSE,NM,https://ClinicalTrials.gov/show/NCT02365636,TRUE,A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN),Postherpetic Neuralgia,Drug:TV-45070; Drug:Placebo,[],6-Jan-16,18,9999,Both,FALSE,186NCT02297698,"Cancer Insight, LLC",FALSE,NM,https://ClinicalTrials.gov/show/NCT02297698,TRUE,Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients,Breast Cancer,Biological:NeuVax vaccine; Drug:Trastuzumab; Drug:GM-CSF,"[u'Alliance Research Centers', u'Sarcoma Oncology Research Center, LLC', u'St Joseph Heritage Healthcare', u'North Colorado Medical Center Cancer Institute', u'Sibley Memorial Hospital', u'Memorial Breast Cancer Center', u'Florida Cancer Research Institute', u'Loyola University Medical Center', u'Memorial Hospital of South Bend', u'Medstar Health (Union Memorial Hospital)', u'New Mexico Cancer Care Alliance/Presbyterian Cancer Center', u'New Mexico Care Alliance/University of New Mexico Cancer Center', u'Eastchester Center for Cancer Care', u'Tisch Cancer Institute/Icahn School of Medicine at Mount Sinai', u'MD Anderson Cancer Center', u'Cancer Care Centers of South Texas', u'University of Virginia Human Immune Therapy Center', u'Providence Regional Medical Center', u""Columbia St. Mary's""]",21-Dec-15,18,9999,Both,FALSE,84NCT02273726,FibroGen,FALSE,NM,https://ClinicalTrials.gov/show/NCT02273726,TRUE,Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects,CKD Anemia in Stable Dialysis Patients,Drug:Epoetin Alfa; Drug:FG-4592,[],9-Dec-15,18,9999,Both,FALSE,109NCT02257567,Hoffmann-La Roche,FALSE,NM,https://ClinicalTrials.gov/show/NCT02257567,TRUE,A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma,"Diffuse Large B-Cell Lymphoma, Lymphoma, Non Hodgkin, Lymphoma, Follicular",Drug:bendamustine; Drug:obinutuzumab; Drug:polatuzumab vedotin; Drug:rituximab,[],1-Feb-16,18,9999,Both,FALSE,119NCT02228681,Gynecologic Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT02228681,TRUE,Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,"Advanced, Persistent, or Recurrent Endometrial Cancer",Drug:Everolimus; Drug:Tamoxifen; Drug:Letrozole; Drug:Medroxyprogesterone Acetate,[],18-Nov-15,18,9999,Female,FALSE,14NCT02187783,Novartis Pharmaceuticals,FALSE,NM,https://ClinicalTrials.gov/show/NCT02187783,TRUE,LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE),Tumors With CDK4/6 Pathway Activation,Drug:LEE011,[],24-Jan-16,18,9999,Both,FALSE,156NCT02186821,Novartis Pharmaceuticals,FALSE,NM,https://ClinicalTrials.gov/show/NCT02186821,TRUE,Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE),Tumors With Aberrations in ALK or ROS1,Drug:Ceritinib (LDK378),[],20-Jan-16,18,9999,Both,FALSE,156NCT02160041,Novartis Pharmaceuticals,FALSE,NM,https://ClinicalTrials.gov/show/NCT02160041,TRUE,BGJ398 for Patients With Tumors With FGFR Genetic Alterations,Solid Tumor; Hematologic Malignancies,Drug:BGJ398,[],24-Jan-16,18,9999,Both,FALSE,156NCT02065791,"Janssen Research & Development, LLC",FALSE,NM,https://ClinicalTrials.gov/show/NCT02065791,TRUE,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],5-Jan-16,30,9999,Both,FALSE,132NCT02065687,Gynecologic Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02032823,AstraZeneca,FALSE,NM,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT02028871,Ajna Hamidovic,FALSE,NM,https://ClinicalTrials.gov/show/NCT02028871,TRUE,Intranasal Insulin for Weight Management During Smoking Cessation,Tobacco Abstinence Syndrome,Drug:Intranasal Insulin; Drug:Placebo,"[u'UNM College of Pharmacy', u'UNM College of Pharmacy']",11-May-15,18,65,Both,TRUE,58NCT02019264,Eisai Inc.,FALSE,NM,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT02194738,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02019264,Eisai Inc.,FALSE,NY,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01991795,AstraZeneca,FALSE,NY,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01975389,Pfizer,FALSE,NY,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,NY,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,NY,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01674140,Southwest Oncology Group,FALSE,NY,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01594333,Brigham and Women's Hospital,FALSE,NY,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,NY,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01471522,New York University School of Medicine,TRUE,NY,https://ClinicalTrials.gov/show/NCT01471522,TRUE,International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA),Cardiovascular Diseases; Coronary Disease; Coronary Artery Disease; Heart Diseases; Myocardial Ischemia,Procedure:cardiac catheterization; Procedure:coronary artery bypass graft surgery; Procedure:percutaneous coronary intervention; Behavioral:Lifestyle; Drug:Medication,[],29-Jan-16,21,9999,Both,FALSE,34NCT01274338,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT00936390,Radiation Therapy Oncology Group,FALSE,NY,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT00273403,The New York Academy of Medicine,FALSE,NY,https://ClinicalTrials.gov/show/NCT00273403,TRUE,Outcome Evaluation of Minority AIDS Initiative Programs in the New York EMA,HIV Infections,Behavioral:Maintenance in Care Services; Behavioral:Access to Care Services,"[u'Health Center at Tremont, North Bronx Healthcare Network', u'Urban Horizons, The Institute for Urban Family Health', u'Health People', u'Planned Parenthood of New York City, Project Street Beat', u'Bronx Lebanon Hospital Center', u'SUNY Downstate Medical Center', u'HHC Cumberland Diagnostic and Treatment Center', u'Interfaith Medical Center', u'Mount Vernon Hospital', u'Betances Health Center', u'Harlem Hospital Center', u'Saint Vincents Hospital and Medical Center', u'Bellevue Hospital Center', u'William F. Ryan Community Health Center', u'African Services Committee', u'The Bridge, Inc.', u'Partnership Homeless Services Corp.', u'New York Presbyterian Hospital', u'New York Harm Reducation Educators, Inc.', u'Settlement Health', u'Greyston Health Services, Inc.', u'Saint Johns Riverside Hospital, Park Care Pavilion (ATC program)', u'Saint Johns Riverside Hospital, Park Care Pavilion (MIC Program)']",21-Sep-06,0,9999,Both,FALSE,189NCT02451137,Sanofi,FALSE,NY,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT01810913,Radiation Therapy Oncology Group,FALSE,NY,https://ClinicalTrials.gov/show/NCT01810913,TRUE,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],14-Nov-15,18,9999,Both,FALSE,4NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,NY,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01013649,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00807768,Gynecologic Oncology Group,FALSE,NY,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT02115282,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01809691,Southwest Oncology Group,FALSE,NY,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01470612,Pfizer,FALSE,NY,https://ClinicalTrials.gov/show/NCT01470612,TRUE,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug:CP-690,550; Drug:CP-690,550",[],11-Jan-16,18,9999,Both,FALSE,10NCT01414608,Gynecologic Oncology Group,FALSE,NY,https://ClinicalTrials.gov/show/NCT01414608,TRUE,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],16-Jul-15,18,9999,Female,FALSE,14NCT02111564,"Janssen Research & Development, LLC",FALSE,NY,https://ClinicalTrials.gov/show/NCT02111564,TRUE,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],26-Jan-16,40,9999,Both,FALSE,132NCT01966107,AstraZeneca,FALSE,NY,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01858532,AbbVie,FALSE,NY,https://ClinicalTrials.gov/show/NCT01858532,TRUE,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],20-Jan-16,18,85,Both,FALSE,51NCT01190930,Children's Oncology Group,FALSE,NY,https://ClinicalTrials.gov/show/NCT01190930,TRUE,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],6-Aug-15,1,30,Both,FALSE,17NCT00565851,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02065687,Gynecologic Oncology Group,FALSE,NY,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01751906,Abbott Vascular,FALSE,NY,https://ClinicalTrials.gov/show/NCT01751906,TRUE,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],11-Oct-15,18,9999,Both,FALSE,50NCT01242800,Eastern Cooperative Oncology Group,FALSE,NY,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT01120249,Southwest Oncology Group,FALSE,NY,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT00858364,Amgen,FALSE,NY,https://ClinicalTrials.gov/show/NCT00858364,TRUE,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],27-Jan-16,18,9999,Both,FALSE,16NCT02344290,National Institute of Allergy and Infectious Diseases (NIAID),FALSE,NY,https://ClinicalTrials.gov/show/NCT02344290,TRUE,Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults,HIV Infections; Cardiovascular Diseases,Drug:Pitavastatin; Drug:Placebo,[],1-Feb-16,40,75,Both,FALSE,7NCT02180867,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT02180867,TRUE,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],1-Feb-16,2,9999,Both,FALSE,9NCT02112916,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT02112916,TRUE,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],28-Jan-16,2,30,Both,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01872975,NSABP Foundation Inc,FALSE,NY,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01870778,Novartis Pharmaceuticals,FALSE,NY,https://ClinicalTrials.gov/show/NCT01870778,TRUE,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],16-Sep-15,18,9999,Both,FALSE,156NCT02451137,Sanofi,FALSE,NC,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02311933,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,NC,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02194738,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,NC,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02164513,GlaxoSmithKline,FALSE,NC,https://ClinicalTrials.gov/show/NCT02164513,TRUE,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],4-Feb-16,40,9999,Both,FALSE,8NCT02154490,Southwest Oncology Group,FALSE,NC,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02032823,AstraZeneca,FALSE,NC,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT02019264,Eisai Inc.,FALSE,NC,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT02003209,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01966107,AstraZeneca,FALSE,NC,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,NC,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,NC,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,NC,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01674140,Southwest Oncology Group,FALSE,NC,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,NC,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT01349881,Southwest Oncology Group,FALSE,NC,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,NC,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01120249,Southwest Oncology Group,FALSE,NC,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01991795,AstraZeneca,FALSE,NC,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT02488967,NRG Oncology,FALSE,NC,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02115282,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02065687,Gynecologic Oncology Group,FALSE,NC,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01975376,Pfizer,FALSE,NC,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01101451,Gynecologic Oncology Group,FALSE,NC,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT00888615,Gynecologic Oncology Group,FALSE,NC,https://ClinicalTrials.gov/show/NCT00888615,TRUE,"Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Ovarian Carcinoma,Drug:Elesclomol Sodium; Drug:Paclitaxel,[],23-Dec-14,18,9999,Female,FALSE,14NCT01903811,Southwest Oncology Group,FALSE,NC,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01416688,Southwest Oncology Group,FALSE,NC,https://ClinicalTrials.gov/show/NCT01416688,TRUE,"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride",Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity,Procedure:assessment of therapy complications; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],15-Oct-15,18,120,Both,FALSE,3NCT02065791,"Janssen Research & Development, LLC",FALSE,NC,https://ClinicalTrials.gov/show/NCT02065791,TRUE,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],5-Jan-16,30,9999,Both,FALSE,132NCT01575548,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01573442,Alliance for Clinical Trials in Oncology,FALSE,NC,https://ClinicalTrials.gov/show/NCT01573442,TRUE,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],3-Nov-15,18,9999,Female,FALSE,1NCT00858364,Amgen,FALSE,NC,https://ClinicalTrials.gov/show/NCT00858364,TRUE,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],27-Jan-16,18,9999,Both,FALSE,16NCT02048813,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01975389,Pfizer,FALSE,NC,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01872975,NSABP Foundation Inc,FALSE,NC,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01856192,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01652872,Amgen,FALSE,NC,https://ClinicalTrials.gov/show/NCT01652872,TRUE,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],9-Dec-15,18,9999,Both,FALSE,16NCT01101035,Takeda,TRUE,NC,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT02406677,AstraZeneca,FALSE,NC,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02104817,AstraZeneca,FALSE,NC,https://ClinicalTrials.gov/show/NCT02104817,TRUE,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],21-Dec-15,18,99,Both,FALSE,13NCT01897532,Boehringer Ingelheim,FALSE,NC,https://ClinicalTrials.gov/show/NCT01897532,TRUE,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],26-Jan-16,18,9999,Both,FALSE,75NCT01594333,Brigham and Women's Hospital,FALSE,NC,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01298570,UNC Lineberger Comprehensive Cancer Center,FALSE,NC,https://ClinicalTrials.gov/show/NCT01298570,TRUE,Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,Colorectal Cancer Metastatic,Drug:Regorafenib (BAY 73-4506); Drug:FOLFIRI; Drug:Placebo; Drug:FOLFIRI,[],9-Dec-15,18,9999,Both,FALSE,195NCT01064648,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT01064648,TRUE,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],1-Feb-16,18,9999,Both,FALSE,9NCT00936390,Radiation Therapy Oncology Group,FALSE,NC,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT00719303,Gynecologic Oncology Group,FALSE,NC,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01107626,Eastern Cooperative Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT01274338,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT02003209,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01674140,Southwest Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT02311933,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02194738,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02115282,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01242800,Eastern Cooperative Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT01124695,Eastern Cooperative Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01124695,TRUE,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],6-Dec-12,18,9999,Both,FALSE,17NCT00936390,Radiation Therapy Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT00632853,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT00632853,TRUE,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],10-Aug-15,18,9999,Both,FALSE,1NCT02488967,NRG Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02164916,Southwest Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02048813,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01950390,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01349881,Southwest Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01272037,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT02562716,Southwest Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT02562716,TRUE,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],26-Jan-16,18,75,Both,FALSE,3NCT02506153,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT02506153,TRUE,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,18,9999,Both,FALSE,9NCT02438722,Southwest Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT02438722,TRUE,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],1-Sep-15,0,9999,Both,FALSE,3NCT02375204,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT02375204,TRUE,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],8-Dec-15,14,9999,Male,FALSE,1NCT02339571,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT02339571,TRUE,Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma of the Skin; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Biological:Sargramostim,[],4-Feb-16,18,9999,Both,FALSE,9NCT02152982,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT02152982,TRUE,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02143414,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT02143414,TRUE,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],15-Jan-16,65,9999,Both,FALSE,9NCT02101788,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT02065687,Gynecologic Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01903811,Southwest Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT01856192,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01809691,Southwest Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01668719,Southwest Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT01595061,Gynecologic Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01595061,TRUE,"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva",Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVA Vulvar Cancer; Vulvar Squamous Cell Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Gemcitabine Hydrochloride; Drug:Cisplatin; Procedure:Therapeutic Conventional Surgery,[],23-Dec-14,18,9999,Female,FALSE,14NCT01533207,Gynecologic Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01533207,TRUE,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],23-Dec-14,18,9999,Female,FALSE,14NCT01216683,Eastern Cooperative Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01216683,TRUE,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,18,9999,Both,FALSE,17NCT01169337,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00719303,Gynecologic Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT00565851,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02085408,Eastern Cooperative Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT02085408,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],16-Sep-14,60,9999,Both,FALSE,17NCT02019264,Eisai Inc.,FALSE,ND,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01663402,Sanofi,FALSE,ND,https://ClinicalTrials.gov/show/NCT01663402,TRUE,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],3-Feb-16,40,9999,Both,FALSE,12NCT01652872,Amgen,FALSE,ND,https://ClinicalTrials.gov/show/NCT01652872,TRUE,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],9-Dec-15,18,9999,Both,FALSE,16NCT01573442,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT01573442,TRUE,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],3-Nov-15,18,9999,Female,FALSE,1NCT02673190,Radiation Therapy Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02562716,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT02562716,TRUE,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],26-Jan-16,18,75,Both,FALSE,3NCT02523014,Alliance for Clinical Trials in Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT02523014,TRUE,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],8-Dec-15,18,9999,Both,FALSE,1NCT02516423,Alliance for Clinical Trials in Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT02516423,TRUE,"Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone",Solitary Osseous Plasmacytoma,Drug:ixazomib; Drug:lenalidomide; Drug:dexamethasone; Drug:zoledronic acid,"[u'Strecker Cancer Center-Belpre', u'Adena Regional Medical Center', u'Mount Carmel Health Center West', u'Columbus Oncology and Hematology Associates Inc', u'Riverside Methodist Hospital', u'Columbus NCI Community Oncology Research Program', u'Grant Medical Center', u'The Mark H Zangmeister Center', u'Mount Carmel East Hospital', u'Doctors Hospital', u'Delaware Health Center-Grady Cancer Center', u'Delaware Radiation Oncology', u'Grady Memorial Hospital', u'Fairfield Medical Center', u'OhioHealth MedCentral Hospital', u'Marietta Memorial Hospital', u'OhioHealth Marion General Hospital', u'Knox Community Hospital', u'Newark Radiation Oncology', u'Licking Memorial Hospital', u'Southern Ohio Medical Center', u""Saint Ann's Hospital"", u'Genesis Healthcare System Cancer Care Center']",21-Jan-16,18,9999,Both,FALSE,1NCT02506153,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02506153,TRUE,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,18,9999,Both,FALSE,9NCT02488967,NRG Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02451137,Sanofi,FALSE,OH,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02438722,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT02438722,TRUE,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],1-Sep-15,0,9999,Both,FALSE,3NCT02315469,NRG Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT02315469,TRUE,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],13-Jul-15,70,9999,Female,FALSE,159NCT02311933,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02194738,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02180867,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02180867,TRUE,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],1-Feb-16,2,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02143414,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02143414,TRUE,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],15-Jan-16,65,9999,Both,FALSE,9NCT02134912,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT02134912,TRUE,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Drug:crizotinib; Drug:pemetrexed disodium; Other:laboratory biomarker analysis; Other:pharmacological study,[],5-Feb-15,18,9999,Both,FALSE,3NCT02115282,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02101788,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT02085408,Eastern Cooperative Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT02085408,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],16-Sep-14,60,9999,Both,FALSE,17NCT02059265,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02059265,TRUE,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Female,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,OH,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT02003222,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02003222,TRUE,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],28-Jan-16,30,70,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01950390,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01903811,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT01872975,NSABP Foundation Inc,FALSE,OH,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01856192,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01850654,Ohio State University Comprehensive Cancer Center,TRUE,OH,https://ClinicalTrials.gov/show/NCT01850654,TRUE,Ohio Colorectal Cancer Prevention Initiative,Lynch Syndrome; Colorectal Cancer,Genetic:LS tumor screening; Genetic:Genetic testing; Behavioral:Genetic Counseling; Other:Biorepository; Behavioral:Questionnaire,[],1-Dec-15,18,9999,Both,FALSE,35NCT01824875,Eastern Cooperative Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01824875,TRUE,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],7-May-15,18,9999,Both,FALSE,17NCT01810913,Radiation Therapy Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01810913,TRUE,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],14-Nov-15,18,9999,Both,FALSE,4NCT01809691,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01674140,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01668719,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT01622868,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01622868,TRUE,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],4-Feb-16,18,9999,Both,FALSE,9NCT01575548,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01573442,Alliance for Clinical Trials in Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT01573442,TRUE,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],3-Nov-15,18,9999,Female,FALSE,1NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT01535053,Gynecologic Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01535053,TRUE,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01533207,Gynecologic Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01533207,TRUE,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],23-Dec-14,18,9999,Female,FALSE,14NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01415752,Eastern Cooperative Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01349881,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01674140,Southwest Oncology Group,FALSE,OK,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,OK,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01575548,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01975376,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT00565851,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT01975389,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01966107,AstraZeneca,FALSE,OK,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01903811,Southwest Oncology Group,FALSE,OK,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01877915,"Janssen Research & Development, LLC",FALSE,OK,https://ClinicalTrials.gov/show/NCT01877915,TRUE,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],26-Jan-16,18,95,Both,FALSE,132NCT02488967,NRG Oncology,FALSE,OK,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02431806,Forest Laboratories,FALSE,OK,https://ClinicalTrials.gov/show/NCT02431806,TRUE,Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder,Major Depressive Disorder (MDD),Drug:Placebo; Drug:Levomilnacipran ER; Drug:Fluoxetine,[],23-Dec-15,12,17,Both,FALSE,110NCT02194738,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02092467,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT02092467,TRUE,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],15-Jan-16,50,9999,Both,FALSE,10NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,OK,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01872975,NSABP Foundation Inc,FALSE,OK,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,OK,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT02670083,Hoffmann-La Roche,FALSE,OK,https://ClinicalTrials.gov/show/NCT02670083,TRUE,"CREAD Study"" A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)",Alzheimer's Disease,Drug:Crenezumab; Drug:Placebo,[],3-Feb-16,50,85,Both,FALSE,119NCT02528253,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT02528253,TRUE,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],1-Feb-16,18,9999,Both,FALSE,10NCT02504216,Bayer,FALSE,OK,https://ClinicalTrials.gov/show/NCT02504216,TRUE,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],1-Feb-16,50,9999,Both,FALSE,23NCT02451137,Sanofi,FALSE,OK,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02439320,CoLucid Pharmaceuticals,FALSE,OK,https://ClinicalTrials.gov/show/NCT02439320,TRUE,Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:,Acute Migraine,Drug:Lasmiditan 100 mg; Drug:Lasmiditan 200 mg; Drug:Placebo (matches lasmiditan doses),[],13-Nov-15,18,9999,Both,FALSE,91NCT02412917,"ContraVir Pharmaceuticals, Inc.",FALSE,OK,https://ClinicalTrials.gov/show/NCT02412917,TRUE,A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia,Shingles; Herpes Zoster; Postherpetic Neuralgia,Drug:FV-100; Drug:valacyclovir,[],1-Sep-15,50,9999,Both,FALSE,92NCT02154490,Southwest Oncology Group,FALSE,OK,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02153502,Avanir Pharmaceuticals,FALSE,OK,https://ClinicalTrials.gov/show/NCT02153502,TRUE,"Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","Depressive Disorder, Treatment-Resistant",Drug:AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination); Drug:Placebo,[],28-Jan-15,18,9999,Both,FALSE,71NCT02104817,AstraZeneca,FALSE,OK,https://ClinicalTrials.gov/show/NCT02104817,TRUE,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],21-Dec-15,18,99,Both,FALSE,13NCT02075047,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT02075047,TRUE,Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder,Bipolar Disorder,Drug:placebo oral capsules; Drug:ziprasidone oral capsules,[],16-Jan-16,10,17,Both,FALSE,10NCT02060630,New England Research Institutes,FALSE,OK,https://ClinicalTrials.gov/show/NCT02060630,TRUE,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],7-Dec-15,18,9999,Both,FALSE,33NCT02047097,Biogen,FALSE,OK,https://ClinicalTrials.gov/show/NCT02047097,TRUE,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],31-Jul-15,18,9999,Both,FALSE,73NCT02019264,Eisai Inc.,FALSE,OK,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01950390,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01919697,Synergy Pharmaceuticals Inc.,FALSE,OK,https://ClinicalTrials.gov/show/NCT01919697,TRUE,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],10-Dec-15,18,81,Both,FALSE,183NCT01878292,Forest Laboratories,FALSE,OK,https://ClinicalTrials.gov/show/NCT01878292,TRUE,Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder,Major Depressive Disorder,Drug:Placebo; Drug:Vilazodone; Drug:Vilazodone,[],17-Dec-15,12,17,Both,FALSE,110NCT01751906,Abbott Vascular,FALSE,OK,https://ClinicalTrials.gov/show/NCT01751906,TRUE,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],11-Oct-15,18,9999,Both,FALSE,50NCT01729455,"Human Genome Sciences Inc., a GSK Company",FALSE,OK,https://ClinicalTrials.gov/show/NCT01729455,TRUE,Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry,Systemic Lupus Erythematosus,Biological:BENLYSTA; Other:SLE treatment,[],4-Feb-16,18,9999,Both,FALSE,122NCT01715805,Forest Laboratories,FALSE,OK,https://ClinicalTrials.gov/show/NCT01715805,TRUE,"An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)",Major Depressive Disorder,Drug:Cariprazine; Drug:Placebo,[],23-Dec-15,18,65,Both,FALSE,110NCT01663402,Sanofi,FALSE,OK,https://ClinicalTrials.gov/show/NCT01663402,TRUE,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],3-Feb-16,40,9999,Both,FALSE,12NCT01633112,Novartis Pharmaceuticals,FALSE,OK,https://ClinicalTrials.gov/show/NCT01633112,TRUE,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Relapsing-remitting Multiple Sclerosis (RRMS),Drug:fingolimod; Drug:copaxone,[],9-Dec-15,18,65,Both,FALSE,156NCT01622868,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT01622868,TRUE,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],4-Feb-16,18,9999,Both,FALSE,9NCT01594333,Brigham and Women's Hospital,FALSE,OK,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,OK,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01471340,Merck Sharp & Dohme Corp.,FALSE,OK,https://ClinicalTrials.gov/show/NCT01471340,TRUE,A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3),Asthma,Drug:Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug:Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug:Mometasone Furoate MDI 100 mcg; Drug:Mometasone Furoate MDI 200 mcg; Drug:Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug:Prednisone/prednisolone,[],30-Oct-15,12,9999,Both,FALSE,145NCT01107626,Eastern Cooperative Oncology Group,FALSE,OK,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT02674386,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT02674386,TRUE,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],1-Feb-16,18,9999,Both,FALSE,10NCT02671981,Radiation Therapy Oncology Group,FALSE,OK,https://ClinicalTrials.gov/show/NCT02671981,TRUE,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],2-Feb-16,18,9999,Both,FALSE,4NCT01272037,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01674140,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT02488967,NRG Oncology,FALSE,OR,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT01274338,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT00936390,Radiation Therapy Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT00565851,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,OR,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01668719,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT01013649,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02194738,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,OR,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01781468,Alliance for Clinical Trials in Oncology,FALSE,OR,https://ClinicalTrials.gov/show/NCT01781468,TRUE,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],13-Nov-15,18,9999,Both,FALSE,1NCT00956007,Radiation Therapy Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT00956007,TRUE,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Both,FALSE,4NCT02375204,Alliance for Clinical Trials in Oncology,FALSE,OR,https://ClinicalTrials.gov/show/NCT02375204,TRUE,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],8-Dec-15,14,9999,Male,FALSE,1NCT02311933,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,OR,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02003222,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT02003222,TRUE,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],28-Jan-16,30,70,Both,FALSE,9NCT01169337,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01101451,Gynecologic Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01064648,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT01064648,TRUE,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],1-Feb-16,18,9999,Both,FALSE,9NCT00887146,Alliance for Clinical Trials in Oncology,FALSE,OR,https://ClinicalTrials.gov/show/NCT00887146,TRUE,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],18-Dec-15,18,9999,Both,FALSE,1NCT02085408,Eastern Cooperative Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT02085408,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],16-Sep-14,60,9999,Both,FALSE,17NCT01835145,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT01835145,TRUE,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],1-Feb-16,18,9999,Both,FALSE,9NCT01742065,Kaiser Permanente,TRUE,OR,https://ClinicalTrials.gov/show/NCT01742065,TRUE,Strategies and Opportunities to Stop Colon Cancer in Priority Populations,Colorectal Cancer,Other:Auto Plus,"[u'Open Door Health Center', u'Mosaic Medical', u'Benton and Linn County Health Centers', u'Virginia Garcia Memorial Health Center', u'La Clinica Health Care', u'Community Health Center', u'Multnomah County Health Department', u'Oregon Health and Science University']",12-Nov-15,50,74,Both,TRUE,31NCT01511562,Alliance for Clinical Trials in Oncology,FALSE,OR,https://ClinicalTrials.gov/show/NCT01511562,TRUE,Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma,Lymphoma,Drug:carmustine; Drug:cytarabine; Drug:etoposide; Drug:thiotepa; Procedure:stem cell transplant; Drug:G-CSF,[],20-Oct-15,18,75,Both,FALSE,1NCT01415752,Eastern Cooperative Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01085630,Alliance for Clinical Trials in Oncology,FALSE,OR,https://ClinicalTrials.gov/show/NCT01085630,TRUE,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],3-Aug-15,18,9999,Both,FALSE,1NCT01041703,Eastern Cooperative Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT01041703,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],24-Jul-14,60,9999,Both,FALSE,17NCT02673190,Radiation Therapy Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02301156,"TG Therapeutics, Inc.",FALSE,OR,https://ClinicalTrials.gov/show/NCT02301156,TRUE,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],2-Feb-16,18,9999,Both,FALSE,188NCT02154490,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,OR,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01809691,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,OR,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT02164513,GlaxoSmithKline,FALSE,OR,https://ClinicalTrials.gov/show/NCT02164513,TRUE,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],4-Feb-16,40,9999,Both,FALSE,8NCT01368588,Radiation Therapy Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT01368588,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:radiation therapy; Radiation:Whole-pelvic radiotherapy (WPRT),[],13-Oct-15,18,9999,Male,FALSE,4NCT00499330,Alliance for Clinical Trials in Oncology,FALSE,OR,https://ClinicalTrials.gov/show/NCT00499330,TRUE,Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer,Lung Cancer,Procedure:lobectomy; Procedure:segmentectomy or wedge resection,[],28-Aug-15,18,9999,Both,FALSE,1NCT02671981,Radiation Therapy Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT02671981,TRUE,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],2-Feb-16,18,9999,Both,FALSE,4NCT02234583,Daiichi Sankyo Inc.,FALSE,OR,https://ClinicalTrials.gov/show/NCT02234583,TRUE,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],4-Nov-15,18,9999,Both,FALSE,95NCT02104817,AstraZeneca,FALSE,OR,https://ClinicalTrials.gov/show/NCT02104817,TRUE,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],21-Dec-15,18,99,Both,FALSE,13NCT02060630,New England Research Institutes,FALSE,OR,https://ClinicalTrials.gov/show/NCT02060630,TRUE,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],7-Dec-15,18,9999,Both,FALSE,33NCT02032823,AstraZeneca,FALSE,OR,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT01888120,Jazz Pharmaceuticals,FALSE,OR,https://ClinicalTrials.gov/show/NCT01888120,TRUE,Patient Registry of Intrathecal Ziconotide Management(PRIZM),Patients With Severe Chronic Pain,Drug:Ziconotide,[],18-Jun-15,18,9999,Both,FALSE,134NCT01856192,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT02488967,NRG Oncology,FALSE,PA,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02406677,AstraZeneca,FALSE,PA,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02376296,"Saladax Biomedical, Inc.",FALSE,PA,https://ClinicalTrials.gov/show/NCT02376296,TRUE,Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients,Prostate Cancer,Drug:docetaxel; Other:Blood draws,"[u'UPMC CancerCenter - Beaver', u'UPMC CancerCenter - Upper St. Clair', u'UPMC CancerCenter - Horizon', u'Arnold Palmer Cancer Center - Oakbrook', u'Arnold Palmer Cancer Center', u'UPMC CancerCenter - Greenville', u'UPMC CancerCenter - Indiana', u'UPMC CancerCenter at John P. Murtha Regional Cancer Center', u'UPMC CancerCenter - Mckeesport', u'UPMC CancerCenter - Monroeville', u'Arnold Palmer Medical Oncology - Mount Pleasant', u'UPMC CancerCenter - New Castle', u'UPMC CancerCenter - St. Margaret', u'UPMC CancerCenter - Hillman Cancer Center', u'UPMC CancerCenter - Passavant HOA', u'UPMC CancerCenter - Passavant OHA', u'UPMC CancerCenter - Northwest', u'UPMC CancerCenter - Uniontown', u'UPMC CancerCenter - Washington', u'UPMC CancerCenter - Jefferson']",2-Dec-15,18,9999,Male,FALSE,173NCT02194738,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02154490,Southwest Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02111564,"Janssen Research & Development, LLC",FALSE,PA,https://ClinicalTrials.gov/show/NCT02111564,TRUE,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],26-Jan-16,40,9999,Both,FALSE,132NCT02065687,Gynecologic Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02048813,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,PA,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT02019264,Eisai Inc.,FALSE,PA,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT02003209,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01975389,Pfizer,FALSE,PA,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,PA,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01966107,AstraZeneca,FALSE,PA,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,PA,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01950390,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01872975,NSABP Foundation Inc,FALSE,PA,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01856192,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01674140,Southwest Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01594333,Brigham and Women's Hospital,FALSE,PA,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01535053,Gynecologic Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT01535053,TRUE,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01533207,Gynecologic Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT01533207,TRUE,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],23-Dec-14,18,9999,Female,FALSE,14NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,PA,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01274338,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,PA,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01120249,Southwest Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01107626,Eastern Cooperative Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT01079780,Pam Cogliano,FALSE,PA,https://ClinicalTrials.gov/show/NCT01079780,TRUE,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],19-Sep-14,18,9999,Both,FALSE,161NCT01013649,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00936390,Radiation Therapy Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT00843882,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT00807768,Gynecologic Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT02671981,Radiation Therapy Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT02671981,TRUE,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],2-Feb-16,18,9999,Both,FALSE,4NCT01853748,Dana-Farber Cancer Institute,FALSE,PA,https://ClinicalTrials.gov/show/NCT01853748,TRUE,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),Breast Cancer,Drug:Trastuzumab; Drug:Paclitaxel; Drug:Trastuzumab emtansine,[],3-Feb-16,18,9999,Both,FALSE,96NCT01216683,Eastern Cooperative Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT01216683,TRUE,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,18,9999,Both,FALSE,17NCT02523014,Alliance for Clinical Trials in Oncology,FALSE,PA,https://ClinicalTrials.gov/show/NCT02523014,TRUE,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],8-Dec-15,18,9999,Both,FALSE,1NCT02451137,Sanofi,FALSE,PA,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02164916,Southwest Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT01810913,Radiation Therapy Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT01810913,TRUE,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],14-Nov-15,18,9999,Both,FALSE,4NCT01236547,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT01236547,TRUE,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT01903811,Southwest Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01169337,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01751906,Abbott Vascular,FALSE,PA,https://ClinicalTrials.gov/show/NCT01751906,TRUE,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],11-Oct-15,18,9999,Both,FALSE,50NCT01242800,Eastern Cooperative Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT02104817,AstraZeneca,FALSE,PA,https://ClinicalTrials.gov/show/NCT02104817,TRUE,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],21-Dec-15,18,99,Both,FALSE,13NCT01272037,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02194738,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02161757,AstraZeneca,FALSE,RI,https://ClinicalTrials.gov/show/NCT02161757,TRUE,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Tralokinumab; Other:Placebo,[],5-Jan-16,12,75,Both,FALSE,13NCT01557244,Pfizer,FALSE,RI,https://ClinicalTrials.gov/show/NCT01557244,TRUE,A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition,"Urinary Bladder, Neurogenic",Drug:Fesoterodine PR 4 mg; Drug:Fesoterodine PR 8 mg; Drug:Fesoterodine PR 8 mg; Drug:Oxybutynin; Drug:Fesoterodine PR; Drug:Fesoterodine BIC 2 mg; Drug:Fesoterodine BIC 4 mg,[],1-Feb-16,6,17,Both,FALSE,10NCT02412228,"Eric Winer, MD",FALSE,RI,https://ClinicalTrials.gov/show/NCT02412228,TRUE,"BrUOG 299 :Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.",Multiple Myeloma,Drug:Ixazomib; Drug:Cyclophosphamide; Drug:Dexamethasone,"[u'Memorial Hospital of Rhode Island', u'Rhode Island Hospital', u'The Miriam Hospital']",28-Jan-16,18,9999,Both,FALSE,105NCT02213822,Rhode Island Hospital,FALSE,RI,https://ClinicalTrials.gov/show/NCT02213822,TRUE,"Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis",Solid Tumors; Hematological Malignancies,Other:Molecular Analysis of Cancer,"[u'Rhode Island Comprehensive Cancer Center at East Greenwich', u'Rhode Island Hospital', u'The Miriam Hospital']",26-Aug-14,18,9999,Both,FALSE,168NCT02032277,AbbVie,FALSE,RI,https://ClinicalTrials.gov/show/NCT02032277,TRUE,A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,Triple Negative Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Placebo; Drug:Placebo,[],9-Oct-15,18,99,Female,FALSE,51NCT02022033,howard safran,FALSE,RI,https://ClinicalTrials.gov/show/NCT02022033,TRUE,BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial,Pancreatic Cancer,Drug:FOLFOXA,"[u'Memorial Hospital', u'Rhode Island Hospital (East Greenwich and Newport Hospital)', u'The Miriam Hospital']",11-Jan-16,18,9999,Both,FALSE,121NCT02019264,Eisai Inc.,FALSE,RI,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01991795,AstraZeneca,FALSE,RI,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01887912,"Sanofi Pasteur, a Sanofi Company",FALSE,RI,https://ClinicalTrials.gov/show/NCT01887912,TRUE,Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection,Clostridium Difficile Infection,Biological:C. difficile Toxoid Vaccine; Biological:Placebo: 0.9% normal saline,[],11-Dec-15,50,9999,Both,TRUE,38NCT01885988,"Martin M. Miner, MD",FALSE,RI,https://ClinicalTrials.gov/show/NCT01885988,TRUE,Nebivolol Effects on Endothelial Function and Erectile Function,Erectile Dysfunction,Drug:Nebivolol; Drug:Sugar Pill,"[u'University Medicine', u'Miriam Cardiology', u""The Miriam Hospital / The Men's Health Center""]",21-Jun-13,25,65,Male,FALSE,139NCT01845025,Novartis Pharmaceuticals,FALSE,RI,https://ClinicalTrials.gov/show/NCT01845025,TRUE,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],3-Feb-16,12,9999,Both,FALSE,156NCT01701817,"Janssen Scientific Affairs, LLC",FALSE,RI,https://ClinicalTrials.gov/show/NCT01701817,TRUE,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],7-Jan-16,21,9999,Both,FALSE,133NCT01274338,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,RI,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01101035,Takeda,TRUE,RI,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT01013649,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00858364,Amgen,FALSE,RI,https://ClinicalTrials.gov/show/NCT00858364,TRUE,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],27-Jan-16,18,9999,Both,FALSE,16NCT02506153,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT02506153,TRUE,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,18,9999,Both,FALSE,9NCT02477800,Biogen,FALSE,RI,https://ClinicalTrials.gov/show/NCT02477800,TRUE,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],14-Jan-16,50,85,Both,FALSE,73NCT02469701,howard safran,FALSE,RI,https://ClinicalTrials.gov/show/NCT02469701,TRUE,BrUOG 317:Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease,Non-small Cell Lung Cancer; Lung Cancer; Metastatic Lung Cancer; NSCLC,Drug:nivolumab and ablation,"[u'Rhode Island Hospital', u'The Miriam Hospital']",17-Dec-15,18,9999,Both,FALSE,121NCT02452190,"Teva Branded Pharmaceutical Products, R&D Inc.",FALSE,RI,https://ClinicalTrials.gov/show/NCT02452190,TRUE,Study of Reslizumab in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils,Asthma,Drug:Reslizumab; Drug:Placebo,[],4-Feb-16,12,9999,Both,FALSE,186NCT02412371,AbbVie,FALSE,RI,https://ClinicalTrials.gov/show/NCT02412371,TRUE,A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer Stage III,Drug:Veliparib; Drug:Paclitaxel; Drug:Carboplatin; Radiation:Radiotherapy; Other:Placebo for Veliparib,"[u'Site Reference ID/Investigator# 133037', u'Site Reference ID/Investigator# 133486', u'Site Reference ID/Investigator# 133828', u'Site Reference ID/Investigator# 132944', u'Site Reference ID/Investigator# 133494', u'Site Reference ID/Investigator# 133492', u'Site Reference ID/Investigator# 134438', u'Site Reference ID/Investigator# 133496', u'Site Reference ID/Investigator# 133497', u'Site Reference ID/Investigator# 134608', u'Site Reference ID/Investigator# 133493', u'Site Reference ID/Investigator# 133910', u'Site Reference ID/Investigator# 141321', u'Site Reference ID/Investigator# 133495']",18-Jan-16,18,99,Both,FALSE,51NCT02406677,AstraZeneca,FALSE,RI,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02395549,Mimetica Pty Limited,FALSE,RI,https://ClinicalTrials.gov/show/NCT02395549,TRUE,A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris,Acne Vulgaris,Drug:0.375% (w/w) MTC896 Gel; Drug:0.75% (w/w) MTC896 Gel; Drug:1.5% (w/w) MTC896 Gel; Drug:Vehicle Control Gel,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']",21-Jan-16,16,65,Both,FALSE,147NCT02386072,"Astellas Scientific & Medical Affairs, Inc.",FALSE,RI,https://ClinicalTrials.gov/show/NCT02386072,TRUE,"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",Overactive Bladder; Urinary Bladder Overactive; Urinary Bladder Diseases; Urologic Diseases,Drug:mirabegron; Drug:antimuscarinic medication,[],16-Dec-15,18,9999,Both,FALSE,69NCT02352883,ECOG-ACRIN Cancer Research Group,FALSE,RI,https://ClinicalTrials.gov/show/NCT02352883,TRUE,MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ,Ductal Breast Carcinoma In Situ,Procedure:Magnetic Resonance Imaging; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Surgical Procedure; Radiation:Radiation Therapy; Drug:Endocrine Therapy; Other:Quality-of-Life Assessment; Other:Laboratory Biomarker Analysis; Other:Cytology Specimen Collection Procedure,[],22-Sep-15,18,9999,Female,FALSE,101NCT02322814,Hoffmann-La Roche,FALSE,RI,https://ClinicalTrials.gov/show/NCT02322814,TRUE,A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer,Breast Cancer,Drug:cobimetinib; Drug:paclitaxel; Drug:placebo,[],1-Feb-16,18,9999,Both,FALSE,119NCT02316184,Butler Hospital,FALSE,RI,https://ClinicalTrials.gov/show/NCT02316184,TRUE,Comparing Brief Alcohol Interventions For HIV-HCV Co-infected Persons,HIV; Hepatitis C,Behavioral:Motivational Interviewing; Behavioral:Brief Advice,"[u'Butler Hospital', u'Miriam Hospital']",19-Aug-15,18,9999,Both,FALSE,82NCT02273063,Butler Hospital,FALSE,RI,https://ClinicalTrials.gov/show/NCT02273063,TRUE,rTMS for PTSD Comorbid With Major Depressive Disorder,"Posttraumatic Stress Disorder; Major Depressive Disorder; Transcranial Magnetic Stimulation, Repetitive",Device:Transcranial Magnetic Stimulation,"[u'Butler Hospital', u'Providence VA Medical Center']",18-Nov-15,18,70,Both,FALSE,82NCT02244606,"Scynexis, Inc.",FALSE,RI,https://ClinicalTrials.gov/show/NCT02244606,TRUE,Oral SCY-078 vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis,"Mycoses; Candidiasis, Invasive; Candidemia",Drug:SCY-078; Drug:Fluconazole; Drug:Micafungin,[],10-Jan-16,18,80,Both,FALSE,175NCT02243293,AbbVie,FALSE,RI,https://ClinicalTrials.gov/show/NCT02243293,TRUE,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection",Chronic Hepatitis C; Hepatitis C Virus,Drug:ABT-493; Drug:ABT-530; Drug:Ribavirin (RBV); Drug:ABT-493/ABT-530,[],4-Feb-16,18,100,Both,FALSE,51NCT02239120,Boehringer Ingelheim,FALSE,RI,https://ClinicalTrials.gov/show/NCT02239120,TRUE,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],26-Jan-16,18,150,Both,FALSE,75NCT02173379,Abbott Vascular,FALSE,RI,https://ClinicalTrials.gov/show/NCT02173379,TRUE,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],17-Jul-15,18,9999,Both,FALSE,50NCT02164864,Boehringer Ingelheim,FALSE,RI,https://ClinicalTrials.gov/show/NCT02164864,TRUE,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],26-Jan-16,18,9999,Both,FALSE,75NCT02154490,Southwest Oncology Group,FALSE,RI,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02104583,Gilead Sciences,FALSE,RI,https://ClinicalTrials.gov/show/NCT02104583,TRUE,Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator,Ventricular Arrhythmia,Drug:Eleclazine; Drug:Placebo to match eleclazine,[],8-Jan-16,18,80,Both,FALSE,114NCT02080364,vTv Therapeutics,FALSE,RI,https://ClinicalTrials.gov/show/NCT02080364,TRUE,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,Alzheimer's Disease,Drug:Azeliragon; Drug:Placebo,[],15-Jan-16,50,9999,Both,FALSE,220NCT02080221,howard safran,FALSE,RI,https://ClinicalTrials.gov/show/NCT02080221,TRUE,BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial,Metastatic Pancreatic Cancer,Drug:FOLFOXA,"[u'Southcoast centers for cancer care', u'Memorial Hospital of Rhode Island', u'Lifespan Hospitals (The Miriam and RI Hospital, East Greenwich, Newport)']",18-Dec-15,18,9999,Both,FALSE,121NCT02060630,New England Research Institutes,FALSE,RI,https://ClinicalTrials.gov/show/NCT02060630,TRUE,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],7-Dec-15,18,9999,Both,FALSE,33NCT02008357,Eli Lilly and Company,FALSE,RI,https://ClinicalTrials.gov/show/NCT02008357,TRUE,Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss,Cognition Disorders,Drug:Solanezumab; Drug:Placebo,[],12-Jan-16,65,85,Both,TRUE,104NCT02003209,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01983683,Actelion,FALSE,RI,https://ClinicalTrials.gov/show/NCT01983683,TRUE,Phase 3 Study With Cadazolid in Clostridium Difficile-associated Diarrhea (CDAD),Clostridium Difficile Infection,Drug:Cadazolid; Drug:vancomycin,[],10-Dec-15,18,9999,Both,FALSE,55NCT01960075,University of Virginia,FALSE,RI,https://ClinicalTrials.gov/show/NCT01960075,TRUE,Established Status Epilepticus Treatment Trial,Benzodiazepine Refractory Status Epilepticus,Drug:Fosphenytoin; Drug:Levetiracetam; Drug:Valproic acid,[],30-Oct-15,2,9999,Both,FALSE,211NCT01953601,Merck Sharp & Dohme Corp.,FALSE,RI,https://ClinicalTrials.gov/show/NCT01953601,TRUE,Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019),Amnestic Mild Cognitive Impairment; Alzheimer's Disease; Prodromal Alzheimer's Disease,Drug:Verubecestat (Part I and Part II); Drug:Verubecestat (Part I and Part II); Drug:Placebo (Part I); Drug:Verubecestat (Part II),[],31-Dec-15,50,85,Both,FALSE,145NCT01870778,Novartis Pharmaceuticals,FALSE,RI,https://ClinicalTrials.gov/show/NCT01870778,TRUE,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],16-Sep-15,18,9999,Both,FALSE,156NCT02194738,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02152982,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT02152982,TRUE,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01966107,AstraZeneca,FALSE,SC,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01674140,Southwest Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01809691,Southwest Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT02164916,Southwest Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02003209,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT02003222,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT02003222,TRUE,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],28-Jan-16,30,70,Both,FALSE,9NCT02488967,NRG Oncology,FALSE,SC,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT01349881,Southwest Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01169337,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01013649,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,SC,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,SC,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,SC,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,SC,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,SC,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT01595061,Gynecologic Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT01595061,TRUE,"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva",Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVA Vulvar Cancer; Vulvar Squamous Cell Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Gemcitabine Hydrochloride; Drug:Cisplatin; Procedure:Therapeutic Conventional Surgery,[],23-Dec-14,18,9999,Female,FALSE,14NCT02523014,Alliance for Clinical Trials in Oncology,FALSE,SC,https://ClinicalTrials.gov/show/NCT02523014,TRUE,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],8-Dec-15,18,9999,Both,FALSE,1NCT02487498,Novartis Pharmaceuticals,FALSE,SC,https://ClinicalTrials.gov/show/NCT02487498,TRUE,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol ); Drug:Placebo (QVA149),[],29-Jun-15,40,9999,Both,FALSE,156NCT02180867,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT02180867,TRUE,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],1-Feb-16,2,9999,Both,FALSE,9NCT02164513,GlaxoSmithKline,FALSE,SC,https://ClinicalTrials.gov/show/NCT02164513,TRUE,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],4-Feb-16,40,9999,Both,FALSE,8NCT01872975,NSABP Foundation Inc,FALSE,SC,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT02562716,Southwest Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT02562716,TRUE,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],26-Jan-16,18,75,Both,FALSE,3NCT01107626,Eastern Cooperative Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT01101035,Takeda,TRUE,SC,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT00843882,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT02673190,Radiation Therapy Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02536508,"Pearl Therapeutics, Inc.",FALSE,SC,https://ClinicalTrials.gov/show/NCT02536508,TRUE,"Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",COPD,Drug:BGF MDI (PT010) 320/14.4/9.6 g; Drug:GFF MDI (PT003) 14.4/9.6 g; Drug:BFF MDI (PT009) 320/9.6 g,[],6-Jan-16,40,80,Both,FALSE,163NCT02465567,"Pearl Therapeutics, Inc.",FALSE,SC,https://ClinicalTrials.gov/show/NCT02465567,TRUE,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],22-Dec-15,40,80,Both,FALSE,163NCT02115282,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01781468,Alliance for Clinical Trials in Oncology,FALSE,SC,https://ClinicalTrials.gov/show/NCT01781468,TRUE,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],13-Nov-15,18,9999,Both,FALSE,1NCT00978458,Eastern Cooperative Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT00978458,TRUE,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],4-Dec-12,18,9999,Both,FALSE,17NCT00936390,Radiation Therapy Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT02315469,NRG Oncology,FALSE,SC,https://ClinicalTrials.gov/show/NCT02315469,TRUE,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],13-Jul-15,70,9999,Female,FALSE,159NCT02311933,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02104817,AstraZeneca,FALSE,SC,https://ClinicalTrials.gov/show/NCT02104817,TRUE,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],21-Dec-15,18,99,Both,FALSE,13NCT01950390,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01575548,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01533207,Gynecologic Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT01533207,TRUE,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],23-Dec-14,18,9999,Female,FALSE,14NCT01064648,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT01064648,TRUE,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],1-Feb-16,18,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT02154490,Southwest Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02152982,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT02152982,TRUE,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02115282,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02065687,Gynecologic Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01674140,Southwest Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,SD,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT00565851,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,SD,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02048813,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01950390,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,SD,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01856192,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01274338,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01169337,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01107626,Eastern Cooperative Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT00666731,University of Nebraska,FALSE,SD,https://ClinicalTrials.gov/show/NCT00666731,TRUE,A Breast Cancer Information Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer,Breast Cancer; Precancerous Condition,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:Excess human biological tissue; Procedure:quality-of-life assessment,[],30-Nov-15,19,120,Both,FALSE,206NCT02488967,NRG Oncology,FALSE,SD,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02164916,Southwest Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02101788,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT02085408,Eastern Cooperative Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT02085408,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],16-Sep-14,60,9999,Both,FALSE,17NCT02003209,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01781468,Alliance for Clinical Trials in Oncology,FALSE,SD,https://ClinicalTrials.gov/show/NCT01781468,TRUE,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],13-Nov-15,18,9999,Both,FALSE,1NCT01668719,Southwest Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT01349881,Southwest Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01345019,Amgen,FALSE,SD,https://ClinicalTrials.gov/show/NCT01345019,TRUE,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma,Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions,Drug:Denosumab; Drug:Zoledronic acid,[],20-Nov-15,18,9999,Both,FALSE,16NCT01101451,Gynecologic Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01042522,Gynecologic Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT01042522,TRUE,"Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",Malignant Ovarian Surface Epithelial-Stromal Tumor,Drug:Paclitaxel; Drug:Carboplatin; Biological:Bleomycin Sulfate; Drug:Etoposide Phosphate; Drug:Cisplatin,[],23-Dec-14,18,9999,Female,FALSE,14NCT00897442,Gynecologic Oncology Group,TRUE,SD,https://ClinicalTrials.gov/show/NCT00897442,TRUE,Collecting Tumor Samples From Patients With Gynecological Tumors,Cancer,Other:biologic sample preservation procedure,[],30-Aug-12,0,9999,Female,FALSE,14NCT00888615,Gynecologic Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT00888615,TRUE,"Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Ovarian Carcinoma,Drug:Elesclomol Sodium; Drug:Paclitaxel,[],23-Dec-14,18,9999,Female,FALSE,14NCT00858364,Amgen,FALSE,SD,https://ClinicalTrials.gov/show/NCT00858364,TRUE,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],27-Jan-16,18,9999,Both,FALSE,16NCT00843882,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT00807768,Gynecologic Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT02671981,Radiation Therapy Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT02671981,TRUE,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],2-Feb-16,18,9999,Both,FALSE,4NCT02562716,Southwest Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT02562716,TRUE,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],26-Jan-16,18,75,Both,FALSE,3NCT02506153,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT02506153,TRUE,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,18,9999,Both,FALSE,9NCT02480153,Pfizer,FALSE,SD,https://ClinicalTrials.gov/show/NCT02480153,TRUE,A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).,Rheumatoid Arthritis,Biological:PF-06410293; Biological:Adalimumab,[],25-Jan-16,18,9999,Both,FALSE,10NCT02465515,GlaxoSmithKline,FALSE,SD,https://ClinicalTrials.gov/show/NCT02465515,TRUE,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Diabetes Mellitus,Biological:Albiglutide 30 mg; Biological:Albiglutide 50 mg; Biological:Albiglutide matching placebo,[],4-Feb-16,40,9999,Both,FALSE,8NCT02438722,Southwest Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT02438722,TRUE,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],1-Sep-15,0,9999,Both,FALSE,3NCT02367820,Nektar Therapeutics,FALSE,SD,https://ClinicalTrials.gov/show/NCT02367820,TRUE,Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain,Low Back Pain; Chronic Pain,Drug:NKTR-181,[],21-Dec-15,18,75,Both,FALSE,151NCT02339571,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT02339571,TRUE,Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma of the Skin; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Biological:Sargramostim,[],4-Feb-16,18,9999,Both,FALSE,9NCT02311933,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02301156,"TG Therapeutics, Inc.",FALSE,SD,https://ClinicalTrials.gov/show/NCT02301156,TRUE,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],2-Feb-16,18,9999,Both,FALSE,188NCT02243592,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT02243592,TRUE,Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment,Malignant Neoplasm,Other:Laboratory Biomarker Analysis,[],22-Jan-16,0,9999,Both,FALSE,9NCT02234583,Daiichi Sankyo Inc.,FALSE,SD,https://ClinicalTrials.gov/show/NCT02234583,TRUE,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],4-Nov-15,18,9999,Both,FALSE,95NCT02194738,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,TN,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02343406,AbbVie,FALSE,TN,https://ClinicalTrials.gov/show/NCT02343406,TRUE,ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma,Glioblastoma Multiforme,Drug:ABT-414; Drug:Lomustine; Drug:Temozolomide,[],7-Jan-16,18,99,Both,FALSE,51NCT01975389,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01674140,Southwest Oncology Group,FALSE,TN,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01120249,Southwest Oncology Group,FALSE,TN,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT02301156,"TG Therapeutics, Inc.",FALSE,TN,https://ClinicalTrials.gov/show/NCT02301156,TRUE,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],2-Feb-16,18,9999,Both,FALSE,188NCT02194738,National Cancer Institute (NCI),FALSE,TN,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,TN,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT01101035,Takeda,TRUE,TN,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT02488967,NRG Oncology,FALSE,TN,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02019264,Eisai Inc.,FALSE,TN,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01845025,Novartis Pharmaceuticals,FALSE,TN,https://ClinicalTrials.gov/show/NCT01845025,TRUE,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],3-Feb-16,12,9999,Both,FALSE,156NCT00761267,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00761267,TRUE,"Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis",Candidemia,Drug:Anidulafungin; Drug:Fluconazole,[],25-Jan-16,1,17,Both,FALSE,10NCT02451137,Sanofi,FALSE,TN,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,TN,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01575548,National Cancer Institute (NCI),FALSE,TN,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,TN,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01991795,AstraZeneca,FALSE,TN,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01966107,AstraZeneca,FALSE,TN,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01652872,Amgen,FALSE,TN,https://ClinicalTrials.gov/show/NCT01652872,TRUE,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],9-Dec-15,18,9999,Both,FALSE,16NCT01274338,National Cancer Institute (NCI),FALSE,TN,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT00565851,National Cancer Institute (NCI),FALSE,TN,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02562716,Southwest Oncology Group,FALSE,TN,https://ClinicalTrials.gov/show/NCT02562716,TRUE,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],26-Jan-16,18,75,Both,FALSE,3NCT02429349,University of Tennessee,TRUE,TN,https://ClinicalTrials.gov/show/NCT02429349,TRUE,Preservation of Ovarian Tissue and Chemo-Radiotherapy,Endocrine Disorders of Female Reproductive System; Secondary Infertility; Infertility Involuntary,Procedure:surgery,"[u'Methodist/LeBonheur Hospital', u""LeBonheur Children's Hospital"", u'Regional One Health Ob-Gyn Clinic', u'Regional One Health, Regional Medical Center, Operating Room', u'Methodist University Hospital', u""St. Jude Children's Research Hospital"", u'Baptist Memorial Hospital']",28-Jul-15,8,40,Female,FALSE,44NCT02111564,"Janssen Research & Development, LLC",FALSE,TN,https://ClinicalTrials.gov/show/NCT02111564,TRUE,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],26-Jan-16,40,9999,Both,FALSE,132NCT01919697,Synergy Pharmaceuticals Inc.,FALSE,TN,https://ClinicalTrials.gov/show/NCT01919697,TRUE,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],10-Dec-15,18,81,Both,FALSE,183NCT01663402,Sanofi,FALSE,TN,https://ClinicalTrials.gov/show/NCT01663402,TRUE,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],3-Feb-16,40,9999,Both,FALSE,12NCT01573442,Alliance for Clinical Trials in Oncology,FALSE,TN,https://ClinicalTrials.gov/show/NCT01573442,TRUE,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],3-Nov-15,18,9999,Female,FALSE,1NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,TN,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT02216214,"Astellas Pharma Global Development, Inc.",FALSE,TN,https://ClinicalTrials.gov/show/NCT02216214,TRUE,"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",Overactive Bladder (OAB),Drug:Mirabegron; Drug:Placebo,[],18-Nov-15,65,9999,Both,FALSE,67NCT02182830,Boehringer Ingelheim,FALSE,TN,https://ClinicalTrials.gov/show/NCT02182830,TRUE,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],26-Jan-16,18,9999,Both,FALSE,75NCT02154490,Southwest Oncology Group,FALSE,TN,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02104817,AstraZeneca,FALSE,TN,https://ClinicalTrials.gov/show/NCT02104817,TRUE,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],21-Dec-15,18,99,Both,FALSE,13NCT01920711,Novartis Pharmaceuticals,FALSE,TN,https://ClinicalTrials.gov/show/NCT01920711,TRUE,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],14-Oct-15,50,9999,Both,FALSE,156NCT01771809,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT01771809,TRUE,Long-Term Safety Of PF-00547659 In Ulcerative Colitis,Ulcerative Colitis,Drug:PF-00547659; Drug:PF-00547659; Drug:PF-00547659,[],16-Jan-16,18,65,Both,FALSE,10NCT01701817,"Janssen Scientific Affairs, LLC",FALSE,TN,https://ClinicalTrials.gov/show/NCT01701817,TRUE,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],7-Jan-16,21,9999,Both,FALSE,133NCT01492361,Amarin Pharma Inc.,FALSE,TN,https://ClinicalTrials.gov/show/NCT01492361,TRUE,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],14-Jul-15,45,9999,Both,FALSE,62NCT01470612,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT01470612,TRUE,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug:CP-690,550; Drug:CP-690,550",[],11-Jan-16,18,9999,Both,FALSE,10NCT01349881,Southwest Oncology Group,FALSE,TN,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01227967,National Institute of Allergy and Infectious Diseases (NIAID),TRUE,TN,https://ClinicalTrials.gov/show/NCT01227967,TRUE,"Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications",Influenza,"Drug:Amantadine, Ribavirin, Oseltamivir; Drug:Oseltamivir",[],11-Jan-16,18,9999,Both,FALSE,7NCT02409355,Hoffmann-La Roche,FALSE,TN,https://ClinicalTrials.gov/show/NCT02409355,TRUE,A Study of Atezolizumab (MPDL3280A) Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer [IMpower111],Non-Squamous Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Cisplatin; Drug:Gemcitabine,[],1-Feb-16,18,9999,Both,FALSE,119NCT02406677,AstraZeneca,FALSE,TN,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02352948,AstraZeneca,FALSE,TN,https://ClinicalTrials.gov/show/NCT02352948,TRUE,"A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",Non-Small Cell Lung Cancer (NSCLC),Drug:MEDI4736; Drug:Vinorelbine; Drug:Gemcitabine; Drug:Erlotinib; Drug:MEDI4736 in combination with tremelimumab (anti-CTLA4); Drug:tremelimumab (anti-CTLA4),[],11-Jan-16,18,130,Both,FALSE,13NCT02164916,Southwest Oncology Group,FALSE,TN,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02066636,Bristol-Myers Squibb,FALSE,TN,https://ClinicalTrials.gov/show/NCT02066636,TRUE,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],26-Jan-16,18,9999,Both,FALSE,80NCT02574078,Bristol-Myers Squibb,FALSE,TX,https://ClinicalTrials.gov/show/NCT02574078,TRUE,A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),Non-Small Cell Lung Cancer,Drug:Nivolumab; Drug:Bevacizumab; Drug:Pemetrexed; Other:Palliative radiation; Drug:nab-Paclitaxel; Drug:Paclitaxel; Drug:Docetaxel; Drug:Gemcitabine; Drug:Erlotinib; Drug:Crizotinib; Drug:Carboplatin,[],26-Jan-16,18,9999,Both,FALSE,80NCT02545049,Bayer,FALSE,TX,https://ClinicalTrials.gov/show/NCT02545049,TRUE,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],21-Jan-16,18,9999,Both,FALSE,23NCT02540993,Bayer,FALSE,TX,https://ClinicalTrials.gov/show/NCT02540993,TRUE,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],21-Jan-16,18,9999,Both,FALSE,23NCT02504216,Bayer,FALSE,TX,https://ClinicalTrials.gov/show/NCT02504216,TRUE,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],1-Feb-16,50,9999,Both,FALSE,23NCT02451137,Sanofi,FALSE,TX,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02019264,Eisai Inc.,FALSE,TX,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01991795,AstraZeneca,FALSE,TX,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01975389,Pfizer,FALSE,TX,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,TX,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01966107,AstraZeneca,FALSE,TX,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01897532,Boehringer Ingelheim,FALSE,TX,https://ClinicalTrials.gov/show/NCT01897532,TRUE,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],26-Jan-16,18,9999,Both,FALSE,75NCT01858532,AbbVie,FALSE,TX,https://ClinicalTrials.gov/show/NCT01858532,TRUE,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],20-Jan-16,18,85,Both,FALSE,51NCT01652872,Amgen,FALSE,TX,https://ClinicalTrials.gov/show/NCT01652872,TRUE,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],9-Dec-15,18,9999,Both,FALSE,16NCT01594333,Brigham and Women's Hospital,FALSE,TX,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01272037,National Cancer Institute (NCI),FALSE,TX,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01101035,Takeda,TRUE,TX,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT01013649,National Cancer Institute (NCI),FALSE,TX,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00936390,Radiation Therapy Oncology Group,FALSE,TX,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT00858364,Amgen,FALSE,TX,https://ClinicalTrials.gov/show/NCT00858364,TRUE,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],27-Jan-16,18,9999,Both,FALSE,16NCT02342249,Vertex Pharmaceuticals Incorporated,FALSE,TX,https://ClinicalTrials.gov/show/NCT02342249,TRUE,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],28-Jul-15,18,64,Both,FALSE,218NCT02164513,GlaxoSmithKline,FALSE,TX,https://ClinicalTrials.gov/show/NCT02164513,TRUE,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],4-Feb-16,40,9999,Both,FALSE,8NCT01872975,NSABP Foundation Inc,FALSE,TX,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01663402,Sanofi,FALSE,TX,https://ClinicalTrials.gov/show/NCT01663402,TRUE,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],3-Feb-16,40,9999,Both,FALSE,12NCT02406677,AstraZeneca,FALSE,TX,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02092467,Pfizer,FALSE,TX,https://ClinicalTrials.gov/show/NCT02092467,TRUE,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],15-Jan-16,50,9999,Both,FALSE,10NCT02066636,Bristol-Myers Squibb,FALSE,TX,https://ClinicalTrials.gov/show/NCT02066636,TRUE,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],26-Jan-16,18,9999,Both,FALSE,80NCT01492361,Amarin Pharma Inc.,FALSE,TX,https://ClinicalTrials.gov/show/NCT01492361,TRUE,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],14-Jul-15,45,9999,Both,FALSE,62NCT02065687,Gynecologic Oncology Group,FALSE,TX,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01919697,Synergy Pharmaceuticals Inc.,FALSE,TX,https://ClinicalTrials.gov/show/NCT01919697,TRUE,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],10-Dec-15,18,81,Both,FALSE,183NCT01701817,"Janssen Scientific Affairs, LLC",FALSE,TX,https://ClinicalTrials.gov/show/NCT01701817,TRUE,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],7-Jan-16,21,9999,Both,FALSE,133NCT00956007,Radiation Therapy Oncology Group,FALSE,TX,https://ClinicalTrials.gov/show/NCT00956007,TRUE,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Both,FALSE,4NCT02106546,AbbVie,FALSE,TX,https://ClinicalTrials.gov/show/NCT02106546,TRUE,"Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",Squamous Non-Small Cell Lung Cancer,Drug:veliparib; Drug:carboplatin; Drug:paclitaxel; Drug:placebo,[],13-Jan-16,18,99,Both,FALSE,51NCT01190930,Children's Oncology Group,FALSE,TX,https://ClinicalTrials.gov/show/NCT01190930,TRUE,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],6-Aug-15,1,30,Both,FALSE,17NCT02526524,"Elcelyx Therapeutics, Inc.",FALSE,TX,https://ClinicalTrials.gov/show/NCT02526524,TRUE,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],7-Jan-16,25,9999,Both,FALSE,103NCT02164864,Boehringer Ingelheim,FALSE,TX,https://ClinicalTrials.gov/show/NCT02164864,TRUE,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],26-Jan-16,18,9999,Both,FALSE,75NCT02161757,AstraZeneca,FALSE,TX,https://ClinicalTrials.gov/show/NCT02161757,TRUE,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Tralokinumab; Other:Placebo,[],5-Jan-16,12,75,Both,FALSE,13NCT02155660,AstraZeneca,FALSE,TX,https://ClinicalTrials.gov/show/NCT02155660,TRUE,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],7-Jan-16,40,85,Both,FALSE,13NCT01968967,Pfizer,FALSE,TX,https://ClinicalTrials.gov/show/NCT01968967,TRUE,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],25-Jan-16,18,9999,Both,FALSE,10NCT01406756,Children's Oncology Group,FALSE,TX,https://ClinicalTrials.gov/show/NCT01406756,TRUE,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],3-Feb-16,1,30,Both,FALSE,17NCT00807768,Gynecologic Oncology Group,FALSE,TX,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT02461589,Novo Nordisk A/S,FALSE,TX,https://ClinicalTrials.gov/show/NCT02461589,TRUE,Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:liraglutide; Drug:placebo,[],29-Oct-15,18,9999,Both,FALSE,158NCT01272037,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02488967,NRG Oncology,FALSE,UT,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02065687,Gynecologic Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02003222,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT02003222,TRUE,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],28-Jan-16,30,70,Both,FALSE,9NCT01674140,Southwest Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01101451,Gynecologic Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01013649,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02194738,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02154490,Southwest Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02101788,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT01975389,Pfizer,FALSE,UT,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,UT,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,UT,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01236547,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT01236547,TRUE,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00887146,Alliance for Clinical Trials in Oncology,FALSE,UT,https://ClinicalTrials.gov/show/NCT00887146,TRUE,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],18-Dec-15,18,9999,Both,FALSE,1NCT02032823,AstraZeneca,FALSE,UT,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT01991795,AstraZeneca,FALSE,UT,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01808573,"Puma Biotechnology, Inc.",FALSE,UT,https://ClinicalTrials.gov/show/NCT01808573,TRUE,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],26-Jan-16,18,9999,Both,FALSE,166NCT00936390,Radiation Therapy Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT00807768,Gynecologic Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT02673190,Radiation Therapy Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT01966107,AstraZeneca,FALSE,UT,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT00565851,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02638129,Takeda,FALSE,UT,https://ClinicalTrials.gov/show/NCT02638129,TRUE,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],28-Jan-16,18,9999,Both,FALSE,5NCT02583256,Novartis Vaccines,FALSE,UT,https://ClinicalTrials.gov/show/NCT02583256,TRUE,"Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)",Influenza,Biological:aQIV-aQIV; Biological:aQIV-QIV; Biological:QIV-aQIV; Biological:QIV-QIV,[],15-Jan-16,18,85,Both,TRUE,157NCT02509078,Massachusetts General Hospital,FALSE,UT,https://ClinicalTrials.gov/show/NCT02509078,TRUE,Reevaluation Of Systemic Early Neuromuscular Blockade,Acute Respiratory Distress Syndrome,Drug:cisastracurium besylate,[],19-Jan-16,18,9999,Both,FALSE,140NCT02451137,Sanofi,FALSE,UT,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02342249,Vertex Pharmaceuticals Incorporated,FALSE,UT,https://ClinicalTrials.gov/show/NCT02342249,TRUE,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],28-Jul-15,18,64,Both,FALSE,218NCT02310763,Pfizer,FALSE,UT,https://ClinicalTrials.gov/show/NCT02310763,TRUE,"A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy",Duchenne Muscular Dystrophy,Biological:PF-06252616; Drug:Placebo,[],19-Jan-16,6,9,Male,FALSE,10NCT02299414,University of Alabama at Birmingham,FALSE,UT,https://ClinicalTrials.gov/show/NCT02299414,TRUE,Chronic Hypertension and Pregnancy (CHAP) Project,Hypertension,Other:Anti-hypertensive therapy; Other:No anti-hypertensive therapy (unless BP is severe),[],5-Nov-15,12,9999,Female,FALSE,197NCT02179086,NRG Oncology,FALSE,UT,https://ClinicalTrials.gov/show/NCT02179086,TRUE,Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy; Radiation:photon beam radiation therapy; Radiation:intensity-modulated radiation therapy; Radiation:proton beam radiation therapy; Drug:temozolomide; Other:laboratory biomarker analysis,[],25-Aug-15,18,9999,Both,FALSE,159NCT02132247,IBSA Institut Biochimique SA,FALSE,UT,https://ClinicalTrials.gov/show/NCT02132247,TRUE,Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries,Athletic Injuries,Drug:Diclofenac hydroxyethylpyrrolidine,"[u'Applied Research Center of Arkansas', u'SCORE Physician Alliance', u'Pediatrics and Adolescent Medicine P.A.', u'Arlington Family Research Center Inc.', u'Utah Valley Pediatrics', u'J. Lewis Research Inc./Foothill Family Clininc', u'J. Lewis Research Inc./FirstMed East', u'J. Lewis Research Inc./Foothill Family Clinic South', u'Legacy Point Family Medicine', u'Pediatric Research of Charlottesville']",7-Aug-15,6,16,Both,FALSE,123NCT02019264,Eisai Inc.,FALSE,UT,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01672892,Radiation Therapy Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT01672892,TRUE,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],14-Nov-15,18,9999,Female,FALSE,4NCT01543087,Pfizer,FALSE,UT,https://ClinicalTrials.gov/show/NCT01543087,TRUE,Duration of Immunity Study,Meningococcal Infection,Procedure:blood sampling; Drug:bivalent rLP2086,[],25-Jan-16,10,18,Both,TRUE,10NCT01414608,Gynecologic Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT01414608,TRUE,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],16-Jul-15,18,9999,Female,FALSE,14NCT01101035,Takeda,TRUE,UT,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT00956007,Radiation Therapy Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT00956007,TRUE,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Both,FALSE,4NCT02573311,Boehringer Ingelheim,FALSE,UT,https://ClinicalTrials.gov/show/NCT02573311,TRUE,Actual Use Study of Tamsulosin in Men,Urological Manifestations,Drug:tamsulosin hydrochloride,[],25-Jan-16,18,9999,Male,FALSE,75NCT02407236,"Janssen Research & Development, LLC",FALSE,UT,https://ClinicalTrials.gov/show/NCT02407236,TRUE,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative; Inflammatory Bowel Diseases",Drug:Placebo IV; Drug:Placebo SC; Drug:Ustekinumab IV; Drug:Ustekinumab SC,[],2-Feb-16,18,9999,Both,FALSE,132NCT02387359,Synergy Pharmaceuticals Inc.,FALSE,UT,https://ClinicalTrials.gov/show/NCT02387359,TRUE,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],10-Dec-15,18,85,Both,FALSE,183NCT02160041,Novartis Pharmaceuticals,FALSE,UT,https://ClinicalTrials.gov/show/NCT02160041,TRUE,BGJ398 for Patients With Tumors With FGFR Genetic Alterations,Solid Tumor; Hematologic Malignancies,Drug:BGJ398,[],24-Jan-16,18,9999,Both,FALSE,156NCT02104817,AstraZeneca,FALSE,UT,https://ClinicalTrials.gov/show/NCT02104817,TRUE,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],21-Dec-15,18,99,Both,FALSE,13NCT01919697,Synergy Pharmaceuticals Inc.,FALSE,UT,https://ClinicalTrials.gov/show/NCT01919697,TRUE,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],10-Dec-15,18,81,Both,FALSE,183NCT01897532,Boehringer Ingelheim,FALSE,UT,https://ClinicalTrials.gov/show/NCT01897532,TRUE,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],26-Jan-16,18,9999,Both,FALSE,75NCT01810913,Radiation Therapy Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT01810913,TRUE,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],14-Nov-15,18,9999,Both,FALSE,4NCT02673190,Radiation Therapy Oncology Group,FALSE,VT,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02194738,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT01674140,Southwest Oncology Group,FALSE,VT,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01272037,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,VT,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT02193282,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,VT,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02003209,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01622868,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT01622868,TRUE,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],4-Feb-16,18,9999,Both,FALSE,9NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,VT,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,VT,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01311336,University of Vermont,FALSE,VT,https://ClinicalTrials.gov/show/NCT01311336,TRUE,Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain,Pegfilgrastim-induced Back and Leg Pain,Drug:Loratadine; Drug:placebo,"[u'Cancer Care of Maine', u'Maine Center for Cancer Medicine', u'York Hospital', u'CR Wood Cancer Center', u'Mountainview Medical Center', u'Vermont Cancer Center', u'Vermont Center for Cancer Medicine']",23-Jan-13,18,9999,Both,FALSE,45NCT00982436,University of Vermont,FALSE,VT,https://ClinicalTrials.gov/show/NCT00982436,TRUE,Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer,Head and Neck Neoplasms,Drug:Docetaxel/cisplatin; Radiation:Radiotherapy; Drug:Carboplatin,"[u'Mountainview Medical Center', u'Fletcher Allen Health Care', u'Vermont Center for Cancer Medicine']",21-Mar-12,18,9999,Both,FALSE,45NCT00936390,Radiation Therapy Oncology Group,FALSE,VT,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT02671981,Radiation Therapy Oncology Group,FALSE,VT,https://ClinicalTrials.gov/show/NCT02671981,TRUE,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],2-Feb-16,18,9999,Both,FALSE,4NCT02402543,University of Vermont,TRUE,VT,https://ClinicalTrials.gov/show/NCT02402543,TRUE,Pre-Emptive Analgesia in Ano-Rectal Surgery,Hemorrhoids; Fissure in Ano; Rectal Fistula; Anal Condyloma,Drug:Gabapentin; Drug:Ketamine; Drug:Acetaminophen; Drug:Dexamethasone; Drug:Placebo,"[u'University of Vermont Medical Center', u'University of Vermont Medical Center Fanny Allen Campus']",6-Apr-15,18,9999,Both,FALSE,45NCT02186847,NRG Oncology,FALSE,VT,https://ClinicalTrials.gov/show/NCT02186847,TRUE,Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,Adenosquamous Lung Carcinoma; Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Non-Small Cell Lung Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Squamous Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Radiation:Volume Modulated Arc Therapy,[],29-Jan-16,18,9999,Both,FALSE,159NCT02154490,Southwest Oncology Group,FALSE,VT,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02065791,"Janssen Research & Development, LLC",FALSE,VT,https://ClinicalTrials.gov/show/NCT02065791,TRUE,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],5-Jan-16,30,9999,Both,FALSE,132NCT02065687,Gynecologic Oncology Group,FALSE,VT,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02048813,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,VT,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT01966107,AstraZeneca,FALSE,VT,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,VT,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,VT,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01921751,Radiation Therapy Oncology Group,FALSE,VT,https://ClinicalTrials.gov/show/NCT01921751,TRUE,High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery,Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation,[],29-Jan-16,18,9999,Both,FALSE,4NCT01858532,AbbVie,FALSE,VT,https://ClinicalTrials.gov/show/NCT01858532,TRUE,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],20-Jan-16,18,85,Both,FALSE,51NCT01274338,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT00492778,Gynecologic Oncology Group,FALSE,VT,https://ClinicalTrials.gov/show/NCT00492778,TRUE,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],13-Jul-15,0,9999,Female,FALSE,14NCT00430183,Alliance for Clinical Trials in Oncology,FALSE,VT,https://ClinicalTrials.gov/show/NCT00430183,TRUE,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],13-Mar-15,18,9999,Male,FALSE,1NCT00048958,Alliance for Clinical Trials in Oncology,TRUE,VT,https://ClinicalTrials.gov/show/NCT00048958,TRUE,Cytogenetic Studies in Acute Leukemia and Multiple Myeloma,Acute Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Multiple Myeloma,Genetic:cytogenetic analysis,[],6-Aug-15,18,9999,Both,FALSE,1NCT02659748,University of Vermont Medical Center,FALSE,VT,https://ClinicalTrials.gov/show/NCT02659748,TRUE,Milk Fat Intake and Metabolic Health Markers,Insulin Sensitivity; Type 2 Diabetes,Dietary Supplement:Milk Fat; Dietary Supplement:Control Fat,"[u'Clinical Research Center, University of Vermont Medical Center']",15-Jan-16,18,40,Both,TRUE,210NCT02655354,University of Washington,FALSE,VT,https://ClinicalTrials.gov/show/NCT02655354,TRUE,A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity,Posttraumatic Stress Disorder; Depression; Alcohol-Related Disorders; Suicidal Ideation; Substance-Related Disorders; Mild Cognitive Impairment; Quality of Life; Pain; Wounds and Injury; Brain Injuries; Chronic Disease,Behavioral:Motivational Interviewing; Behavioral:Cognitive Behavioral Therapy Elements; Behavioral:Care Management; Drug:Fluoxetine; Drug:Fluvoxamine; Drug:Paroxetine; Drug:Setraline; Drug:Citalopram; Drug:Venlafaxine; Drug:Duloxetine; Drug:Mirtazapine; Drug:Diphenhydramine; Drug:Trazodone; Drug:Prazosin,[],11-Jan-16,18,9999,Both,FALSE,212NCT02618031,Akron General Medical Center,TRUE,VT,https://ClinicalTrials.gov/show/NCT02618031,TRUE,The Capillary Index Score Trial,Acute Stroke; Brain Ischemia; Ischemic Stroke,Procedure:Endovascular Treatment (EVT),"[u'New York University Langone Medical Center', u'Rochester General Hospital', u'University of North Carolina Hospital', u'Akron General Medical Center', u'Thomas Jefferson University Hospital', u'University of Vermont Medical Center']",13-Jan-16,18,9999,Both,FALSE,20NCT02596893,Celgene Corporation,FALSE,VT,https://ClinicalTrials.gov/show/NCT02596893,TRUE,Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease,Crohn Disease,Drug:GED-0301; Drug:Placebo,[],21-Jan-16,18,9999,Both,FALSE,86NCT02556203,Bayer,FALSE,VT,https://ClinicalTrials.gov/show/NCT02556203,TRUE,Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes,Transcatheter Aortic Valve Replacement,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Acetylsalicylic acid; Drug:Clopidogrel",[],20-Jan-16,18,9999,Both,FALSE,23NCT02545049,Bayer,FALSE,VT,https://ClinicalTrials.gov/show/NCT02545049,TRUE,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],21-Jan-16,18,9999,Both,FALSE,23NCT02540993,Bayer,FALSE,VT,https://ClinicalTrials.gov/show/NCT02540993,TRUE,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],21-Jan-16,18,9999,Both,FALSE,23NCT02514473,Vertex Pharmaceuticals Incorporated,FALSE,VT,https://ClinicalTrials.gov/show/NCT02514473,TRUE,"A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Drug:VX-809; Drug:Placebo; Drug:VX-770,[],1-Sep-15,6,11,Both,FALSE,218NCT02489396,University of Vermont,FALSE,VT,https://ClinicalTrials.gov/show/NCT02489396,TRUE,Promoting Healthier Food Purchases By Leveraging the Online-Grocery Environment,Obesity,Behavioral:Nutrition facts automatically or not automatically displayed; Behavioral:Nutrition facts in color; Behavioral:Nutrition Facts Label in Larger Font; Behavioral:Healthier Items First,[u'University of Vermont'],30-Jun-15,0,9999,Both,TRUE,45NCT02484690,Hoffmann-La Roche,FALSE,VT,https://ClinicalTrials.gov/show/NCT02484690,TRUE,AVENUE: A Proof-of-Concept Study of RG7716 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD),"Macular Degeneration, Choroidal Neovascularization",Drug:RG7716; Drug:Ranibizumab,[],9-Sep-15,50,9999,Both,FALSE,119NCT02484547,Biogen,FALSE,VT,https://ClinicalTrials.gov/show/NCT02484547,TRUE,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],14-Jan-16,50,85,Both,FALSE,73NCT02481674,Vaccinex Inc.,TRUE,VT,https://ClinicalTrials.gov/show/NCT02481674,TRUE,VX15/2503 Treatment for Huntington's Disease,Huntington's Disease,Drug:VX15/2503; Drug:Placebo,"[u'University of Alabama at Birmingham', u'University of California, San Diego', u'University of Colorado - Denver', u'Georgetown University', u'Emory University School of Medicine', u'University of Iowa', u'University of Louisville', u'Massachusetts General Hospital', u'University of Michigan', u'Washington University', u'Columbia University', u'University of Rochester', u'Duke University Health Center', u'Wake Forest University', u'University of Cincinnati', u'Ohio State University', u'University of Toledo', u'Vanderbilt University', u'University of Vermont']",26-Jan-16,21,9999,Both,FALSE,46NCT02477891,"Janssen Research & Development, LLC",FALSE,VT,https://ClinicalTrials.gov/show/NCT02477891,TRUE,Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma,Multiple Myeloma,Drug:Daratumumab,[],27-Jan-16,18,9999,Both,FALSE,132NCT01674140,Southwest Oncology Group,FALSE,VA,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01272037,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02451137,Sanofi,FALSE,VA,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02194738,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02019264,Eisai Inc.,FALSE,VA,https://ClinicalTrials.gov/show/NCT02019264,TRUE,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],5-Nov-15,40,9999,Both,FALSE,102NCT01120249,Southwest Oncology Group,FALSE,VA,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01966107,AstraZeneca,FALSE,VA,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT02003209,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,VA,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT01652872,Amgen,FALSE,VA,https://ClinicalTrials.gov/show/NCT01652872,TRUE,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],9-Dec-15,18,9999,Both,FALSE,16NCT02154490,Southwest Oncology Group,FALSE,VA,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT01663402,Sanofi,FALSE,VA,https://ClinicalTrials.gov/show/NCT01663402,TRUE,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],3-Feb-16,40,9999,Both,FALSE,12NCT01975389,Pfizer,FALSE,VA,https://ClinicalTrials.gov/show/NCT01975389,TRUE,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01975376,Pfizer,FALSE,VA,https://ClinicalTrials.gov/show/NCT01975376,TRUE,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],19-Jan-16,18,9999,Both,FALSE,10NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,VA,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT02488967,NRG Oncology,FALSE,VA,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,VA,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT00936390,Radiation Therapy Oncology Group,FALSE,VA,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT02673190,Radiation Therapy Oncology Group,FALSE,VA,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT01872975,NSABP Foundation Inc,FALSE,VA,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01594333,Brigham and Women's Hospital,FALSE,VA,https://ClinicalTrials.gov/show/NCT01594333,TRUE,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],13-Nov-15,18,9999,Both,FALSE,79NCT01101035,Takeda,TRUE,VA,https://ClinicalTrials.gov/show/NCT01101035,TRUE,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],11-Aug-15,50,9999,Both,FALSE,5NCT02115282,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,VA,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT01991795,AstraZeneca,FALSE,VA,https://ClinicalTrials.gov/show/NCT01991795,TRUE,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],11-Jan-16,50,130,Both,FALSE,13NCT01274338,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT02406677,AstraZeneca,FALSE,VA,https://ClinicalTrials.gov/show/NCT02406677,TRUE,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],29-Jan-16,18,130,Both,FALSE,13NCT02112916,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT02112916,TRUE,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],28-Jan-16,2,30,Both,FALSE,9NCT01406756,Children's Oncology Group,FALSE,VA,https://ClinicalTrials.gov/show/NCT01406756,TRUE,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],3-Feb-16,1,30,Both,FALSE,17NCT01190930,Children's Oncology Group,FALSE,VA,https://ClinicalTrials.gov/show/NCT01190930,TRUE,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],6-Aug-15,1,30,Both,FALSE,17NCT00956007,Radiation Therapy Oncology Group,FALSE,VA,https://ClinicalTrials.gov/show/NCT00956007,TRUE,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Both,FALSE,4NCT00843882,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT02164513,GlaxoSmithKline,FALSE,VA,https://ClinicalTrials.gov/show/NCT02164513,TRUE,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],4-Feb-16,40,9999,Both,FALSE,8NCT01919697,Synergy Pharmaceuticals Inc.,FALSE,VA,https://ClinicalTrials.gov/show/NCT01919697,TRUE,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],10-Dec-15,18,81,Both,FALSE,183NCT01897532,Boehringer Ingelheim,FALSE,VA,https://ClinicalTrials.gov/show/NCT01897532,TRUE,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],26-Jan-16,18,9999,Both,FALSE,75NCT02164864,Boehringer Ingelheim,FALSE,VA,https://ClinicalTrials.gov/show/NCT02164864,TRUE,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],26-Jan-16,18,9999,Both,FALSE,75NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,VA,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01701817,"Janssen Scientific Affairs, LLC",FALSE,VA,https://ClinicalTrials.gov/show/NCT01701817,TRUE,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],7-Jan-16,21,9999,Both,FALSE,133NCT00719303,Gynecologic Oncology Group,FALSE,VA,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02388165,Pfizer,FALSE,VA,https://ClinicalTrials.gov/show/NCT02388165,TRUE,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],25-Jan-16,18,85,Both,FALSE,10NCT02488967,NRG Oncology,FALSE,WA,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02375204,Alliance for Clinical Trials in Oncology,FALSE,WA,https://ClinicalTrials.gov/show/NCT02375204,TRUE,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],8-Dec-15,14,9999,Male,FALSE,1NCT02315469,NRG Oncology,FALSE,WA,https://ClinicalTrials.gov/show/NCT02315469,TRUE,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],13-Jul-15,70,9999,Female,FALSE,159NCT02311933,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,WA,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02194738,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02101788,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02003222,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT02003222,TRUE,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],28-Jan-16,30,70,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01901094,Alliance for Clinical Trials in Oncology,FALSE,WA,https://ClinicalTrials.gov/show/NCT01901094,TRUE,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],27-Aug-15,18,9999,Both,FALSE,1NCT01674140,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01575548,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,WA,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01349881,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,WA,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01120249,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01101451,Gynecologic Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01101451,TRUE,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01064648,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01064648,TRUE,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],1-Feb-16,18,9999,Both,FALSE,9NCT01013649,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00887146,Alliance for Clinical Trials in Oncology,FALSE,WA,https://ClinicalTrials.gov/show/NCT00887146,TRUE,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],18-Dec-15,18,9999,Both,FALSE,1NCT00807768,Gynecologic Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT00807768,TRUE,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],3-Feb-12,18,9999,Female,FALSE,14NCT00565851,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT01124695,Eastern Cooperative Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01124695,TRUE,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],6-Dec-12,18,9999,Both,FALSE,17NCT00840177,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT00840177,TRUE,"S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia",Leukemia,Drug:cytarabine; Drug:idarubicin; Drug:pravastatin sodium,[],25-Sep-15,18,9999,Both,FALSE,3NCT01781468,Alliance for Clinical Trials in Oncology,FALSE,WA,https://ClinicalTrials.gov/show/NCT01781468,TRUE,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],13-Nov-15,18,9999,Both,FALSE,1NCT01359592,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01359592,TRUE,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],17-Nov-15,18,9999,Both,FALSE,3NCT01169337,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02154490,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT01415752,Eastern Cooperative Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01107626,Eastern Cooperative Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT01872975,NSABP Foundation Inc,FALSE,WA,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT00843882,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT00719303,Gynecologic Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT00430183,Alliance for Clinical Trials in Oncology,FALSE,WA,https://ClinicalTrials.gov/show/NCT00430183,TRUE,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],13-Mar-15,18,9999,Male,FALSE,1NCT00936390,Radiation Therapy Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT02115282,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,WA,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,WA,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT02163694,AbbVie,FALSE,WA,https://ClinicalTrials.gov/show/NCT02163694,TRUE,"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",Metastatic Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Other:Placebo,[],26-Jan-16,18,99,Both,FALSE,51NCT02152982,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT02152982,TRUE,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01809691,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,WA,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT01533207,Gynecologic Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01533207,TRUE,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],23-Dec-14,18,9999,Female,FALSE,14NCT00956007,Radiation Therapy Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT00956007,TRUE,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Both,FALSE,4NCT01674140,Southwest Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01272037,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT02194738,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02154490,Southwest Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT01966107,AstraZeneca,FALSE,WV,https://ClinicalTrials.gov/show/NCT01966107,TRUE,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],14-Jan-16,40,130,Both,FALSE,13NCT01274338,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT00843882,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT02155660,AstraZeneca,FALSE,WV,https://ClinicalTrials.gov/show/NCT02155660,TRUE,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],7-Jan-16,40,85,Both,FALSE,13NCT02027428,Celgene Corporation,FALSE,WV,https://ClinicalTrials.gov/show/NCT02027428,TRUE,Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer,"Squamous Cell Carcinoma, Non-Small-Cell Lung",Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Drug:Abraxane (Maintenance); Other:Best Supportive Care (Maintenance); Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Other:Best Supportive Care (Maintenance),[],8-Dec-15,18,9999,Both,FALSE,86NCT01120249,Southwest Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01013649,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02506153,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT02506153,TRUE,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,18,9999,Both,FALSE,9NCT02496884,Daiichi Sankyo Inc.,FALSE,WV,https://ClinicalTrials.gov/show/NCT02496884,TRUE,Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease,Fibromyalgia,Drug:DS-5565; Drug:placebo,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']",15-Jan-16,18,9999,Both,FALSE,95NCT02488967,NRG Oncology,FALSE,WV,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02451137,Sanofi,FALSE,WV,https://ClinicalTrials.gov/show/NCT02451137,TRUE,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],3-Feb-16,18,9999,Both,FALSE,12NCT02388165,Pfizer,FALSE,WV,https://ClinicalTrials.gov/show/NCT02388165,TRUE,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],25-Jan-16,18,85,Both,FALSE,10NCT02387359,Synergy Pharmaceuticals Inc.,FALSE,WV,https://ClinicalTrials.gov/show/NCT02387359,TRUE,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],10-Dec-15,18,85,Both,FALSE,183NCT02180867,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT02180867,TRUE,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],1-Feb-16,2,9999,Both,FALSE,9NCT02166463,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT02166463,TRUE,Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma,Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Biological:Bleomycin Sulfate; Drug:Brentuximab Vedotin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Vincristine Sulfate,[],1-Dec-15,2,18,Both,FALSE,9NCT02115282,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02112916,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT02112916,TRUE,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],28-Jan-16,2,30,Both,FALSE,9NCT02101853,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT02101853,TRUE,Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Asparaginase; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Mitoxantrone Hydrochloride; Drug:Pegaspargase; Other:Pharmacological Study; Drug:Therapeutic Hydrocortisone; Drug:Thioguanine; Drug:Vincristine Sulfate,[],1-Feb-16,1,30,Both,FALSE,9NCT02085408,Eastern Cooperative Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT02085408,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],16-Sep-14,60,9999,Both,FALSE,17NCT02065687,Gynecologic Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT02065687,TRUE,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT01888120,Jazz Pharmaceuticals,FALSE,WV,https://ClinicalTrials.gov/show/NCT01888120,TRUE,Patient Registry of Intrathecal Ziconotide Management(PRIZM),Patients With Severe Chronic Pain,Drug:Ziconotide,[],18-Jun-15,18,9999,Both,FALSE,134NCT01810913,Radiation Therapy Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT01810913,TRUE,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],14-Nov-15,18,9999,Both,FALSE,4NCT01705977,"Human Genome Sciences Inc., a GSK Company",FALSE,WV,https://ClinicalTrials.gov/show/NCT01705977,TRUE,Belimumab Assessment of Safety in SLE,Systemic Lupus Erythematosus,Biological:Placebo plus standard therapy; Biological:Belimumab 10 mg/kg plus standard therapy; Other:Standard therapy,[],4-Feb-16,18,9999,Both,FALSE,122NCT01575548,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01406756,Children's Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT01406756,TRUE,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],3-Feb-16,1,30,Both,FALSE,17NCT01216683,Eastern Cooperative Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT01216683,TRUE,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,18,9999,Both,FALSE,17NCT01190930,Children's Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT01190930,TRUE,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],6-Aug-15,1,30,Both,FALSE,17NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,WV,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01107626,Eastern Cooperative Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT01041703,Eastern Cooperative Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT01041703,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],24-Jul-14,60,9999,Both,FALSE,17NCT00956007,Radiation Therapy Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT00956007,TRUE,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Both,FALSE,4NCT00430183,Alliance for Clinical Trials in Oncology,FALSE,WV,https://ClinicalTrials.gov/show/NCT00430183,TRUE,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],13-Mar-15,18,9999,Male,FALSE,1NCT02673190,Radiation Therapy Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02673190,Radiation Therapy Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT02673190,TRUE,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],29-Jan-16,18,9999,Male,FALSE,4NCT02523014,Alliance for Clinical Trials in Oncology,FALSE,WI,https://ClinicalTrials.gov/show/NCT02523014,TRUE,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],8-Dec-15,18,9999,Both,FALSE,1NCT02488967,NRG Oncology,FALSE,WI,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,WI,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02194738,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02180867,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT02180867,TRUE,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],1-Feb-16,2,9999,Both,FALSE,9NCT02154490,Southwest Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02152982,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT02152982,TRUE,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02115282,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02101788,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT02059265,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT02059265,TRUE,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Female,FALSE,9NCT02048813,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02032823,AstraZeneca,FALSE,WI,https://ClinicalTrials.gov/show/NCT02032823,TRUE,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],27-Jan-16,18,130,Both,FALSE,13NCT02003209,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01950390,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01949337,Alliance for Clinical Trials in Oncology,FALSE,WI,https://ClinicalTrials.gov/show/NCT01949337,TRUE,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],18-Sep-15,18,9999,Male,FALSE,1NCT01903811,Southwest Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01872975,NSABP Foundation Inc,FALSE,WI,https://ClinicalTrials.gov/show/NCT01872975,TRUE,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],4-Jan-16,18,9999,Female,FALSE,2NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01856192,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01856192,TRUE,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01809691,Southwest Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01809691,TRUE,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],8-Dec-15,18,9999,Male,FALSE,3NCT01674140,Southwest Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01668719,Southwest Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01668719,TRUE,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],28-Sep-15,18,120,Both,FALSE,3NCT01575548,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01573442,Alliance for Clinical Trials in Oncology,FALSE,WI,https://ClinicalTrials.gov/show/NCT01573442,TRUE,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],3-Nov-15,18,9999,Female,FALSE,1NCT01535053,Gynecologic Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01535053,TRUE,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,WI,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01415752,Eastern Cooperative Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01349881,Southwest Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01274338,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01272037,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01242800,Eastern Cooperative Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01242800,TRUE,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],16-Sep-14,18,9999,Both,FALSE,17NCT01216683,Eastern Cooperative Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01216683,TRUE,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,18,9999,Both,FALSE,17NCT01169337,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,WI,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01124695,Eastern Cooperative Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01124695,TRUE,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],6-Dec-12,18,9999,Both,FALSE,17NCT01120249,Southwest Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT01107626,Eastern Cooperative Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01107626,TRUE,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],5-Dec-12,18,9999,Both,FALSE,17NCT01079780,Pam Cogliano,FALSE,WI,https://ClinicalTrials.gov/show/NCT01079780,TRUE,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],19-Sep-14,18,9999,Both,FALSE,161NCT01013649,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00936390,Radiation Therapy Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT00936390,TRUE,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],11-Nov-15,18,9999,Male,FALSE,4NCT00897767,Eastern Cooperative Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT00897767,TRUE,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],5-Dec-12,0,9999,Both,FALSE,17NCT00843882,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT00719303,Gynecologic Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT00700882,Eastern Cooperative Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT00700882,TRUE,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],16-Sep-14,18,9999,Both,FALSE,17NCT00565851,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00565851,TRUE,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT02164916,Southwest Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT00897442,Gynecologic Oncology Group,TRUE,WI,https://ClinicalTrials.gov/show/NCT00897442,TRUE,Collecting Tumor Samples From Patients With Gynecological Tumors,Cancer,Other:biologic sample preservation procedure,[],30-Aug-12,0,9999,Female,FALSE,14NCT00074282,Eastern Cooperative Oncology Group,TRUE,WI,https://ClinicalTrials.gov/show/NCT00074282,TRUE,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],9-Nov-12,18,9999,Both,FALSE,17NCT02048813,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02048813,TRUE,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,18,70,Both,FALSE,9NCT02003209,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02003209,TRUE,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01349881,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01349881,TRUE,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],18-Aug-15,18,9999,Both,FALSE,3NCT01272037,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01272037,TRUE,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,9999,Female,FALSE,9NCT01120249,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01120249,TRUE,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],8-Dec-15,18,120,Both,FALSE,3NCT00719303,Gynecologic Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT00719303,TRUE,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],13-Jul-15,18,9999,Female,FALSE,14NCT02488967,NRG Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT02488967,TRUE,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],4-Jan-16,18,9999,Both,FALSE,159NCT02194738,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02194738,TRUE,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],22-Jan-16,18,9999,Both,FALSE,9NCT02193282,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02193282,TRUE,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],6-Jan-16,18,9999,Both,FALSE,9NCT02003222,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02003222,TRUE,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],28-Jan-16,30,70,Both,FALSE,9NCT01903811,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01903811,TRUE,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],18-Aug-15,18,9999,Both,FALSE,3NCT01863550,ECOG-ACRIN Cancer Research Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01863550,TRUE,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],29-Dec-15,18,9999,Both,FALSE,101NCT01835145,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01835145,TRUE,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],1-Feb-16,18,9999,Both,FALSE,9NCT01575548,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01575548,TRUE,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],4-Feb-16,18,9999,Both,FALSE,9NCT01573442,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT01573442,TRUE,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],3-Nov-15,18,9999,Female,FALSE,1NCT01535053,Gynecologic Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01535053,TRUE,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],13-Jul-15,18,9999,Female,FALSE,14NCT01515787,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT01515787,TRUE,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],25-Jun-15,18,9999,Both,FALSE,1NCT01415752,Eastern Cooperative Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01415752,TRUE,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],13-Mar-15,60,9999,Both,FALSE,17NCT01064648,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01064648,TRUE,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],1-Feb-16,18,9999,Both,FALSE,9NCT02601209,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02601209,TRUE,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02562716,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT02562716,TRUE,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],26-Jan-16,18,75,Both,FALSE,3NCT02523014,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT02523014,TRUE,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],8-Dec-15,18,9999,Both,FALSE,1NCT02315469,NRG Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT02315469,TRUE,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],13-Jul-15,70,9999,Female,FALSE,159NCT02311933,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02311933,TRUE,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],4-Feb-16,18,9999,Female,FALSE,9NCT02134912,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT02134912,TRUE,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Drug:crizotinib; Drug:pemetrexed disodium; Other:laboratory biomarker analysis; Other:pharmacological study,[],5-Feb-15,18,9999,Both,FALSE,3NCT01953588,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT01953588,TRUE,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],9-Sep-15,18,9999,Female,FALSE,1NCT01950390,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01950390,TRUE,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],1-Feb-16,18,9999,Both,FALSE,9NCT01814813,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT01814813,TRUE,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],26-Jan-16,18,9999,Both,FALSE,1NCT01674140,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01674140,TRUE,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],26-Jan-16,18,9999,Both,FALSE,3NCT01556243,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT01556243,TRUE,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],11-Dec-15,40,9999,Female,FALSE,1NCT00887146,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT00887146,TRUE,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],18-Dec-15,18,9999,Both,FALSE,1NCT02154490,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT02154490,TRUE,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],22-Sep-15,18,9999,Both,FALSE,3NCT02085408,Eastern Cooperative Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT02085408,TRUE,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],16-Sep-14,60,9999,Both,FALSE,17NCT01533207,Gynecologic Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01533207,TRUE,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],23-Dec-14,18,9999,Female,FALSE,14NCT01414608,Gynecologic Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01414608,TRUE,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],16-Jul-15,18,9999,Female,FALSE,14NCT01274338,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01274338,TRUE,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],4-Feb-16,12,9999,Both,FALSE,9NCT01169337,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01169337,TRUE,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01150045,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT01150045,TRUE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],3-Sep-15,18,9999,Both,FALSE,1NCT01013649,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01013649,TRUE,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00843882,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT00843882,TRUE,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],4-Feb-16,18,9999,Both,FALSE,9NCT00492778,Gynecologic Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT00492778,TRUE,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],13-Jul-15,0,9999,Female,FALSE,14NCT00430183,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT00430183,TRUE,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],13-Mar-15,18,9999,Male,FALSE,1NCT02672748,University of Wyoming,FALSE,WY,https://ClinicalTrials.gov/show/NCT02672748,TRUE,Growing Resilience in Wind River Indian Reservation,Obesity; Overweight; Diabetes,Other:Garden,[u'University of Wyoming'],2-Feb-16,5,80,Both,TRUE,213NCT02229539,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT02229539,TRUE,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],4-Aug-15,18,9999,Both,FALSE,1NCT02177695,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT02177695,TRUE,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",Bladder Cancer,Drug:Gemcitabine; Drug:Cisplatin; Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin; Drug:Filgrastim,[],8-Dec-15,18,9999,Both,FALSE,3NCT02164916,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT02164916,TRUE,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],26-Jan-16,18,9999,Both,FALSE,3NCT02115282,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02115282,TRUE,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02101788,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02101788,TRUE,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],27-Jan-16,19,9999,Female,FALSE,9NCT01359592,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01359592,TRUE,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],17-Nov-15,18,9999,Both,FALSE,3NCT01124695,Eastern Cooperative Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01124695,TRUE,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],6-Dec-12,18,9999,Both,FALSE,17NCT00373685,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00264901,Novo Nordisk A/S,FALSE,AL,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00346216,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00347620,University of Alabama at Birmingham,FALSE,AL,https://ClinicalTrials.gov/show/NCT00347620,FALSE,Improving Vision and Quality of Life in the Nursing Home,Refractive Error; Cataract,Device:spectacles; Procedure:Cataract Surgery,"[u'Integrated Health Services at Briarcliff', u'Shelby Ridge Nursing Home', u'Beverly Healthcare Meadowood', u'Southgate Village', u'Livingston Health Care Center', u'Beverly Healthcare Riverchase', u'Fair Haven Retirement Center', u'Beverly Healthcare Center Forestdale', u'Beverly Healthcare East', u'South Haven', u'Estes Nursing Facility Civic Center', u'Estes Nursing Facility Northway', u'Fairview Health & Rehabilitation Center', u'Beverly Health Care Center West', u'The Self Nursing Home, Inc', u'Beverly Healthcare Pleasant Grove', u'Consult America Cottage Hills']",12-Mar-10,60,9999,Both,TRUE,197NCT01313676,GlaxoSmithKline,FALSE,AL,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT00239681,AstraZeneca,FALSE,AL,https://ClinicalTrials.gov/show/NCT00239681,FALSE,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],6-Feb-14,50,9999,Both,FALSE,13NCT01475721,GlaxoSmithKline,FALSE,AL,https://ClinicalTrials.gov/show/NCT01475721,FALSE,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],10-Dec-15,12,9999,Both,FALSE,8NCT01543178,"Valeant Pharmaceuticals International, Inc.",FALSE,AL,https://ClinicalTrials.gov/show/NCT01543178,FALSE,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],15-Jun-15,18,9999,Both,FALSE,47NCT01126437,Boehringer Ingelheim,FALSE,AL,https://ClinicalTrials.gov/show/NCT01126437,FALSE,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:tiotropium 18 mcg; Drug:tiotropium 1.25 mcg (2 actuations/day); Drug:tiotropium 2.5 mcg (2 actuations/day),[],20-May-14,40,9999,Both,FALSE,75NCT00643409,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT00643409,FALSE,"A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults",Maxillary Sinusitis,"Drug:azithromycin SR (Zithromax; compound: CP-62,993); Other:placebo; Drug:levofloxacin; Other:placebo",[],10-May-11,18,9999,Both,FALSE,10NCT01510158,"Ardea Biosciences, Inc.",FALSE,AL,https://ClinicalTrials.gov/show/NCT01510158,FALSE,Combining Lesinurad With Allopurinol in Inadequate Responders,Gout,Drug:Lesinurad; Drug:Lesinurad; Drug:Placebo; Drug:Allopurinol,[],18-May-15,18,85,Both,FALSE,65NCT01508026,Forest Laboratories,FALSE,AL,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT01437397,Forest Laboratories,FALSE,AL,https://ClinicalTrials.gov/show/NCT01437397,FALSE,"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide; Drug:Formoterol Fumarate; Drug:placebo,[],5-Apr-13,40,9999,Both,FALSE,110NCT01327846,Novartis Pharmaceuticals,FALSE,AL,https://ClinicalTrials.gov/show/NCT01327846,FALSE,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),Atherosclerosis,Drug:Canakinumab; Drug:Placebo,[],19-May-15,18,9999,Both,FALSE,156NCT01130272,"Furiex Pharmaceuticals, Inc",FALSE,AL,https://ClinicalTrials.gov/show/NCT01130272,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],11-Jun-12,18,65,Both,FALSE,112NCT00649389,Daiichi Sankyo Inc.,FALSE,AL,https://ClinicalTrials.gov/show/NCT00649389,FALSE,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,Hypertension,Drug:Olmesartan medoxomil; Drug:Amlodipine; Drug:Hydrochlorothiazide,[],31-Aug-10,18,80,Both,FALSE,95NCT00430248,Takeda,TRUE,AL,https://ClinicalTrials.gov/show/NCT00430248,FALSE,Efficacy and Safety of Oral Febuxostat in Participants With Gout,Gout,Drug:Febuxostat; Drug:Febuxostat; Drug:Allopurinol,[],31-Jan-12,18,85,Both,FALSE,5NCT00373256,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT00373256,FALSE,A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer,Breast Neoplasms,Drug:Sunitinib; Drug:paclitaxel; Drug:bevacizumab; Drug:paclitaxel,[],5-Sep-12,18,9999,Both,FALSE,10NCT01789957,AstraZeneca,FALSE,AL,https://ClinicalTrials.gov/show/NCT01789957,FALSE,Extension Study for 2993-112,Type 2 Diabetes Mellitus,Drug:AC2993,[],23-Feb-15,16,75,Both,FALSE,13NCT01572792,Forest Laboratories,FALSE,AL,https://ClinicalTrials.gov/show/NCT01572792,FALSE,"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide; Drug:Formoterol Fumarate; Drug:Placebo,[],27-Feb-15,40,9999,Both,FALSE,110NCT01553747,"Furiex Pharmaceuticals, Inc",FALSE,AL,https://ClinicalTrials.gov/show/NCT01553747,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Other:Placebo Comparator,[],26-Apr-15,18,80,Both,FALSE,112NCT00849056,GlaxoSmithKline,FALSE,AL,https://ClinicalTrials.gov/show/NCT00849056,FALSE,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:placebo,[],29-May-14,18,9999,Both,FALSE,8NCT00643760,"XenoPort, Inc.",FALSE,AL,https://ClinicalTrials.gov/show/NCT00643760,FALSE,A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN),"Neuropathy, Diabetic",Drug:Placebo; Drug:GEn 1200mg/day; Drug:GEn 2400mg/day; Drug:GEn 3600mg/day; Drug:Pregabalin,[],15-Jul-13,18,9999,Both,FALSE,225NCT00571649,Bayer,TRUE,AL,https://ClinicalTrials.gov/show/NCT00571649,FALSE,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,Venous Thromboembolism,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Enoxaparin; Drug:Rivaroxaban placebo; Drug:Enoxaparin placebo",[],28-Nov-14,40,9999,Both,FALSE,23NCT00557921,Cogentus Pharmaceuticals,FALSE,AL,https://ClinicalTrials.gov/show/NCT00557921,FALSE,Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1),Acute Coronary Syndrome; Myocardial Infarction; Coronary Artery Disease; Percutaneous Coronary Intervention,Drug:CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin; Drug:Plavix (clopidogrel 75 mg) and aspirin,[],27-Jan-09,21,9999,Both,FALSE,89NCT00347360,GlaxoSmithKline,FALSE,AL,https://ClinicalTrials.gov/show/NCT00347360,FALSE,The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial,Hypertension,Drug:lisinopril; Drug:carvedilol controlled release formulation,[],20-Apr-15,18,9999,Both,FALSE,8NCT00255190,Takeda,TRUE,AL,https://ClinicalTrials.gov/show/NCT00255190,FALSE,Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn,Gastroesophageal Reflux Disease,Drug:Dexlansoprazole MR; Drug:Dexlansoprazole MR,[],25-Apr-11,18,9999,Both,FALSE,5NCT00168779,Boehringer Ingelheim,FALSE,AL,https://ClinicalTrials.gov/show/NCT00168779,FALSE,"Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension",Hypertension,Drug:telmisartan 80 mg / hydrochlorothiazide 25 mg; Drug:valsartan 160 mg / hydrochlorothiazide 25 mg; Drug:placebo,[],31-Oct-13,18,9999,Both,FALSE,75NCT00088179,Alexion Pharmaceuticals,FALSE,AL,https://ClinicalTrials.gov/show/NCT00088179,FALSE,Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II),Coronary Artery Disease,Drug:pexelizumab in conjunction with CABG,[],28-Aug-05,18,9999,Both,FALSE,59NCT00067938,GlaxoSmithKline,FALSE,AL,https://ClinicalTrials.gov/show/NCT00067938,FALSE,Bipolar Study in Adults at Least 18 Years of Age,Bipolar Disorder,Drug:lamotrigine,[],11-Oct-12,18,9999,Both,FALSE,8NCT00039026,AstraZeneca,TRUE,AL,https://ClinicalTrials.gov/show/NCT00039026,FALSE,Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea,"Diabetes Mellitus, Non-Insulin-Dependent",Drug:AC2993; Drug:AC2993; Drug:Placebo; Drug:Placebo,[],23-Feb-15,16,75,Both,FALSE,13NCT00039013,AstraZeneca,TRUE,AL,https://ClinicalTrials.gov/show/NCT00039013,FALSE,Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin,"Diabetes Mellitus, Type 2",Drug:AC2993; Drug:AC2993; Drug:Placebo; Drug:Placebo,[],23-Feb-15,16,75,Both,FALSE,13NCT00005088,Radiation Therapy Oncology Group,TRUE,AL,https://ClinicalTrials.gov/show/NCT00005088,FALSE,Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer,Head and Neck Cancer,Drug:cisplatin; Radiation:radiation therapy,[],18-Nov-13,0,9999,Both,FALSE,4NCT00003825,Radiation Therapy Oncology Group,TRUE,AL,https://ClinicalTrials.gov/show/NCT00003825,FALSE,Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy,Diarrhea; Radiation Enteritis,Drug:pentosan polysulfate sodium; Procedure:quality-of-life assessment,[],9-Aug-13,0,9999,Both,FALSE,4NCT00002708,Radiation Therapy Oncology Group,TRUE,AL,https://ClinicalTrials.gov/show/NCT00002708,FALSE,Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases,Metastatic Cancer,Procedure:surgical procedure; Radiation:radiation therapy; Radiation:stereotactic radiosurgery,[],18-Nov-13,18,9999,Both,FALSE,4NCT01942135,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT01942135,FALSE,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),Metastatic Breast Cancer,Drug:Palbociclib; Drug:Fulvestrant; Drug:Placebo; Drug:Fulvestrant,[],16-Nov-15,18,9999,Female,FALSE,10NCT01462344,GlaxoSmithKline,FALSE,AL,https://ClinicalTrials.gov/show/NCT01462344,FALSE,6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg,[],1-Oct-15,4,11,Both,FALSE,8NCT01360554,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT01360554,FALSE,ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer (NSCLC),Drug:Dacomitinib (PF-00299804); Drug:Active Comparator (erlotinib); Drug:Placebo erlotinib; Drug:Placebo PF00299804,[],4-Jan-16,18,9999,Both,FALSE,10NCT01302067,Pfizer,FALSE,AL,https://ClinicalTrials.gov/show/NCT01302067,FALSE,A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine,Overactive Bladder,Drug:Fesoterodine 8mg; Drug:Fesoterodine 4mg; Drug:Placebo,[],25-Feb-14,18,9999,Both,FALSE,10NCT01298219,"Sucampo Pharmaceuticals, Inc.",FALSE,AL,https://ClinicalTrials.gov/show/NCT01298219,FALSE,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL),Opioid-induced Bowel Dysfunction,Drug:Lubiprostone; Drug:Placebo,[],1-Feb-13,18,9999,Both,FALSE,179NCT01165710,"Janssen Scientific Affairs, LLC",FALSE,AL,https://ClinicalTrials.gov/show/NCT01165710,FALSE,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF),Atrial Fibrillation,Other:Patients with Atrial Fibrillation (AF),[],9-Jan-15,18,9999,Both,FALSE,133NCT01147250,Sanofi,FALSE,AL,https://ClinicalTrials.gov/show/NCT01147250,FALSE,Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide),Acute Coronary Syndrome,Drug:lixisenatide (AVE0010); Drug:placebo,[],12-Nov-15,30,9999,Both,FALSE,12NCT00891020,Hoffmann-La Roche,FALSE,AL,https://ClinicalTrials.gov/show/NCT00891020,FALSE,A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs),Rheumatoid Arthritis,Drug:tocilizumab [RoActemra/Actemra]; Drug:tocilizumab [RoActemra/Actemra]; Drug:Nonbiologic DMARDs of investigator's choice,[],19-Oct-12,18,9999,Both,FALSE,119NCT00887536,NSABP Foundation Inc,FALSE,AL,https://ClinicalTrials.gov/show/NCT00887536,FALSE,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],24-Jun-15,18,70,Female,FALSE,2NCT00878709,"Puma Biotechnology, Inc.",FALSE,AL,https://ClinicalTrials.gov/show/NCT00878709,FALSE,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Breast Cancer,Drug:neratinib; Other:placebo,[],20-Aug-15,18,9999,Female,FALSE,166NCT00839527,GlaxoSmithKline,FALSE,AL,https://ClinicalTrials.gov/show/NCT00839527,FALSE,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:placebo to match albiglutide; Biological:albiglutide; Drug:metformin; Drug:glimepiride; Drug:pioglitazone; Drug:placebo to match pioglitazone,[],29-May-14,18,9999,Both,FALSE,8NCT00838916,GlaxoSmithKline,FALSE,AL,https://ClinicalTrials.gov/show/NCT00838916,FALSE,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:insulin glargine,[],22-May-14,18,9999,Both,FALSE,8NCT00743652,Pfizer,FALSE,AK,https://ClinicalTrials.gov/show/NCT00743652,FALSE,Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.,Pneumococcal Disease; 13-valent Pneumococcal Vaccine,Biological:13-valent Pneumococcal Conjugate Vaccine; Biological:13-valent Pneumococcal Conjugate Vaccine; Biological:13-valent Pneumococcal Conjugate Vaccine; Biological:13-valent Pneumococcal Conjugate Vaccine; Biological:13-valent Pneumococcal Conjugate Vaccine,"[u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site']",13-Mar-12,42,5,Both,TRUE,10NCT02465060,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02116530,Alliance for Clinical Trials in Oncology,FALSE,AK,https://ClinicalTrials.gov/show/NCT02116530,FALSE,Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy,"Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:Olanzapine; Drug:Chemotherapy (cisplatin or cyclophosphamide and doxorubicin); Drug:Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant); Other:Placebo,[],15-Jun-15,18,9999,Both,FALSE,1NCT02315430,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT02315430,FALSE,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Female,FALSE,9NCT02257528,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT02257528,FALSE,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],3-Feb-16,18,9999,Female,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01802333,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT00946712,Southwest Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT01275677,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT02137837,Southwest Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT02137837,FALSE,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",Breast Cancer,Drug:Fulvestrant; Drug:Anastrozole; Drug:Everolimus; Drug:Placebo - Anastrozole; Drug:Placebo - Everolimus,[],20-May-15,18,9999,Female,FALSE,3NCT02042443,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT02042443,FALSE,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],3-Feb-16,0,9999,Both,FALSE,9NCT01841736,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT01841736,FALSE,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01824823,Eastern Cooperative Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT01824823,FALSE,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],11-Sep-15,18,9999,Both,FALSE,17NCT01609790,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT01609790,FALSE,Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors,Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Placebo; Biological:Trebananib,[],31-Jul-15,18,9999,Both,FALSE,9NCT01196390,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT00942357,Gynecologic Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00775645,Southwest Oncology Group,TRUE,AK,https://ClinicalTrials.gov/show/NCT00775645,FALSE,"S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy",Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity,Dietary Supplement:acetyl-L-carnitine hydrochloride; Other:placebo,[],13-Jan-14,18,9999,Female,FALSE,3NCT00733408,University of Washington,FALSE,AK,https://ClinicalTrials.gov/show/NCT00733408,FALSE,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer,Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer,Drug:paclitaxel albumin-stabilized nanoparticle formulation; Biological:bevacizumab; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,"[u'Anchorage Oncology Centre', u'Katmai Oncology Group', u'Providence Alaska Medical Center', u'Yuma Cancer Center', u'Saint Joseph Regional Medical Center', u'Bozeman Deaconess Hospital', u'Kalispell Regional Medical Center', u'Bend Memorial Clinic', u'Kadlec Clinic Hematology and Oncology', u'Evergreen Hospital Medical Center', u'Skagit Valley Hospital Regional Cancer Care Center', u'Group Health Cooperative, Redmond', u'Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium', u'Olympic Medical Cancer Care Center', u'Spokane Valley Cancer Center-Mayfair', u'Multicare Medical Oncology Hematology', u'Wenatchee Valley Medical Center']",5-Jan-16,0,9999,Female,FALSE,212NCT00310180,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT01385137,Southwest Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT01385137,FALSE,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],15-Oct-15,18,120,Female,FALSE,3NCT01243424,Boehringer Ingelheim,FALSE,AK,https://ClinicalTrials.gov/show/NCT01243424,FALSE,CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:linagliptin; Drug:glimepiride; Drug:linagliptin placebo; Drug:glimepride placebo,[],12-Jan-16,40,85,Both,FALSE,75NCT01194830,Boehringer Ingelheim,FALSE,AK,https://ClinicalTrials.gov/show/NCT01194830,FALSE,Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study,"Diabetes Mellitus, Type 2",Drug:Linagliptin; Drug:Placebo,[],12-Dec-13,18,80,Both,FALSE,75NCT01101438,NCIC Clinical Trials Group,TRUE,AK,https://ClinicalTrials.gov/show/NCT01101438,FALSE,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,Breast Cancer,Drug:metformin hydrochloride; Other:placebo,[],5-May-15,18,74,Both,FALSE,11NCT01097278,Southwest Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT01097278,FALSE,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],7-Jan-15,18,50,Female,FALSE,3NCT01088503,Eli Lilly and Company,FALSE,AK,https://ClinicalTrials.gov/show/NCT01088503,FALSE,Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome,Acute Coronary Syndrome,Drug:ADP receptor inhibitors,[],22-Dec-15,18,9999,Both,FALSE,104NCT01015833,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00920010,Southwest Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT00920010,FALSE,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],5-Feb-15,0,9999,Both,FALSE,3NCT00874211,Southwest Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT00874211,FALSE,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],4-Mar-15,0,9999,Both,FALSE,3NCT00746967,Pfizer,FALSE,AK,https://ClinicalTrials.gov/show/NCT00746967,FALSE,"An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder","Sexual Dysfunctions, Psychological; Sexual Arousal Disorder",Drug:sildenafil,[],3-Sep-08,18,9999,Female,FALSE,10NCT00513695,University of Washington,FALSE,AK,https://ClinicalTrials.gov/show/NCT00513695,FALSE,"Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer",Inflammatory Breast Cancer; Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:sunitinib malate; Drug:paclitaxel; Drug:doxorubicin hydrochloride; Drug:cyclophosphamide; Biological:filgrastim; Procedure:therapeutic conventional surgery; Other:laboratory biomarker analysis; Other:flow cytometry,"[u'Anchorage Oncology Centre', u'Katmai Oncology Group', u'Arizona Cancer Center', u""Saint Luke's Mountain States Tumor Institute"", u'Skagit Valley Hospital', u'Olympic Medical Center', u'Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium']",5-Jan-16,0,9999,Both,FALSE,212NCT00490139,GlaxoSmithKline,FALSE,AK,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT00433511,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00410813,Southwest Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT00410813,FALSE,"S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone",Breast Cancer; Metastatic Cancer,Drug:dasatinib,[],22-May-13,18,9999,Both,FALSE,3NCT00382070,NSABP Foundation Inc,TRUE,AK,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00382018,Southwest Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT00382018,FALSE,S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy,Breast Cancer,Drug:chemotherapy,[],15-Sep-15,18,9999,Female,FALSE,3NCT00376961,Southwest Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT00376961,FALSE,"S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",Lymphoma,Biological:rituximab; Drug:bortezomib; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate,[],8-May-15,18,9999,Both,FALSE,3NCT00326898,National Cancer Institute (NCI),FALSE,AK,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00309985,Eastern Cooperative Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT00309985,FALSE,Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer,Prostate Cancer,Drug:antiandrogen therapy; Drug:docetaxel,[],15-May-15,18,9999,Male,FALSE,17NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,AK,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00134056,Southwest Oncology Group,TRUE,AK,https://ClinicalTrials.gov/show/NCT00134056,FALSE,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],6-May-15,18,9999,Male,FALSE,3NCT00107276,Southwest Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT00107276,FALSE,S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer,Breast Cancer,Drug:capecitabine; Drug:cyclophosphamide,[],3-Jul-13,18,9999,Female,FALSE,3NCT00075764,Southwest Oncology Group,FALSE,AK,https://ClinicalTrials.gov/show/NCT00075764,FALSE,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:fulvestrant,[],8-May-14,18,9999,Female,FALSE,3NCT00075686,Southwest Oncology Group,TRUE,AK,https://ClinicalTrials.gov/show/NCT00075686,FALSE,S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer,Pancreatic Cancer,Biological:cetuximab; Drug:gemcitabine hydrochloride,[],16-Nov-15,18,9999,Both,FALSE,3NCT00070018,Southwest Oncology Group,TRUE,AK,https://ClinicalTrials.gov/show/NCT00070018,FALSE,"S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",Lymphoma,Biological:rituximab; Drug:Cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Radiation:radiation therapy; Biological:Yttrium-90 ibritumomab tiuxetan; Biological:Indium-111 ibritumomab tiuxetan,[],17-Jan-14,18,9999,Both,FALSE,3NCT00346216,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00264901,Novo Nordisk A/S,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00373685,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT01942135,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01942135,FALSE,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),Metastatic Breast Cancer,Drug:Palbociclib; Drug:Fulvestrant; Drug:Placebo; Drug:Fulvestrant,[],16-Nov-15,18,9999,Female,FALSE,10NCT01508026,Forest Laboratories,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT02565186,CoLucid Pharmaceuticals,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02565186,FALSE,"An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine",Acute Treatment of Migraine in Adults,Drug:lasmiditan 100 mg; Drug:lasmiditan 200 mg,[],13-Nov-15,18,9999,Both,FALSE,91NCT01475721,GlaxoSmithKline,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01475721,FALSE,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],10-Dec-15,12,9999,Both,FALSE,8NCT00887536,NSABP Foundation Inc,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00887536,FALSE,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],24-Jun-15,18,70,Female,FALSE,2NCT00809354,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00809354,FALSE,Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip,Osteoarthritis; Arthritis,Drug:NSAID; Biological:tanezumab; Biological:tanezumab; Biological:tanezumab; Drug:NSAID; Biological:tanezumab; Drug:NSAID,[],4-Mar-15,18,9999,Both,FALSE,10NCT00347360,GlaxoSmithKline,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00347360,FALSE,The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial,Hypertension,Drug:lisinopril; Drug:carvedilol controlled release formulation,[],20-Apr-15,18,9999,Both,FALSE,8NCT02117479,Incyte Corporation,FALSE,AZ,https://ClinicalTrials.gov/show/NCT02117479,FALSE,Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1),Metastatic Pancreatic Adenocarcinoma,Drug:Ruxolitinib; Drug:Placebo; Drug:Capecitabine,[],13-Jan-16,18,9999,Both,FALSE,125NCT00205777,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00205777,FALSE,Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women,Osteoporosis,Drug:Bazedoxifene Acetate; Other:Placebo,[],28-Feb-13,55,80,Female,FALSE,10NCT00036270,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00036270,FALSE,Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane,Breast Neoplasms,Drug:exemestane (Aromasin); Drug:tamoxifen + exemestane,[],6-Oct-15,50,9999,Female,FALSE,10NCT01306890,Dendreon,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01306890,FALSE,A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer,Advanced Prostate Cancer; Prostatic Neoplasms,Biological:sipuleucel-T,[],5-Oct-15,18,9999,Male,FALSE,97NCT01130272,"Furiex Pharmaceuticals, Inc",FALSE,AZ,https://ClinicalTrials.gov/show/NCT01130272,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],11-Jun-12,18,65,Both,FALSE,112NCT01126437,Boehringer Ingelheim,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01126437,FALSE,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:tiotropium 18 mcg; Drug:tiotropium 1.25 mcg (2 actuations/day); Drug:tiotropium 2.5 mcg (2 actuations/day),[],20-May-14,40,9999,Both,FALSE,75NCT00839527,GlaxoSmithKline,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00839527,FALSE,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:placebo to match albiglutide; Biological:albiglutide; Drug:metformin; Drug:glimepiride; Drug:pioglitazone; Drug:placebo to match pioglitazone,[],29-May-14,18,9999,Both,FALSE,8NCT00683137,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00683137,FALSE,Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery,Pain; Hallux Valgus,Drug:valdecoxib; Drug:valdecoxib; Drug:valdecoxib/placebo,[],22-May-08,18,9999,Both,FALSE,10NCT00241722,Cubist Pharmaceuticals LLC,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00241722,FALSE,Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain,Bowel Dysfunction; Constipation,Drug:Alvimopan; Drug:Placebo,[],1-Sep-15,18,9999,Both,FALSE,94NCT01701362,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01701362,FALSE,Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain,Neuropathic Pain,Drug:pregabalin; Drug:placebo,[],30-Sep-15,18,9999,Both,FALSE,10NCT01642914,Forest Laboratories,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01642914,FALSE,Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating,Chronic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Matching placebo,[],30-Sep-13,18,9999,Both,TRUE,110NCT01070836,Biogen,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01070836,FALSE,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],14-Jan-16,0,9999,Both,FALSE,73NCT00999518,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00999518,FALSE,A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome,"Cystitis, Interstitial",Biological:Tanezumab; Biological:Tanezumab; Biological:Tanezumab; Biological:Tanezumab; Other:Placebo,[],23-Aug-12,18,9999,Both,FALSE,10NCT00808132,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00808132,FALSE,Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis,Menopause; Osteoporosis,Drug:bazedoxifene 20 mg/ conjugated estrogens 0.45 mg; Drug:bazedoxifene 20 mg/ conjugated estrogens 0.625 mg; Drug:bazedoxifene 20 mg; Drug:conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg; Drug:Placebo,[],10-Mar-14,40,64,Female,FALSE,10NCT00661635,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00661635,FALSE,"A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain",Laparoscopic Cholecystectomy; Pain,Drug:placebo; Drug:valdecoxib; Drug:valdecoxib,[],21-Apr-08,18,75,Both,FALSE,10NCT00658515,Hoffmann-La Roche,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00649389,Daiichi Sankyo Inc.,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00649389,FALSE,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,Hypertension,Drug:Olmesartan medoxomil; Drug:Amlodipine; Drug:Hydrochlorothiazide,[],31-Aug-10,18,80,Both,FALSE,95NCT01543178,"Valeant Pharmaceuticals International, Inc.",FALSE,AZ,https://ClinicalTrials.gov/show/NCT01543178,FALSE,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],15-Jun-15,18,9999,Both,FALSE,47NCT01510158,"Ardea Biosciences, Inc.",FALSE,AZ,https://ClinicalTrials.gov/show/NCT01510158,FALSE,Combining Lesinurad With Allopurinol in Inadequate Responders,Gout,Drug:Lesinurad; Drug:Lesinurad; Drug:Placebo; Drug:Allopurinol,[],18-May-15,18,85,Both,FALSE,65NCT01415505,Forest Laboratories,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01415505,FALSE,Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension,Hypertension,"Drug:Nebivolol, Valsartan and Hydrochlorothiazide",[],31-May-13,18,9999,Both,FALSE,110NCT01313676,GlaxoSmithKline,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT01227564,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01227564,FALSE,Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease,Alzheimer's Disease,Biological:ACC-001 3 g/ QS-21 50 g; Biological:ACC-001 10 g/ QS-21 50 g; Other:Placebo- Phosphate buffered saline (PBS),[],13-Jun-14,50,80,Both,FALSE,10NCT01089790,Forest Laboratories,FALSE,AZ,https://ClinicalTrials.gov/show/NCT01089790,FALSE,Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone,"Diabetes Mellitus, Type 2",Drug:Dutogliptin; Drug:Sitagliptin,[],14-Sep-11,18,86,Both,FALSE,110NCT01073878,"Athena Feminine Technologies, Inc.",FALSE,AZ,https://ClinicalTrials.gov/show/NCT01073878,FALSE,Athena Pelvic Muscle Trainer - DUETS Trial,Urinary Incontinence,Device:Athena Pelvic Muscle Trainer,[],13-Jul-11,30,70,Female,FALSE,70NCT00948818,Forest Laboratories,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00948818,FALSE,Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation,Irritable Bowel Syndrome Characterized by Constipation,Drug:Linaclotide 290 micrograms; Drug:Matching placebo,[],19-Dec-12,18,9999,Both,FALSE,110NCT00878709,"Puma Biotechnology, Inc.",FALSE,AZ,https://ClinicalTrials.gov/show/NCT00878709,FALSE,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Breast Cancer,Drug:neratinib; Other:placebo,[],20-Aug-15,18,9999,Female,FALSE,166NCT00876187,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00876187,FALSE,A Study of Tanezumab in Adults With Chronic Low Back Pain,Low Back Pain,Biological:Tanezumab 20 mg IV; Drug:Placebo for naproxen; Biological:Tanezumab 10 mg IV; Drug:Placebo for naproxen; Biological:Tanezumab 5 mg IV; Drug:Placebo for naproxen; Biological:Placebo for tanezumab; Drug:Naproxen; Biological:Placebo for tanezumab; Drug:Placebo for naproxen,[],19-Jul-11,18,9999,Both,FALSE,10NCT00849056,GlaxoSmithKline,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00849056,FALSE,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:placebo,[],29-May-14,18,9999,Both,FALSE,8NCT00838903,GlaxoSmithKline,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00838903,FALSE,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:sitagliptin; Drug:glimepiride; Drug:metformin; Biological:placebo albiglutide; Drug:placebo sitagliptin; Drug:placebo glimepiride,[],11-Aug-14,18,9999,Both,FALSE,8NCT00830063,Pfizer,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00830063,FALSE,Tanezumab In Osteoarthritis Of The Knee (2),Arthritis; Osteoarthritis,Biological:tanezumab 10 mg; Biological:tanezumab 5 mg; Drug:naproxen; Other:placebo,[],7-Jun-11,18,9999,Both,FALSE,10NCT00821977,Novartis,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00821977,FALSE,Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:Vildagliptin; Drug:Vildagliptin; Drug:Placebo,[],2-Jan-13,18,9999,Both,FALSE,155NCT00804141,"Valeant Pharmaceuticals International, Inc.",TRUE,AZ,https://ClinicalTrials.gov/show/NCT00804141,FALSE,Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation,Constipation,Drug:N-methylnaltrexone bromide (MOA-728),[],29-Aug-14,18,9999,Both,FALSE,47NCT00765999,Forest Laboratories,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00765999,FALSE,"An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation",Chronic Constipation; Irritable Bowel Syndrome With Constipation,Drug:Linaclotide 300 micrograms,[],11-Jan-13,18,9999,Both,FALSE,110NCT00616772,"AbbVie (prior sponsor, Abbott)",FALSE,AZ,https://ClinicalTrials.gov/show/NCT00616772,FALSE,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Coronary Artery Disease; Coronary Heart Disease; Dyslipidemia,Drug:ABT-335; Drug:Placebo; Other:Atorvastatin,[],3-Dec-13,45,9999,Both,FALSE,52NCT00467259,Warner Chilcott,FALSE,AZ,https://ClinicalTrials.gov/show/NCT00467259,FALSE,Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women,Hypoactive Sexual Desire Disorder,Drug:Testosterone Transdermal System; Drug:Placebo patch,[],10-Nov-11,45,70,Female,FALSE,221NCT00430248,Takeda,TRUE,AZ,https://ClinicalTrials.gov/show/NCT00430248,FALSE,Efficacy and Safety of Oral Febuxostat in Participants With Gout,Gout,Drug:Febuxostat; Drug:Febuxostat; Drug:Allopurinol,[],31-Jan-12,18,85,Both,FALSE,5NCT00079274,National Cancer Institute (NCI),FALSE,AZ,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT00264901,Novo Nordisk A/S,FALSE,AR,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT02604836,Hoffmann-La Roche,FALSE,AR,https://ClinicalTrials.gov/show/NCT02604836,FALSE,A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia,Postmenopausal Osteoporosis,Drug:Ibandronate,[],1-Feb-16,0,9999,Female,FALSE,119NCT00262600,Boehringer Ingelheim,FALSE,AR,https://ClinicalTrials.gov/show/NCT00262600,FALSE,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation; Stroke,Drug:warfarin; Drug:Dabigatran dose 1; Drug:Dabigatran dose 2,[],5-Nov-14,18,9999,Both,FALSE,75NCT01543178,"Valeant Pharmaceuticals International, Inc.",FALSE,AR,https://ClinicalTrials.gov/show/NCT01543178,FALSE,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],15-Jun-15,18,9999,Both,FALSE,47NCT00849056,GlaxoSmithKline,FALSE,AR,https://ClinicalTrials.gov/show/NCT00849056,FALSE,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:placebo,[],29-May-14,18,9999,Both,FALSE,8NCT00838916,GlaxoSmithKline,FALSE,AR,https://ClinicalTrials.gov/show/NCT00838916,FALSE,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:insulin glargine,[],22-May-14,18,9999,Both,FALSE,8NCT00806195,Novartis,FALSE,AR,https://ClinicalTrials.gov/show/NCT00806195,FALSE,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis; Meningococcal Infection,"Biological:MenACWY-CRM197; Biological:DTaP (Diptheria, Tetanus, Pertussis) Vaccine; Biological:Hib (Haemophilus influenza b) Vaccine; Biological:IPV (Inactivated Polio Vaccine) Vaccine; Biological:Pneumococcal conjugate Vaccine; Biological:MMR (Measles, Mumps, and Rubella) Vaccine; Biological:Varicella Vaccine; Biological:Hepatitis A Virus",[],13-May-13,55,89,Both,TRUE,155NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,FALSE,AR,https://ClinicalTrials.gov/show/NCT00444457,FALSE,Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,"Vaccines, Pneumococcal",Biological:13-valent Pneumococcal Conjugate Vaccine; Biological:7vPnC,[],10-Oct-12,42,98,Both,TRUE,224NCT00345579,GlaxoSmithKline,TRUE,AR,https://ClinicalTrials.gov/show/NCT00345579,FALSE,"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age",Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine; Haemophilus Influenza Infections,Biological:GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014; Biological:ActHIB; Biological:Pediarix/Infanrix Penta,[],7-Feb-13,6,12,Both,TRUE,8NCT00324805,National Cancer Institute (NCI),FALSE,AR,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,AR,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00080340,Telik,FALSE,AR,https://ClinicalTrials.gov/show/NCT00080340,FALSE,Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Non Small Cell Lung Carcinoma,Drug:TLK286 (Telcyta) HCl for Injection; Drug:gefitinib (Iressa),[],10-Jan-08,18,9999,Both,FALSE,185NCT01499095,Sanofi,TRUE,AR,https://ClinicalTrials.gov/show/NCT01499095,FALSE,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy,Type 2 Diabetes Mellitus,Drug:Lantus (Insulin glargine); Drug:HOE901-U300 (new formulation of insulin glargine),[],22-Apr-15,18,9999,Both,FALSE,12NCT01302067,Pfizer,FALSE,AR,https://ClinicalTrials.gov/show/NCT01302067,FALSE,A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine,Overactive Bladder,Drug:Fesoterodine 8mg; Drug:Fesoterodine 4mg; Drug:Placebo,[],25-Feb-14,18,9999,Both,FALSE,10NCT01091246,MedImmune LLC,FALSE,AR,https://ClinicalTrials.gov/show/NCT01091246,FALSE,A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children,Healthy or Stable Chronic Illness,Biological:Q/LAIV (MEDI3250); Biological:FluMist/B/Yamagata; Biological:FluMist/B/Victoria,[],22-Sep-11,2,17,Both,TRUE,15NCT00853658,Novartis Pharmaceuticals,FALSE,AR,https://ClinicalTrials.gov/show/NCT00853658,FALSE,Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure,Chronic Heart Failure,Drug:Enalapril monotherapy; Drug:Aliskiren monotherapy; Drug:Aliskiren / Enalapril combination therapy,[],23-Jun-14,18,9999,Both,FALSE,156NCT00849017,GlaxoSmithKline,FALSE,AR,https://ClinicalTrials.gov/show/NCT00849017,FALSE,Safety and Efficacy Study of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Biological:albiglutide uptitration; Biological:placebo,[],29-May-14,18,9999,Both,FALSE,8NCT00839527,GlaxoSmithKline,FALSE,AR,https://ClinicalTrials.gov/show/NCT00839527,FALSE,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:placebo to match albiglutide; Biological:albiglutide; Drug:metformin; Drug:glimepiride; Drug:pioglitazone; Drug:placebo to match pioglitazone,[],29-May-14,18,9999,Both,FALSE,8NCT00838903,GlaxoSmithKline,FALSE,AR,https://ClinicalTrials.gov/show/NCT00838903,FALSE,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:sitagliptin; Drug:glimepiride; Drug:metformin; Biological:placebo albiglutide; Drug:placebo sitagliptin; Drug:placebo glimepiride,[],11-Aug-14,18,9999,Both,FALSE,8NCT00764790,GlaxoSmithKline,FALSE,AR,https://ClinicalTrials.gov/show/NCT00764790,FALSE,Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children,Influenza,Biological:Fluarix; Biological:Fluzone,[],11-Oct-12,6,35,Both,TRUE,8NCT00658515,Hoffmann-La Roche,FALSE,AR,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00649389,Daiichi Sankyo Inc.,FALSE,AR,https://ClinicalTrials.gov/show/NCT00649389,FALSE,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,Hypertension,Drug:Olmesartan medoxomil; Drug:Amlodipine; Drug:Hydrochlorothiazide,[],31-Aug-10,18,80,Both,FALSE,95NCT00639418,MedImmune LLC,TRUE,AR,https://ClinicalTrials.gov/show/NCT00639418,FALSE,A Study to Describe Pediatric Influenza Vaccine Coverage,Healthy,Biological:Influenza vaccination,[],12-Sep-14,6,9999,Both,TRUE,15NCT00518115,GlaxoSmithKline,TRUE,AR,https://ClinicalTrials.gov/show/NCT00518115,FALSE,Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only,"Diabetes Mellitus, Type 2",Drug:Albiglutide (GSK716155) or exenatide,[],19-Jun-14,18,75,Both,FALSE,8NCT00503698,Novo Nordisk A/S,FALSE,AR,https://ClinicalTrials.gov/show/NCT00503698,FALSE,The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis,Chronic Kidney Disease; End-Stage Renal Disease,Drug:somatropin; Drug:placebo,[],28-Oct-14,18,9999,Both,FALSE,158NCT00334607,GlaxoSmithKline,TRUE,AR,https://ClinicalTrials.gov/show/NCT00334607,FALSE,Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA,Rotavirus Gastroenteritis,Biological:2-dose oral live attenuated G1P[8] human rotavirus vaccine,[],2-Feb-12,6,16,Both,TRUE,8NCT00240370,Bristol-Myers Squibb,FALSE,AR,https://ClinicalTrials.gov/show/NCT00240370,FALSE,A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics,Type 2 Diabetes,Drug:Muraglitazar,[],10-Sep-10,18,70,Both,FALSE,80NCT00143520,Daiichi Sankyo Inc.,FALSE,AR,https://ClinicalTrials.gov/show/NCT00143520,FALSE,Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes,Type 2 Diabetes,Drug:Rivoglitazone; Drug:Pioglitazone; Drug:Placebo,[],8-Apr-11,18,75,Both,FALSE,95NCT00111020,Bayer,FALSE,AR,https://ClinicalTrials.gov/show/NCT00111020,FALSE,Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma,"Carcinoma, Renal Cell","Drug:Sorafenib (Nexavar, BAY43-9006)",[],5-Aug-14,15,9999,Both,FALSE,23NCT00102973,Telik,FALSE,AR,https://ClinicalTrials.gov/show/NCT00102973,FALSE,TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer,Ovarian Neoplasms,Drug:TLK286 in Combination with Carboplatin; Drug:Doxorubicin HCl Liposome Injection,[],30-May-12,18,9999,Female,FALSE,185NCT01855789,Hoffmann-La Roche,FALSE,AR,https://ClinicalTrials.gov/show/NCT01855789,FALSE,A Study on the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous RoActemra/Actemra (Tocilizumab) With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:methotrexate; Drug:placebo; Drug:tocilizumab [RoActemra/Actemra],[],1-Feb-16,18,9999,Both,FALSE,119NCT01508026,Forest Laboratories,FALSE,AR,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT01499082,Sanofi,TRUE,AR,https://ClinicalTrials.gov/show/NCT01499082,FALSE,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin,Type 2 Diabetes Mellitus,Drug:HOE901-U300 (new formulation of insulin glargine); Drug:Lantus (insulin glargine),[],22-Apr-15,18,9999,Both,FALSE,12NCT01462344,GlaxoSmithKline,FALSE,AR,https://ClinicalTrials.gov/show/NCT01462344,FALSE,6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg,[],1-Oct-15,4,11,Both,FALSE,8NCT01372423,"Anchen Pharmaceuticals, Inc",FALSE,AR,https://ClinicalTrials.gov/show/NCT01372423,FALSE,Evaluation of Clinical Equivalence Between Two Lubiprostone Products,Chronic Idiopathic Constipation,Drug:Lubiprostone; Drug:Placebo,[],10-Jul-12,18,9999,Both,FALSE,63NCT01336205,AstraZeneca,FALSE,AR,https://ClinicalTrials.gov/show/NCT01336205,FALSE,Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Drug:NKTR-118; Drug:Usual care,[],13-Oct-14,18,84,Both,FALSE,13NCT01327846,Novartis Pharmaceuticals,FALSE,AR,https://ClinicalTrials.gov/show/NCT01327846,FALSE,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),Atherosclerosis,Drug:Canakinumab; Drug:Placebo,[],19-May-15,18,9999,Both,FALSE,156NCT01323790,AstraZeneca,FALSE,AR,https://ClinicalTrials.gov/show/NCT01323790,FALSE,Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Drug:NKTR-118; Drug:NKTR-118; Drug:Placebo,[],1-Jun-15,18,84,Both,FALSE,13NCT01224795,BioCryst Pharmaceuticals,FALSE,AR,https://ClinicalTrials.gov/show/NCT01224795,FALSE,A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.,Influenza,Drug:Peramivir; Drug:Placebo Comparator,[],15-Dec-14,12,9999,Both,FALSE,72NCT01179477,St. Jude Medical,FALSE,AR,https://ClinicalTrials.gov/show/NCT01179477,FALSE,QuickFlex Micro Post Approval Study,Heart Failure,Device:Implantation of a QuickFlex  Model 1258T LV Lead,[],9-Dec-14,18,9999,Both,FALSE,177NCT01147250,Sanofi,FALSE,AR,https://ClinicalTrials.gov/show/NCT01147250,FALSE,Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide),Acute Coronary Syndrome,Drug:lixisenatide (AVE0010); Drug:placebo,[],12-Nov-15,30,9999,Both,FALSE,12NCT01130272,"Furiex Pharmaceuticals, Inc",FALSE,AR,https://ClinicalTrials.gov/show/NCT01130272,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],11-Jun-12,18,65,Both,FALSE,112NCT01104792,Forest Laboratories,FALSE,AR,https://ClinicalTrials.gov/show/NCT01104792,FALSE,Long-term Study of Cariprazine in Patients With Schizophrenia,Schizophrenia,Drug:Cariprazine,[],28-Mar-14,18,60,Both,FALSE,110NCT01000974,GlaxoSmithKline,FALSE,AR,https://ClinicalTrials.gov/show/NCT01000974,FALSE,Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants,Haemophilus Influenzae Type b,Biological:GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108); Biological:ActHIB; Biological:Pentacel; Biological:Pediarix; Biological:Prevnar 13; Biological:Rotarix; Biological:Engerix-B; Biological:Infanrix,[],30-Oct-14,6,12,Both,TRUE,8NCT00968708,Takeda,FALSE,AR,https://ClinicalTrials.gov/show/NCT00968708,FALSE,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,"Diabetes Mellitus, Type 2; Acute Coronary Syndrome",Drug:Alogliptin; Drug:Placebo,[],15-Apr-14,18,9999,Both,FALSE,5NCT00959049,CSL Limited,FALSE,AR,https://ClinicalTrials.gov/show/NCT00959049,FALSE,A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population,Influenza,Biological:CSL's Influenza Virus Vaccine (Afluria); Biological:Influenza Virus Vaccine (Fluzone),"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u""Cincinnati Children's Hospital Medical Center- Division of Infectious Disease"", u'', u'UPMC / Community Medicine Inc', u'Pediatric Associates of Latrobe', u'Pediatric Alliance Greentree Division', u'South Hills Pediatrics', u'', u'', u'', u'', u'', u'', u'']",14-Jul-15,6,17,Both,TRUE,93NCT02649478,Roxane Laboratories,FALSE,CA,https://ClinicalTrials.gov/show/NCT02649478,FALSE,Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate,Asthma,Drug:Fluticasone / Salmeterol; Drug:Placebo; Drug:Advair Diskus 100/50,[],13-Jan-16,12,9999,Both,FALSE,170NCT02500797,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02500797,FALSE,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],11-Jan-16,18,9999,Both,FALSE,9NCT02467816,"University of California, Berkeley",FALSE,CA,https://ClinicalTrials.gov/show/NCT02467816,FALSE,Technology and Design Innovation for School Lunch,Childhood Obesity,Behavioral:SmartMeal application; Behavioral:Distributed points of sale; Behavioral:Staff wellness curriculum,"[u""John O'Connell High School"", u'AP Giannini Middle School', u'Aptos Middle School', u'Balboa High School', u'Burton High School', u'Everett Middle School', u'Francisco Middle School', u'Galileo High School', u'Herbert Hoover Middle School', u'James Denman Middle School', u'James Lick Middle School', u'Washington High School', u'June Jordan High School', u'Lincoln High School', u'Lowell High School', u'Marina Middle School', u'Marshall High School', u'Martin Luther King Middle School', u'Mission High School', u'Presidio Middle School', u'Roosevelt Middle School', u'Visitacion Valley Middle School', u'Wallenberg High School', u'Academy High School and Ruth Asawa School of the Arts']",8-Jun-15,0,9999,Both,TRUE,198NCT02465060,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02315430,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02315430,FALSE,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Female,FALSE,9NCT02257528,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02257528,FALSE,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],3-Feb-16,18,9999,Female,FALSE,9NCT02245672,Mylan Inc.,FALSE,CA,https://ClinicalTrials.gov/show/NCT02245672,FALSE,MGR001 / Advair Diskus Local Equivalence Study in Asthma,Asthma,Drug:MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate); Drug:Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate); Drug:Placebo,[],14-Oct-15,18,9999,Both,FALSE,150NCT02224781,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02224781,FALSE,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02139046,Takeda,FALSE,CA,https://ClinicalTrials.gov/show/NCT02139046,FALSE,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Drug:Febuxostat IR; Drug:Febuxostat XR; Drug:Febuxostat placebo; Drug:Colchicine; Drug:Naproxen; Drug:Lansoprazole,[],13-Nov-15,18,9999,Both,FALSE,5NCT02122471,Synergy Pharmaceuticals Inc.,FALSE,CA,https://ClinicalTrials.gov/show/NCT02122471,FALSE,12-Week Study of Plecanatide for CIC (The National CIC3 Study),Chronic Idiopathic Constipation,Drug:Plecanatide; Drug:Placebo,[],29-Jan-15,18,80,Both,FALSE,183NCT02117479,Incyte Corporation,FALSE,CA,https://ClinicalTrials.gov/show/NCT02117479,FALSE,Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1),Metastatic Pancreatic Adenocarcinoma,Drug:Ruxolitinib; Drug:Placebo; Drug:Capecitabine,[],13-Jan-16,18,9999,Both,FALSE,125NCT02058147,Sanofi,FALSE,CA,https://ClinicalTrials.gov/show/NCT02058147,FALSE,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,Type 2 Diabetes,Drug:Insulin glargine/lixisenatide HOE901/AVE0010; Drug:Insulin glargine HOE901; Drug:Lixisenatide AVE0010; Drug:Metformin,[],13-Nov-15,18,9999,Both,FALSE,12NCT02042443,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT02042443,FALSE,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],3-Feb-16,0,9999,Both,FALSE,9NCT02008344,"MDVI, LLC",FALSE,CA,https://ClinicalTrials.gov/show/NCT02008344,FALSE,Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults,Influenza,Drug:favipiravir; Drug:placebo,[],20-Oct-15,18,80,Both,FALSE,143NCT02008227,Hoffmann-La Roche,FALSE,CA,https://ClinicalTrials.gov/show/NCT02008227,FALSE,"A Randomized Phase 3 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - ""OAK""",Non-Squamous Non-Small Cell Lung Cancer,Drug:Atezolizumab; Drug:docetaxel,[],1-Feb-16,18,9999,Both,FALSE,119NCT01982240,Synergy Pharmaceuticals Inc.,FALSE,CA,https://ClinicalTrials.gov/show/NCT01982240,FALSE,12-Week Study of Plecanatide for CIC (The CIC3 Study),Chronic Idiopathic Constipation,Drug:Plecanatide; Drug:Placebo,[],17-Feb-15,18,80,Both,FALSE,183NCT01959529,Novo Nordisk A/S,FALSE,CA,https://ClinicalTrials.gov/show/NCT01959529,FALSE,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],8-Jan-16,50,9999,Both,FALSE,158NCT01942135,Pfizer,FALSE,CA,https://ClinicalTrials.gov/show/NCT01942135,FALSE,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),Metastatic Breast Cancer,Drug:Palbociclib; Drug:Fulvestrant; Drug:Placebo; Drug:Fulvestrant,[],16-Nov-15,18,9999,Female,FALSE,10NCT01937715,Pfizer,FALSE,CA,https://ClinicalTrials.gov/show/NCT01937715,FALSE,A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,Metastatic Colorectal Carcinoma,Drug:PF-05212384; Drug:FOLFIRI regimen; Biological:Bevacizumab; Drug:FOLFIRI,[],15-Dec-15,18,9999,Both,FALSE,10NCT01900665,Eli Lilly and Company,FALSE,CA,https://ClinicalTrials.gov/show/NCT01900665,FALSE,Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo,Alzheimer's Disease,Drug:Solanezumab; Drug:Placebo,[],29-Apr-15,55,90,Both,FALSE,104NCT01886872,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01841736,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT01841736,FALSE,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Both,FALSE,9NCT01789957,AstraZeneca,FALSE,CA,https://ClinicalTrials.gov/show/NCT01789957,FALSE,Extension Study for 2993-112,Type 2 Diabetes Mellitus,Drug:AC2993,[],23-Feb-15,16,75,Both,FALSE,13NCT01764633,Amgen,FALSE,CA,https://ClinicalTrials.gov/show/NCT01764633,FALSE,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],20-Jan-16,40,85,Both,FALSE,16NCT01740427,Pfizer,FALSE,CA,https://ClinicalTrials.gov/show/NCT01740427,FALSE,A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2),Breast Neoplasms,Drug:PD-0332991; Drug:Letrozole; Drug:Placebo; Drug:Letrozole,[],4-Feb-16,18,9999,Female,FALSE,10NCT01732822,AstraZeneca,FALSE,CA,https://ClinicalTrials.gov/show/NCT01732822,FALSE,A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease,Peripheral Artery Disease,Drug:Ticagrelor; Drug:Clopidogrel,[],21-Dec-15,50,130,Both,FALSE,13NCT01715818,Hoffmann-La Roche,FALSE,CA,https://ClinicalTrials.gov/show/NCT01715818,FALSE,A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities,"Cardiovascular Disease, Diabetes Mellitus, Type 2",Drug:Placebo; Drug:aleglitazar,[],1-Feb-16,40,9999,Both,FALSE,119NCT01714713,FORUM Pharmaceuticals Inc,FALSE,CA,https://ClinicalTrials.gov/show/NCT01714713,FALSE,A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy,Schizophrenia; Impaired Cognition,Drug:EVP-6124,[],14-Sep-15,18,50,Both,FALSE,111NCT01696643,Cubist Pharmaceuticals LLC,FALSE,CA,https://ClinicalTrials.gov/show/NCT01696643,FALSE,Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation,Opioid-Induced Constipation,Drug:CB-5945; Drug:Placebo,[],5-Jan-16,18,80,Both,FALSE,94NCT01693029,Sandoz,FALSE,CA,https://ClinicalTrials.gov/show/NCT01693029,FALSE,Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa,Anemia; Chronic Kidney Disease (CKD),Drug:HX575 epoetin alfa; Drug:US-licensed epoetin alfa,[],20-May-15,18,9999,Both,FALSE,174NCT01688973,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT01688973,FALSE,Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery,Childhood Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Tivantinib,[],11-Jan-16,0,9999,Both,FALSE,9NCT01664923,"Medivation, Inc.",FALSE,CA,https://ClinicalTrials.gov/show/NCT01664923,FALSE,Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer,Prostate Cancer,Drug:Enzalutamide; Drug:Bicalutamide,[],26-May-15,18,9999,Male,FALSE,144NCT01658943,National Cancer Institute (NCI),FALSE,CA,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01655680,"AbbVie (prior sponsor, Abbott)",FALSE,CA,https://ClinicalTrials.gov/show/NCT01655680,FALSE,A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia,Schizophrenia,Drug:ABT-126; Drug:ABT-126; Drug:ABT-126; Drug:Placebo,[],28-Apr-15,20,65,Both,FALSE,52NCT01609582,Takeda,FALSE,CA,https://ClinicalTrials.gov/show/NCT01609582,FALSE,Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease,Type 2 Diabetes; Cardiovascular Disease,Drug:TAK-875; Drug:TAK-875 Placebo,[],15-Oct-15,18,9999,Both,FALSE,5NCT01576718,Teva Pharmaceutical Industries,FALSE,CA,https://ClinicalTrials.gov/show/NCT01576718,FALSE,A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications,Asthma,Drug:Fluticasone propionate DPI Dose 1; Drug:Fluticasone propionate DPI Dose 2; Drug:Fluticasone propionate DPI Dose 3; Drug:Fluticasone propionate DPI Dose 4; Other:Placebo DPI; Drug:Flovent Diskus 250 mcg,[],19-Mar-15,12,9999,Both,FALSE,187NCT01553747,"Furiex Pharmaceuticals, Inc",FALSE,CA,https://ClinicalTrials.gov/show/NCT01553747,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Other:Placebo Comparator,[],26-Apr-15,18,80,Both,FALSE,112NCT01553591,"Furiex Pharmaceuticals, Inc",FALSE,CA,https://ClinicalTrials.gov/show/NCT01553591,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],26-Apr-15,18,80,Both,FALSE,112NCT01547741,NSABP Foundation Inc,FALSE,CA,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01543178,"Valeant Pharmaceuticals International, Inc.",FALSE,CA,https://ClinicalTrials.gov/show/NCT01543178,FALSE,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],15-Jun-15,18,9999,Both,FALSE,47NCT01515800,Southwest Oncology Group,FALSE,CA,https://ClinicalTrials.gov/show/NCT01515800,FALSE,S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer,Breast Cancer,Behavioral:Text message reminder,[],23-Oct-15,18,120,Female,FALSE,3NCT01508026,Forest Laboratories,FALSE,CA,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT01498289,Southwest Oncology Group,FALSE,CA,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01479621,Teva Pharmaceutical Industries,FALSE,CA,https://ClinicalTrials.gov/show/NCT01479621,FALSE,A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids,Asthma,Drug:Placebo; Drug:Flovent Diskus; Drug:Fluticasone propionate DPI Dose 1; Drug:Fluticasone propionate DPI Dose 2; Drug:Fluticasone propionate DPI Dose 3; Drug:Fluticasone propionate DPI Dose 4,[],19-Mar-15,12,9999,Both,FALSE,187NCT02500797,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT02500797,FALSE,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],11-Jan-16,18,9999,Both,FALSE,9NCT02465060,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02311907,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT02311907,FALSE,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],22-May-15,18,9999,Female,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02116530,Alliance for Clinical Trials in Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT02116530,FALSE,Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy,"Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:Olanzapine; Drug:Chemotherapy (cisplatin or cyclophosphamide and doxorubicin); Drug:Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant); Other:Placebo,[],15-Jun-15,18,9999,Both,FALSE,1NCT01886872,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01841736,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01841736,FALSE,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01708954,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01708954,FALSE,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],23-Oct-15,18,9999,Both,FALSE,9NCT01708941,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01708941,FALSE,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Recombinant Interferon Alfa-2b,[],11-Jan-16,18,9999,Both,FALSE,9NCT01658943,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01653028,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01653028,FALSE,Alisertib in Treating Patients With Advanced or Metastatic Sarcoma,Myxofibrosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Leiomyosarcoma; Recurrent Liposarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis,[],2-Feb-16,18,9999,Both,FALSE,9NCT01642251,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01642251,FALSE,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,CO,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01522976,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01522976,FALSE,Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia,Adult Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts,Drug:Azacitidine; Drug:Lenalidomide; Drug:Vorinostat,[],24-Jun-15,18,9999,Both,FALSE,9NCT01498289,Southwest Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01403649,"University of Colorado, Denver",FALSE,CO,https://ClinicalTrials.gov/show/NCT01403649,FALSE,Collaborative Efforts to Increase Flu Vaccination,Influenza; Collaboration,Behavioral:Private/public collaboration to increase flu vaccination; Other:Usual care,"[u'Tri County Health dept', u'Aurora Family Medicine', u'Forum Family Medicine', u'Premier Pediatrics', u'Indian Crest Pediatrics', u'Centennial Pediatrics', u'Advanced Pediatrics', u'Greenwood Pediatrics', u'Pediatric Pathways', u'Pediatrics 5280', u'CIIS', u'Hampden Medical Group', u'Ft. Morgan Medical Group', u'Family Practice Clinic', u'Haxtun Family Medicine', u'Valley Medical Center', u'Denver West Pediatrics', u'Kids First', u'Jefferson County Health dept', u'Focus on Kids', u'Lone Tree Family Medicine', u'Crown Point Pediatrics', u'Northeast County Health Dept', u'Mountain Land Pediatrics', u'Pediatrics West', u'Wray Clinic', u'Yuma Clinic']",29-May-15,6,18,Both,TRUE,199NCT01376349,Alliance for Clinical Trials in Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT01376349,FALSE,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],24-Sep-15,18,9999,Female,FALSE,1NCT01275677,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01256398,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01256398,FALSE,Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Alemtuzumab; Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Procedure:Autologous Hematopoietic Stem Cell Transplantation; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dasatinib; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide Phosphate; Biological:Filgrastim; Drug:Fludarabine Phosphate; Procedure:In Vitro-Treated Peripheral Blood Stem Cell Transplantation; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Melphalan; Drug:Mercaptopurine; Drug:Methotrexate; Biological:Pegfilgrastim; Other:Pharmacological Study; Drug:Tacrolimus; Drug:Vincristine Sulfate,[],3-Feb-16,18,9999,Both,FALSE,9NCT01251861,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01251861,FALSE,Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer,Recurrent Prostate Carcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer,Drug:Akt Inhibitor MK2206; Drug:Bicalutamide; Other:Clinical Observation; Other:Laboratory Biomarker Analysis,[],18-Jan-16,18,9999,Male,FALSE,9NCT01229943,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01229943,FALSE,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],22-Apr-15,18,9999,Both,FALSE,9NCT01198158,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01196390,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01142388,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01142388,FALSE,Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Recurrent Esophageal Carcinoma; Stage IV Esophageal Cancer,Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Pharmacological Study,[],2-Jun-15,18,9999,Both,FALSE,9NCT01134614,National Cancer Institute (NCI),TRUE,CO,https://ClinicalTrials.gov/show/NCT01134614,FALSE,Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,Recurrent Melanoma; Stage III Melanoma; Stage IV Melanoma,Biological:ipilimumab; Biological:sargramostim,[],23-Mar-15,18,9999,Both,FALSE,9NCT01099449,Alliance for Clinical Trials in Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT01099449,FALSE,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],4-Jul-15,18,9999,Both,FALSE,1NCT01097278,Southwest Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT01097278,FALSE,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],7-Jan-15,18,50,Female,FALSE,3NCT01091454,Alliance for Clinical Trials in Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT01091454,FALSE,Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer,Triple-negative Breast Cancer,Drug:brostallicin; Drug:cisplatin,[],23-Jul-15,18,9999,Both,FALSE,1NCT01084083,Eastern Cooperative Oncology Group,TRUE,CO,https://ClinicalTrials.gov/show/NCT01084083,FALSE,Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer,Head and Neck Cancer; Precancerous Condition,Biological:cetuximab; Radiation:intensity-modulated radiation therapy (IMRT); Drug:Paclitaxel; Drug:Cisplatin,[],22-Sep-15,18,9999,Both,FALSE,17NCT01081262,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01081262,FALSE,Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer,Borderline Ovarian Mucinous Tumor; Ovarian Mucinous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer,Biological:Bevacizumab; Drug:Capecitabine; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Oxaliplatin; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],12-Jan-16,18,9999,Female,FALSE,9NCT01078454,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01078454,FALSE,Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis,Light Chain Deposition Disease; Primary Systemic Amyloidosis,Drug:melphalan; Drug:dexamethasone; Drug:bortezomib,[],20-Nov-14,18,9999,Both,FALSE,9NCT01078441,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01078441,FALSE,"Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant",Refractory Multiple Myeloma,Drug:liposomal doxorubicin; Drug:bortezomib; Drug:dexamethasone; Drug:cyclophosphamide,[],5-Jan-15,18,9999,Both,FALSE,9NCT01012297,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT01012297,FALSE,Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma,Recurrent Uterine Corpus Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Biological:Bevacizumab; Drug:Docetaxel; Biological:Filgrastim; Drug:Gemcitabine Hydrochloride; Biological:Pegfilgrastim; Other:Placebo,[],11-Nov-15,18,9999,Female,FALSE,9NCT01011478,NSABP Foundation Inc,TRUE,CO,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT00954174,Gynecologic Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT00954174,FALSE,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00946712,Southwest Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00942331,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00887536,NSABP Foundation Inc,FALSE,CO,https://ClinicalTrials.gov/show/NCT00887536,FALSE,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],24-Jun-15,18,70,Female,FALSE,2NCT00880191,Alliance for Clinical Trials in Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT00880191,FALSE,Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy,"Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:dexamethasone; Drug:gabapentin; Other:placebo,[],23-Nov-15,18,9999,Both,FALSE,1NCT00874211,Southwest Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT00874211,FALSE,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],4-Mar-15,0,9999,Both,FALSE,3NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,CO,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT00861705,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT00861705,FALSE,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],28-Sep-15,18,9999,Both,FALSE,9NCT00860041,Alliance for Clinical Trials in Oncology,TRUE,CO,https://ClinicalTrials.gov/show/NCT00860041,FALSE,Acute Pain Caused by Paclitaxel in Patients With Cancer,"Chemotherapeutic Agent Toxicity; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific",Behavioral:pain questionnaires,[],7-Jul-15,18,9999,Both,FALSE,1NCT00822120,Southwest Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT00822120,FALSE,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,Lymphoma; Nonneoplastic Condition,Biological:bleomycin sulfate; Biological:filgrastim; Drug:ABVD regimen; Drug:BEACOPP regimen; Drug:cyclophosphamide; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:prednisone; Drug:procarbazine hydrochloride; Drug:vinblastine sulfate; Drug:vincristine sulfate,[],8-May-15,18,60,Both,FALSE,3NCT00803062,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT00803062,FALSE,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],22-May-15,18,9999,Female,FALSE,9NCT00789958,Southwest Oncology Group,FALSE,CO,https://ClinicalTrials.gov/show/NCT00789958,FALSE,"S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct",Extrahepatic Bile Duct Cancer; Gallbladder Cancer,Drug:capecitabine; Drug:gemcitabine hydrochloride; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],16-Feb-15,18,9999,Both,FALSE,3NCT00785291,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00770809,National Cancer Institute (NCI),FALSE,CO,https://ClinicalTrials.gov/show/NCT00770809,FALSE,Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,HER2/Neu Positive; Male Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Lapatinib Ditosylate; Biological:Trastuzumab; Drug:Paclitaxel; Other:Laboratory Biomarker Analysis,[],7-May-15,18,9999,Both,FALSE,9NCT01691430,Yale University,FALSE,CT,https://ClinicalTrials.gov/show/NCT01691430,FALSE,A Trial of Cranberry Capsules for Urinary Tract Infection Prevention in Nursing Home Residents,Bacteriuria,Dietary Supplement:2 cranberry capsules; Dietary Supplement:Placebo,"[u'Branford Hills Health Care', u'Northbridge Health Care Center', u'Bridgeport Health Care Center', u'Bridgeport Manor', u'Riverside Health & Rehabilitation Center', u'Ludlowe Health Care Center', u'Glastonbury Health Care Center', u'The Nathaniel Witherell', u'Hamden Health Care Center', u'Arden House Care and Rehabilitation Center', u'Avery Heights', u'Wadsworth Glen Health Care and Rehabilitation Center', u""Water's Edge Center for Health & Rehabilitation"", u'Advanced Nursing & Rehab Center of New Haven', u'Mary Wade Home', u'Grimes Center', u'Shady Knoll Health Center', u'Lord Chamberlain Nursing & Rehabilitation Center', u'Village Green of Wallingford', u'Abbott Terrace Health Center', u'Hughes Health & Rehab Center']",22-Oct-15,65,9999,Female,TRUE,48NCT00034879,AstraZeneca,FALSE,CT,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT01886872,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT00625898,NSABP Foundation Inc,FALSE,CT,https://ClinicalTrials.gov/show/NCT00625898,FALSE,BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab,Breast Cancer,Drug:Docetaxel; Drug:Trastuzumab; Drug:Carboplatin; Drug:Bevacizumab; Drug:5-Fluorouracil; Drug:Epirubicin; Drug:Cyclophosphamide,[],7-Jul-14,18,9999,Female,FALSE,2NCT01033383,Yale University,TRUE,CT,https://ClinicalTrials.gov/show/NCT01033383,FALSE,Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents,Bacteriuria,Dietary Supplement:Placebo; Dietary Supplement:Cranberry Capsule,"[u'Northbridge Health Care Center', u'Sheriden Woods Health Care Center', u'The Carolton Chronic and Convalescent Hospital', u'Glastonbury Health Care Center', u'Middlesex Health Care Center', u'Wadsworth Glen Health Care and Rehabilitation Center', u'Beacon Brook Health Care Center', u'Laurel Ridge Health Care Center', u'Shady Knoll Health Center', u'Litchfield Woods Health Care Center', u'Maefair Health Care Center', u'Masonicare Health Center', u'Abbott Terracee Health Center', u'Saint Mary Home']",12-Jul-13,65,9999,Female,TRUE,48NCT00667810,Pfizer,FALSE,CT,https://ClinicalTrials.gov/show/NCT00667810,FALSE,Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients,Alzheimer Disease,Drug:bapineuzumab; Drug:bapineuzumab; Drug:placebo,[],4-Dec-15,50,89,Both,FALSE,10NCT00310180,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00003906,NSABP Foundation Inc,TRUE,CT,https://ClinicalTrials.gov/show/NCT00003906,FALSE,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],5-Oct-15,35,9999,Female,FALSE,2NCT00382070,NSABP Foundation Inc,TRUE,CT,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00942331,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00080340,Telik,FALSE,CT,https://ClinicalTrials.gov/show/NCT00080340,FALSE,Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Non Small Cell Lung Carcinoma,Drug:TLK286 (Telcyta) HCl for Injection; Drug:gefitinib (Iressa),[],10-Jan-08,18,9999,Both,FALSE,185NCT00650039,Pfizer,FALSE,CT,https://ClinicalTrials.gov/show/NCT00650039,FALSE,"Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction",Pain,Drug:placebo; Drug:valdecoxib; Drug:valdecoxib,[],3-Jun-08,18,75,Both,FALSE,10NCT00346216,Pfizer,FALSE,CT,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00264901,Novo Nordisk A/S,FALSE,CT,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT01275677,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00781391,Daiichi Sankyo Inc.,FALSE,CT,https://ClinicalTrials.gov/show/NCT00781391,FALSE,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke; Atrial Fibrillation; Embolism,Drug:warfarin tablets; Drug:Edoxaban tablets (high dose regimen-60mg); Drug:Edoxaban tablets (low dose regimen-30mg); Drug:placebo warfarin; Drug:placebo edoxaban,[],12-Mar-15,21,9999,Both,FALSE,95NCT00769379,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00111020,Bayer,FALSE,CT,https://ClinicalTrials.gov/show/NCT00111020,FALSE,Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma,"Carcinoma, Renal Cell","Drug:Sorafenib (Nexavar, BAY43-9006)",[],5-Aug-14,15,9999,Both,FALSE,23NCT00079274,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT02042443,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT02042443,FALSE,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],3-Feb-16,0,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,CT,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01070836,Biogen,FALSE,CT,https://ClinicalTrials.gov/show/NCT01070836,FALSE,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],14-Jan-16,0,9999,Both,FALSE,73NCT00942357,Gynecologic Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00217737,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00160173,ASCEND Therapeutics,FALSE,CT,https://ClinicalTrials.gov/show/NCT00160173,FALSE,Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy,Postmenopausal Symptoms,Drug:Estradiol,[],11-Jul-13,45,65,Female,FALSE,66NCT01366183,Gynecologic Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT01366183,FALSE,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],23-Dec-14,75,9999,Both,FALSE,14NCT01196390,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01167712,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT00751946,University of Connecticut Health Center,TRUE,CT,https://ClinicalTrials.gov/show/NCT00751946,FALSE,Girls In Recovery From Life Stress (GIRLS) Study,Posttraumatic Stress Disorder; PTSD,Behavioral:Trauma Adaptive Recovery Group Education and Therapy; Behavioral:Enhanced Treatment As Usual,"[u'Polaris School', u'University of Connecticut Health Center', u'Gray Lodge Shelter for Women', u'Weaver High School', u'Bellizzi Middle School', u'Quirk Middle School', u'UCONN Health Partners']",24-Sep-10,13,17,Female,FALSE,43NCT00676143,Pfizer,FALSE,CT,https://ClinicalTrials.gov/show/NCT00676143,FALSE,Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients,Alzheimer Disease,Drug:bapineuzumab; Drug:placebo,[],20-Dec-12,50,88,Both,FALSE,10NCT00450970,Agennix,FALSE,CT,https://ClinicalTrials.gov/show/NCT00450970,FALSE,Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC),Prostate Cancer,Drug:Oral Satraplatin,[],9-Aug-12,18,9999,Male,FALSE,57NCT00433511,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00373685,Pfizer,FALSE,CT,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00326898,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00262847,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT00262847,FALSE,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],18-Aug-15,18,9999,Female,FALSE,9NCT00245739,"Tibotec Pharmaceuticals, Ireland",FALSE,CT,https://ClinicalTrials.gov/show/NCT00245739,FALSE,"TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.",HIV Infections,Drug:TMC-114,[],10-Apr-14,18,9999,Both,FALSE,191NCT00003594,Alliance for Clinical Trials in Oncology,TRUE,CT,https://ClinicalTrials.gov/show/NCT00003594,FALSE,Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,Colorectal Cancer,Drug:irinotecan; Drug:fluorouracil; Drug:leucovorin calcium; Drug:oxaliplatin,[],9-Jul-15,18,9999,Both,FALSE,1NCT01620528,"AbbVie (prior sponsor, Abbott)",FALSE,CT,https://ClinicalTrials.gov/show/NCT01620528,FALSE,A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain,Endometriosis,Drug:Elagolix; Other:placebo,[],13-Nov-15,18,49,Female,FALSE,52NCT01217697,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",FALSE,CT,https://ClinicalTrials.gov/show/NCT01217697,FALSE,Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer,"Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male",Drug:Abiraterone Acetate,[],3-Feb-16,18,99,Both,FALSE,136NCT01101438,NCIC Clinical Trials Group,TRUE,CT,https://ClinicalTrials.gov/show/NCT01101438,FALSE,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,Breast Cancer,Drug:metformin hydrochloride; Other:placebo,[],5-May-15,18,74,Both,FALSE,11NCT01011478,NSABP Foundation Inc,TRUE,CT,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT00954174,Gynecologic Oncology Group,FALSE,CT,https://ClinicalTrials.gov/show/NCT00954174,FALSE,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00951496,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT00951496,FALSE,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00937352,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",FALSE,CT,https://ClinicalTrials.gov/show/NCT00937352,FALSE,A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease,Alzheimer's Disease,Drug:Bapineuzumab,[],26-Nov-13,51,9999,Both,FALSE,131NCT00601900,National Cancer Institute (NCI),FALSE,CT,https://ClinicalTrials.gov/show/NCT00601900,FALSE,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],23-Apr-15,18,9999,Female,FALSE,9NCT00575055,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",FALSE,CT,https://ClinicalTrials.gov/show/NCT00575055,FALSE,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier),Alzheimer's Disease,Drug:Bapineuzumab 0.5 mg/kg; Drug:Placebo Control; Drug:Bapineuzumab 1.0 m/kg,[],30-Oct-13,50,88,Both,FALSE,131NCT00574132,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",FALSE,CT,https://ClinicalTrials.gov/show/NCT00574132,FALSE,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier),Alzheimer's Disease,Drug:Bapineuzumab 0.5 mg/kg; Drug:Placebo Control; Drug:Bapineuzumab 1.0 m/kg,[],30-Oct-13,50,88,Both,FALSE,131NCT00454701,Astellas Pharma Inc,FALSE,CT,https://ClinicalTrials.gov/show/NCT00454701,FALSE,Assessment and Tracking of Long-term Alefacept Safety,Psoriasis,Drug:Alefacept exposure,[],10-Dec-13,18,9999,Both,FALSE,68NCT01275677,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00946712,Southwest Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00588770,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT02465060,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02257528,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT02257528,FALSE,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],3-Feb-16,18,9999,Female,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02116530,Alliance for Clinical Trials in Oncology,FALSE,DE,https://ClinicalTrials.gov/show/NCT02116530,FALSE,Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy,"Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:Olanzapine; Drug:Chemotherapy (cisplatin or cyclophosphamide and doxorubicin); Drug:Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant); Other:Placebo,[],15-Jun-15,18,9999,Both,FALSE,1NCT02066181,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT02066181,FALSE,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,Desmoid-Type Fibromatosis,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate,[],25-Jan-16,18,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01841736,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01841736,FALSE,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01824823,Eastern Cooperative Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT01824823,FALSE,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],11-Sep-15,18,9999,Both,FALSE,17NCT01708954,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01708954,FALSE,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],23-Oct-15,18,9999,Both,FALSE,9NCT01708941,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01708941,FALSE,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Recombinant Interferon Alfa-2b,[],11-Jan-16,18,9999,Both,FALSE,9NCT01658943,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01648348,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01648348,FALSE,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01498289,Southwest Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01256398,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01256398,FALSE,Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Alemtuzumab; Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Procedure:Autologous Hematopoietic Stem Cell Transplantation; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dasatinib; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide Phosphate; Biological:Filgrastim; Drug:Fludarabine Phosphate; Procedure:In Vitro-Treated Peripheral Blood Stem Cell Transplantation; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Melphalan; Drug:Mercaptopurine; Drug:Methotrexate; Biological:Pegfilgrastim; Other:Pharmacological Study; Drug:Tacrolimus; Drug:Vincristine Sulfate,[],3-Feb-16,18,9999,Both,FALSE,9NCT01015833,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00942357,Gynecologic Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00942331,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01366183,Gynecologic Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT01366183,FALSE,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],23-Dec-14,75,9999,Both,FALSE,14NCT00956670,Gynecologic Oncology Group,FALSE,DE,https://ClinicalTrials.gov/show/NCT00956670,FALSE,"Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer",Lymphedema; Stage IA Cervical Cancer; Stage IA Uterine Corpus Cancer; Stage IA Vulvar Cancer; Stage IB Cervical Cancer; Stage IB Uterine Corpus Cancer; Stage IB Vulvar Cancer; Stage II Uterine Corpus Cancer; Stage II Vulvar Cancer; Stage IIA Cervical Cancer; Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVB Vulvar Cancer,Procedure:Therapeutic Lymphadenectomy; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Laparoscopic Surgery; Procedure:Study of High Risk Factors; Other:Questionnaire Administration; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT01196390,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT00264901,Novo Nordisk A/S,FALSE,DE,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT02224781,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT02224781,FALSE,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT00640042,Pfizer,TRUE,DE,https://ClinicalTrials.gov/show/NCT00640042,FALSE,"Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",Pain,Drug:morphine sulfate extended release capsules,[],6-Jun-12,21,9999,Both,FALSE,10NCT01547741,NSABP Foundation Inc,FALSE,DE,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01004640,Alliance for Clinical Trials in Oncology,FALSE,DE,https://ClinicalTrials.gov/show/NCT01004640,FALSE,Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial,Leukemia,Genetic:DNA analysis; Genetic:Southern blotting; Genetic:cytogenetic analysis; Genetic:polymerase chain reaction,[],23-Jul-15,0,9999,Both,FALSE,1NCT00072046,Alliance for Clinical Trials in Oncology,TRUE,DE,https://ClinicalTrials.gov/show/NCT00072046,FALSE,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],23-Jun-15,18,9999,Both,FALSE,1NCT00022087,Alliance for Clinical Trials in Oncology,TRUE,DE,https://ClinicalTrials.gov/show/NCT00022087,FALSE,"Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer",Breast Cancer; Osteoporosis,Dietary Supplement:calcium salts; Dietary Supplement:cholecalciferol; Drug:zoledronic acid,[],26-Sep-13,40,9999,Female,FALSE,1NCT02498600,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT02498600,FALSE,"Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],11-Jan-16,18,9999,Female,FALSE,9NCT01764633,Amgen,FALSE,DE,https://ClinicalTrials.gov/show/NCT01764633,FALSE,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],20-Jan-16,40,85,Both,FALSE,16NCT01730534,AstraZeneca,FALSE,DE,https://ClinicalTrials.gov/show/NCT01730534,FALSE,Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events,"Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event",Drug:Dapagliflozin 10 mg; Drug:Placebo tablet,[],10-Dec-15,40,130,Both,FALSE,13NCT01011478,NSABP Foundation Inc,TRUE,DE,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT00892177,Alliance for Clinical Trials in Oncology,FALSE,DE,https://ClinicalTrials.gov/show/NCT00892177,FALSE,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],23-Nov-15,18,9999,Both,FALSE,1NCT00805740,Pfizer,FALSE,DE,https://ClinicalTrials.gov/show/NCT00805740,FALSE,An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida,Candidiasis; Fungemia,Drug:Active anidulafungin; Drug:Active Caspofungin,"[u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site']",30-May-13,16,9999,Both,FALSE,10NCT00785291,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00693992,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT00693992,FALSE,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],26-Jun-15,18,9999,Both,FALSE,9NCT00496197,Pfizer,FALSE,DE,https://ClinicalTrials.gov/show/NCT00496197,FALSE,Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis,Candidiasis,Drug:Eraxis (anidulafungin); Drug:Diflucan (fluconazole); Drug:Vfend (voriconazole),[],29-Aug-11,18,9999,Both,FALSE,10NCT00433511,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00373685,Pfizer,FALSE,DE,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00326898,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00267748,Pfizer,FALSE,DE,https://ClinicalTrials.gov/show/NCT00267748,FALSE,Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC),"Carcinoma, Renal Cell",Drug:Sunitinib Malate Continuous Daily Dosing; Drug:Sunitinib Malate Schedule 4/2,[],3-Aug-11,18,9999,Both,FALSE,10NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,DE,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00262847,National Cancer Institute (NCI),FALSE,DE,https://ClinicalTrials.gov/show/NCT00262847,FALSE,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],18-Aug-15,18,9999,Female,FALSE,9NCT00243503,Pfizer,FALSE,DE,https://ClinicalTrials.gov/show/NCT00243503,FALSE,Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer,Breast Neoplasms,Drug:SU011248/Trastuzumab,[],20-Jul-11,18,9999,Both,FALSE,10NCT02245568,TauRx Therapeutics Ltd,FALSE,FL,https://ClinicalTrials.gov/show/NCT02245568,FALSE,Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD),Alzheimer's Disease; Behavioral Variant Frontotemporal Dementia,Drug:TRx0237,[],17-Sep-14,0,9999,Both,FALSE,184NCT02139046,Takeda,FALSE,FL,https://ClinicalTrials.gov/show/NCT02139046,FALSE,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Drug:Febuxostat IR; Drug:Febuxostat XR; Drug:Febuxostat placebo; Drug:Colchicine; Drug:Naproxen; Drug:Lansoprazole,[],13-Nov-15,18,9999,Both,FALSE,5NCT02122471,Synergy Pharmaceuticals Inc.,FALSE,FL,https://ClinicalTrials.gov/show/NCT02122471,FALSE,12-Week Study of Plecanatide for CIC (The National CIC3 Study),Chronic Idiopathic Constipation,Drug:Plecanatide; Drug:Placebo,[],29-Jan-15,18,80,Both,FALSE,183NCT02030600,Novo Nordisk A/S,FALSE,FL,https://ClinicalTrials.gov/show/NCT02030600,FALSE,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes","Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],8-Dec-15,18,9999,Both,FALSE,158NCT02008344,"MDVI, LLC",FALSE,FL,https://ClinicalTrials.gov/show/NCT02008344,FALSE,Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults,Influenza,Drug:favipiravir; Drug:placebo,[],20-Oct-15,18,80,Both,FALSE,143NCT02004522,"Infinity Pharmaceuticals, Inc.",FALSE,FL,https://ClinicalTrials.gov/show/NCT02004522,FALSE,A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO),Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,Drug:IPI-145 (duvelisib); Drug:Ofatumumab,[],17-Nov-15,18,9999,Both,FALSE,126NCT01982240,Synergy Pharmaceuticals Inc.,FALSE,FL,https://ClinicalTrials.gov/show/NCT01982240,FALSE,12-Week Study of Plecanatide for CIC (The CIC3 Study),Chronic Idiopathic Constipation,Drug:Plecanatide; Drug:Placebo,[],17-Feb-15,18,80,Both,FALSE,183NCT01959529,Novo Nordisk A/S,FALSE,FL,https://ClinicalTrials.gov/show/NCT01959529,FALSE,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],8-Jan-16,50,9999,Both,FALSE,158NCT01789957,AstraZeneca,FALSE,FL,https://ClinicalTrials.gov/show/NCT01789957,FALSE,Extension Study for 2993-112,Type 2 Diabetes Mellitus,Drug:AC2993,[],23-Feb-15,16,75,Both,FALSE,13NCT01764633,Amgen,FALSE,FL,https://ClinicalTrials.gov/show/NCT01764633,FALSE,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],20-Jan-16,40,85,Both,FALSE,16NCT01732822,AstraZeneca,FALSE,FL,https://ClinicalTrials.gov/show/NCT01732822,FALSE,A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease,Peripheral Artery Disease,Drug:Ticagrelor; Drug:Clopidogrel,[],21-Dec-15,50,130,Both,FALSE,13NCT01730534,AstraZeneca,FALSE,FL,https://ClinicalTrials.gov/show/NCT01730534,FALSE,Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events,"Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event",Drug:Dapagliflozin 10 mg; Drug:Placebo tablet,[],10-Dec-15,40,130,Both,FALSE,13NCT01715818,Hoffmann-La Roche,FALSE,FL,https://ClinicalTrials.gov/show/NCT01715818,FALSE,A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities,"Cardiovascular Disease, Diabetes Mellitus, Type 2",Drug:Placebo; Drug:aleglitazar,[],1-Feb-16,40,9999,Both,FALSE,119NCT01696643,Cubist Pharmaceuticals LLC,FALSE,FL,https://ClinicalTrials.gov/show/NCT01696643,FALSE,Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation,Opioid-Induced Constipation,Drug:CB-5945; Drug:Placebo,[],5-Jan-16,18,80,Both,FALSE,94NCT01687998,Eli Lilly and Company,FALSE,FL,https://ClinicalTrials.gov/show/NCT01687998,FALSE,A Study of Evacetrapib in High-Risk Vascular Disease,Cardiovascular Diseases,Drug:Evacetrapib; Drug:Placebo,[],25-Jan-16,18,9999,Both,FALSE,104NCT01676220,Sanofi,TRUE,FL,https://ClinicalTrials.gov/show/NCT01676220,FALSE,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy,Type 2 Diabetes Mellitus,Drug:HOE901-U300 (new formulation of insulin glargine); Drug:Lantus (insulin glargine),[],28-May-15,18,9999,Both,FALSE,12NCT01674530,Dr. Reddy's Laboratories Limited,FALSE,FL,https://ClinicalTrials.gov/show/NCT01674530,FALSE,Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Drug:Lubiprostone; Drug:Lubiprostone; Drug:Placebo,[],2-Apr-14,18,9999,Both,FALSE,98NCT01642914,Forest Laboratories,FALSE,FL,https://ClinicalTrials.gov/show/NCT01642914,FALSE,Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating,Chronic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Matching placebo,[],30-Sep-13,18,9999,Both,TRUE,110NCT01626742,Abbott Nutrition,FALSE,FL,https://ClinicalTrials.gov/show/NCT01626742,FALSE,A Trial of an Oral Nutritional Supplement in Older Hospitalized Patients - NOURISH Study,Hospitalized Elderly,Other:Ready to Drink Flavored Beverage; Other:Ready to drink flavored beverage w/ AN 777,[],24-Apr-15,65,9999,Both,FALSE,49NCT01620255,Pfizer,FALSE,FL,https://ClinicalTrials.gov/show/NCT01620255,FALSE,A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis,Ulcerative Colitis,Drug:PF-00547659 SC Injection; Drug:PF-00547659 SC Injection; Drug:PF-00547659 SC Injection; Drug:PF-00547659 SC Injection; Drug:PF-00547659 SC Injection,[],5-Nov-15,18,65,Both,FALSE,10NCT01609582,Takeda,FALSE,FL,https://ClinicalTrials.gov/show/NCT01609582,FALSE,Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease,Type 2 Diabetes; Cardiovascular Disease,Drug:TAK-875; Drug:TAK-875 Placebo,[],15-Oct-15,18,9999,Both,FALSE,5NCT01601704,Takeda,FALSE,FL,https://ClinicalTrials.gov/show/NCT01601704,FALSE,Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study),Obesity; Overweight,Drug:NB32; Drug:PBO; Behavioral:Weight Management Program,[],26-Feb-15,45,9999,Both,FALSE,5NCT01576718,Teva Pharmaceutical Industries,FALSE,FL,https://ClinicalTrials.gov/show/NCT01576718,FALSE,A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications,Asthma,Drug:Fluticasone propionate DPI Dose 1; Drug:Fluticasone propionate DPI Dose 2; Drug:Fluticasone propionate DPI Dose 3; Drug:Fluticasone propionate DPI Dose 4; Other:Placebo DPI; Drug:Flovent Diskus 250 mcg,[],19-Mar-15,12,9999,Both,FALSE,187NCT01572792,Forest Laboratories,FALSE,FL,https://ClinicalTrials.gov/show/NCT01572792,FALSE,"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide; Drug:Formoterol Fumarate; Drug:Placebo,[],27-Feb-15,40,9999,Both,FALSE,110NCT01553747,"Furiex Pharmaceuticals, Inc",FALSE,FL,https://ClinicalTrials.gov/show/NCT01553747,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Other:Placebo Comparator,[],26-Apr-15,18,80,Both,FALSE,112NCT01553591,"Furiex Pharmaceuticals, Inc",FALSE,FL,https://ClinicalTrials.gov/show/NCT01553591,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],26-Apr-15,18,80,Both,FALSE,112NCT01543178,"Valeant Pharmaceuticals International, Inc.",FALSE,FL,https://ClinicalTrials.gov/show/NCT01543178,FALSE,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],15-Jun-15,18,9999,Both,FALSE,47NCT01508026,Forest Laboratories,FALSE,FL,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT01507831,Sanofi,TRUE,FL,https://ClinicalTrials.gov/show/NCT01507831,FALSE,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),Hypercholesterolemia,Drug:Placebo (for alirocumab); Drug:Alirocumab; Drug:Lipid-Modifying Therapy (LMT),[],18-Nov-15,18,9999,Both,FALSE,12NCT01475721,GlaxoSmithKline,FALSE,FL,https://ClinicalTrials.gov/show/NCT01475721,FALSE,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],10-Dec-15,12,9999,Both,FALSE,8NCT01462344,GlaxoSmithKline,FALSE,FL,https://ClinicalTrials.gov/show/NCT01462344,FALSE,6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg,[],1-Oct-15,4,11,Both,FALSE,8NCT01455857,Intarcia Therapeutics,FALSE,FL,https://ClinicalTrials.gov/show/NCT01455857,FALSE,A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes,Type 2 Diabetes,Drug:ITCA 650; Other:ITCA placebo,[],28-Jul-15,18,80,Both,FALSE,128NCT01452529,Purdue Pharma LP,TRUE,FL,https://ClinicalTrials.gov/show/NCT01452529,FALSE,Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain,Chronic Low Back Pain,Drug:Hydrocodone bitartrate q24h film-coated tablets; Drug:Placebo to match hydrocodone bitartrate q24h tablets,[],27-Aug-15,18,9999,Both,FALSE,36NCT01444430,AstraZeneca,FALSE,FL,https://ClinicalTrials.gov/show/NCT01444430,FALSE,A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents,Asthma,Drug:Symbicort pMDI; Drug:Symbicort pMDI; Drug:budesonide pMDI; Drug:budesonide pMDI,[],12-Nov-15,12,130,Both,FALSE,13NCT01437397,Forest Laboratories,FALSE,FL,https://ClinicalTrials.gov/show/NCT01437397,FALSE,"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide; Drug:Formoterol Fumarate; Drug:placebo,[],5-Apr-13,40,9999,Both,FALSE,110NCT01436175,Shire,FALSE,FL,https://ClinicalTrials.gov/show/NCT01436175,FALSE,SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study,Major Depressive Disorder,Drug:SPD489 (Lisdexamfetamine dimesylate) + Antidepressant,[],5-Feb-15,18,65,Both,FALSE,176NCT01432444,"Otsuka Pharmaceutical Development & Commercialization, Inc.",FALSE,FL,https://ClinicalTrials.gov/show/NCT01432444,FALSE,Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole,Schizophrenia,Drug:Aripiprazole (Abilify) IM Depot Injection,[],20-Apr-15,18,65,Both,FALSE,160NCT01427283,Purdue Pharma LP,FALSE,FL,https://ClinicalTrials.gov/show/NCT01427283,FALSE,A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain,Low Back Pain,Drug:Oxycodone/Naloxone controlled-release; Drug:Oxycodone HCl controlled-release; Drug:Placebo,[],11-Feb-15,18,9999,Both,FALSE,36NCT01427270,Purdue Pharma LP,FALSE,FL,https://ClinicalTrials.gov/show/NCT01427270,FALSE,Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain,Low Back Pain,Drug:Oxycodone/Naloxone controlled-release; Drug:Oxycodone HCl controlled-release; Drug:Placebo,[],6-Nov-14,18,9999,Both,FALSE,36NCT01415505,Forest Laboratories,FALSE,FL,https://ClinicalTrials.gov/show/NCT01415505,FALSE,Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension,Hypertension,"Drug:Nebivolol, Valsartan and Hydrochlorothiazide",[],31-May-13,18,9999,Both,FALSE,110NCT01395524,AstraZeneca,FALSE,FL,https://ClinicalTrials.gov/show/NCT01395524,FALSE,A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Drug:NKTR-118; Drug:NKTR-118; Drug:Placebo,[],15-Jun-15,18,84,Both,FALSE,13NCT01391325,"Ardea Biosciences, Inc.",FALSE,FL,https://ClinicalTrials.gov/show/NCT01391325,FALSE,Allopurinol Outcome Study,Gout,Drug:Allopurinol,[],16-May-14,18,85,Both,FALSE,65NCT01358526,Purdue Pharma LP,FALSE,FL,https://ClinicalTrials.gov/show/NCT01358526,FALSE,Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain,Low Back Pain,Drug:Oxycodone/Naloxone Controlled-release; Drug:Placebo,[],14-Oct-15,18,9999,Both,FALSE,36NCT01349322,Radiation Therapy Oncology Group,FALSE,FL,https://ClinicalTrials.gov/show/NCT01349322,FALSE,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],14-Nov-15,18,9999,Female,FALSE,4NCT01336205,AstraZeneca,FALSE,FL,https://ClinicalTrials.gov/show/NCT01336205,FALSE,Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Drug:NKTR-118; Drug:Usual care,[],13-Oct-14,18,84,Both,FALSE,13NCT01327846,Novartis Pharmaceuticals,FALSE,FL,https://ClinicalTrials.gov/show/NCT01327846,FALSE,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),Atherosclerosis,Drug:Canakinumab; Drug:Placebo,[],19-May-15,18,9999,Both,FALSE,156NCT01313676,GlaxoSmithKline,FALSE,FL,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT01309841,AstraZeneca,FALSE,FL,https://ClinicalTrials.gov/show/NCT01309841,FALSE,Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Drug:NKTR-118; Drug:NKTR-118; Drug:Placebo,[],29-May-15,18,84,Both,FALSE,13NCT01306890,Dendreon,FALSE,GA,https://ClinicalTrials.gov/show/NCT01306890,FALSE,A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer,Advanced Prostate Cancer; Prostatic Neoplasms,Biological:sipuleucel-T,[],5-Oct-15,18,9999,Male,FALSE,97NCT01275677,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00433511,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00382070,NSABP Foundation Inc,TRUE,GA,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00373685,Pfizer,FALSE,GA,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00346216,Pfizer,FALSE,GA,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00326898,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,GA,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00264901,Novo Nordisk A/S,FALSE,GA,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00217737,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00072046,Alliance for Clinical Trials in Oncology,TRUE,GA,https://ClinicalTrials.gov/show/NCT00072046,FALSE,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],23-Jun-15,18,9999,Both,FALSE,1NCT00053898,NSABP Foundation Inc,TRUE,GA,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT01360554,Pfizer,FALSE,GA,https://ClinicalTrials.gov/show/NCT01360554,FALSE,ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer (NSCLC),Drug:Dacomitinib (PF-00299804); Drug:Active Comparator (erlotinib); Drug:Placebo erlotinib; Drug:Placebo PF00299804,[],4-Jan-16,18,9999,Both,FALSE,10NCT00209092,Emory University,TRUE,GA,https://ClinicalTrials.gov/show/NCT00209092,FALSE,Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer,Breast Cancer,Drug:Docetaxel; Drug:Capecitabine,"[u'Grady Memorial Hospital', u'Emory Crawford Long Hospital', u'Emory University Winship Cancer Institute', u'Augusta Oncology Associates, PC 1348 Walton Way, Ste. 4300', u'Augusta Oncology Associates, PC 3696 Wheeler Road', u'WellStar Health System-Northwest Georgia Oncology Center, PC', u'WellStar Health System-Georgia Cancer Specialists', u'WellStar Health System-Northwest Georgia Oncology Center, PC', u'John B. Amos Cancer Center', u'Suburban Hematology-Oncology Associates, PC', u'South Atlanta Hematology-Oncology Group', u'Suburban Hematology-Oncology Associates, PC', u'Central Georgia Cancer Care, PC', u'WellStar Health System-Georgia Cancer Specialists', u'WellStar Health System-Northwest Georgia Oncology Center, PC', u'South Atlanta Hematology-Oncology Group', u'Suburban Hematology-Oncology Associates, PC', u'South Atlanta Hematology-Oncology Group', u'Central Georgia Cancer Care, PC']",6-Mar-15,18,9999,Female,FALSE,27NCT00803062,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00803062,FALSE,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],22-May-15,18,9999,Female,FALSE,9NCT00601900,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00601900,FALSE,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],23-Apr-15,18,9999,Female,FALSE,9NCT00588770,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT00856492,Southwest Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT00856492,FALSE,"S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer",Breast Cancer,Biological:bevacizumab; Biological:pegfilgrastim; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel albumin-stabilized nanoparticle formulation,[],8-May-15,18,9999,Female,FALSE,3NCT00079274,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT00003641,Eastern Cooperative Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT00003641,FALSE,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,Melanoma (Skin),Biological:recombinant interferon alfa; Other:clinical observation,[],11-Jul-12,18,9999,Both,FALSE,17NCT01099449,Alliance for Clinical Trials in Oncology,FALSE,GA,https://ClinicalTrials.gov/show/NCT01099449,FALSE,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],4-Jul-15,18,9999,Both,FALSE,1NCT00946712,Southwest Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00942331,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00920010,Southwest Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT00920010,FALSE,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],5-Feb-15,0,9999,Both,FALSE,3NCT00861705,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00861705,FALSE,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],28-Sep-15,18,9999,Both,FALSE,9NCT00785291,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00602641,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00602641,FALSE,"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma",Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:melphalan; Drug:prednisone; Drug:thalidomide; Drug:lenalidomide,[],9-Jun-15,18,9999,Both,FALSE,9NCT00490139,GlaxoSmithKline,FALSE,GA,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT02311907,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT02311907,FALSE,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],22-May-15,18,9999,Female,FALSE,9NCT01011478,NSABP Foundation Inc,TRUE,GA,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT00874211,Southwest Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT00874211,FALSE,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],4-Mar-15,0,9999,Both,FALSE,3NCT00658515,Hoffmann-La Roche,FALSE,GA,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00450281,Southwest Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT00450281,FALSE,"S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",Lung Cancer,Genetic:chromogenic in situ hybridization; Genetic:gene expression analysis; Genetic:mutation analysis; Genetic:polymerase chain reaction; Genetic:polymorphism analysis; Other:fluorescent antibody technique; Other:immunohistochemistry staining method; Other:laboratory biomarker analysis; Other:matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other:study of socioeconomic and demographic variables; Procedure:study of high risk factors,[],23-Oct-15,18,120,Both,FALSE,3NCT00303628,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00303628,FALSE,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],20-May-14,18,9999,Both,FALSE,9NCT00265941,Radiation Therapy Oncology Group,TRUE,GA,https://ClinicalTrials.gov/show/NCT00265941,FALSE,Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Drug:cisplatin,[],11-Nov-15,18,9999,Both,FALSE,4NCT00087178,NSABP Foundation Inc,FALSE,GA,https://ClinicalTrials.gov/show/NCT00087178,FALSE,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],5-Oct-15,18,9999,Female,FALSE,2NCT00063999,Gynecologic Oncology Group,FALSE,GA,https://ClinicalTrials.gov/show/NCT00063999,FALSE,"Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",Endometrial Cancer,Biological:filgrastim; Drug:carboplatin; Drug:cisplatin; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],23-Apr-09,18,9999,Female,FALSE,14NCT00034879,AstraZeneca,FALSE,GA,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT01313676,GlaxoSmithKline,FALSE,GA,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT00849056,GlaxoSmithKline,FALSE,GA,https://ClinicalTrials.gov/show/NCT00849056,FALSE,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:placebo,[],29-May-14,18,9999,Both,FALSE,8NCT00828139,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00828139,FALSE,Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Biological:ziv-aflibercept; Drug:topotecan hydrochloride,[],9-Apr-14,18,9999,Both,FALSE,9NCT00775645,Southwest Oncology Group,TRUE,GA,https://ClinicalTrials.gov/show/NCT00775645,FALSE,"S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy",Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity,Dietary Supplement:acetyl-L-carnitine hydrochloride; Other:placebo,[],13-Jan-14,18,9999,Female,FALSE,3NCT00770809,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00770809,FALSE,Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,HER2/Neu Positive; Male Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Lapatinib Ditosylate; Biological:Trastuzumab; Drug:Paclitaxel; Other:Laboratory Biomarker Analysis,[],7-May-15,18,9999,Both,FALSE,9NCT00665561,ViiV Healthcare,FALSE,GA,https://ClinicalTrials.gov/show/NCT00665561,FALSE,Prospective Observational Epidemiologic Study of Maraviroc's Safety,Human Immunodeficiency Virus,Drug:Maraviroc along with an optimized background antiretroviral drug regimen; Drug:Optimized background antiretroviral drug regimen without maraviroc,[],11-Dec-15,18,9999,Both,FALSE,219NCT00617708,National Cancer Institute (NCI),FALSE,GA,https://ClinicalTrials.gov/show/NCT00617708,FALSE,S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery,Stage IV Pancreatic Cancer,Biological:cixutumumab; Drug:erlotinib hydrochloride; Drug:gemcitabine hydrochloride,[],25-Jul-14,18,9999,Both,FALSE,9NCT00070564,Southwest Oncology Group,TRUE,GA,https://ClinicalTrials.gov/show/NCT00070564,FALSE,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",Breast Cancer,Biological:pegfilgrastim; Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],15-Sep-15,18,9999,Both,FALSE,3NCT02465060,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT01041781,Alliance for Clinical Trials in Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT01041781,FALSE,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT02315430,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT02315430,FALSE,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Female,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02116530,Alliance for Clinical Trials in Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT02116530,FALSE,Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy,"Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:Olanzapine; Drug:Chemotherapy (cisplatin or cyclophosphamide and doxorubicin); Drug:Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant); Other:Placebo,[],15-Jun-15,18,9999,Both,FALSE,1NCT01886872,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01229943,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01229943,FALSE,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],22-Apr-15,18,9999,Both,FALSE,9NCT00972478,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT00972478,FALSE,"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",Stage II Contiguous Adult Diffuse Large Cell Lymphoma; Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate; Drug:Vorinostat,[],30-Dec-15,18,9999,Both,FALSE,9NCT00946712,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00892177,Alliance for Clinical Trials in Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT00892177,FALSE,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],23-Nov-15,18,9999,Both,FALSE,1NCT00822120,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT00822120,FALSE,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,Lymphoma; Nonneoplastic Condition,Biological:bleomycin sulfate; Biological:filgrastim; Drug:ABVD regimen; Drug:BEACOPP regimen; Drug:cyclophosphamide; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:prednisone; Drug:procarbazine hydrochloride; Drug:vinblastine sulfate; Drug:vincristine sulfate,[],8-May-15,18,60,Both,FALSE,3NCT00769379,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,HI,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01515800,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01515800,FALSE,S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer,Breast Cancer,Behavioral:Text message reminder,[],23-Oct-15,18,120,Female,FALSE,3NCT01309672,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01309672,FALSE,S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy,Prostate Cancer,Drug:abiraterone acetate; Drug:degarelix; Drug:leuprolide acetate; Procedure:orchiectomy,[],8-Dec-15,18,120,Male,FALSE,3NCT01198158,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01097278,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01097278,FALSE,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],7-Jan-15,18,50,Female,FALSE,3NCT00996047,Southwest Oncology Group,TRUE,HI,https://ClinicalTrials.gov/show/NCT00996047,FALSE,"S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers",Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms,Genetic:cytogenetic analysis; Genetic:fluorescence in situ hybridization,[],5-Mar-15,0,9999,Both,FALSE,3NCT00942357,Gynecologic Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00919425,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT00919425,FALSE,"S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer",Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms,Other:biologic sample preservation procedure,[],5-Mar-15,0,9999,Both,FALSE,3NCT00861705,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT00861705,FALSE,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],28-Sep-15,18,9999,Both,FALSE,9NCT00785291,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00719563,Alliance for Clinical Trials in Oncology,TRUE,HI,https://ClinicalTrials.gov/show/NCT00719563,FALSE,American Ginseng in Treating Patients With Fatigue Caused by Cancer,"Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific",Drug:American ginseng; Other:placebo,[],14-Jul-14,18,9999,Both,FALSE,1NCT00644228,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT00644228,FALSE,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],12-Sep-14,18,9999,Both,FALSE,9NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,HI,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00070564,Southwest Oncology Group,TRUE,HI,https://ClinicalTrials.gov/show/NCT00070564,FALSE,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",Breast Cancer,Biological:pegfilgrastim; Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],15-Sep-15,18,9999,Both,FALSE,3NCT02311907,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT02311907,FALSE,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],22-May-15,18,9999,Female,FALSE,9NCT01642251,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01642251,FALSE,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01498289,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01466881,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01466881,FALSE,Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma,Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-Cell Lymphoma; Hepatosplenic T-Cell Lymphoma; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Adult T-Cell Leukemia/Lymphoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],26-Jun-15,18,9999,Both,FALSE,9NCT01439945,Alliance for Clinical Trials in Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT01439945,FALSE,Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer,Breast Cancer; Cancer Survivor; Hot Flashes,Drug:magnesium oxide; Other:placebo,[],31-Jul-15,18,9999,Female,FALSE,1NCT01376349,Alliance for Clinical Trials in Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT01376349,FALSE,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],24-Sep-15,18,9999,Female,FALSE,1NCT01260701,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01260701,FALSE,Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Diffuse Gastric Adenocarcinoma; Gastric Intestinal Type Adenocarcinoma; Gastric Mixed Adenocarcinoma; Recurrent Gastric Carcinoma,Drug:Akt Inhibitor MK2206,[],14-Dec-15,18,9999,Both,FALSE,9NCT01167712,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT01120236,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01120236,FALSE,Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer,Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer,Drug:Bicalutamide; Biological:Cixutumumab; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Drug:Leuprolide Acetate; Other:Pharmacological Study,[],25-Jun-15,18,9999,Male,FALSE,9NCT01099449,Alliance for Clinical Trials in Oncology,FALSE,HI,https://ClinicalTrials.gov/show/NCT01099449,FALSE,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],4-Jul-15,18,9999,Both,FALSE,1NCT01078454,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01078454,FALSE,Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis,Light Chain Deposition Disease; Primary Systemic Amyloidosis,Drug:melphalan; Drug:dexamethasone; Drug:bortezomib,[],20-Nov-14,18,9999,Both,FALSE,9NCT01015833,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00874211,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT00874211,FALSE,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],4-Mar-15,0,9999,Both,FALSE,3NCT00860041,Alliance for Clinical Trials in Oncology,TRUE,HI,https://ClinicalTrials.gov/show/NCT00860041,FALSE,Acute Pain Caused by Paclitaxel in Patients With Cancer,"Chemotherapeutic Agent Toxicity; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific",Behavioral:pain questionnaires,[],7-Jul-15,18,9999,Both,FALSE,1NCT00856492,Southwest Oncology Group,FALSE,HI,https://ClinicalTrials.gov/show/NCT00856492,FALSE,"S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer",Breast Cancer,Biological:bevacizumab; Biological:pegfilgrastim; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel albumin-stabilized nanoparticle formulation,[],8-May-15,18,9999,Female,FALSE,3NCT00731731,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT00731731,FALSE,"Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Cognitive/Functional Effects,Radiation:3-dimensional conformal radiation therapy; Drug:temozolomide; Drug:vorinostat; Procedure:cognitive assessment; Other:laboratory biomarker analysis,[],28-Apr-15,18,9999,Both,FALSE,9NCT00326898,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT02066181,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT02066181,FALSE,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,Desmoid-Type Fibromatosis,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate,[],25-Jan-16,18,9999,Both,FALSE,9NCT01841736,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01841736,FALSE,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Both,FALSE,9NCT01658943,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01653028,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01653028,FALSE,Alisertib in Treating Patients With Advanced or Metastatic Sarcoma,Myxofibrosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Leiomyosarcoma; Recurrent Liposarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis,[],2-Feb-16,18,9999,Both,FALSE,9NCT01275677,National Cancer Institute (NCI),FALSE,HI,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT02465060,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01802333,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,ID,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01275677,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00942331,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT02315430,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT02315430,FALSE,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Female,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01385137,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT01385137,FALSE,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],15-Oct-15,18,120,Female,FALSE,3NCT01309672,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT01309672,FALSE,S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy,Prostate Cancer,Drug:abiraterone acetate; Drug:degarelix; Drug:leuprolide acetate; Procedure:orchiectomy,[],8-Dec-15,18,120,Male,FALSE,3NCT00874211,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT00874211,FALSE,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],4-Mar-15,0,9999,Both,FALSE,3NCT00644293,Pfizer,FALSE,ID,https://ClinicalTrials.gov/show/NCT00644293,FALSE,"A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults",Pharyngitis; Tonsillitis,Drug:azithromycin (Zithromax); Drug:placebo; Drug:azithromycin SR; Drug:placebo,[],3-Jun-11,13,9999,Both,FALSE,10NCT00643227,Pfizer,FALSE,ID,https://ClinicalTrials.gov/show/NCT00643227,FALSE,"A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients",Pneumonia,Drug:clarithromycin extended release (ER); Drug:azithromycin SR,[],19-Mar-08,16,9999,Both,FALSE,10NCT00588770,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT00346216,Pfizer,FALSE,ID,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT02116530,Alliance for Clinical Trials in Oncology,FALSE,ID,https://ClinicalTrials.gov/show/NCT02116530,FALSE,Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy,"Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:Olanzapine; Drug:Chemotherapy (cisplatin or cyclophosphamide and doxorubicin); Drug:Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant); Other:Placebo,[],15-Jun-15,18,9999,Both,FALSE,1NCT01004978,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01004978,FALSE,Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,Hepatocellular Carcinoma; Non-Resectable Hepatocellular Carcinoma,Drug:Cisplatin; Drug:Doxorubicin Hydrochloride; Drug:Doxorubicin-Eluting Beads; Other:Laboratory Biomarker Analysis; Drug:Mitomycin; Other:Pharmacological Study; Other:Placebo; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00661193,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT00661193,FALSE,S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:erlotinib hydrochloride; Drug:paclitaxel,[],5-Feb-15,18,9999,Both,FALSE,3NCT00309985,Eastern Cooperative Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT00309985,FALSE,Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer,Prostate Cancer,Drug:antiandrogen therapy; Drug:docetaxel,[],15-May-15,18,9999,Male,FALSE,17NCT00205777,Pfizer,FALSE,ID,https://ClinicalTrials.gov/show/NCT00205777,FALSE,Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women,Osteoporosis,Drug:Bazedoxifene Acetate; Other:Placebo,[],28-Feb-13,55,80,Female,FALSE,10NCT02257528,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT02257528,FALSE,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],3-Feb-16,18,9999,Female,FALSE,9NCT02224781,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT02224781,FALSE,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01824823,Eastern Cooperative Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT01824823,FALSE,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],11-Sep-15,18,9999,Both,FALSE,17NCT01764633,Amgen,FALSE,ID,https://ClinicalTrials.gov/show/NCT01764633,FALSE,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],20-Jan-16,40,85,Both,FALSE,16NCT01508026,Forest Laboratories,FALSE,ID,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT01313676,GlaxoSmithKline,FALSE,ID,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT01198158,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01130272,"Furiex Pharmaceuticals, Inc",FALSE,ID,https://ClinicalTrials.gov/show/NCT01130272,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],11-Jun-12,18,65,Both,FALSE,112NCT01126437,Boehringer Ingelheim,FALSE,ID,https://ClinicalTrials.gov/show/NCT01126437,FALSE,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:tiotropium 18 mcg; Drug:tiotropium 1.25 mcg (2 actuations/day); Drug:tiotropium 2.5 mcg (2 actuations/day),[],20-May-14,40,9999,Both,FALSE,75NCT01097278,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT01097278,FALSE,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],7-Jan-15,18,50,Female,FALSE,3NCT00829166,Hoffmann-La Roche,FALSE,ID,https://ClinicalTrials.gov/show/NCT00829166,FALSE,An Open-label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Drug:Trastuzumab emtansine [Kadcyla]; Drug:Lapatinib; Drug:Capecitabine,[],2-Apr-15,18,9999,Both,FALSE,119NCT00678392,Pfizer,FALSE,ID,https://ClinicalTrials.gov/show/NCT00678392,FALSE,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,Kidney Neoplasms,Drug:Axitinib (AG-013736); Drug:Sorafenib,[],10-Dec-15,18,9999,Both,FALSE,10NCT00264901,Novo Nordisk A/S,FALSE,ID,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT02137837,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT02137837,FALSE,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",Breast Cancer,Drug:Fulvestrant; Drug:Anastrozole; Drug:Everolimus; Drug:Placebo - Anastrozole; Drug:Placebo - Everolimus,[],20-May-15,18,9999,Female,FALSE,3NCT02042443,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT02042443,FALSE,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],3-Feb-16,0,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01648348,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01648348,FALSE,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01543178,"Valeant Pharmaceuticals International, Inc.",FALSE,ID,https://ClinicalTrials.gov/show/NCT01543178,FALSE,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],15-Jun-15,18,9999,Both,FALSE,47NCT01498289,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01331837,Hoffmann-La Roche,FALSE,ID,https://ClinicalTrials.gov/show/NCT01331837,FALSE,A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors,"Cardiovascular Disease, Rheumatoid Arthritis",Drug:Etanercept; Drug:Tocilizumab,[],18-Sep-15,50,9999,Both,FALSE,119NCT01196390,National Cancer Institute (NCI),FALSE,ID,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01070836,Biogen,FALSE,ID,https://ClinicalTrials.gov/show/NCT01070836,FALSE,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],14-Jan-16,0,9999,Both,FALSE,73NCT00946712,Southwest Oncology Group,FALSE,ID,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00809354,Pfizer,FALSE,ID,https://ClinicalTrials.gov/show/NCT00809354,FALSE,Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip,Osteoarthritis; Arthritis,Drug:NSAID; Biological:tanezumab; Biological:tanezumab; Biological:tanezumab; Drug:NSAID; Biological:tanezumab; Drug:NSAID,[],4-Mar-15,18,9999,Both,FALSE,10NCT00685113,Duramed Research,FALSE,ID,https://ClinicalTrials.gov/show/NCT00685113,FALSE,A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder,Overactive Bladder,Drug:DR-3001; Drug:DR-3001; Drug:Placebo,[],30-Aug-13,18,9999,Female,TRUE,99NCT00560482,Active Biotech AB,TRUE,ID,https://ClinicalTrials.gov/show/NCT00560482,FALSE,Efficacy Study of ABR-215050 to Treat Prostate Cancer,Prostate Cancer,"Drug:ABR-215050, tasquinimod; Drug:Placebo",[],2-Oct-15,18,9999,Male,FALSE,19NCT00430248,Takeda,TRUE,ID,https://ClinicalTrials.gov/show/NCT00430248,FALSE,Efficacy and Safety of Oral Febuxostat in Participants With Gout,Gout,Drug:Febuxostat; Drug:Febuxostat; Drug:Allopurinol,[],31-Jan-12,18,85,Both,FALSE,5NCT02500797,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02500797,FALSE,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],11-Jan-16,18,9999,Both,FALSE,9NCT02465060,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02315430,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02315430,FALSE,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Female,FALSE,9NCT02311907,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02311907,FALSE,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],22-May-15,18,9999,Female,FALSE,9NCT02257528,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02257528,FALSE,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],3-Feb-16,18,9999,Female,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02042443,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT02042443,FALSE,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],3-Feb-16,0,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01802333,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT01708954,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01708954,FALSE,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],23-Oct-15,18,9999,Both,FALSE,9NCT01708941,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01708941,FALSE,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Recombinant Interferon Alfa-2b,[],11-Jan-16,18,9999,Both,FALSE,9NCT01658943,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01648348,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01648348,FALSE,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01642251,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01642251,FALSE,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01623869,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01623869,FALSE,Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery,Adult Angiosarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma,Other:Laboratory Biomarker Analysis; Biological:Trebananib,[],28-Sep-15,18,9999,Both,FALSE,9NCT01609790,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01609790,FALSE,Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors,Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Placebo; Biological:Trebananib,[],31-Jul-15,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,IL,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01522976,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01522976,FALSE,Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia,Adult Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts,Drug:Azacitidine; Drug:Lenalidomide; Drug:Vorinostat,[],24-Jun-15,18,9999,Both,FALSE,9NCT01498289,Southwest Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01439945,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT01439945,FALSE,Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer,Breast Cancer; Cancer Survivor; Hot Flashes,Drug:magnesium oxide; Other:placebo,[],31-Jul-15,18,9999,Female,FALSE,1NCT01412879,Southwest Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01412879,FALSE,S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:cyclophosphamide; Drug:cytarabine; Drug:dexamethasone; Drug:doxorubicin hydrochloride; Drug:leucovorin calcium; Drug:methotrexate; Drug:vincristine sulfate,[],15-Sep-15,18,65,Both,FALSE,3NCT01376349,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT01376349,FALSE,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],24-Sep-15,18,9999,Female,FALSE,1NCT01286233,NSABP Foundation Inc,FALSE,IL,https://ClinicalTrials.gov/show/NCT01286233,FALSE,Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32,Breast Cancer; Depression; Fatigue; Sleep Disorders,Drug:Metformin; Drug:Placebo,[],8-Sep-15,18,74,Female,FALSE,2NCT01275677,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01251861,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01251861,FALSE,Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer,Recurrent Prostate Carcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer,Drug:Akt Inhibitor MK2206; Drug:Bicalutamide; Other:Clinical Observation; Other:Laboratory Biomarker Analysis,[],18-Jan-16,18,9999,Male,FALSE,9NCT01238211,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01238211,FALSE,Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:Cytarabine; Drug:Dasatinib; Drug:Daunorubicin Hydrochloride; Other:Laboratory Biomarker Analysis,[],25-Dec-15,18,9999,Both,FALSE,9NCT01198158,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01196390,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01190449,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT01190449,FALSE,"Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma",Lymphoma,Biological:ofatumumab,[],9-Jul-15,18,9999,Both,FALSE,1NCT01189227,NSABP Foundation Inc,FALSE,IL,https://ClinicalTrials.gov/show/NCT01189227,FALSE,Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery,Colorectal Cancer; Metastatic Cancer,Procedure:Postoperative chemotherapy; Procedure:Perioperative chemotherapy,[],8-May-13,18,9999,Both,FALSE,2NCT01167712,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT01145495,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01145495,FALSE,"Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma",Stage II Grade 1 Contiguous Follicular Lymphoma; Stage II Grade 1 Non-Contiguous Follicular Lymphoma; Stage II Grade 2 Contiguous Follicular Lymphoma; Stage II Grade 2 Non-Contiguous Follicular Lymphoma; Stage II Grade 3 Contiguous Follicular Lymphoma; Stage II Grade 3 Non-Contiguous Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma,Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,[],18-Dec-15,18,9999,Both,FALSE,9NCT01142388,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01142388,FALSE,Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Recurrent Esophageal Carcinoma; Stage IV Esophageal Cancer,Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Pharmacological Study,[],2-Jun-15,18,9999,Both,FALSE,9NCT01134614,National Cancer Institute (NCI),TRUE,IL,https://ClinicalTrials.gov/show/NCT01134614,FALSE,Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,Recurrent Melanoma; Stage III Melanoma; Stage IV Melanoma,Biological:ipilimumab; Biological:sargramostim,[],23-Mar-15,18,9999,Both,FALSE,9NCT01105312,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT01105312,FALSE,Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer,Breast Cancer,Drug:letrozole; Drug:panobinostat; Genetic:RNA analysis; Genetic:microarray analysis; Genetic:reverse transcriptase-polymerase chain reaction; Other:enzyme-linked immunosorbent assay; Other:immunohistochemistry staining method; Other:laboratory biomarker analysis,[],31-Jul-15,18,9999,Both,FALSE,1NCT01099449,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT01099449,FALSE,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],4-Jul-15,18,9999,Both,FALSE,1NCT01097278,Southwest Oncology Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01097278,FALSE,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],7-Jan-15,18,50,Female,FALSE,3NCT01091454,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT01091454,FALSE,Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer,Triple-negative Breast Cancer,Drug:brostallicin; Drug:cisplatin,[],23-Jul-15,18,9999,Both,FALSE,1NCT01086605,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT01086605,FALSE,Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer,Breast Cancer,Drug:pixantrone dimaleate,[],4-Aug-15,18,9999,Both,FALSE,1NCT01081262,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01081262,FALSE,Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer,Borderline Ovarian Mucinous Tumor; Ovarian Mucinous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer,Biological:Bevacizumab; Drug:Capecitabine; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Oxaliplatin; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],12-Jan-16,18,9999,Female,FALSE,9NCT01078454,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01078454,FALSE,Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis,Light Chain Deposition Disease; Primary Systemic Amyloidosis,Drug:melphalan; Drug:dexamethasone; Drug:bortezomib,[],20-Nov-14,18,9999,Both,FALSE,9NCT01070836,Biogen,FALSE,IL,https://ClinicalTrials.gov/show/NCT01070836,FALSE,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],14-Jan-16,0,9999,Both,FALSE,73NCT01041781,Alliance for Clinical Trials in Oncology,FALSE,IL,https://ClinicalTrials.gov/show/NCT01041781,FALSE,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01015833,National Cancer Institute (NCI),FALSE,IL,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01013961,ECOG-ACRIN Cancer Research Group,FALSE,IL,https://ClinicalTrials.gov/show/NCT01013961,FALSE,Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Biological:alemtuzumab; Biological:rituximab,[],1-Feb-16,65,9999,Both,FALSE,101NCT01011478,NSABP Foundation Inc,TRUE,IL,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT01658943,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01642251,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01642251,FALSE,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,IN,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01275677,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01167712,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT00954174,Gynecologic Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT00954174,FALSE,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00942357,Gynecologic Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00942331,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00803062,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00803062,FALSE,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],22-May-15,18,9999,Female,FALSE,9NCT00785291,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00588770,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT00433511,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00378703,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00378703,FALSE,"Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer",Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Sorafenib; Drug:temsirolimus; Biological:bevacizumab,[],14-Apr-15,18,9999,Both,FALSE,9NCT00346216,Pfizer,FALSE,IN,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00326898,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00264901,Novo Nordisk A/S,FALSE,IN,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00217737,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT01708954,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01708954,FALSE,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],23-Oct-15,18,9999,Both,FALSE,9NCT01498289,Southwest Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01198158,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT00946712,Southwest Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,IN,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00079274,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT00003641,Eastern Cooperative Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT00003641,FALSE,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,Melanoma (Skin),Biological:recombinant interferon alfa; Other:clinical observation,[],11-Jul-12,18,9999,Both,FALSE,17NCT01886872,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01366183,Gynecologic Oncology Group,FALSE,IN,https://ClinicalTrials.gov/show/NCT01366183,FALSE,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],23-Dec-14,75,9999,Both,FALSE,14NCT01196390,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT00951496,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00951496,FALSE,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00134056,Southwest Oncology Group,TRUE,IN,https://ClinicalTrials.gov/show/NCT00134056,FALSE,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],6-May-15,18,9999,Male,FALSE,3NCT02311907,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT02311907,FALSE,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],22-May-15,18,9999,Female,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01648348,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01648348,FALSE,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01015833,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01012297,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01012297,FALSE,Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma,Recurrent Uterine Corpus Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Biological:Bevacizumab; Drug:Docetaxel; Biological:Filgrastim; Drug:Gemcitabine Hydrochloride; Biological:Pegfilgrastim; Other:Placebo,[],11-Nov-15,18,9999,Female,FALSE,9NCT00693992,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00693992,FALSE,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],26-Jun-15,18,9999,Both,FALSE,9NCT00684983,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00684983,FALSE,"Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer",HER2/Neu Positive; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Capecitabine; Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Other:Quality-of-Life Assessment,[],23-Dec-15,18,9999,Both,FALSE,9NCT00313573,Indiana University Melvin and Bren Simon Cancer Center,TRUE,IN,https://ClinicalTrials.gov/show/NCT00313573,FALSE,Telemedicine or Standard Care in Treating Patients With Depression and/or Pain Caused By Cancer,"Depression; Pain; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:management of therapy complications; Procedure:pain therapy; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,"[u'Community Cancer Center at Community Hospital of Anderson', u'Community Cancer Care at Bedford Oncology Specialty Clinic', u'Columbus Regional Hospital Cancer Center', u'Community Cancer Care at Putnam County Hospital', u'Community Cancer Care at Decatur County Hospital', u'Community Regional Cancer Care at Community Hospital East', u'Community Cancer Care', u'Veterans Affairs Medical Center - Indianapolis', u'William N. Wishard Memorial Hospital', u'Methodist Cancer Center at Methodist Hospital', u'Community Regional Cancer Care at Community Hospital North', u'Regenstrief Institute, Incorporated', u'Community Cancer Care at Howard Regional Health System', u""Community Cancer Care at King's Daughters' Hospital"", u'Schneck Medical Center', u'Community Cancer Care at Perry County Hospital', u'Community Cancer Care at Tipton County Memorial Hospital']",19-Sep-13,18,9999,Both,FALSE,29NCT01081262,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT01081262,FALSE,Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer,Borderline Ovarian Mucinous Tumor; Ovarian Mucinous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer,Biological:Bevacizumab; Drug:Capecitabine; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Oxaliplatin; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],12-Jan-16,18,9999,Female,FALSE,9NCT01011478,NSABP Foundation Inc,TRUE,IN,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,IN,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT00861705,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00861705,FALSE,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],28-Sep-15,18,9999,Both,FALSE,9NCT00658515,Hoffmann-La Roche,FALSE,IN,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00644228,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00644228,FALSE,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],12-Sep-14,18,9999,Both,FALSE,9NCT00625898,NSABP Foundation Inc,FALSE,IN,https://ClinicalTrials.gov/show/NCT00625898,FALSE,BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab,Breast Cancer,Drug:Docetaxel; Drug:Trastuzumab; Drug:Carboplatin; Drug:Bevacizumab; Drug:5-Fluorouracil; Drug:Epirubicin; Drug:Cyclophosphamide,[],7-Jul-14,18,9999,Female,FALSE,2NCT00602459,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00602459,FALSE,Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,[],22-Apr-15,18,9999,Both,FALSE,9NCT00601900,National Cancer Institute (NCI),FALSE,IN,https://ClinicalTrials.gov/show/NCT00601900,FALSE,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],23-Apr-15,18,9999,Female,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01841736,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01841736,FALSE,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01824823,Eastern Cooperative Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01824823,FALSE,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],11-Sep-15,18,9999,Both,FALSE,17NCT01763216,University of Iowa,FALSE,IA,https://ClinicalTrials.gov/show/NCT01763216,FALSE,Improving Mood in Assisted Living Settings,Depressive Symptoms; Clinical Depression,Other:Road Tour; Other:Boatload of Crosswords,"[u'Lakeview Village Retirement', u'The Fountains Senior Community Living', u'Carlise Center for Assisted Living', u'Western Home Communities', u'Irving Point Affordable Assistant Living', u'Keystone Cedars', u'Meth-Wick Community', u'Prairie Hills at Cedar Rapids', u'Bickford of Clinton', u'Woodlands Creek Active Retirement Community', u'Petersen Commons Assisted Living Community of Marycrest', u'Ridgecrest Village', u'Silvercrest Garner Active Retirement Community', u'Senior Star at Elmore Place', u'Wesley Acres', u'Valley View Village', u'The Kensington Assisted Living Community', u'University of Iowa Colleges of Nursing and Public Health', u'Emerson Point', u'Melrose Meadows', u'Oaknoll Retirement Residence', u'Legacy Senior Living Community', u'Bishop Drumm--Martina Place', u'The Villages at Marion', u'Summit Pointe', u""Iowa Veteran's Home"", u'Lutheran Living Senior Campus', u'Manor Health Care Center', u'Prairie Hills Assisted Living', u'Friendship Village Retirement Community', u'Simpson Memorial Home, Inc.', u'Highland Ridge Senior Living Community']",11-Nov-15,55,9999,Both,TRUE,201NCT01708954,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01708954,FALSE,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],23-Oct-15,18,9999,Both,FALSE,9NCT01653028,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01653028,FALSE,Alisertib in Treating Patients With Advanced or Metastatic Sarcoma,Myxofibrosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Leiomyosarcoma; Recurrent Liposarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis,[],2-Feb-16,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,IA,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01366183,Gynecologic Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT01366183,FALSE,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],23-Dec-14,75,9999,Both,FALSE,14NCT01275677,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01198158,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01041781,Alliance for Clinical Trials in Oncology,FALSE,IA,https://ClinicalTrials.gov/show/NCT01041781,FALSE,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01011478,NSABP Foundation Inc,TRUE,IA,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT00946712,Southwest Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00942357,Gynecologic Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00942331,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00920010,Southwest Oncology Group,FALSE,IA,https://ClinicalTrials.gov/show/NCT00920010,FALSE,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],5-Feb-15,0,9999,Both,FALSE,3NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,IA,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT00785291,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00693992,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00693992,FALSE,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],26-Jun-15,18,9999,Both,FALSE,9NCT00588770,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT00513747,Alliance for Clinical Trials in Oncology,FALSE,IA,https://ClinicalTrials.gov/show/NCT00513747,FALSE,Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia,Leukemia,Biological:rituximab; Drug:fludarabine phosphate,[],26-Oct-15,18,9999,Both,FALSE,1NCT00433511,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00382070,NSABP Foundation Inc,TRUE,IA,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00326898,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00303628,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00303628,FALSE,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],20-May-14,18,9999,Both,FALSE,9NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,IA,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00262847,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00262847,FALSE,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],18-Aug-15,18,9999,Female,FALSE,9NCT00217737,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00134056,Southwest Oncology Group,TRUE,IA,https://ClinicalTrials.gov/show/NCT00134056,FALSE,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],6-May-15,18,9999,Male,FALSE,3NCT00087399,Alliance for Clinical Trials in Oncology,TRUE,IA,https://ClinicalTrials.gov/show/NCT00087399,FALSE,Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy,Breast Cancer; Hot Flashes,Drug:gabapentin; Drug:antidepressant,[],7-Jul-15,18,9999,Female,FALSE,1NCT00087139,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00087139,FALSE,Ixabepilone in Treating Patients With Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:ixabepilone,[],21-Apr-14,18,9999,Male,FALSE,9NCT00079274,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT00072046,Alliance for Clinical Trials in Oncology,TRUE,IA,https://ClinicalTrials.gov/show/NCT00072046,FALSE,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],23-Jun-15,18,9999,Both,FALSE,1NCT00054418,Alliance for Clinical Trials in Oncology,TRUE,IA,https://ClinicalTrials.gov/show/NCT00054418,FALSE,Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer,Breast Cancer; Osteoporosis,Dietary Supplement:calcium carbonate; Dietary Supplement:vitamin D; Drug:risedronate sodium; Other:placebo,[],12-Nov-13,18,9999,Female,FALSE,1NCT00053898,NSABP Foundation Inc,TRUE,IA,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT00052910,Alliance for Clinical Trials in Oncology,TRUE,IA,https://ClinicalTrials.gov/show/NCT00052910,FALSE,Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer,Esophageal Cancer; Gastric Cancer,Drug:cisplatin; Drug:epirubicin hydrochloride; Drug:fluorouracil; Drug:leucovorin calcium; Radiation:radiation therapy,[],23-Jun-15,18,9999,Both,FALSE,1NCT00049127,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00049127,FALSE,Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor,Adult Anaplastic Oligodendroglioma; Adult Mixed Glioma; Adult Oligodendroglioma; Recurrent Adult Brain Tumor,Drug:imatinib mesylate; Other:laboratory biomarker analysis; Other:pharmacological study,[],1-Oct-14,18,9999,Both,FALSE,9NCT00045162,Southwest Oncology Group,TRUE,IA,https://ClinicalTrials.gov/show/NCT00045162,FALSE,S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Drug:cisplatin; Drug:etoposide; Drug:irinotecan hydrochloride,[],3-Jul-13,18,9999,Both,FALSE,3NCT00040885,Alliance for Clinical Trials in Oncology,TRUE,IA,https://ClinicalTrials.gov/show/NCT00040885,FALSE,"Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)",Anorexia; Cachexia; Fatigue; Lung Cancer,Biological:infliximab; Drug:docetaxel; Other:placebo,[],7-Jul-15,18,9999,Both,FALSE,1NCT00039494,National Cancer Institute (NCI),FALSE,IA,https://ClinicalTrials.gov/show/NCT00039494,FALSE,Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma,Drug:erlotinib hydrochloride; Radiation:3-dimensional conformal radiation therapy; Drug:temozolomide,[],1-Aug-13,18,9999,Both,FALSE,9NCT00016406,Southwest Oncology Group,TRUE,IA,https://ClinicalTrials.gov/show/NCT00016406,FALSE,"S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer",Breast Cancer,Biological:filgrastim; Drug:cyclophosphamide; Drug:doxorubicin; Drug:paclitaxel; Procedure:surgery,[],23-Jan-13,18,9999,Female,FALSE,3NCT00014534,Alliance for Clinical Trials in Oncology,FALSE,IA,https://ClinicalTrials.gov/show/NCT00014534,FALSE,Combination Chemotherapy in Treating Patients With Bladder Cancer,Bladder Cancer,Biological:filgrastim; Drug:cisplatin; Drug:doxorubicin hydrochloride; Drug:gemcitabine hydrochloride,[],27-Sep-13,18,9999,Both,FALSE,1NCT00003596,Radiation Therapy Oncology Group,TRUE,IA,https://ClinicalTrials.gov/show/NCT00003596,FALSE,Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer,Anal Cancer,Drug:cisplatin; Drug:fluorouracil; Drug:mitomycin C; Radiation:radiation therapy,[],18-Nov-13,18,9999,Both,FALSE,4NCT00003594,Alliance for Clinical Trials in Oncology,TRUE,IA,https://ClinicalTrials.gov/show/NCT00003594,FALSE,Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,Colorectal Cancer,Drug:irinotecan; Drug:fluorouracil; Drug:leucovorin calcium; Drug:oxaliplatin,[],9-Jul-15,18,9999,Both,FALSE,1NCT00003389,Eastern Cooperative Oncology Group,TRUE,IA,https://ClinicalTrials.gov/show/NCT00003389,FALSE,Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma,Lymphoma,Drug:Doxorubicin; Drug:Bleomycin; Drug:Vinblastine; Drug:Dacarbazine; Drug:Vincristine; Drug:Mechlorethamine; Drug:Etoposide; Drug:Prednisone; Drug:Cyclophosphamide; Radiation:Radiotherapy,[],25-Sep-15,16,9999,Both,FALSE,17NCT02311907,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT02311907,FALSE,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],22-May-15,18,9999,Female,FALSE,9NCT02224781,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT02224781,FALSE,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02042443,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT02042443,FALSE,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],3-Feb-16,0,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01824823,Eastern Cooperative Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01824823,FALSE,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],11-Sep-15,18,9999,Both,FALSE,17NCT01802333,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT01716715,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01716715,FALSE,"Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],12-Jan-16,18,9999,Female,FALSE,9NCT01708954,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01708954,FALSE,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],23-Oct-15,18,9999,Both,FALSE,9NCT01708941,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01708941,FALSE,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Recombinant Interferon Alfa-2b,[],11-Jan-16,18,9999,Both,FALSE,9NCT01688973,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01688973,FALSE,Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery,Childhood Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Tivantinib,[],11-Jan-16,0,9999,Both,FALSE,9NCT01658943,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01653028,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01653028,FALSE,Alisertib in Treating Patients With Advanced or Metastatic Sarcoma,Myxofibrosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Leiomyosarcoma; Recurrent Liposarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis,[],2-Feb-16,18,9999,Both,FALSE,9NCT01648348,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01648348,FALSE,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,KS,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01498289,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01466881,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01466881,FALSE,Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma,Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-Cell Lymphoma; Hepatosplenic T-Cell Lymphoma; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Adult T-Cell Leukemia/Lymphoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],26-Jun-15,18,9999,Both,FALSE,9NCT01412879,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01412879,FALSE,S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:cyclophosphamide; Drug:cytarabine; Drug:dexamethasone; Drug:doxorubicin hydrochloride; Drug:leucovorin calcium; Drug:methotrexate; Drug:vincristine sulfate,[],15-Sep-15,18,65,Both,FALSE,3NCT01385137,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01385137,FALSE,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],15-Oct-15,18,120,Female,FALSE,3NCT01376349,Alliance for Clinical Trials in Oncology,FALSE,KS,https://ClinicalTrials.gov/show/NCT01376349,FALSE,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],24-Sep-15,18,9999,Female,FALSE,1NCT01366183,Gynecologic Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01366183,FALSE,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],23-Dec-14,75,9999,Both,FALSE,14NCT01309672,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01309672,FALSE,S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy,Prostate Cancer,Drug:abiraterone acetate; Drug:degarelix; Drug:leuprolide acetate; Procedure:orchiectomy,[],8-Dec-15,18,120,Male,FALSE,3NCT01286233,NSABP Foundation Inc,FALSE,KS,https://ClinicalTrials.gov/show/NCT01286233,FALSE,Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32,Breast Cancer; Depression; Fatigue; Sleep Disorders,Drug:Metformin; Drug:Placebo,[],8-Sep-15,18,74,Female,FALSE,2NCT01275677,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01260701,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01260701,FALSE,Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Diffuse Gastric Adenocarcinoma; Gastric Intestinal Type Adenocarcinoma; Gastric Mixed Adenocarcinoma; Recurrent Gastric Carcinoma,Drug:Akt Inhibitor MK2206,[],14-Dec-15,18,9999,Both,FALSE,9NCT01256398,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01256398,FALSE,Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Alemtuzumab; Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Procedure:Autologous Hematopoietic Stem Cell Transplantation; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dasatinib; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide Phosphate; Biological:Filgrastim; Drug:Fludarabine Phosphate; Procedure:In Vitro-Treated Peripheral Blood Stem Cell Transplantation; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Melphalan; Drug:Mercaptopurine; Drug:Methotrexate; Biological:Pegfilgrastim; Other:Pharmacological Study; Drug:Tacrolimus; Drug:Vincristine Sulfate,[],3-Feb-16,18,9999,Both,FALSE,9NCT01229943,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01229943,FALSE,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],22-Apr-15,18,9999,Both,FALSE,9NCT01189227,NSABP Foundation Inc,FALSE,KS,https://ClinicalTrials.gov/show/NCT01189227,FALSE,Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery,Colorectal Cancer; Metastatic Cancer,Procedure:Postoperative chemotherapy; Procedure:Perioperative chemotherapy,[],8-May-13,18,9999,Both,FALSE,2NCT01142388,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01142388,FALSE,Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Recurrent Esophageal Carcinoma; Stage IV Esophageal Cancer,Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Pharmacological Study,[],2-Jun-15,18,9999,Both,FALSE,9NCT01120236,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01120236,FALSE,Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer,Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer,Drug:Bicalutamide; Biological:Cixutumumab; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Drug:Leuprolide Acetate; Other:Pharmacological Study,[],25-Jun-15,18,9999,Male,FALSE,9NCT01099449,Alliance for Clinical Trials in Oncology,FALSE,KS,https://ClinicalTrials.gov/show/NCT01099449,FALSE,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],4-Jul-15,18,9999,Both,FALSE,1NCT01098630,Gynecologic Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01098630,FALSE,"Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer",Recurrent Cervical Carcinoma; Recurrent Uterine Corpus Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Uterine Corpus Cancer; Stage I Uterine Sarcoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage II Uterine Corpus Cancer; Stage II Uterine Sarcoma; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage III Uterine Corpus Cancer; Stage III Uterine Sarcoma; Stage IV Uterine Corpus Cancer; Stage IV Uterine Sarcoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Medical Chart Review; Other:Questionnaire Administration,[],23-Dec-14,0,9999,Female,FALSE,14NCT01097278,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01097278,FALSE,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],7-Jan-15,18,50,Female,FALSE,3NCT01093222,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01093222,FALSE,"Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma",Extrahepatic Bile Duct Adenocarcinoma; Gallbladder Adenocarcinoma; Gallbladder Adenocarcinoma With Squamous Metaplasia; Hilar Cholangiocarcinoma; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Undifferentiated Gallbladder Carcinoma; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma,Drug:Erlotinib Hydrochloride; Drug:Sorafenib Tosylate,[],3-Jun-15,18,9999,Both,FALSE,9NCT01080521,Gynecologic Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01080521,FALSE,"Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy",Cognitive Side Effects of Cancer Therapy; Malignant Ovarian Mixed Epithelial Tumor; Malignant Ovarian Surface Epithelial-Stromal Tumor; Ovarian Brenner Tumor; Ovarian Carcinosarcoma; Ovarian Choriocarcinoma; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Dysgerminoma; Ovarian Embryonal Carcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Germ Cell Tumor; Ovarian Mucinous Cystadenocarcinoma; Ovarian Polyembryoma; Ovarian Sarcoma; Ovarian Serous Cystadenocarcinoma; Ovarian Teratoma; Ovarian Yolk Sac Tumor; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Procedure:Cognitive Assessment; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT01078441,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01078441,FALSE,"Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant",Refractory Multiple Myeloma,Drug:liposomal doxorubicin; Drug:bortezomib; Drug:dexamethasone; Drug:cyclophosphamide,[],5-Jan-15,18,9999,Both,FALSE,9NCT01017601,Alliance for Clinical Trials in Oncology,FALSE,KS,https://ClinicalTrials.gov/show/NCT01017601,FALSE,Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Biological:Seneca Valley virus-001; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01015833,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01011478,NSABP Foundation Inc,TRUE,KS,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT01000558,Southwest Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT01000558,FALSE,SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma,Lymphoma,Other:biologic sample preservation procedure,[],17-May-13,18,9999,Both,FALSE,3NCT00996047,Southwest Oncology Group,TRUE,KS,https://ClinicalTrials.gov/show/NCT00996047,FALSE,"S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers",Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms,Genetic:cytogenetic analysis; Genetic:fluorescence in situ hybridization,[],5-Mar-15,0,9999,Both,FALSE,3NCT00993928,Alliance for Clinical Trials in Oncology,FALSE,KS,https://ClinicalTrials.gov/show/NCT00993928,FALSE,Home-Based Programs for Improving Sleep in Cancer Survivors,Cancer Survivor; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders,Behavioral:Home-based sleep intervention,[],23-Nov-15,18,9999,Both,FALSE,1NCT00977574,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT00977574,FALSE,"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Biological:Bevacizumab; Drug:Carboplatin; Drug:Ixabepilone; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Temsirolimus,[],3-Feb-16,18,9999,Female,FALSE,9NCT00976573,Alliance for Clinical Trials in Oncology,FALSE,KS,https://ClinicalTrials.gov/show/NCT00976573,FALSE,"Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",Melanoma (Skin),Biological:bevacizumab; Drug:carboplatin; Drug:everolimus; Drug:paclitaxel,[],18-Sep-15,18,9999,Both,FALSE,1NCT00972478,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT00972478,FALSE,"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",Stage II Contiguous Adult Diffuse Large Cell Lymphoma; Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate; Drug:Vorinostat,[],30-Dec-15,18,9999,Both,FALSE,9NCT00956670,Gynecologic Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT00956670,FALSE,"Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer",Lymphedema; Stage IA Cervical Cancer; Stage IA Uterine Corpus Cancer; Stage IA Vulvar Cancer; Stage IB Cervical Cancer; Stage IB Uterine Corpus Cancer; Stage IB Vulvar Cancer; Stage II Uterine Corpus Cancer; Stage II Vulvar Cancer; Stage IIA Cervical Cancer; Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVB Vulvar Cancer,Procedure:Therapeutic Lymphadenectomy; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Laparoscopic Surgery; Procedure:Study of High Risk Factors; Other:Questionnaire Administration; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00955305,National Cancer Institute (NCI),FALSE,KS,https://ClinicalTrials.gov/show/NCT00955305,FALSE,"Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer",Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cixutumumab; Drug:Paclitaxel,[],31-Dec-15,18,9999,Both,FALSE,9NCT00954174,Gynecologic Oncology Group,FALSE,KS,https://ClinicalTrials.gov/show/NCT00954174,FALSE,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT01275677,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02465060,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT02054026,"Mathematica Policy Research, Inc.",FALSE,KY,https://ClinicalTrials.gov/show/NCT02054026,FALSE,Impact Evaluation of the Reducing the Risk Program,Sexual Behavior,Behavioral:Reducing the Risk,"[u'Bardstown High School', u'Warren Central High School', u'Warren East High School', u'Greenwood High School', u'Central Hardin High School', u'Metcalfe County High School', u'Elizabethtown High School', u'Franklin-Simpson High School', u'LaRue High School', u'Marion County High School', u'North Hardin High School', u'Logan County High School', u'Russellville Junior/Senior High School']",21-Sep-15,0,9999,Both,TRUE,141NCT00346216,Pfizer,FALSE,KY,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00264901,Novo Nordisk A/S,FALSE,KY,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT01411878,University of Louisville,FALSE,KY,https://ClinicalTrials.gov/show/NCT01411878,FALSE,Louisville Teen Pregnancy Prevention Project,Pregnancy; Sexually Transmitted Diseases,Behavioral:Reducing the Risk; Behavioral:Love Notes,"[u'Jewish Family and Career Services', u'House of Ruth', u'Presbyterian Community Center', u""The Steward's Staff"", u'Gate of Hope Ministries', u'St George Community Center', u'Neighborhood House', u'One Plus One Equals You', u'Americana Community Center', u'Canaan Community Development Corporation', u'Maryhurst', u'Department for Community Based Services: Jefferson County Region']",6-Sep-11,14,19,Both,TRUE,203NCT01802333,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT00588770,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT02315430,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT02315430,FALSE,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Female,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01015833,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00942331,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00658515,Hoffmann-La Roche,FALSE,KY,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT02498600,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT02498600,FALSE,"Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],11-Jan-16,18,9999,Female,FALSE,9NCT02257528,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT02257528,FALSE,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],3-Feb-16,18,9999,Female,FALSE,9NCT01967394,University of Louisville,FALSE,KY,https://ClinicalTrials.gov/show/NCT01967394,FALSE,"Social Media, Teen Moms and PPD",Postpartum Depression,Other:Use of internet based social marketing intervention; Other:No use of social media,"[u'Three Rivers', u'Hands Program of Kenton County (Young Families of Children, Inc)', u'Lincoln Trail Health Department', u'St. Joseph Hospital', u'University of Louisville Hospital', u'Hands Program of Boone and Campbell Counties (Every Child Succeeds)', u'Three Rivers Health Department', u'Lake Cumberland Health Department']",25-Dec-15,13,21,Female,FALSE,203NCT00626327,Novartis Vaccines,FALSE,KY,https://ClinicalTrials.gov/show/NCT00626327,FALSE,Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers,Meningococcal Infections,Biological:MenACWY-CRM + MMRV; Biological:MMRV; Biological:MenACWY-CRM,[],12-Apr-13,7,1,Both,TRUE,157NCT00373685,Pfizer,FALSE,KY,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00053898,NSABP Foundation Inc,TRUE,KY,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT00034879,AstraZeneca,FALSE,KY,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT00003906,NSABP Foundation Inc,TRUE,KY,https://ClinicalTrials.gov/show/NCT00003906,FALSE,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],5-Oct-15,35,9999,Female,FALSE,2NCT01553591,"Furiex Pharmaceuticals, Inc",FALSE,KY,https://ClinicalTrials.gov/show/NCT01553591,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],26-Apr-15,18,80,Both,FALSE,112NCT01543178,"Valeant Pharmaceuticals International, Inc.",FALSE,KY,https://ClinicalTrials.gov/show/NCT01543178,FALSE,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],15-Jun-15,18,9999,Both,FALSE,47NCT01313676,GlaxoSmithKline,FALSE,KY,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT00942357,Gynecologic Oncology Group,FALSE,KY,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00806195,Novartis,FALSE,KY,https://ClinicalTrials.gov/show/NCT00806195,FALSE,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis; Meningococcal Infection,"Biological:MenACWY-CRM197; Biological:DTaP (Diptheria, Tetanus, Pertussis) Vaccine; Biological:Hib (Haemophilus influenza b) Vaccine; Biological:IPV (Inactivated Polio Vaccine) Vaccine; Biological:Pneumococcal conjugate Vaccine; Biological:MMR (Measles, Mumps, and Rubella) Vaccine; Biological:Varicella Vaccine; Biological:Hepatitis A Virus",[],13-May-13,55,89,Both,TRUE,155NCT00403767,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",FALSE,KY,https://ClinicalTrials.gov/show/NCT00403767,FALSE,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation; Stroke; Embolism,Drug:Rivaroxaban; Drug:Warfarin; Drug:Matching placebo for Rivaroxaban arm (Warfarin placebo); Drug:Matching placebo for Warfarin arm (Rivaroxaban placebo),[],10-Apr-14,18,9999,Both,FALSE,136NCT00382070,NSABP Foundation Inc,TRUE,KY,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00310180,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00247416,Susanne Arnold,TRUE,KY,https://ClinicalTrials.gov/show/NCT00247416,FALSE,Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer,Stage IV Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer,Drug:Gemcitabine; Drug:Dexamethasone; Drug:Carboplatin,"[u'Commonwealth Cancer Center', u'Markey Cancer Center', u'Brown Cancer Center', u'St. Claire Regional Medical Center', u'Montgomery Cancer Center', u'Owensboro Medical HealthCare System', u'West Kentucky Hematology & Oncology Group, PSC']",16-Jan-14,18,9999,Both,FALSE,40NCT00053053,Radiation Therapy Oncology Group,TRUE,KY,https://ClinicalTrials.gov/show/NCT00053053,FALSE,Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer,"Cachexia; Lymphoma; Lymphoproliferative Disorder; Unspecified Adult Solid Tumor, Protocol Specific",Dietary Supplement:Juven; Dietary Supplement:Non-Juven Supplement,[],8-Oct-13,17,9999,Both,FALSE,4NCT00047125,European Organisation for Research and Treatment of Cancer - EORTC,FALSE,KY,https://ClinicalTrials.gov/show/NCT00047125,FALSE,Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor,Carcinoma of Unknown Primary,Radiation:radiation therapy,[],19-Jun-12,18,9999,Female,FALSE,106NCT00004917,Radiation Therapy Oncology Group,TRUE,KY,https://ClinicalTrials.gov/show/NCT00004917,FALSE,Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer,Anemia; Head and Neck Cancer,Biological:epoetin alfa; Drug:cisplatin; Radiation:radiation therapy,[],14-Nov-15,18,9999,Both,FALSE,4NCT00003591,Radiation Therapy Oncology Group,TRUE,KY,https://ClinicalTrials.gov/show/NCT00003591,FALSE,"Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer",Pancreatic Cancer,Drug:paclitaxel; Radiation:radiation therapy,[],11-Nov-13,18,9999,Both,FALSE,4NCT00003312,Radiation Therapy Oncology Group,TRUE,KY,https://ClinicalTrials.gov/show/NCT00003312,FALSE,Brachytherapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:iodine I 125,[],23-Jan-14,0,9999,Male,FALSE,4NCT00003139,Radiation Therapy Oncology Group,TRUE,KY,https://ClinicalTrials.gov/show/NCT00003139,FALSE,Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer,Head and Neck Cancer; Oral Complications,Drug:pilocarpine hydrochloride; Other:Placebo,[],14-Nov-15,18,120,Both,FALSE,4NCT00002873,Radiation Therapy Oncology Group,TRUE,KY,https://ClinicalTrials.gov/show/NCT00002873,FALSE,Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer,Breast Cancer,Radiation:brachytherapy,[],17-Jul-13,0,9999,Female,FALSE,4NCT00002791,Radiation Therapy Oncology Group,TRUE,KY,https://ClinicalTrials.gov/show/NCT00002791,FALSE,Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma,Sarcoma,Biological:filgrastim; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:ifosfamide; Drug:mesna; Procedure:conventional surgery; Radiation:brachytherapy; Radiation:intraoperative radiation therapy; Radiation:radioisotope therapy,[],23-Jan-14,18,9999,Both,FALSE,4NCT00002622,Alliance for Clinical Trials in Oncology,TRUE,KY,https://ClinicalTrials.gov/show/NCT00002622,FALSE,Talc in Treating Patients With Malignant Pleural Effusion,Metastatic Cancer,Drug:talc; Drug:Talc,[],27-Sep-13,18,9999,Both,FALSE,1NCT00002545,Radiation Therapy Oncology Group,TRUE,KY,https://ClinicalTrials.gov/show/NCT00002545,FALSE,Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme,Brain and Central Nervous System Tumors,Drug:carmustine; Radiation:low-LET photon therapy,[],9-Aug-13,18,9999,Both,FALSE,4NCT02139046,Takeda,FALSE,KY,https://ClinicalTrials.gov/show/NCT02139046,FALSE,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Drug:Febuxostat IR; Drug:Febuxostat XR; Drug:Febuxostat placebo; Drug:Colchicine; Drug:Naproxen; Drug:Lansoprazole,[],13-Nov-15,18,9999,Both,FALSE,5NCT01648348,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT01648348,FALSE,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,KY,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01167712,National Cancer Institute (NCI),FALSE,KY,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT01100684,Tioga Pharmaceuticals,FALSE,KY,https://ClinicalTrials.gov/show/NCT01100684,FALSE,Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS),Diarrhea Predominant Irritable Bowel Syndrome,Drug:Asimadoline; Drug:Placebo,[],17-Dec-13,18,79,Both,FALSE,192NCT02465060,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT01327846,Novartis Pharmaceuticals,FALSE,LA,https://ClinicalTrials.gov/show/NCT01327846,FALSE,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),Atherosclerosis,Drug:Canakinumab; Drug:Placebo,[],19-May-15,18,9999,Both,FALSE,156NCT01275677,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01015833,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00264901,Novo Nordisk A/S,FALSE,LA,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00310180,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT01042769,Hoffmann-La Roche,FALSE,LA,https://ClinicalTrials.gov/show/NCT01042769,FALSE,A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Aleglitazar; Drug:Placebo,[],1-Feb-16,18,9999,Both,FALSE,119NCT00769379,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01658943,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT00373685,Pfizer,FALSE,LA,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00079274,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,LA,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01011478,NSABP Foundation Inc,TRUE,LA,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT00946712,Southwest Oncology Group,FALSE,LA,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00569127,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT00569127,FALSE,"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor",Neuroendocrine Carcinoma,Biological:Recombinant Interferon Alfa-2b; Drug:Octreotide Acetate; Biological:Bevacizumab,[],5-Jan-15,0,9999,Both,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00262600,Boehringer Ingelheim,FALSE,LA,https://ClinicalTrials.gov/show/NCT00262600,FALSE,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation; Stroke,Drug:warfarin; Drug:Dabigatran dose 1; Drug:Dabigatran dose 2,[],5-Nov-14,18,9999,Both,FALSE,75NCT00003389,Eastern Cooperative Oncology Group,TRUE,LA,https://ClinicalTrials.gov/show/NCT00003389,FALSE,Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma,Lymphoma,Drug:Doxorubicin; Drug:Bleomycin; Drug:Vinblastine; Drug:Dacarbazine; Drug:Vincristine; Drug:Mechlorethamine; Drug:Etoposide; Drug:Prednisone; Drug:Cyclophosphamide; Radiation:Radiotherapy,[],25-Sep-15,16,9999,Both,FALSE,17NCT00942357,Gynecologic Oncology Group,FALSE,LA,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00658515,Hoffmann-La Roche,FALSE,LA,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00382070,NSABP Foundation Inc,TRUE,LA,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00217737,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00056407,GlaxoSmithKline,TRUE,LA,https://ClinicalTrials.gov/show/NCT00056407,FALSE,"""REDUCE"" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk","Neoplasms, Prostate",Drug:Dutasteride; Drug:Placebo,[],23-Apr-15,50,75,Male,FALSE,8NCT01886872,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT00693992,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT00693992,FALSE,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],26-Jun-15,18,9999,Both,FALSE,9NCT00588770,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT00433511,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00412984,Bristol-Myers Squibb,FALSE,LA,https://ClinicalTrials.gov/show/NCT00412984,FALSE,Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation,Atrial Fibrillation; Atrial Flutter,Drug:warfarin; Drug:apixaban,[],27-Sep-13,18,9999,Both,FALSE,80NCT00070564,Southwest Oncology Group,TRUE,LA,https://ClinicalTrials.gov/show/NCT00070564,FALSE,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",Breast Cancer,Biological:pegfilgrastim; Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],15-Sep-15,18,9999,Both,FALSE,3NCT00052910,Alliance for Clinical Trials in Oncology,TRUE,LA,https://ClinicalTrials.gov/show/NCT00052910,FALSE,Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer,Esophageal Cancer; Gastric Cancer,Drug:cisplatin; Drug:epirubicin hydrochloride; Drug:fluorouracil; Drug:leucovorin calcium; Radiation:radiation therapy,[],23-Jun-15,18,9999,Both,FALSE,1NCT00034879,AstraZeneca,FALSE,LA,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT01968798,Minneapolis Medical Research Foundation,FALSE,LA,https://ClinicalTrials.gov/show/NCT01968798,FALSE,ASPREE Cancer Endpoints Study,Cancer,Drug:Aspirin; Drug:Placebo,[],8-Dec-14,65,9999,Both,TRUE,148NCT01764633,Amgen,FALSE,LA,https://ClinicalTrials.gov/show/NCT01764633,FALSE,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],20-Jan-16,40,85,Both,FALSE,16NCT01553591,"Furiex Pharmaceuticals, Inc",FALSE,LA,https://ClinicalTrials.gov/show/NCT01553591,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],26-Apr-15,18,80,Both,FALSE,112NCT01070836,Biogen,FALSE,LA,https://ClinicalTrials.gov/show/NCT01070836,FALSE,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],14-Jan-16,0,9999,Both,FALSE,73NCT01038583,Minneapolis Medical Research Foundation,FALSE,LA,https://ClinicalTrials.gov/show/NCT01038583,FALSE,Aspirin in Reducing Events in the Elderly,Functional Disability; Dementia; Heart Disease; Stroke; Cancer; Bleeding; Depression,Drug:100 mg enteric-coated aspirin; Drug:Placebo,[],23-Sep-15,65,9999,Both,TRUE,148NCT00822120,Southwest Oncology Group,FALSE,LA,https://ClinicalTrials.gov/show/NCT00822120,FALSE,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,Lymphoma; Nonneoplastic Condition,Biological:bleomycin sulfate; Biological:filgrastim; Drug:ABVD regimen; Drug:BEACOPP regimen; Drug:cyclophosphamide; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:prednisone; Drug:procarbazine hydrochloride; Drug:vinblastine sulfate; Drug:vincristine sulfate,[],8-May-15,18,60,Both,FALSE,3NCT00601900,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT00601900,FALSE,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],23-Apr-15,18,9999,Female,FALSE,9NCT00580216,Sanofi,FALSE,LA,https://ClinicalTrials.gov/show/NCT00580216,FALSE,Evaluation of Weekly Subcutaneous Biotinylated Idraparinux Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation,Atrial Fibrillation,Drug:Idrabiotaparinux; Drug:Warfarin; Drug:Placebo (for idrabiotaparinux); Drug:Placebo (for warfarin); Drug:Avidin; Drug:Placebo (for avidin),[],26-Feb-14,18,9999,Both,FALSE,12NCT00326898,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00303953,National Cancer Institute (NCI),FALSE,LA,https://ClinicalTrials.gov/show/NCT00303953,FALSE,PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma,Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma,Drug:belinostat,[],23-Apr-14,18,9999,Both,FALSE,9NCT00087178,NSABP Foundation Inc,FALSE,LA,https://ClinicalTrials.gov/show/NCT00087178,FALSE,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],5-Oct-15,18,9999,Female,FALSE,2NCT00075946,Eastern Cooperative Oncology Group,TRUE,LA,https://ClinicalTrials.gov/show/NCT00075946,FALSE,Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma,Lymphoma,Biological:rituximab,[],3-Jun-15,18,9999,Both,FALSE,17NCT00072046,Alliance for Clinical Trials in Oncology,TRUE,LA,https://ClinicalTrials.gov/show/NCT00072046,FALSE,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],23-Jun-15,18,9999,Both,FALSE,1NCT00049179,Southwest Oncology Group,FALSE,LA,https://ClinicalTrials.gov/show/NCT00049179,FALSE,S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia,Leukemia,Drug:cytarabine; Drug:gemtuzumab ozogamicin,[],5-Mar-15,18,9999,Both,FALSE,3NCT00041119,Alliance for Clinical Trials in Oncology,TRUE,LA,https://ClinicalTrials.gov/show/NCT00041119,FALSE,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],23-Jul-15,18,9999,Female,FALSE,1NCT00310180,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT01275677,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT02465060,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT00878709,"Puma Biotechnology, Inc.",FALSE,ME,https://ClinicalTrials.gov/show/NCT00878709,FALSE,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Breast Cancer,Drug:neratinib; Other:placebo,[],20-Aug-15,18,9999,Female,FALSE,166NCT00324805,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01942135,Pfizer,FALSE,ME,https://ClinicalTrials.gov/show/NCT01942135,FALSE,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),Metastatic Breast Cancer,Drug:Palbociclib; Drug:Fulvestrant; Drug:Placebo; Drug:Fulvestrant,[],16-Nov-15,18,9999,Female,FALSE,10NCT01886872,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,ME,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT00769379,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00658515,Hoffmann-La Roche,FALSE,ME,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00433511,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00239681,AstraZeneca,FALSE,ME,https://ClinicalTrials.gov/show/NCT00239681,FALSE,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],6-Feb-14,50,9999,Both,FALSE,13NCT01764633,Amgen,FALSE,ME,https://ClinicalTrials.gov/show/NCT01764633,FALSE,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],20-Jan-16,40,85,Both,FALSE,16NCT01730534,AstraZeneca,FALSE,ME,https://ClinicalTrials.gov/show/NCT01730534,FALSE,Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events,"Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event",Drug:Dapagliflozin 10 mg; Drug:Placebo tablet,[],10-Dec-15,40,130,Both,FALSE,13NCT01642251,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT01642251,FALSE,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01577381,Pfizer,FALSE,ME,https://ClinicalTrials.gov/show/NCT01577381,FALSE,"Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration",Age-Related Maculopathy,Biological:RN6G; Biological:Placebo,[],6-Nov-15,60,90,Both,FALSE,10NCT01225562,AstraZeneca,TRUE,ME,https://ClinicalTrials.gov/show/NCT01225562,FALSE,"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin",Myocardial Infarction; Cardiovascular Death; Atherothrombosis; Stroke,Drug:Ticagrelor 90 mg; Drug:Ticagrelor 60 mg; Drug:Ticagrelor Placebo,[],18-Dec-15,50,130,Both,FALSE,13NCT01154140,Pfizer,FALSE,ME,https://ClinicalTrials.gov/show/NCT01154140,FALSE,A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung,Non Squamous Lung Cancer,Drug:treatment; Drug:treatment,[],30-Nov-15,18,9999,Both,FALSE,10NCT01070836,Biogen,FALSE,ME,https://ClinicalTrials.gov/show/NCT01070836,FALSE,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],14-Jan-16,0,9999,Both,FALSE,73NCT00402363,GlaxoSmithKline,TRUE,ME,https://ClinicalTrials.gov/show/NCT00402363,FALSE,"Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation","Fibrillation, Atrial; Atrial Fibrillation",Drug:omega-3-acid ethyl esters; Drug:Placebo,[],7-Feb-13,18,9999,Both,FALSE,8NCT00382070,NSABP Foundation Inc,TRUE,ME,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00326898,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00245739,"Tibotec Pharmaceuticals, Ireland",FALSE,ME,https://ClinicalTrials.gov/show/NCT00245739,FALSE,"TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.",HIV Infections,Drug:TMC-114,[],10-Apr-14,18,9999,Both,FALSE,191NCT00134173,Pfizer,FALSE,ME,https://ClinicalTrials.gov/show/NCT00134173,FALSE,A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease,Coronary Disease; Coronary Arteriosclerosis; Hyperlipidemia,Drug:torcetrapib/atorvastatin; Drug:atorvastatin,[],6-Dec-07,18,75,Both,FALSE,10NCT00034879,AstraZeneca,FALSE,ME,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT00024102,Alliance for Clinical Trials in Oncology,TRUE,ME,https://ClinicalTrials.gov/show/NCT00024102,FALSE,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,Breast Cancer,Drug:Standard Treatment; Drug:capecitabine,[],23-Jun-15,65,9999,Female,FALSE,1NCT02074488,University of Maine,FALSE,ME,https://ClinicalTrials.gov/show/NCT02074488,FALSE,Balancing Act: Impact on Falls in Older Adults With Vision Impairment,Postural Balance,Other:Balancing Act exercise curriculum; Other:Informational Brochure,"[u'University of New England', u'University of Maine', u'The Iris Network']",1-Dec-15,62,9999,Both,FALSE,204NCT01954394,Sanofi,FALSE,ME,https://ClinicalTrials.gov/show/NCT01954394,FALSE,Open Label Study of Long Term Safety Evaluation of Alirocumab,Hypercholesterolemia,Drug:Alirocumab SAR236553 (REGN727),[],21-Aug-15,18,9999,Both,FALSE,12NCT01854918,Amgen,FALSE,ME,https://ClinicalTrials.gov/show/NCT01854918,FALSE,Open Label Study of Long Term Evaluation Against LDL-C Trial-2,Hyperlipidemia and Mixed Dyslipidemia,Biological:evolocumab (AMG 145) and standard of care; Other:Standard of care,[],1-Oct-15,18,85,Both,FALSE,16NCT01835158,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01824823,Eastern Cooperative Oncology Group,FALSE,ME,https://ClinicalTrials.gov/show/NCT01824823,FALSE,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],11-Sep-15,18,9999,Both,FALSE,17NCT01802333,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT01763866,Amgen,TRUE,ME,https://ClinicalTrials.gov/show/NCT01763866,FALSE,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,Hyperlipidemia,Biological:Evolocumab; Drug:Ezetimibe; Drug:Placebo to Evolocumab; Drug:Placebo to Ezetimibe; Drug:Atorvastatin; Drug:Rosuvastatin; Drug:Simvastatin,[],18-Nov-15,18,80,Both,FALSE,16NCT01648348,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT01648348,FALSE,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01380730,Amgen,TRUE,ME,https://ClinicalTrials.gov/show/NCT01380730,FALSE,LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy,Hyperlipidemia,Biological:Evolocumab; Other:Placebo to Evolocumab,[],1-Sep-15,18,80,Both,FALSE,16NCT01366183,Gynecologic Oncology Group,FALSE,ME,https://ClinicalTrials.gov/show/NCT01366183,FALSE,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],23-Dec-14,75,9999,Both,FALSE,14NCT01313676,GlaxoSmithKline,FALSE,ME,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT01238172,Alliance for Clinical Trials in Oncology,FALSE,ME,https://ClinicalTrials.gov/show/NCT01238172,FALSE,Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance,Prostate Cancer,Other:dietary education and counseling; Other:prostate cancer foundation booklet,[],20-Aug-15,50,80,Male,FALSE,1NCT01126437,Boehringer Ingelheim,FALSE,ME,https://ClinicalTrials.gov/show/NCT01126437,FALSE,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:tiotropium 18 mcg; Drug:tiotropium 1.25 mcg (2 actuations/day); Drug:tiotropium 2.5 mcg (2 actuations/day),[],20-May-14,40,9999,Both,FALSE,75NCT01107886,AstraZeneca,FALSE,ME,https://ClinicalTrials.gov/show/NCT01107886,FALSE,Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications,Type 2 Diabetes Mellitus,Drug:Saxagliptin; Drug:Placebo,[],9-Jul-14,40,9999,Both,FALSE,13NCT01041781,Alliance for Clinical Trials in Oncology,FALSE,ME,https://ClinicalTrials.gov/show/NCT01041781,FALSE,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01011478,NSABP Foundation Inc,TRUE,ME,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT01000727,GlaxoSmithKline,FALSE,ME,https://ClinicalTrials.gov/show/NCT01000727,FALSE,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Drug:Darapladib 160 mg; Drug:Placebo; Other:Standard Therapy,[],3-Sep-15,18,9999,Both,FALSE,8NCT00990327,Forest Laboratories,FALSE,ME,https://ClinicalTrials.gov/show/NCT00990327,FALSE,Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI,Coronary Artery Disease,Drug:Apadenoson SPECT-MPI; Drug:Adenosine SPECT-MPI,[],27-Apr-12,18,9999,Both,FALSE,110NCT00951496,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT00951496,FALSE,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00942357,Gynecologic Oncology Group,FALSE,ME,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00942331,National Cancer Institute (NCI),FALSE,ME,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00844649,Celgene Corporation,FALSE,ME,https://ClinicalTrials.gov/show/NCT00844649,FALSE,Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas,Metastatic Pancreatic Cancer,Drug:Albumin-bound paclitaxel (ABI-007); Drug:Gemcitabine,[],19-Oct-15,18,79,Both,FALSE,86NCT00829166,Hoffmann-La Roche,FALSE,ME,https://ClinicalTrials.gov/show/NCT00829166,FALSE,An Open-label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Drug:Trastuzumab emtansine [Kadcyla]; Drug:Lapatinib; Drug:Capecitabine,[],2-Apr-15,18,9999,Both,FALSE,119NCT01275677,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00346216,Pfizer,FALSE,MD,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00264901,Novo Nordisk A/S,FALSE,MD,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00769379,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00373685,Pfizer,FALSE,MD,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00324805,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00808808,MedImmune LLC,TRUE,MD,https://ClinicalTrials.gov/show/NCT00808808,FALSE,Assessing Choice in the Employer Setting (ACES) Study,Healthy,Biological:Choice of TIV or FluMist with baseline advertisement; Other:Choice of TIV or FluMist with enhanced advertisement and incentives; Biological:Control - Usual care offering TIV only with baseline advertisement,[],28-Oct-13,18,9999,Both,TRUE,15NCT01547741,NSABP Foundation Inc,FALSE,MD,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT00262600,Boehringer Ingelheim,FALSE,MD,https://ClinicalTrials.gov/show/NCT00262600,FALSE,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation; Stroke,Drug:warfarin; Drug:Dabigatran dose 1; Drug:Dabigatran dose 2,[],5-Nov-14,18,9999,Both,FALSE,75NCT00053898,NSABP Foundation Inc,TRUE,MD,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT00808067,Boehringer Ingelheim,FALSE,MD,https://ClinicalTrials.gov/show/NCT00808067,FALSE,RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial,Atrial Fibrillation,Drug:dabigatran dose 1; Drug:dabigatran dose 2,[],3-Jun-14,18,9999,Both,FALSE,75NCT00658515,Hoffmann-La Roche,FALSE,MD,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00625898,NSABP Foundation Inc,FALSE,MD,https://ClinicalTrials.gov/show/NCT00625898,FALSE,BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab,Breast Cancer,Drug:Docetaxel; Drug:Trastuzumab; Drug:Carboplatin; Drug:Bevacizumab; Drug:5-Fluorouracil; Drug:Epirubicin; Drug:Cyclophosphamide,[],7-Jul-14,18,9999,Female,FALSE,2NCT00433511,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02465060,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT00887536,NSABP Foundation Inc,FALSE,MD,https://ClinicalTrials.gov/show/NCT00887536,FALSE,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],24-Jun-15,18,70,Female,FALSE,2NCT00087178,NSABP Foundation Inc,FALSE,MD,https://ClinicalTrials.gov/show/NCT00087178,FALSE,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],5-Oct-15,18,9999,Female,FALSE,2NCT00327691,Pfizer,TRUE,MD,https://ClinicalTrials.gov/show/NCT00327691,FALSE,A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels,Cardiovascular Disease; Cerebrovascular Accident; Coronary Heart Disease,Drug:Atorvastatin,[],1-May-07,35,75,Both,FALSE,10NCT00326898,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00262847,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT00262847,FALSE,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],18-Aug-15,18,9999,Female,FALSE,9NCT01764633,Amgen,FALSE,MD,https://ClinicalTrials.gov/show/NCT01764633,FALSE,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],20-Jan-16,40,85,Both,FALSE,16NCT00079274,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT00067938,GlaxoSmithKline,FALSE,MD,https://ClinicalTrials.gov/show/NCT00067938,FALSE,Bipolar Study in Adults at Least 18 Years of Age,Bipolar Disorder,Drug:lamotrigine,[],11-Oct-12,18,9999,Both,FALSE,8NCT01313676,GlaxoSmithKline,FALSE,MD,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT01000727,GlaxoSmithKline,FALSE,MD,https://ClinicalTrials.gov/show/NCT01000727,FALSE,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Drug:Darapladib 160 mg; Drug:Placebo; Other:Standard Therapy,[],3-Sep-15,18,9999,Both,FALSE,8NCT00601900,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT00601900,FALSE,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],23-Apr-15,18,9999,Female,FALSE,9NCT00412984,Bristol-Myers Squibb,FALSE,MD,https://ClinicalTrials.gov/show/NCT00412984,FALSE,Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation,Atrial Fibrillation; Atrial Flutter,Drug:warfarin; Drug:apixaban,[],27-Sep-13,18,9999,Both,FALSE,80NCT00382070,NSABP Foundation Inc,TRUE,MD,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,MD,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00103181,NSABP Foundation Inc,TRUE,MD,https://ClinicalTrials.gov/show/NCT00103181,FALSE,Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer,Breast Cancer,Radiation:3-dimensional conformal accelerated partial breast irradiation; Radiation:brachytherapy; Radiation:whole breast irradiation; Radiation:MammoSite or other single-entry intracavitary device,[],8-Oct-15,18,9999,Female,FALSE,2NCT00067457,GlaxoSmithKline,FALSE,MD,https://ClinicalTrials.gov/show/NCT00067457,FALSE,Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy,Irritable Colon; Irritable Bowel Syndrome (IBS),Drug:alosetron,[],15-Apr-15,18,9999,Female,FALSE,8NCT00951496,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT00951496,FALSE,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,MD,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT00549796,Johns Hopkins University,FALSE,MD,https://ClinicalTrials.gov/show/NCT00549796,FALSE,Randomized Comparison Angioplasty Outcomes at Hospitals With and Without On-site Cardiac Surgery,Coronary Arteriosclerosis; Angina Pectoris,Other:Percutaneous coronary intervention (PCI),[],10-Sep-14,18,9999,Both,FALSE,135NCT00507416,"Millennium Pharmaceuticals, Inc.",FALSE,MD,https://ClinicalTrials.gov/show/NCT00507416,FALSE,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",Multiple Myeloma,Drug:Bortezomib; Drug:Dexamethasone; Drug:Melphalan; Drug:Prednisone; Drug:Thalidomide,[],28-Mar-14,18,9999,Both,FALSE,146NCT00505778,Warner Chilcott,FALSE,MD,https://ClinicalTrials.gov/show/NCT00505778,FALSE,A Comparison of Once a Day Dose Compared to 2 Doses/Day,Ulcerative Colitis,Drug:Mesalamine Once-Daily; Drug:Mesalamine Twice-Daily,[],15-Apr-13,18,9999,Both,FALSE,221NCT00490139,GlaxoSmithKline,FALSE,MD,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT00217737,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00079001,Alliance for Clinical Trials in Oncology,TRUE,MD,https://ClinicalTrials.gov/show/NCT00079001,FALSE,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer; Prostate Cancer,Drug:zoledronic acid; Other:placebo; Drug:androgen deprivation therapy; Drug:GnRH agonist; Dietary Supplement:Calcium supplement; Dietary Supplement:Vitamin D,[],23-Nov-15,18,9999,Male,FALSE,1NCT00042081,"Anesiva, Inc.",TRUE,MD,https://ClinicalTrials.gov/show/NCT00042081,FALSE,Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures,Coronary Artery Disease,Drug:CGT003 (E2F Duplex Decoy),[],4-May-06,18,80,Both,FALSE,22NCT01886872,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01475721,GlaxoSmithKline,FALSE,MD,https://ClinicalTrials.gov/show/NCT01475721,FALSE,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],10-Dec-15,12,9999,Both,FALSE,8NCT01349322,Radiation Therapy Oncology Group,FALSE,MD,https://ClinicalTrials.gov/show/NCT01349322,FALSE,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],14-Nov-15,18,9999,Female,FALSE,4NCT01167712,National Cancer Institute (NCI),FALSE,MD,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT01011478,NSABP Foundation Inc,TRUE,MD,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT00942357,Gynecologic Oncology Group,FALSE,MD,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00781391,Daiichi Sankyo Inc.,FALSE,MD,https://ClinicalTrials.gov/show/NCT00781391,FALSE,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke; Atrial Fibrillation; Embolism,Drug:warfarin tablets; Drug:Edoxaban tablets (high dose regimen-60mg); Drug:Edoxaban tablets (low dose regimen-30mg); Drug:placebo warfarin; Drug:placebo edoxaban,[],12-Mar-15,21,9999,Both,FALSE,95NCT01454947,University of Southern California,FALSE,MA,https://ClinicalTrials.gov/show/NCT01454947,FALSE,Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study),Acute Respiratory Infections (ARIs),Behavioral:Clinical Decision Support: Justification Alerts; Behavioral:Audit and Feedback: Social Norms; Behavioral:CDS Order Sets: Alternative Prescriptions,[],2-Nov-11,18,9999,Both,FALSE,209NCT00382070,NSABP Foundation Inc,TRUE,MA,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00324805,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00079274,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT00053898,NSABP Foundation Inc,TRUE,MA,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT01275677,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00034879,AstraZeneca,FALSE,MA,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT01198886,Tufts University,FALSE,MA,https://ClinicalTrials.gov/show/NCT01198886,FALSE,"The Vitality, Independence, and Vigor in Elders Study I Clinical Trial",Functionally Limited; Sedentary,Other:Successful Aging Program; Other:Exercise-Nutrition Program,"[u'Drake Village', u'Nashoba Park', u'Compass on the Bay', u'Chestnut Park at Cleveland Circle', u'Neville Place at Fresh Pond', u'Youville House', u'Chelmsford Crossings', u'Putnam Farms at Danvers', u'Standish Village at Lower Mills', u'Youville Place', u'Methuen Village', u'Golda Meir House', u'Evans Park at Newton Center', u'Coleman House', u'The Falls at Cordingly Dam', u'Holland Street Center', u'Waltham Crossings']",11-May-15,65,9999,Both,TRUE,194NCT01116882,Harvard Clinical Research Institute,FALSE,MA,https://ClinicalTrials.gov/show/NCT01116882,FALSE,Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings,Coronary Artery Diseases,Procedure:PCI,"[u'Beth Israel Deaconnes Medical Center', u'Massachusetts General Hospital', u'Boston University Medical Center', u""Brigham and Women's Hospital"", u'Tufts New England Medical Center', u""Caritas St. Elizabeth's Hospital"", u'Brockton Hospital', u'Caritas Good Samaritan Medical Center', u'Lahey Clinic', u'Metrowest Medical Center', u'Lawrence General Hospital', u'Saints Memorial Medical Center', u'Lowell General Hospital', u'Melrose Wakefield Hospital', u'Caritas Holy Family Hospital', u'Caritas Norwood Hospital', u'South Shore Hospital']",18-Mar-15,18,9999,Both,FALSE,117NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,MA,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00217737,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00433511,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00087178,NSABP Foundation Inc,FALSE,MA,https://ClinicalTrials.gov/show/NCT00087178,FALSE,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],5-Oct-15,18,9999,Female,FALSE,2NCT00052910,Alliance for Clinical Trials in Oncology,TRUE,MA,https://ClinicalTrials.gov/show/NCT00052910,FALSE,Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer,Esophageal Cancer; Gastric Cancer,Drug:cisplatin; Drug:epirubicin hydrochloride; Drug:fluorouracil; Drug:leucovorin calcium; Radiation:radiation therapy,[],23-Jun-15,18,9999,Both,FALSE,1NCT00041119,Alliance for Clinical Trials in Oncology,TRUE,MA,https://ClinicalTrials.gov/show/NCT00041119,FALSE,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],23-Jul-15,18,9999,Female,FALSE,1NCT01886872,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT00658515,Hoffmann-La Roche,FALSE,MA,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00003906,NSABP Foundation Inc,TRUE,MA,https://ClinicalTrials.gov/show/NCT00003906,FALSE,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],5-Oct-15,35,9999,Female,FALSE,2NCT00003857,Radiation Therapy Oncology Group,TRUE,MA,https://ClinicalTrials.gov/show/NCT00003857,FALSE,Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ,Breast Cancer,Drug:tamoxifen citrate; Procedure:adjuvant therapy; Radiation:radiation therapy,[],14-Nov-15,26,120,Female,FALSE,4NCT01547741,NSABP Foundation Inc,FALSE,MA,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT00264901,Novo Nordisk A/S,FALSE,MA,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00346216,Pfizer,FALSE,MA,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT02378051,Massachusetts General Hospital,FALSE,MA,https://ClinicalTrials.gov/show/NCT02378051,FALSE,Staying Strong With Schools - A School-Based Resilience Support Intervention for Military-Connected Children,Staying Strong With Schools Intervention; Waitlist Control,Behavioral:Staying Strong with Schools Intervention,"[u'Community Charter School', u'East Falmouth Elementary School', u'North Falmouth Elementary School', u'Mullen-Hall School', u'Morse Pond School', u'Hyannis West Elementary School', u'Barnstable United Elementary School', u'West Villages Elementary School', u'Teaticket Elementary School', u'West Barnstable Elementary School']",26-Feb-15,6,9999,Both,FALSE,140NCT02072421,Harvard Clinical Research Institute,FALSE,MA,https://ClinicalTrials.gov/show/NCT02072421,FALSE,The MASS COMM Post-Randomization Phase Cohort Study,Coronary Artery Disease,Procedure:PCI,"[u'Good Samaritan Medical Center', u'Brockton Hospital', u'Metrowest Medical Center', u'Lawrence General Hospital', u'Lowell General Hospital', u'Saints Memorial Medical Center', u'Melrose-Wakefield Hospital', u'Holy Family Hospital', u'Norwood Hospital', u'South Shore Hospital']",18-Mar-15,18,9999,Both,FALSE,117NCT01196390,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01070836,Biogen,FALSE,MA,https://ClinicalTrials.gov/show/NCT01070836,FALSE,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],14-Jan-16,0,9999,Both,FALSE,73NCT00951496,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT00951496,FALSE,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00785291,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00667810,Pfizer,FALSE,MA,https://ClinicalTrials.gov/show/NCT00667810,FALSE,Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients,Alzheimer Disease,Drug:bapineuzumab; Drug:bapineuzumab; Drug:placebo,[],4-Dec-15,50,89,Both,FALSE,10NCT00574132,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",FALSE,MA,https://ClinicalTrials.gov/show/NCT00574132,FALSE,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier),Alzheimer's Disease,Drug:Bapineuzumab 0.5 mg/kg; Drug:Placebo Control; Drug:Bapineuzumab 1.0 m/kg,[],30-Oct-13,50,88,Both,FALSE,131NCT00326898,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00262600,Boehringer Ingelheim,FALSE,MA,https://ClinicalTrials.gov/show/NCT00262600,FALSE,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation; Stroke,Drug:warfarin; Drug:Dabigatran dose 1; Drug:Dabigatran dose 2,[],5-Nov-14,18,9999,Both,FALSE,75NCT00239681,AstraZeneca,FALSE,MA,https://ClinicalTrials.gov/show/NCT00239681,FALSE,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],6-Feb-14,50,9999,Both,FALSE,13NCT00094302,New England Research Institutes,TRUE,MA,https://ClinicalTrials.gov/show/NCT00094302,FALSE,Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function,"Cardiovascular Diseases; Heart Diseases; Heart Failure, Congestive",Drug:Spironolactone; Drug:Placebo,[],11-Feb-15,50,9999,Both,FALSE,33NCT00056407,GlaxoSmithKline,TRUE,MA,https://ClinicalTrials.gov/show/NCT00056407,FALSE,"""REDUCE"" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk","Neoplasms, Prostate",Drug:Dutasteride; Drug:Placebo,[],23-Apr-15,50,75,Male,FALSE,8NCT00024102,Alliance for Clinical Trials in Oncology,TRUE,MA,https://ClinicalTrials.gov/show/NCT00024102,FALSE,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,Breast Cancer,Drug:Standard Treatment; Drug:capecitabine,[],23-Jun-15,65,9999,Female,FALSE,1NCT01764633,Amgen,FALSE,MA,https://ClinicalTrials.gov/show/NCT01764633,FALSE,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],20-Jan-16,40,85,Both,FALSE,16NCT01303458,Boston Medical Center,FALSE,MA,https://ClinicalTrials.gov/show/NCT01303458,FALSE,Addressing Low-Income Families' Basic Social Needs at Pediatric Visits,The Focus of This Study is to Address Low-income Families' Basic Social Needs at Pediatric Visits.,Behavioral:Basic Needs Surveillance (BNS) protocol,"[u'Arvin Garg', u'Codman Square Health Center', u'Dorchester House Multi-Service Center', u'Neponset Health Center', u""Upham's Corner Health Center"", u'Harvard Street Neighborhood Health Center', u'Greater Roslindale Medical and Dental Center', u'The Dimock Center', u'South Boston Community Health Center']",22-Dec-14,18,9999,Both,FALSE,77NCT01167712,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT00770809,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT00770809,FALSE,Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,HER2/Neu Positive; Male Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Lapatinib Ditosylate; Biological:Trastuzumab; Drug:Paclitaxel; Other:Laboratory Biomarker Analysis,[],7-May-15,18,9999,Both,FALSE,9NCT00644228,National Cancer Institute (NCI),FALSE,MA,https://ClinicalTrials.gov/show/NCT00644228,FALSE,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],12-Sep-14,18,9999,Both,FALSE,9NCT00490139,GlaxoSmithKline,FALSE,MA,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT00402857,Tufts Medical Center,FALSE,MA,https://ClinicalTrials.gov/show/NCT00402857,FALSE,Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders,Attention Deficit Disorder With Hyperactivity; Attention Deficit and Disruptive Behavior Disorders,Behavioral:Incredible Years Program,"[u'MGH Chelsea Healthcare Center', u'Codman Square Health Center', u'Martha Eliot Health Center', u'Medical Associates Pediatrics', u'Southboro Medical Group', u'Pediatrics West', u'Westwood-Mansfield Pediatric Associates', u'Wilmington Pediatrics', u'Woburn Pediatric Associates']",11-Feb-13,22,38,Both,TRUE,193NCT00003596,Radiation Therapy Oncology Group,TRUE,MA,https://ClinicalTrials.gov/show/NCT00003596,FALSE,Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer,Anal Cancer,Drug:cisplatin; Drug:fluorouracil; Drug:mitomycin C; Radiation:radiation therapy,[],18-Nov-13,18,9999,Both,FALSE,4NCT01546987,Radiation Therapy Oncology Group,FALSE,MA,https://ClinicalTrials.gov/show/NCT01546987,FALSE,"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer",Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:orteronel; Drug:triptorelin,[],14-Nov-15,18,9999,Male,FALSE,4NCT02465060,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02311907,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT02311907,FALSE,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],22-May-15,18,9999,Female,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02137837,Southwest Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT02137837,FALSE,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",Breast Cancer,Drug:Fulvestrant; Drug:Anastrozole; Drug:Everolimus; Drug:Placebo - Anastrozole; Drug:Placebo - Everolimus,[],20-May-15,18,9999,Female,FALSE,3NCT02042443,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT02042443,FALSE,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],3-Feb-16,0,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01841736,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01841736,FALSE,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01824823,Eastern Cooperative Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01824823,FALSE,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],11-Sep-15,18,9999,Both,FALSE,17NCT01802333,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT01708954,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01708954,FALSE,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],23-Oct-15,18,9999,Both,FALSE,9NCT01688973,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01688973,FALSE,Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery,Childhood Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Tivantinib,[],11-Jan-16,0,9999,Both,FALSE,9NCT01658943,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01648348,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01648348,FALSE,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,MI,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01515800,Southwest Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01515800,FALSE,S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer,Breast Cancer,Behavioral:Text message reminder,[],23-Oct-15,18,120,Female,FALSE,3NCT01498289,Southwest Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01468909,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01468909,FALSE,"Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],12-Jan-16,18,9999,Female,FALSE,9NCT01439945,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT01439945,FALSE,Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer,Breast Cancer; Cancer Survivor; Hot Flashes,Drug:magnesium oxide; Other:placebo,[],31-Jul-15,18,9999,Female,FALSE,1NCT01385137,Southwest Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01385137,FALSE,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],15-Oct-15,18,120,Female,FALSE,3NCT01376349,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT01376349,FALSE,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],24-Sep-15,18,9999,Female,FALSE,1NCT01366183,Gynecologic Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01366183,FALSE,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],23-Dec-14,75,9999,Both,FALSE,14NCT01349322,Radiation Therapy Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01349322,FALSE,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],14-Nov-15,18,9999,Female,FALSE,4NCT01309672,Southwest Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01309672,FALSE,S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy,Prostate Cancer,Drug:abiraterone acetate; Drug:degarelix; Drug:leuprolide acetate; Procedure:orchiectomy,[],8-Dec-15,18,120,Male,FALSE,3NCT01275677,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01260701,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01260701,FALSE,Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Diffuse Gastric Adenocarcinoma; Gastric Intestinal Type Adenocarcinoma; Gastric Mixed Adenocarcinoma; Recurrent Gastric Carcinoma,Drug:Akt Inhibitor MK2206,[],14-Dec-15,18,9999,Both,FALSE,9NCT01251861,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01251861,FALSE,Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer,Recurrent Prostate Carcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer,Drug:Akt Inhibitor MK2206; Drug:Bicalutamide; Other:Clinical Observation; Other:Laboratory Biomarker Analysis,[],18-Jan-16,18,9999,Male,FALSE,9NCT01238172,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT01238172,FALSE,Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance,Prostate Cancer,Other:dietary education and counseling; Other:prostate cancer foundation booklet,[],20-Aug-15,50,80,Male,FALSE,1NCT01229943,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01229943,FALSE,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],22-Apr-15,18,9999,Both,FALSE,9NCT01198158,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01196429,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01196429,FALSE,"Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer",Ovarian Clear Cell Cystadenocarcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer,Drug:Carboplatin; Drug:Docetaxel; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Temsirolimus,[],20-Nov-15,18,9999,Female,FALSE,9NCT01196390,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01189227,NSABP Foundation Inc,FALSE,MI,https://ClinicalTrials.gov/show/NCT01189227,FALSE,Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery,Colorectal Cancer; Metastatic Cancer,Procedure:Postoperative chemotherapy; Procedure:Perioperative chemotherapy,[],8-May-13,18,9999,Both,FALSE,2NCT01167712,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT01156142,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT01156142,FALSE,Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy,Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy; Pain,Drug:doxepin hydrochloride; Other:placebo,[],30-Jul-15,18,9999,Both,FALSE,1NCT01142388,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01142388,FALSE,Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Recurrent Esophageal Carcinoma; Stage IV Esophageal Cancer,Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Pharmacological Study,[],2-Jun-15,18,9999,Both,FALSE,9NCT01139957,Gynecologic Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01139957,FALSE,Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer,Breast Carcinoma; Fallopian Tube Carcinoma; Ovarian Neoplasm; Primary Peritoneal Carcinoma,Procedure:Evaluation of Cancer Risk Factors; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Procedure:Study of High Risk Factors,[],3-Jun-15,30,9999,Female,FALSE,14NCT01120275,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01120275,FALSE,Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma,Acral Lentiginous Malignant Melanoma; Lentigo Maligna Malignant Melanoma; Nodular Malignant Melanoma; Recurrent Melanoma; Solar Radiation-related Skin Melanoma; Stage IV Melanoma; Superficial Spreading Malignant Melanoma,Drug:gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other:laboratory biomarker analysis,[],9-Jun-14,18,9999,Both,FALSE,9NCT01120236,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01120236,FALSE,Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer,Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer,Drug:Bicalutamide; Biological:Cixutumumab; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Drug:Leuprolide Acetate; Other:Pharmacological Study,[],25-Jun-15,18,9999,Male,FALSE,9NCT01099449,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT01099449,FALSE,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],4-Jul-15,18,9999,Both,FALSE,1NCT01098630,Gynecologic Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01098630,FALSE,"Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer",Recurrent Cervical Carcinoma; Recurrent Uterine Corpus Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Uterine Corpus Cancer; Stage I Uterine Sarcoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage II Uterine Corpus Cancer; Stage II Uterine Sarcoma; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage III Uterine Corpus Cancer; Stage III Uterine Sarcoma; Stage IV Uterine Corpus Cancer; Stage IV Uterine Sarcoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Medical Chart Review; Other:Questionnaire Administration,[],23-Dec-14,0,9999,Female,FALSE,14NCT01097278,Southwest Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01097278,FALSE,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],7-Jan-15,18,50,Female,FALSE,3NCT01091454,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT01091454,FALSE,Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer,Triple-negative Breast Cancer,Drug:brostallicin; Drug:cisplatin,[],23-Jul-15,18,9999,Both,FALSE,1NCT01086605,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT01086605,FALSE,Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer,Breast Cancer,Drug:pixantrone dimaleate,[],4-Aug-15,18,9999,Both,FALSE,1NCT01080521,Gynecologic Oncology Group,FALSE,MI,https://ClinicalTrials.gov/show/NCT01080521,FALSE,"Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy",Cognitive Side Effects of Cancer Therapy; Malignant Ovarian Mixed Epithelial Tumor; Malignant Ovarian Surface Epithelial-Stromal Tumor; Ovarian Brenner Tumor; Ovarian Carcinosarcoma; Ovarian Choriocarcinoma; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Dysgerminoma; Ovarian Embryonal Carcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Germ Cell Tumor; Ovarian Mucinous Cystadenocarcinoma; Ovarian Polyembryoma; Ovarian Sarcoma; Ovarian Serous Cystadenocarcinoma; Ovarian Teratoma; Ovarian Yolk Sac Tumor; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Procedure:Cognitive Assessment; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT01041781,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT01041781,FALSE,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01017601,Alliance for Clinical Trials in Oncology,FALSE,MI,https://ClinicalTrials.gov/show/NCT01017601,FALSE,Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Biological:Seneca Valley virus-001; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01015833,National Cancer Institute (NCI),FALSE,MI,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01011478,NSABP Foundation Inc,TRUE,MI,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT02500797,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT02500797,FALSE,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],11-Jan-16,18,9999,Both,FALSE,9NCT02465060,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02315430,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT02315430,FALSE,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Female,FALSE,9NCT02311907,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT02311907,FALSE,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],22-May-15,18,9999,Female,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02066181,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT02066181,FALSE,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,Desmoid-Type Fibromatosis,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate,[],25-Jan-16,18,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01841736,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01841736,FALSE,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01824823,Eastern Cooperative Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01824823,FALSE,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],11-Sep-15,18,9999,Both,FALSE,17NCT01802333,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT01708954,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01708954,FALSE,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],23-Oct-15,18,9999,Both,FALSE,9NCT01708941,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01708941,FALSE,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Recombinant Interferon Alfa-2b,[],11-Jan-16,18,9999,Both,FALSE,9NCT01688973,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01688973,FALSE,Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery,Childhood Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Tivantinib,[],11-Jan-16,0,9999,Both,FALSE,9NCT01658943,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01653028,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01653028,FALSE,Alisertib in Treating Patients With Advanced or Metastatic Sarcoma,Myxofibrosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Leiomyosarcoma; Recurrent Liposarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis,[],2-Feb-16,18,9999,Both,FALSE,9NCT01648348,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01648348,FALSE,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01642251,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01642251,FALSE,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,MN,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01540565,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01540565,FALSE,"Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Veliparib,[],5-Jan-16,18,9999,Female,FALSE,9NCT01522976,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01522976,FALSE,Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia,Adult Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts,Drug:Azacitidine; Drug:Lenalidomide; Drug:Vorinostat,[],24-Jun-15,18,9999,Both,FALSE,9NCT01466881,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01466881,FALSE,Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma,Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-Cell Lymphoma; Hepatosplenic T-Cell Lymphoma; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Adult T-Cell Leukemia/Lymphoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],26-Jun-15,18,9999,Both,FALSE,9NCT01439945,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT01439945,FALSE,Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer,Breast Cancer; Cancer Survivor; Hot Flashes,Drug:magnesium oxide; Other:placebo,[],31-Jul-15,18,9999,Female,FALSE,1NCT01412879,Southwest Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01412879,FALSE,S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:cyclophosphamide; Drug:cytarabine; Drug:dexamethasone; Drug:doxorubicin hydrochloride; Drug:leucovorin calcium; Drug:methotrexate; Drug:vincristine sulfate,[],15-Sep-15,18,65,Both,FALSE,3NCT01376349,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT01376349,FALSE,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],24-Sep-15,18,9999,Female,FALSE,1NCT01369849,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01369849,FALSE,"Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia,Drug:Akt Inhibitor MK2206; Drug:Bendamustine Hydrochloride; Other:Laboratory Biomarker Analysis; Biological:Rituximab,[],24-Aug-15,18,9999,Both,FALSE,9NCT01366183,Gynecologic Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01366183,FALSE,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],23-Dec-14,75,9999,Both,FALSE,14NCT01286233,NSABP Foundation Inc,FALSE,MN,https://ClinicalTrials.gov/show/NCT01286233,FALSE,Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32,Breast Cancer; Depression; Fatigue; Sleep Disorders,Drug:Metformin; Drug:Placebo,[],8-Sep-15,18,74,Female,FALSE,2NCT01275677,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01251861,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01251861,FALSE,Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer,Recurrent Prostate Carcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer,Drug:Akt Inhibitor MK2206; Drug:Bicalutamide; Other:Clinical Observation; Other:Laboratory Biomarker Analysis,[],18-Jan-16,18,9999,Male,FALSE,9NCT01229943,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01229943,FALSE,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],22-Apr-15,18,9999,Both,FALSE,9NCT01198158,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01198145,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT01198145,FALSE,Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy,"Diarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific",Drug:sulfasalazine; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01196390,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01189227,NSABP Foundation Inc,FALSE,MN,https://ClinicalTrials.gov/show/NCT01189227,FALSE,Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery,Colorectal Cancer; Metastatic Cancer,Procedure:Postoperative chemotherapy; Procedure:Perioperative chemotherapy,[],8-May-13,18,9999,Both,FALSE,2NCT01167712,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT01156142,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT01156142,FALSE,Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy,Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy; Pain,Drug:doxepin hydrochloride; Other:placebo,[],30-Jul-15,18,9999,Both,FALSE,1NCT01142388,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01142388,FALSE,Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Recurrent Esophageal Carcinoma; Stage IV Esophageal Cancer,Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Pharmacological Study,[],2-Jun-15,18,9999,Both,FALSE,9NCT01139957,Gynecologic Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01139957,FALSE,Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer,Breast Carcinoma; Fallopian Tube Carcinoma; Ovarian Neoplasm; Primary Peritoneal Carcinoma,Procedure:Evaluation of Cancer Risk Factors; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Procedure:Study of High Risk Factors,[],3-Jun-15,30,9999,Female,FALSE,14NCT01134614,National Cancer Institute (NCI),TRUE,MN,https://ClinicalTrials.gov/show/NCT01134614,FALSE,Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,Recurrent Melanoma; Stage III Melanoma; Stage IV Melanoma,Biological:ipilimumab; Biological:sargramostim,[],23-Mar-15,18,9999,Both,FALSE,9NCT01097278,Southwest Oncology Group,FALSE,MN,https://ClinicalTrials.gov/show/NCT01097278,FALSE,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],7-Jan-15,18,50,Female,FALSE,3NCT01091454,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT01091454,FALSE,Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer,Triple-negative Breast Cancer,Drug:brostallicin; Drug:cisplatin,[],23-Jul-15,18,9999,Both,FALSE,1NCT01086605,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT01086605,FALSE,Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer,Breast Cancer,Drug:pixantrone dimaleate,[],4-Aug-15,18,9999,Both,FALSE,1NCT01078454,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01078454,FALSE,Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis,Light Chain Deposition Disease; Primary Systemic Amyloidosis,Drug:melphalan; Drug:dexamethasone; Drug:bortezomib,[],20-Nov-14,18,9999,Both,FALSE,9NCT01078441,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01078441,FALSE,"Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant",Refractory Multiple Myeloma,Drug:liposomal doxorubicin; Drug:bortezomib; Drug:dexamethasone; Drug:cyclophosphamide,[],5-Jan-15,18,9999,Both,FALSE,9NCT01041781,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT01041781,FALSE,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01017601,Alliance for Clinical Trials in Oncology,FALSE,MN,https://ClinicalTrials.gov/show/NCT01017601,FALSE,Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Biological:Seneca Valley virus-001; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01015833,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01012297,National Cancer Institute (NCI),FALSE,MN,https://ClinicalTrials.gov/show/NCT01012297,FALSE,Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma,Recurrent Uterine Corpus Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Biological:Bevacizumab; Drug:Docetaxel; Biological:Filgrastim; Drug:Gemcitabine Hydrochloride; Biological:Pegfilgrastim; Other:Placebo,[],11-Nov-15,18,9999,Female,FALSE,9NCT00264901,Novo Nordisk A/S,FALSE,MS,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00373685,Pfizer,FALSE,MS,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00600821,Pfizer,FALSE,MS,https://ClinicalTrials.gov/show/NCT00600821,FALSE,A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.,Non-Small-Cell Lung Carcinoma; Adenocarcinoma,Drug:Bevacizumab; Drug:Carboplatin; Drug:Paclitaxel; Drug:AG-013736 (axitinib); Drug:Carboplatin; Drug:Paclitaxel,[],16-Oct-13,18,9999,Both,FALSE,10NCT00083889,Pfizer,FALSE,MS,https://ClinicalTrials.gov/show/NCT00083889,FALSE,SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma,"Carcinoma, Renal Cell",Drug:Interferon-alfa; Drug:SU011248,[],19-Jan-10,18,9999,Both,FALSE,10NCT00003906,NSABP Foundation Inc,TRUE,MS,https://ClinicalTrials.gov/show/NCT00003906,FALSE,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],5-Oct-15,35,9999,Female,FALSE,2NCT01284062,Pfizer,FALSE,MS,https://ClinicalTrials.gov/show/NCT01284062,FALSE,Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients,"Colitis, Ulcerative",Biological:Anrukinzumab; Biological:Anrukinzumab; Biological:Anrukinzumab; Other:placebo,[],10-Nov-14,18,65,Both,FALSE,10NCT01275677,National Cancer Institute (NCI),FALSE,MS,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,MS,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00596830,Pfizer,FALSE,MS,https://ClinicalTrials.gov/show/NCT00596830,FALSE,"Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology","Carcinoma, Squamous Cell; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung","Drug:CP-751,871 (Figitumumab); Drug:Carboplatin; Drug:Paclitaxel; Drug:Carboplatin; Drug:Paclitaxel",[],11-Dec-13,18,9999,Both,FALSE,10NCT00588770,National Cancer Institute (NCI),FALSE,MS,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT00467844,GTx,FALSE,MS,https://ClinicalTrials.gov/show/NCT00467844,FALSE,Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.,Cachexia,Drug:GTx-024; Drug:GTx-024; Drug:Placebo,[],26-Jun-14,0,9999,Both,FALSE,116NCT00310180,National Cancer Institute (NCI),FALSE,MS,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00240383,Bristol-Myers Squibb,FALSE,MS,https://ClinicalTrials.gov/show/NCT00240383,FALSE,"Dose Ranging Study With LT, Monotherapy, PPAR",Diabetes Mellitus II,Drug:Muraglitazar,[],10-Sep-10,18,70,Both,FALSE,80NCT00239681,AstraZeneca,FALSE,MS,https://ClinicalTrials.gov/show/NCT00239681,FALSE,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],6-Feb-14,50,9999,Both,FALSE,13NCT02102204,Amgen,FALSE,MS,https://ClinicalTrials.gov/show/NCT02102204,FALSE,To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis,"Hyperparathyroidism, Secondary",Drug:AMG 416,[],22-Dec-15,18,110,Both,FALSE,16NCT01785875,Amgen,FALSE,MS,https://ClinicalTrials.gov/show/NCT01785875,FALSE,20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD,"Hyperparathyroidism, Secondary",Drug:AMG 416,[],19-Dec-15,18,100,Both,FALSE,16NCT01547741,NSABP Foundation Inc,FALSE,MS,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01508026,Forest Laboratories,FALSE,MS,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT01356602,Novartis Pharmaceuticals,FALSE,MS,https://ClinicalTrials.gov/show/NCT01356602,FALSE,Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients,Acute Gouty Arthritis,Drug:Canakinumab pre-filled syringe; Drug:Canakinumab lyophilized powder; Drug:Triamcinolone Acetonide; Drug:Placebo,[],10-Dec-13,18,85,Both,FALSE,156NCT00891020,Hoffmann-La Roche,FALSE,MS,https://ClinicalTrials.gov/show/NCT00891020,FALSE,A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs),Rheumatoid Arthritis,Drug:tocilizumab [RoActemra/Actemra]; Drug:tocilizumab [RoActemra/Actemra]; Drug:Nonbiologic DMARDs of investigator's choice,[],19-Oct-12,18,9999,Both,FALSE,119NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,MS,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT00658515,Hoffmann-La Roche,FALSE,MS,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00471146,Pfizer,FALSE,MS,https://ClinicalTrials.gov/show/NCT00471146,FALSE,Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.,"Carcinoma, Pancreatic Ductal",Drug:AG-013736; Drug:Gemcitabine; Drug:Gemcitabine; Drug:placebo,[],14-Jun-12,18,9999,Both,FALSE,10NCT00324805,National Cancer Institute (NCI),FALSE,MS,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00057928,Southwest Oncology Group,FALSE,MS,https://ClinicalTrials.gov/show/NCT00057928,FALSE,"S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer",Cervical Cancer,Drug:cisplatin; Drug:gemcitabine hydrochloride; Drug:paclitaxel,[],11-Jun-12,0,9999,Female,FALSE,3NCT00053833,Southwest Oncology Group,FALSE,MS,https://ClinicalTrials.gov/show/NCT00053833,FALSE,"S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Drug:irinotecan,[],7-Nov-13,0,9999,Female,FALSE,3NCT00045617,Southwest Oncology Group,FALSE,MS,https://ClinicalTrials.gov/show/NCT00045617,FALSE,"S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer",Lung Cancer,Biological:monoclonal antibody 11D10 anti-idiotype vaccine; Biological:monoclonal antibody GD2 anti-idiotype vaccine; Drug:cisplatin; Drug:etoposide; Radiation:radiation therapy,[],11-Jun-12,18,9999,Both,FALSE,3NCT00041119,Alliance for Clinical Trials in Oncology,TRUE,MS,https://ClinicalTrials.gov/show/NCT00041119,FALSE,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],23-Jul-15,18,9999,Female,FALSE,1NCT00034879,AstraZeneca,FALSE,MS,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT00032123,Southwest Oncology Group,TRUE,MS,https://ClinicalTrials.gov/show/NCT00032123,FALSE,Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer,Esophageal Cancer; Gastric Cancer,Drug:erlotinib hydrochloride,[],21-Jun-13,0,9999,Both,FALSE,3NCT00031772,Southwest Oncology Group,TRUE,MS,https://ClinicalTrials.gov/show/NCT00031772,FALSE,S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer,Breast Cancer; Psychosocial Effects of Cancer and Its Treatment,Procedure:psychosocial assessment and care,[],12-Feb-13,18,9999,Female,FALSE,3NCT00030433,Southwest Oncology Group,TRUE,MS,https://ClinicalTrials.gov/show/NCT00030433,FALSE,S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Drug:gemcitabine hydrochloride; Drug:irinotecan hydrochloride,[],12-Feb-13,18,9999,Both,FALSE,3NCT00026520,Southwest Oncology Group,TRUE,MS,https://ClinicalTrials.gov/show/NCT00026520,FALSE,Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma,Melanoma (Skin),Biological:recombinant interferon alfa; Drug:thalidomide,[],20-Jun-13,18,9999,Both,FALSE,3NCT00026156,Southwest Oncology Group,TRUE,MS,https://ClinicalTrials.gov/show/NCT00026156,FALSE,S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:docetaxel; Drug:vinorelbine tartrate,[],12-Feb-13,18,9999,Both,FALSE,3NCT00023777,Southwest Oncology Group,TRUE,MS,https://ClinicalTrials.gov/show/NCT00023777,FALSE,S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia,Leukemia,Biological:filgrastim; Biological:sargramostim; Drug:cytarabine; Drug:daunorubicin hydrochloride,[],5-Mar-15,56,9999,Both,FALSE,3NCT00023751,Alliance for Clinical Trials in Oncology,FALSE,MS,https://ClinicalTrials.gov/show/NCT00023751,FALSE,Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer,Colorectal Cancer,Drug:fluorouracil; Drug:leucovorin calcium; Procedure:conventional surgery; Radiation:radiation therapy,[],13-Jul-15,18,9999,Both,FALSE,1NCT00016965,Southwest Oncology Group,TRUE,MS,https://ClinicalTrials.gov/show/NCT00016965,FALSE,BMS-247550 in Treating Patients With Advanced Pancreatic Cancer,Pancreatic Cancer,Drug:ixabepilone,[],20-Jun-13,18,9999,Both,FALSE,3NCT00016939,Southwest Oncology Group,TRUE,MS,https://ClinicalTrials.gov/show/NCT00016939,FALSE,Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer,Kidney Cancer,Drug:alvocidib,[],20-Jun-13,0,9999,Both,FALSE,3NCT00016419,Southwest Oncology Group,FALSE,MS,https://ClinicalTrials.gov/show/NCT00016419,FALSE,S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome,Leukemia; Myelodysplastic Syndromes,Biological:anti-thymocyte globulin; Drug:cyclosporine,[],5-Mar-15,15,9999,Both,FALSE,3NCT00014196,Southwest Oncology Group,FALSE,MS,https://ClinicalTrials.gov/show/NCT00014196,FALSE,S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer,Lung Cancer,Drug:cisplatin; Drug:docetaxel; Radiation:radiation therapy,[],12-Feb-13,18,9999,Both,FALSE,3NCT00014144,Southwest Oncology Group,FALSE,MS,https://ClinicalTrials.gov/show/NCT00014144,FALSE,"S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract",Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer,Drug:gefitinib,[],5-Oct-12,0,9999,Both,FALSE,3NCT00012363,Southwest Oncology Group,TRUE,MS,https://ClinicalTrials.gov/show/NCT00012363,FALSE,S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus,Esophageal Cancer; Gastric Cancer,Drug:gemcitabine hydrochloride; Drug:irinotecan hydrochloride,[],12-Jun-12,18,9999,Both,FALSE,3NCT00006708,Southwest Oncology Group,FALSE,MS,https://ClinicalTrials.gov/show/NCT00006708,FALSE,S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,Lymphoma,Biological:filgrastim; Biological:rituximab; Drug:carboplatin; Drug:etoposide; Drug:ifosfamide,[],8-Apr-13,18,9999,Both,FALSE,3NCT00006487,Southwest Oncology Group,TRUE,MS,https://ClinicalTrials.gov/show/NCT00006487,FALSE,S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer,Lung Cancer,Drug:cisplatin; Drug:etoposide; Drug:tirapazamine; Radiation:radiation therapy,[],3-Oct-12,18,9999,Both,FALSE,3NCT00006484,Southwest Oncology Group,TRUE,MS,https://ClinicalTrials.gov/show/NCT00006484,FALSE,Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:paclitaxel; Drug:tirapazamine,[],20-Jun-13,18,9999,Both,FALSE,3NCT00006248,Southwest Oncology Group,TRUE,MS,https://ClinicalTrials.gov/show/NCT00006248,FALSE,S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer,Head and Neck Cancer,Drug:cisplatin; Drug:fluorouracil; Drug:paclitaxel,[],8-Apr-13,18,9999,Both,FALSE,3NCT00005834,Southwest Oncology Group,FALSE,MS,https://ClinicalTrials.gov/show/NCT00005834,FALSE,S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma,Multiple Myeloma,Biological:filgrastim; Drug:cisplatin; Drug:cyclophosphamide; Drug:dexamethasone; Drug:etoposide; Drug:thalidomide,[],5-Mar-15,18,9999,Both,FALSE,3NCT02465060,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01841736,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01841736,FALSE,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Both,FALSE,9NCT01802333,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT01658943,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,MO,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01498289,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01275677,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01198158,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01196390,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01097278,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT01097278,FALSE,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],7-Jan-15,18,50,Female,FALSE,3NCT01015833,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00954174,Gynecologic Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT00954174,FALSE,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00946712,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00942357,Gynecologic Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00942331,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00920010,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT00920010,FALSE,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],5-Feb-15,0,9999,Both,FALSE,3NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,MO,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT00861705,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00861705,FALSE,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],28-Sep-15,18,9999,Both,FALSE,9NCT00785291,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00693992,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00693992,FALSE,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],26-Jun-15,18,9999,Both,FALSE,9NCT00640042,Pfizer,TRUE,MO,https://ClinicalTrials.gov/show/NCT00640042,FALSE,"Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",Pain,Drug:morphine sulfate extended release capsules,[],6-Jun-12,21,9999,Both,FALSE,10NCT00602459,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00602459,FALSE,Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,[],22-Apr-15,18,9999,Both,FALSE,9NCT00588770,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT00569127,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00569127,FALSE,"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor",Neuroendocrine Carcinoma,Biological:Recombinant Interferon Alfa-2b; Drug:Octreotide Acetate; Biological:Bevacizumab,[],5-Jan-15,0,9999,Both,FALSE,9NCT00490139,GlaxoSmithKline,FALSE,MO,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT00450281,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT00450281,FALSE,"S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",Lung Cancer,Genetic:chromogenic in situ hybridization; Genetic:gene expression analysis; Genetic:mutation analysis; Genetic:polymerase chain reaction; Genetic:polymorphism analysis; Other:fluorescent antibody technique; Other:immunohistochemistry staining method; Other:laboratory biomarker analysis; Other:matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other:study of socioeconomic and demographic variables; Procedure:study of high risk factors,[],23-Oct-15,18,120,Both,FALSE,3NCT00408408,NSABP Foundation Inc,TRUE,MO,https://ClinicalTrials.gov/show/NCT00408408,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery",Breast Cancer,Biological:bevacizumab; Drug:capecitabine; Drug:cyclophosphamide; Drug:docetaxel; Drug:doxorubicin hydrochloride (Adriamycin); Drug:gemcitabine hydrochloride,[],9-Feb-15,18,9999,Female,FALSE,2NCT00378703,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00378703,FALSE,"Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer",Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Sorafenib; Drug:temsirolimus; Biological:bevacizumab,[],14-Apr-15,18,9999,Both,FALSE,9NCT00326898,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,MO,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00264901,Novo Nordisk A/S,FALSE,MO,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00262847,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00262847,FALSE,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],18-Aug-15,18,9999,Female,FALSE,9NCT00217737,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00134056,Southwest Oncology Group,TRUE,MO,https://ClinicalTrials.gov/show/NCT00134056,FALSE,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],6-May-15,18,9999,Male,FALSE,3NCT00087178,NSABP Foundation Inc,FALSE,MO,https://ClinicalTrials.gov/show/NCT00087178,FALSE,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],5-Oct-15,18,9999,Female,FALSE,2NCT00079274,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT00075946,Eastern Cooperative Oncology Group,TRUE,MO,https://ClinicalTrials.gov/show/NCT00075946,FALSE,Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma,Lymphoma,Biological:rituximab,[],3-Jun-15,18,9999,Both,FALSE,17NCT00075764,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT00075764,FALSE,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:fulvestrant,[],8-May-14,18,9999,Female,FALSE,3NCT00070564,Southwest Oncology Group,TRUE,MO,https://ClinicalTrials.gov/show/NCT00070564,FALSE,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",Breast Cancer,Biological:pegfilgrastim; Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],15-Sep-15,18,9999,Both,FALSE,3NCT00063999,Gynecologic Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT00063999,FALSE,"Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",Endometrial Cancer,Biological:filgrastim; Drug:carboplatin; Drug:cisplatin; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],23-Apr-09,18,9999,Female,FALSE,14NCT00041119,Alliance for Clinical Trials in Oncology,TRUE,MO,https://ClinicalTrials.gov/show/NCT00041119,FALSE,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],23-Jul-15,18,9999,Female,FALSE,1NCT00006721,Southwest Oncology Group,FALSE,MO,https://ClinicalTrials.gov/show/NCT00006721,FALSE,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Radiation:tositumomab and iodine I 131 tositumomab,[],21-Feb-14,18,9999,Both,FALSE,3NCT02042443,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT02042443,FALSE,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],3-Feb-16,0,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,MO,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT02311907,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT02311907,FALSE,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],22-May-15,18,9999,Female,FALSE,9NCT00951496,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00951496,FALSE,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00946712,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00942331,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00920010,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT00920010,FALSE,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],5-Feb-15,0,9999,Both,FALSE,3NCT00828139,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00828139,FALSE,Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Biological:ziv-aflibercept; Drug:topotecan hydrochloride,[],9-Apr-14,18,9999,Both,FALSE,9NCT00803062,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00803062,FALSE,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],22-May-15,18,9999,Female,FALSE,9NCT00785291,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00776100,Alliance for Clinical Trials in Oncology,FALSE,MT,https://ClinicalTrials.gov/show/NCT00776100,FALSE,Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Other:clinical observation; Radiation:radiation therapy,[],8-Jul-15,18,9999,Both,FALSE,1NCT00770809,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00770809,FALSE,Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,HER2/Neu Positive; Male Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Lapatinib Ditosylate; Biological:Trastuzumab; Drug:Paclitaxel; Other:Laboratory Biomarker Analysis,[],7-May-15,18,9999,Both,FALSE,9NCT00684983,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00684983,FALSE,"Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer",HER2/Neu Positive; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Capecitabine; Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Other:Quality-of-Life Assessment,[],23-Dec-15,18,9999,Both,FALSE,9NCT00658814,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00658814,FALSE,Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,Adult Acute Megakaryoblastic Leukemia; Adult Acute Monoblastic Leukemia; Adult Acute Monocytic Leukemia; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With Maturation; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL; Adult Acute Myeloid Leukemia Without Maturation; Adult Acute Myelomonocytic Leukemia; Adult Erythroleukemia; Adult Pure Erythroid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:Azacitidine; Drug:Gemtuzumab Ozogamicin,[],4-Feb-16,60,9999,Both,FALSE,9NCT00644228,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00644228,FALSE,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],12-Sep-14,18,9999,Both,FALSE,9NCT00617708,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00617708,FALSE,S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery,Stage IV Pancreatic Cancer,Biological:cixutumumab; Drug:erlotinib hydrochloride; Drug:gemcitabine hydrochloride,[],25-Jul-14,18,9999,Both,FALSE,9NCT00602641,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00602641,FALSE,"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma",Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:melphalan; Drug:prednisone; Drug:thalidomide; Drug:lenalidomide,[],9-Jun-15,18,9999,Both,FALSE,9NCT00601900,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00601900,FALSE,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],23-Apr-15,18,9999,Female,FALSE,9NCT00588770,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT00569127,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00569127,FALSE,"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor",Neuroendocrine Carcinoma,Biological:Recombinant Interferon Alfa-2b; Drug:Octreotide Acetate; Biological:Bevacizumab,[],5-Jan-15,0,9999,Both,FALSE,9NCT00520975,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00520975,FALSE,First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU,HER2/Neu Positive; Male Breast Carcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],17-Dec-15,18,9999,Both,FALSE,9NCT00513747,Alliance for Clinical Trials in Oncology,FALSE,MT,https://ClinicalTrials.gov/show/NCT00513747,FALSE,Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia,Leukemia,Biological:rituximab; Drug:fludarabine phosphate,[],26-Oct-15,18,9999,Both,FALSE,1NCT00499369,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00499369,FALSE,Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Biological:bevacizumab,[],25-Jul-14,18,9999,Both,FALSE,9NCT00454194,Alliance for Clinical Trials in Oncology,FALSE,MT,https://ClinicalTrials.gov/show/NCT00454194,FALSE,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Drug:pemetrexed disodium; Drug:sorafenib tosylate,[],6-Jul-15,18,9999,Both,FALSE,1NCT00433511,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00352365,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00352365,FALSE,Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia,Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:lenalidomide,[],25-Jul-14,60,9999,Both,FALSE,9NCT00326898,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00313586,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00313586,FALSE,"Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia",Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL; Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA; Alkylating Agent-Related Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome; Untreated Adult Acute Myeloid Leukemia,Drug:Azacitidine; Drug:Entinostat; Other:Laboratory Biomarker Analysis,[],17-Dec-15,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00303953,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00303953,FALSE,PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma,Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma,Drug:belinostat,[],23-Apr-14,18,9999,Both,FALSE,9NCT00303628,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00303628,FALSE,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],20-May-14,18,9999,Both,FALSE,9NCT00262847,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00262847,FALSE,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],18-Aug-15,18,9999,Female,FALSE,9NCT00217737,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00134056,Southwest Oncology Group,TRUE,MT,https://ClinicalTrials.gov/show/NCT00134056,FALSE,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],6-May-15,18,9999,Male,FALSE,3NCT00124618,Alliance for Clinical Trials in Oncology,TRUE,MT,https://ClinicalTrials.gov/show/NCT00124618,FALSE,Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer,Lung Cancer,Biological:cetuximab; Radiation:radiation therapy,[],23-Nov-15,18,9999,Both,FALSE,1NCT00124579,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT00124579,FALSE,"S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",Multiple Myeloma,Drug:bortezomib; Drug:dexamethasone; Drug:thalidomide,[],5-Mar-15,18,9999,Both,FALSE,3NCT00109967,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00109967,FALSE,CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,Recurrent Mantle Cell Lymphoma,Biological:rituximab; Drug:temsirolimus,[],21-Mar-14,18,9999,Both,FALSE,9NCT00109837,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT00109837,FALSE,S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,Leukemia,Biological:filgrastim; Drug:cyclophosphamide; Drug:cytarabine; Drug:daunorubicin; Drug:dexamethasone; Drug:doxorubicin; Drug:leucovorin; Drug:mercaptopurine; Drug:methotrexate; Drug:mitoxantrone; Drug:Asparaginase; Drug:prednisone; Drug:thioguanine; Drug:vincristine; Radiation:radiation therapy; Drug:allopurinol; Drug:bactrim,[],5-Mar-15,18,64,Both,FALSE,3NCT00107380,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT00107380,FALSE,"S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Radiation:tositumomab and iodine I 131 tositumomab,[],28-Sep-15,18,120,Both,FALSE,3NCT00093470,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00093470,FALSE,Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission,Adult Acute Myeloid Leukemia; Adult Acute Myeloid Leukemia in Remission,Procedure:Clinical Observation; Drug:Tipifarnib,[],13-Oct-15,18,9999,Both,FALSE,9NCT00090961,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT00090961,FALSE,"S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer",Lung Cancer; Pulmonary Complications,Other:educational intervention; Other:supervised exercise program,[],31-Oct-12,0,9999,Both,FALSE,3NCT00079274,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT00070499,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00070499,FALSE,Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia,"Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase of Disease",Drug:Dasatinib; Drug:Imatinib Mesylate; Other:Laboratory Biomarker Analysis,[],6-Jan-16,18,9999,Both,FALSE,9NCT00049179,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT00049179,FALSE,S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia,Leukemia,Drug:cytarabine; Drug:gemtuzumab ozogamicin,[],5-Mar-15,18,9999,Both,FALSE,3NCT00049127,National Cancer Institute (NCI),FALSE,MT,https://ClinicalTrials.gov/show/NCT00049127,FALSE,Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor,Adult Anaplastic Oligodendroglioma; Adult Mixed Glioma; Adult Oligodendroglioma; Recurrent Adult Brain Tumor,Drug:imatinib mesylate; Other:laboratory biomarker analysis; Other:pharmacological study,[],1-Oct-14,18,9999,Both,FALSE,9NCT00045162,Southwest Oncology Group,TRUE,MT,https://ClinicalTrials.gov/show/NCT00045162,FALSE,S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Drug:cisplatin; Drug:etoposide; Drug:irinotecan hydrochloride,[],3-Jul-13,18,9999,Both,FALSE,3NCT00040937,Southwest Oncology Group,TRUE,MT,https://ClinicalTrials.gov/show/NCT00040937,FALSE,"S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma",Multiple Myeloma,Biological:filgrastim; Biological:sargramostim; Drug:cyclophosphamide; Drug:dexamethasone; Drug:melphalan; Drug:prednisone; Drug:thalidomide; Procedure:peripheral blood stem cell transplantation,[],5-Mar-15,18,65,Both,FALSE,3NCT00039377,National Cancer Institute (NCI),TRUE,MT,https://ClinicalTrials.gov/show/NCT00039377,FALSE,"Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",Adult Acute Lymphoblastic Leukemia in Remission,Drug:imatinib mesylate; Drug:methotrexate; Drug:vincristine sulfate; Drug:leucovorin calcium; Procedure:peripheral blood stem cell transplantation; Procedure:autologous hematopoietic stem cell transplantation; Procedure:allogeneic hematopoietic stem cell transplantation; Radiation:total-body irradiation; Drug:tacrolimus; Biological:filgrastim; Drug:etoposide; Drug:cyclophosphamide; Drug:cytarabine; Other:laboratory biomarker analysis,[],13-Nov-14,15,59,Both,FALSE,9NCT00008385,Eastern Cooperative Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT00008385,FALSE,Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer,Lung Cancer,Dietary Supplement:selenium; Other:placebo,[],15-May-15,18,9999,Both,FALSE,17NCT00006237,Southwest Oncology Group,FALSE,MT,https://ClinicalTrials.gov/show/NCT00006237,FALSE,S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma,Melanoma (Skin),Biological:interleukin-2; Biological:filgrastim; Biological:interferon alfa; Drug:cisplatin; Drug:dacarbazine; Drug:vinblastine,[],5-Mar-15,18,9999,Both,FALSE,3NCT00003896,Southwest Oncology Group,TRUE,MT,https://ClinicalTrials.gov/show/NCT00003896,FALSE,"S9912 Combination Chemo in Stage III Ovarian Cancer,",Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Drug:cisplatin; Drug:liposomal doxorubicin; Drug:paclitaxel,[],2-Jan-13,0,9999,Female,FALSE,3NCT01275677,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00588770,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT02465060,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT00003594,Alliance for Clinical Trials in Oncology,TRUE,NE,https://ClinicalTrials.gov/show/NCT00003594,FALSE,Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,Colorectal Cancer,Drug:irinotecan; Drug:fluorouracil; Drug:leucovorin calcium; Drug:oxaliplatin,[],9-Jul-15,18,9999,Both,FALSE,1NCT01642251,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT01642251,FALSE,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT00942331,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00079274,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT02066181,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02066181,FALSE,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,Desmoid-Type Fibromatosis,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate,[],25-Jan-16,18,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01015833,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00346216,Pfizer,FALSE,NE,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00264901,Novo Nordisk A/S,FALSE,NE,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00072046,Alliance for Clinical Trials in Oncology,TRUE,NE,https://ClinicalTrials.gov/show/NCT00072046,FALSE,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],23-Jun-15,18,9999,Both,FALSE,1NCT00373685,Pfizer,FALSE,NE,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00326898,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT02498600,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02498600,FALSE,"Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],11-Jan-16,18,9999,Female,FALSE,9NCT02315430,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02315430,FALSE,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Female,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01824823,Eastern Cooperative Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT01824823,FALSE,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],11-Sep-15,18,9999,Both,FALSE,17NCT01802333,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT00892177,Alliance for Clinical Trials in Oncology,FALSE,NE,https://ClinicalTrials.gov/show/NCT00892177,FALSE,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],23-Nov-15,18,9999,Both,FALSE,1NCT00569127,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT00569127,FALSE,"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor",Neuroendocrine Carcinoma,Biological:Recombinant Interferon Alfa-2b; Drug:Octreotide Acetate; Biological:Bevacizumab,[],5-Jan-15,0,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,NE,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00079001,Alliance for Clinical Trials in Oncology,TRUE,NE,https://ClinicalTrials.gov/show/NCT00079001,FALSE,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer; Prostate Cancer,Drug:zoledronic acid; Other:placebo; Drug:androgen deprivation therapy; Drug:GnRH agonist; Dietary Supplement:Calcium supplement; Dietary Supplement:Vitamin D,[],23-Nov-15,18,9999,Male,FALSE,1NCT00003596,Radiation Therapy Oncology Group,TRUE,NE,https://ClinicalTrials.gov/show/NCT00003596,FALSE,Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer,Anal Cancer,Drug:cisplatin; Drug:fluorouracil; Drug:mitomycin C; Radiation:radiation therapy,[],18-Nov-13,18,9999,Both,FALSE,4NCT02257528,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT02257528,FALSE,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],3-Feb-16,18,9999,Female,FALSE,9NCT01313676,GlaxoSmithKline,FALSE,NE,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,NE,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT00463567,Novartis,FALSE,NE,https://ClinicalTrials.gov/show/NCT00463567,FALSE,"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive; COPD; Lung Diseases, Obstructive",Drug:Indacaterol; Drug:Formoterol (12 g b.i.d.); Drug:Tiotropium (18 g o.d.); Drug:Placebo to Indacaterol; Drug:Placebo to Formoterol,[],22-Jul-11,40,9999,Both,FALSE,155NCT00382070,NSABP Foundation Inc,TRUE,NE,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00324805,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00041119,Alliance for Clinical Trials in Oncology,TRUE,NE,https://ClinicalTrials.gov/show/NCT00041119,FALSE,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],23-Jul-15,18,9999,Female,FALSE,1NCT01167712,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT00567580,Radiation Therapy Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT00567580,FALSE,Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:flutamide; Radiation:radiation therapy,[],31-Mar-15,18,9999,Male,FALSE,4NCT00217737,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00087399,Alliance for Clinical Trials in Oncology,TRUE,NE,https://ClinicalTrials.gov/show/NCT00087399,FALSE,Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy,Breast Cancer; Hot Flashes,Drug:gabapentin; Drug:antidepressant,[],7-Jul-15,18,9999,Female,FALSE,1NCT00057876,Eastern Cooperative Oncology Group,TRUE,NE,https://ClinicalTrials.gov/show/NCT00057876,FALSE,Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer,Pancreatic Cancer,Drug:Gemcitabine; Radiation:radiation therapy,[],11-Feb-13,18,9999,Both,FALSE,17NCT00043069,Alliance for Clinical Trials in Oncology,TRUE,NE,https://ClinicalTrials.gov/show/NCT00043069,FALSE,Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer,Osteoporosis; Prostate Cancer,Dietary Supplement:calcium carbonate; Dietary Supplement:cholecalciferol; Drug:Estrogen Antagonists; Drug:risedronate sodium; Other:placebo,[],7-Jul-15,18,9999,Male,FALSE,1NCT01572792,Forest Laboratories,FALSE,NE,https://ClinicalTrials.gov/show/NCT01572792,FALSE,"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide; Drug:Formoterol Fumarate; Drug:Placebo,[],27-Feb-15,40,9999,Both,FALSE,110NCT01547741,NSABP Foundation Inc,FALSE,NE,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01437397,Forest Laboratories,FALSE,NE,https://ClinicalTrials.gov/show/NCT01437397,FALSE,"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide; Drug:Formoterol Fumarate; Drug:placebo,[],5-Apr-13,40,9999,Both,FALSE,110NCT01286233,NSABP Foundation Inc,FALSE,NE,https://ClinicalTrials.gov/show/NCT01286233,FALSE,Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32,Breast Cancer; Depression; Fatigue; Sleep Disorders,Drug:Metformin; Drug:Placebo,[],8-Sep-15,18,74,Female,FALSE,2NCT00942357,Gynecologic Oncology Group,FALSE,NE,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00693992,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT00693992,FALSE,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],26-Jun-15,18,9999,Both,FALSE,9NCT00601900,National Cancer Institute (NCI),FALSE,NE,https://ClinicalTrials.gov/show/NCT00601900,FALSE,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],23-Apr-15,18,9999,Female,FALSE,9NCT00490139,GlaxoSmithKline,FALSE,NE,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT02500797,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02500797,FALSE,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],11-Jan-16,18,9999,Both,FALSE,9NCT02465060,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02097238,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02097238,FALSE,Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma,Recurrent Osteosarcoma,Drug:Eribulin Mesylate; Other:Pharmacological Study,[],18-Dec-15,12,49,Both,FALSE,9NCT02066181,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02066181,FALSE,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,Desmoid-Type Fibromatosis,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate,[],25-Jan-16,18,9999,Both,FALSE,9NCT02042443,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT02042443,FALSE,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],3-Feb-16,0,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01841736,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01841736,FALSE,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01708954,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01708954,FALSE,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],23-Oct-15,18,9999,Both,FALSE,9NCT01275677,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01196390,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01015833,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00946712,Southwest Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00942357,Gynecologic Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00942331,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00588770,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT00346216,Pfizer,FALSE,NV,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00373256,Pfizer,FALSE,NV,https://ClinicalTrials.gov/show/NCT00373256,FALSE,A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer,Breast Neoplasms,Drug:Sunitinib; Drug:paclitaxel; Drug:bevacizumab; Drug:paclitaxel,[],5-Sep-12,18,9999,Both,FALSE,10NCT00264901,Novo Nordisk A/S,FALSE,NV,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT01508026,Forest Laboratories,FALSE,NV,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT00887536,NSABP Foundation Inc,FALSE,NV,https://ClinicalTrials.gov/show/NCT00887536,FALSE,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],24-Jun-15,18,70,Female,FALSE,2NCT00625898,NSABP Foundation Inc,FALSE,NV,https://ClinicalTrials.gov/show/NCT00625898,FALSE,BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab,Breast Cancer,Drug:Docetaxel; Drug:Trastuzumab; Drug:Carboplatin; Drug:Bevacizumab; Drug:5-Fluorouracil; Drug:Epirubicin; Drug:Cyclophosphamide,[],7-Jul-14,18,9999,Female,FALSE,2NCT01942135,Pfizer,FALSE,NV,https://ClinicalTrials.gov/show/NCT01942135,FALSE,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),Metastatic Breast Cancer,Drug:Palbociclib; Drug:Fulvestrant; Drug:Placebo; Drug:Fulvestrant,[],16-Nov-15,18,9999,Female,FALSE,10NCT01937715,Pfizer,FALSE,NV,https://ClinicalTrials.gov/show/NCT01937715,FALSE,A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,Metastatic Colorectal Carcinoma,Drug:PF-05212384; Drug:FOLFIRI regimen; Biological:Bevacizumab; Drug:FOLFIRI,[],15-Dec-15,18,9999,Both,FALSE,10NCT01740427,Pfizer,FALSE,NV,https://ClinicalTrials.gov/show/NCT01740427,FALSE,A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2),Breast Neoplasms,Drug:PD-0332991; Drug:Letrozole; Drug:Placebo; Drug:Letrozole,[],4-Feb-16,18,9999,Female,FALSE,10NCT01441414,Pfizer,FALSE,NV,https://ClinicalTrials.gov/show/NCT01441414,FALSE,PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma,Metastatic Renal Cell Carcinoma,Biological:PF-04856884; Drug:Axitinib (AG-013736); Drug:Axitinib (AG-013736),"[u'Pinnacle Oncology Hematology', u'Arizona Oncology Associates, PC - HOPE', u'Arizona Oncology Associates, PC-HOPE', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Nebraska Methodist Hospital', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada', u'Regional Cancer Care-Durham', u'Investigational Products Center (IPC) (drug shipment only)', u'Texas Oncology-Tyler', u'Seattle Cancer Care Alliance', u'University of Washington Medical Center', u'Masarykuv onkologicky ustav']",11-Dec-15,18,9999,Both,FALSE,10NCT01306890,Dendreon,FALSE,NV,https://ClinicalTrials.gov/show/NCT01306890,FALSE,A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer,Advanced Prostate Cancer; Prostatic Neoplasms,Biological:sipuleucel-T,[],5-Oct-15,18,9999,Male,FALSE,97NCT01298219,"Sucampo Pharmaceuticals, Inc.",FALSE,NV,https://ClinicalTrials.gov/show/NCT01298219,FALSE,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL),Opioid-induced Bowel Dysfunction,Drug:Lubiprostone; Drug:Placebo,[],1-Feb-13,18,9999,Both,FALSE,179NCT00968968,GlaxoSmithKline,FALSE,NV,https://ClinicalTrials.gov/show/NCT00968968,FALSE,Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone,Cancer,Drug:Lapatinib; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,8NCT00920816,Pfizer,FALSE,NV,https://ClinicalTrials.gov/show/NCT00920816,FALSE,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,Kidney Neoplasms,Drug:Axitinib (AG-013736); Drug:Sorafenib,[],12-Nov-15,18,9999,Both,FALSE,10NCT00721409,Pfizer,FALSE,NV,https://ClinicalTrials.gov/show/NCT00721409,FALSE,Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer,Breast Cancer,Drug:PD 0332991; Drug:letrozole; Drug:letrozole,[],4-Nov-15,18,9999,Female,FALSE,10NCT00616772,"AbbVie (prior sponsor, Abbott)",FALSE,NV,https://ClinicalTrials.gov/show/NCT00616772,FALSE,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Coronary Artery Disease; Coronary Heart Disease; Dyslipidemia,Drug:ABT-335; Drug:Placebo; Other:Atorvastatin,[],3-Dec-13,45,9999,Both,FALSE,52NCT00257205,AstraZeneca,FALSE,NV,https://ClinicalTrials.gov/show/NCT00257205,FALSE,"CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy",Melanoma,"Drug:dacarbazine; Drug:CP-675,206; Drug:temozolomide",[],25-Jun-12,18,9999,Both,FALSE,13NCT00196989,GlaxoSmithKline,FALSE,NV,https://ClinicalTrials.gov/show/NCT00196989,FALSE,Study In People With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:Pioglitazone; Drug:GW677954,[],17-Jun-15,18,70,Both,FALSE,8NCT01925274,Pfizer,FALSE,NV,https://ClinicalTrials.gov/show/NCT01925274,FALSE,A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug:PF-05212384; Drug:irinotecan; Drug:Cetuximab; Drug:Irinotecan,"[u'CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center', u'UCLA West Medical Pharmacy', u'Drug Management Only: UCLA West Medical Pharmacy, Att: Steven L Wong, Pharm D', u'TRIO_US', u'TRIO-US Central Administration (Regulatory Management only)', u'TRIO-US Central Administration', u'UCLA West Medical Pharmacy', u'West Valley Hematology/Oncology Group', u'Siteman Cancer Center - West County', u'Drug Shipping Address: Washington University Infusion Center Pharmacy', u'Siteman Cancer Center - South County', u'Barnes Jewish Hospital', u'Washington University School of Medicine', u'Siteman Cancer Center - St Peters', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada - Sunset Rd.', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada', u'Roswell Park Cancer Institute', u'Kadlec Medical Center', u'Outpatient Imaging Center', u'Medical Oncology Associates, PS', u'Spokane Valley Cancer Center', u'Aichi cancer center central hospital', u'National Cancer Center Hospital East', u'National Cancer Center', u'Seoul National University Hospital / Department of Internal Medicine', u'Samsung Medical Center', u'Asan Medical Center', u'Hospital General Universitario Gregorio Mara\xf1\xf3n']",11-Jan-16,18,9999,Both,FALSE,10NCT01767194,National Cancer Institute (NCI),FALSE,NV,https://ClinicalTrials.gov/show/NCT01767194,FALSE,Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma,Ganglioneuroblastoma; Recurrent Neuroblastoma,Biological:Dinutuximab; Drug:Irinotecan Hydrochloride; Other:Laboratory Biomarker Analysis; Biological:Sargramostim; Drug:Temozolomide; Drug:Temsirolimus,[],27-Oct-15,0,9999,Both,FALSE,9NCT01244191,Daiichi Sankyo Inc.,FALSE,NV,https://ClinicalTrials.gov/show/NCT01244191,FALSE,"ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer","Non Squamous, Non-small-cell Lung Cancer",Drug:Tivantinib (ARQ 197) plus erlotinib; Drug:ARQ 197 placebo plus erlotinib,[],22-Oct-15,18,9999,Both,FALSE,95NCT01195662,AstraZeneca,FALSE,NV,https://ClinicalTrials.gov/show/NCT01195662,FALSE,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication,Type 2 Diabetes,Drug:Dapagliflozin; Drug:Placebo matching Dapagliflozin,[],2-Dec-15,18,89,Both,FALSE,13NCT01137474,Bristol-Myers Squibb,FALSE,NV,https://ClinicalTrials.gov/show/NCT01137474,FALSE,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker,Type 2 Diabetes,Drug:Dapagliflozin; Drug:Placebo-matching dapagliflozin; Drug:Oral antidiabetic agent; Drug:Angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB); Drug:With or without insulin,[],1-Apr-14,18,89,Both,FALSE,80NCT00900250,Children's Oncology Group,FALSE,NV,https://ClinicalTrials.gov/show/NCT00900250,FALSE,Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma,Refractory Childhood Hodgkin Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Other:Cytology Specimen Collection Procedure,[],12-May-15,0,9999,Both,FALSE,17NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,NV,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT00839527,GlaxoSmithKline,FALSE,NV,https://ClinicalTrials.gov/show/NCT00839527,FALSE,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:placebo to match albiglutide; Biological:albiglutide; Drug:metformin; Drug:glimepiride; Drug:pioglitazone; Drug:placebo to match pioglitazone,[],29-May-14,18,9999,Both,FALSE,8NCT00838916,GlaxoSmithKline,FALSE,NV,https://ClinicalTrials.gov/show/NCT00838916,FALSE,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:insulin glargine,[],22-May-14,18,9999,Both,FALSE,8NCT00838903,GlaxoSmithKline,FALSE,NV,https://ClinicalTrials.gov/show/NCT00838903,FALSE,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:sitagliptin; Drug:glimepiride; Drug:metformin; Biological:placebo albiglutide; Drug:placebo sitagliptin; Drug:placebo glimepiride,[],11-Aug-14,18,9999,Both,FALSE,8NCT00683137,Pfizer,FALSE,NV,https://ClinicalTrials.gov/show/NCT00683137,FALSE,Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery,Pain; Hallux Valgus,Drug:valdecoxib; Drug:valdecoxib; Drug:valdecoxib/placebo,[],22-May-08,18,9999,Both,FALSE,10NCT00678392,Pfizer,FALSE,NV,https://ClinicalTrials.gov/show/NCT00678392,FALSE,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,Kidney Neoplasms,Drug:Axitinib (AG-013736); Drug:Sorafenib,[],10-Dec-15,18,9999,Both,FALSE,10NCT02515981,Dartmouth-Hitchcock Medical Center,FALSE,NH,https://ClinicalTrials.gov/show/NCT02515981,FALSE,New Hampshire Medicaid Wellness Incentive Program,Tobacco Dependence; Obesity; Mental Illness,Behavioral:NH Medicaid Incentives Program,"[u'New Hampshire Hospital', u'Riverbend Community Mental Health Center', u'Center for Life Management', u'Community Partners', u'Mondadnock Family Services', u'West Central Behavioral Health Care', u'Northern Human Services', u'The Mental Health Center of Greater Manchester', u'Greater Nashua Mental Health Center at Community Council', u'Harbor Homes', u'Genesis Behavioral Heatlh', u'Seacoast Mental Health Center']",21-Jan-16,18,9999,Both,FALSE,26NCT00769379,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT00079274,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT00068328,Alliance for Clinical Trials in Oncology,TRUE,NH,https://ClinicalTrials.gov/show/NCT00068328,FALSE,Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer,Breast Cancer; Psychosocial Effects of Cancer and Its Treatment,Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],23-Jul-15,65,9999,Female,FALSE,1NCT00785291,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00490139,GlaxoSmithKline,FALSE,NH,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,NH,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00041119,Alliance for Clinical Trials in Oncology,TRUE,NH,https://ClinicalTrials.gov/show/NCT00041119,FALSE,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],23-Jul-15,18,9999,Female,FALSE,1NCT01275677,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01041781,Alliance for Clinical Trials in Oncology,FALSE,NH,https://ClinicalTrials.gov/show/NCT01041781,FALSE,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01004640,Alliance for Clinical Trials in Oncology,FALSE,NH,https://ClinicalTrials.gov/show/NCT01004640,FALSE,Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial,Leukemia,Genetic:DNA analysis; Genetic:Southern blotting; Genetic:cytogenetic analysis; Genetic:polymerase chain reaction,[],23-Jul-15,0,9999,Both,FALSE,1NCT00892177,Alliance for Clinical Trials in Oncology,FALSE,NH,https://ClinicalTrials.gov/show/NCT00892177,FALSE,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],23-Nov-15,18,9999,Both,FALSE,1NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,NH,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT00861705,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT00861705,FALSE,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],28-Sep-15,18,9999,Both,FALSE,9NCT00770809,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT00770809,FALSE,Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,HER2/Neu Positive; Male Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Lapatinib Ditosylate; Biological:Trastuzumab; Drug:Paclitaxel; Other:Laboratory Biomarker Analysis,[],7-May-15,18,9999,Both,FALSE,9NCT00655876,Radiation Therapy Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT00655876,FALSE,"Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer",Esophageal Cancer,Biological:cetuximab; Drug:cisplatin; Drug:paclitaxel; Radiation:radiation therapy,[],31-Mar-15,18,74,Both,FALSE,4NCT00601900,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT00601900,FALSE,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],23-Apr-15,18,9999,Female,FALSE,9NCT00489411,Alliance for Clinical Trials in Oncology,TRUE,NH,https://ClinicalTrials.gov/show/NCT00489411,FALSE,Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer,"Neurotoxicity; Pain; Peripheral Neuropathy; Unspecified Adult Solid Tumor, Protocol Specific",Drug:duloxetine hydrochloride; Other:placebo,[],6-Jul-15,25,9999,Both,FALSE,1NCT00433511,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00382070,NSABP Foundation Inc,TRUE,NH,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00316836,Alliance for Clinical Trials in Oncology,FALSE,NH,https://ClinicalTrials.gov/show/NCT00316836,FALSE,"Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole",Breast Cancer,Procedure:mammography,[],13-Jul-15,18,9999,Female,FALSE,1NCT00288080,Radiation Therapy Oncology Group,TRUE,NH,https://ClinicalTrials.gov/show/NCT00288080,FALSE,Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:docetaxel; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:prednisone; Drug:triptorelin; Radiation:radiation therapy,[],20-Mar-15,18,9999,Male,FALSE,4NCT00053898,NSABP Foundation Inc,TRUE,NH,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT01547741,NSABP Foundation Inc,FALSE,NH,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01101438,NCIC Clinical Trials Group,TRUE,NH,https://ClinicalTrials.gov/show/NCT01101438,FALSE,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,Breast Cancer,Drug:metformin hydrochloride; Other:placebo,[],5-May-15,18,74,Both,FALSE,11NCT01099449,Alliance for Clinical Trials in Oncology,FALSE,NH,https://ClinicalTrials.gov/show/NCT01099449,FALSE,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],4-Jul-15,18,9999,Both,FALSE,1NCT00942331,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00899223,Alliance for Clinical Trials in Oncology,TRUE,NH,https://ClinicalTrials.gov/show/NCT00899223,FALSE,"Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes",Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms,Other:biologic sample preservation procedure,[],11-Jul-13,0,9999,Both,FALSE,1NCT00602459,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT00602459,FALSE,Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,[],22-Apr-15,18,9999,Both,FALSE,9NCT00573287,Dartmouth-Hitchcock Medical Center,FALSE,NH,https://ClinicalTrials.gov/show/NCT00573287,FALSE,First Episode Schizophrenia and Cannabis-Related Disorder Study,Cannabis-Related Disorder; Substance-Related Disorders; Schizophrenia; Psychotic Disorders,Drug:clozapine; Drug:risperidone,"[u'New Hampshire Hospital', u'Dartmouth Hitchcock Medical Center', u'West Central Behavioral Health', u'Mental Health Center of Greater Manchester', u'Center for Psychiatric Advancement & Community Council of Nashua']",1-Mar-13,17,45,Both,FALSE,26NCT00417040,Alliance for Clinical Trials in Oncology,FALSE,NH,https://ClinicalTrials.gov/show/NCT00417040,FALSE,Using the Internet to Collect Symptoms and the Ability to Carry Out Daily Activities From Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy,Prostate Cancer,Other:internet-based intervention; Procedure:assessment of therapy complications; Other:Questionnaire Administration,[],23-Jul-15,18,9999,Male,FALSE,1NCT00217737,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00117975,Alliance for Clinical Trials in Oncology,TRUE,NH,https://ClinicalTrials.gov/show/NCT00117975,FALSE,"Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",Lymphoma,Biological:galiximab; Biological:rituximab,[],23-Jun-15,18,9999,Both,FALSE,1NCT00103181,NSABP Foundation Inc,TRUE,NH,https://ClinicalTrials.gov/show/NCT00103181,FALSE,Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer,Breast Cancer,Radiation:3-dimensional conformal accelerated partial breast irradiation; Radiation:brachytherapy; Radiation:whole breast irradiation; Radiation:MammoSite or other single-entry intracavitary device,[],8-Oct-15,18,9999,Female,FALSE,2NCT00079001,Alliance for Clinical Trials in Oncology,TRUE,NH,https://ClinicalTrials.gov/show/NCT00079001,FALSE,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer; Prostate Cancer,Drug:zoledronic acid; Other:placebo; Drug:androgen deprivation therapy; Drug:GnRH agonist; Dietary Supplement:Calcium supplement; Dietary Supplement:Vitamin D,[],23-Nov-15,18,9999,Male,FALSE,1NCT00075764,Southwest Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT00075764,FALSE,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:fulvestrant,[],8-May-14,18,9999,Female,FALSE,3NCT00066690,International Breast Cancer Study Group,TRUE,NH,https://ClinicalTrials.gov/show/NCT00066690,FALSE,Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer,Breast Cancer,Drug:exemestane; Drug:tamoxifen citrate; Drug:triptorelin; Procedure:oophorectomy; Radiation:radiation therapy,[],6-Nov-13,0,9999,Female,FALSE,30NCT00008385,Eastern Cooperative Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT00008385,FALSE,Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer,Lung Cancer,Dietary Supplement:selenium; Other:placebo,[],15-May-15,18,9999,Both,FALSE,17NCT00004124,Southwest Oncology Group,TRUE,NH,https://ClinicalTrials.gov/show/NCT00004124,FALSE,"S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer",Prostate Cancer,Drug:bicalutamide; Drug:goserelin; Drug:mitoxantrone hydrochloride; Drug:prednisone,[],3-Oct-12,18,9999,Male,FALSE,3NCT00003389,Eastern Cooperative Oncology Group,TRUE,NH,https://ClinicalTrials.gov/show/NCT00003389,FALSE,Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma,Lymphoma,Drug:Doxorubicin; Drug:Bleomycin; Drug:Vinblastine; Drug:Dacarbazine; Drug:Vincristine; Drug:Mechlorethamine; Drug:Etoposide; Drug:Prednisone; Drug:Cyclophosphamide; Radiation:Radiotherapy,[],25-Sep-15,16,9999,Both,FALSE,17NCT02334280,Dartmouth-Hitchcock Medical Center,FALSE,NH,https://ClinicalTrials.gov/show/NCT02334280,FALSE,Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI,Schizophrenia; Bipolar Disorder; Schizoaffective Disorder,Behavioral:In SHAPE,"[u'West Central Behavioral Health', u'Mental Health Center of Greater Manchester', u'Greater Nashua Mental Health Center at Community Council', u'Center for Life Management']",7-Jan-15,21,9999,Both,FALSE,26NCT01835158,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01648348,National Cancer Institute (NCI),FALSE,NH,https://ClinicalTrials.gov/show/NCT01648348,FALSE,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01546987,Radiation Therapy Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT01546987,FALSE,"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer",Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:orteronel; Drug:triptorelin,[],14-Nov-15,18,9999,Male,FALSE,4NCT01302834,Radiation Therapy Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT01302834,FALSE,Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer,Head and Neck Cancer; Precancerous Condition,Biological:cetuximab; Drug:cisplatin,[],14-Nov-15,18,120,Both,FALSE,4NCT01262560,Radiation Therapy Oncology Group,FALSE,NH,https://ClinicalTrials.gov/show/NCT01262560,FALSE,Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer,Dysphagia; Lung Cancer; Pain; Esophagitis,Drug:Manuka honey; Drug:Viscous lidocaine and magnesium aluminum oxide (Maalox); Liquid or solid oxycodone,[],17-Mar-15,18,9999,Both,FALSE,4NCT01245621,Dartmouth-Hitchcock Medical Center,TRUE,NH,https://ClinicalTrials.gov/show/NCT01245621,FALSE,Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III),Advanced Cancer,Behavioral:Later entry group; Behavioral:Early palliative care intervention,"[u'Dartmouth-Hitchcock Medical Center - Lebanon', u'Dartmouth-Hitchcock Clinic - Manchester', u'St. Joseph Hospital', u'Dartmouth-Hitchcock NCCC Nashua', u'Providence VA Medical Center', u'Mountainview Medical', u""Veteran's Administration Hospital""]",2-Jan-14,18,9999,Both,FALSE,26NCT00769379,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00658515,Hoffmann-La Roche,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00640042,Pfizer,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00640042,FALSE,"Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",Pain,Drug:morphine sulfate extended release capsules,[],6-Jun-12,21,9999,Both,FALSE,10NCT00433511,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00382070,NSABP Foundation Inc,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00373685,Pfizer,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00324805,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00264901,Novo Nordisk A/S,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00217737,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00079274,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT00053898,NSABP Foundation Inc,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT00034879,AstraZeneca,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT01275677,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00878709,"Puma Biotechnology, Inc.",FALSE,NJ,https://ClinicalTrials.gov/show/NCT00878709,FALSE,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Breast Cancer,Drug:neratinib; Other:placebo,[],20-Aug-15,18,9999,Female,FALSE,166NCT00346216,Pfizer,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT01732822,AstraZeneca,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01732822,FALSE,A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease,Peripheral Artery Disease,Drug:Ticagrelor; Drug:Clopidogrel,[],21-Dec-15,50,130,Both,FALSE,13NCT00003906,NSABP Foundation Inc,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00003906,FALSE,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],5-Oct-15,35,9999,Female,FALSE,2NCT00501059,Bayer,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00501059,FALSE,A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease,Moderate Risk of CVD,"Drug:Aspirin (Acetylsalicylic acid, BAYE4465); Drug:Placebo",[],14-Dec-15,55,9999,Both,FALSE,23NCT00326898,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00490139,GlaxoSmithKline,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT00005044,Radiation Therapy Oncology Group,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00005044,FALSE,Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:flutamide; Drug:releasing hormone agonist therapy; Procedure:neoadjuvant therapy; Radiation:radiation therapy,[],14-Nov-15,18,120,Male,FALSE,4NCT00003162,Radiation Therapy Oncology Group,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00003162,FALSE,Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer,Breast Cancer; Metastatic Cancer; Pain; Prostate Cancer,Procedure:pain therapy; Radiation:radiation therapy,[],14-Nov-15,18,9999,Both,FALSE,4NCT00002874,Radiation Therapy Oncology Group,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00002874,FALSE,"Radiation Therapy With or Without Bicalutamide in Treating Patients With Stage II, Stage III, or Recurrent Prostate Cancer",Prostate Cancer,Drug:bicalutamide; Radiation:low-LET cobalt-60 gamma ray therapy; Radiation:low-LET photon therapy,[],26-Mar-15,0,9999,Male,FALSE,4NCT00245739,"Tibotec Pharmaceuticals, Ireland",FALSE,NJ,https://ClinicalTrials.gov/show/NCT00245739,FALSE,"TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.",HIV Infections,Drug:TMC-114,[],10-Apr-14,18,9999,Both,FALSE,191NCT00003313,Radiation Therapy Oncology Group,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00003313,FALSE,Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer,Drug/Agent Toxicity by Tissue/Organ; Lung Cancer; Oral Complications; Radiation Toxicity,Biological:filgrastim; Drug:amifostine trihydrate; Drug:carboplatin; Drug:paclitaxel; Radiation:radiation therapy,[],19-Nov-14,18,9999,Both,FALSE,4NCT00781391,Daiichi Sankyo Inc.,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00781391,FALSE,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke; Atrial Fibrillation; Embolism,Drug:warfarin tablets; Drug:Edoxaban tablets (high dose regimen-60mg); Drug:Edoxaban tablets (low dose regimen-30mg); Drug:placebo warfarin; Drug:placebo edoxaban,[],12-Mar-15,21,9999,Both,FALSE,95NCT00549796,Johns Hopkins University,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00549796,FALSE,Randomized Comparison Angioplasty Outcomes at Hospitals With and Without On-site Cardiac Surgery,Coronary Arteriosclerosis; Angina Pectoris,Other:Percutaneous coronary intervention (PCI),[],10-Sep-14,18,9999,Both,FALSE,135NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00262847,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT00262847,FALSE,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],18-Aug-15,18,9999,Female,FALSE,9NCT00004917,Radiation Therapy Oncology Group,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00004917,FALSE,Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer,Anemia; Head and Neck Cancer,Biological:epoetin alfa; Drug:cisplatin; Radiation:radiation therapy,[],14-Nov-15,18,9999,Both,FALSE,4NCT00004011,Southwest Oncology Group,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00004011,FALSE,S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:paclitaxel; Procedure:conventional surgery,[],30-Jan-13,18,9999,Both,FALSE,3NCT00003930,Radiation Therapy Oncology Group,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00003930,FALSE,Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer,Bladder Cancer,Drug:cisplatin; Drug:gemcitabine hydrochloride; Drug:paclitaxel; Procedure:conventional surgery; Radiation:radiation therapy,[],13-Oct-15,18,9999,Both,FALSE,4NCT00002597,Radiation Therapy Oncology Group,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00002597,FALSE,Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer,Prostate Cancer,Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Radiation:radiation therapy,[],14-Nov-15,0,9999,Male,FALSE,4NCT01547741,NSABP Foundation Inc,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01070836,Biogen,FALSE,NJ,https://ClinicalTrials.gov/show/NCT01070836,FALSE,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],14-Jan-16,0,9999,Both,FALSE,73NCT01011478,NSABP Foundation Inc,TRUE,NJ,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT00942357,Gynecologic Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00303628,National Cancer Institute (NCI),FALSE,NJ,https://ClinicalTrials.gov/show/NCT00303628,FALSE,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],20-May-14,18,9999,Both,FALSE,9NCT00257608,"Genentech, Inc.",FALSE,NJ,https://ClinicalTrials.gov/show/NCT00257608,FALSE,A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS),Non-Small Cell Lung Cancer,Drug:bevacizumab; Drug:placebo; Drug:erlotinib HCl,[],30-Sep-15,18,9999,Both,FALSE,113NCT00118131,University of Medicine and Dentistry of New Jersey,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00118131,FALSE,Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Drug:cisplatin; Drug:docetaxel,"[u'Central Jersey Oncology Center, PA - East Brunswick', u'JFK Medical Center in Edison', u'CentraState Medical Center', u'Cancer Institute of New Jersey at Hamilton', u'Monmouth Medical Center', u'Mountainside Hospital Cancer Center', u'Jersey Shore University Medical Center', u'Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School', u""Saint Peter's University Hospital"", u'UMDNJ - University Hospital', u'Raritan Bay Medical Center', u'Somerset Medical Center', u'Overlook Hospital']",19-Sep-13,18,9999,Both,FALSE,205NCT00053053,Radiation Therapy Oncology Group,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00053053,FALSE,Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer,"Cachexia; Lymphoma; Lymphoproliferative Disorder; Unspecified Adult Solid Tumor, Protocol Specific",Dietary Supplement:Juven; Dietary Supplement:Non-Juven Supplement,[],8-Oct-13,17,9999,Both,FALSE,4NCT00047125,European Organisation for Research and Treatment of Cancer - EORTC,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00047125,FALSE,Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor,Carcinoma of Unknown Primary,Radiation:radiation therapy,[],19-Jun-12,18,9999,Female,FALSE,106NCT00031967,Radiation Therapy Oncology Group,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00031967,FALSE,Melatonin and Radiation Therapy in Treating Patients With Brain Metastases,"Metastatic Cancer; Radiation Toxicity; Unspecified Adult Solid Tumor, Protocol Specific",Drug:therapeutic melatonin; Radiation:radiation therapy,[],18-Nov-13,0,9999,Both,FALSE,4NCT00023738,Radiation Therapy Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00023738,FALSE,"Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma",Sarcoma,Biological:filgrastim; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:ifosfamide; Drug:semaxanib; Procedure:conventional surgery; Radiation:radiation therapy,[],20-Jun-13,18,9999,Both,FALSE,4NCT00023725,Radiation Therapy Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00023725,FALSE,Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma,Sarcoma,Drug:semaxanib; Procedure:conventional surgery; Radiation:radiation therapy,[],20-Jun-13,18,9999,Both,FALSE,4NCT00017160,Radiation Therapy Oncology Group,FALSE,NJ,https://ClinicalTrials.gov/show/NCT00017160,FALSE,"Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma",Stage III Adult Soft Tissue Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage IVA Adult Soft Tissue Sarcoma; Stage IIB Adult Soft Tissue Sarcoma; Stage IIC Adult Soft Tissue Sarcoma,Drug:doxorubicin; Drug:filgrastim; Drug:ifosfamide; Procedure:biological response modifier therapy; Procedure:brachytherapy; Procedure:chemotherapy; Procedure:colony-stimulating factor therapy; Procedure:conventional surgery; Procedure:cytokine therapy; Procedure:intraoperative radiotherapy; Procedure:radiation therapy; Procedure:surgery,[],25-Jun-13,0,9999,Both,FALSE,4NCT00011999,Radiation Therapy Oncology Group,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00011999,FALSE,Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer,Head and Neck Cancer,Drug:cisplatin; Drug:paclitaxel; Procedure:conventional surgery; Radiation:radiation therapy,[],14-Nov-15,21,9999,Both,FALSE,4NCT00008398,Radiation Therapy Oncology Group,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00008398,FALSE,Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer,Head and Neck Cancer; Oral Complications; Radiation Toxicity,Biological:sargramostim; Procedure:quality-of-life assessment; Radiation:radiation therapy,[],18-Nov-13,0,9999,Both,FALSE,4NCT00006481,Radiation Therapy Oncology Group,TRUE,NJ,https://ClinicalTrials.gov/show/NCT00006481,FALSE,Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer,Head and Neck Cancer; Skin Reactions Secondary to Radiation Therapy,Drug:Biafine cream; Procedure:quality-of-life assessment; Radiation:radiation therapy,[],18-Nov-13,0,9999,Both,FALSE,4NCT00264901,Novo Nordisk A/S,FALSE,NM,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00079274,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,NM,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01374425,"Genentech, Inc.",FALSE,NM,https://ClinicalTrials.gov/show/NCT01374425,FALSE,Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer,Colorectal Cancer,Drug:5-fluorouracil; Drug:Bevacizumab; Drug:Irinotecan; Drug:Leucovorin; Drug:Oxaliplatin,[],8-Jan-16,18,9999,Both,FALSE,113NCT00433511,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00075764,Southwest Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT00075764,FALSE,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:fulvestrant,[],8-May-14,18,9999,Female,FALSE,3NCT01515800,Southwest Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT01515800,FALSE,S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer,Breast Cancer,Behavioral:Text message reminder,[],23-Oct-15,18,120,Female,FALSE,3NCT01275677,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00871169,New Mexico Cancer Care Alliance,FALSE,NM,https://ClinicalTrials.gov/show/NCT00871169,FALSE,"Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer",Pancreatic Cancer,"Drug:Irinotecan, oxaliplatin, and cetuximab","[u'University of New Mexico Cancer Center @ Lovelace Medical Center', u'Hematology Oncology Associates', u'Cancer Center at Presbyterian Hospital', u'University of New Mexico Cancer Center', u'Memorial Medical Center- Cancer Center']",15-Jan-16,18,9999,Both,FALSE,153NCT00659269,New Mexico Cancer Care Alliance,FALSE,NM,https://ClinicalTrials.gov/show/NCT00659269,FALSE,A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients,Cancer,Dietary Supplement:Multivitamin (MV); Dietary Supplement:Multivitamin + Vitamin B12 + Vitamin B6; Drug:Chemotherapy,"[u'University of New Mexico Cancer Center @ Lovelace Medical Center', u'Hematology Oncology Associates', u'Cancer Center at Presbyterian Hospital', u'University of New Mexico Cancer Center', u'New Mexico Cancer Care Associates']",16-Dec-15,18,9999,Both,FALSE,153NCT00391586,New Mexico Cancer Care Alliance,FALSE,NM,https://ClinicalTrials.gov/show/NCT00391586,FALSE,"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung","Carcinoma, Non-Small-Cell Lung",Drug:Erlotinib; Drug:Platinum-based chemotherapy,"[u'Lovelace Medical Group', u'Hematology Oncology Associates NM', u'Presbyterian Medical Group', u'University of New Mexico Cancer Center', u'New Mexico Cancer Care Associates']",14-Aug-15,18,80,Both,FALSE,153NCT00382018,Southwest Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT00382018,FALSE,S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy,Breast Cancer,Drug:chemotherapy,[],15-Sep-15,18,9999,Female,FALSE,3NCT00326898,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00288080,Radiation Therapy Oncology Group,TRUE,NM,https://ClinicalTrials.gov/show/NCT00288080,FALSE,Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:docetaxel; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:prednisone; Drug:triptorelin; Radiation:radiation therapy,[],20-Mar-15,18,9999,Male,FALSE,4NCT00072046,Alliance for Clinical Trials in Oncology,TRUE,NM,https://ClinicalTrials.gov/show/NCT00072046,FALSE,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],23-Jun-15,18,9999,Both,FALSE,1NCT00069745,Agennix,FALSE,NM,https://ClinicalTrials.gov/show/NCT00069745,FALSE,Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen,Prostate Cancer; Hormone Refractory Prostate Cancer,Drug:Satraplatin; Drug:Prednisone,[],1-Aug-12,18,9999,Male,FALSE,57NCT00053898,NSABP Foundation Inc,TRUE,NM,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT00034879,AstraZeneca,FALSE,NM,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT00003906,NSABP Foundation Inc,TRUE,NM,https://ClinicalTrials.gov/show/NCT00003906,FALSE,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],5-Oct-15,35,9999,Female,FALSE,2NCT02224781,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT02224781,FALSE,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01376349,Alliance for Clinical Trials in Oncology,FALSE,NM,https://ClinicalTrials.gov/show/NCT01376349,FALSE,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],24-Sep-15,18,9999,Female,FALSE,1NCT01357291,Pepperdine University,FALSE,NM,https://ClinicalTrials.gov/show/NCT01357291,FALSE,Evaluating New Mexico's Recidivism Reduction Program,Behavior,Behavioral:Recidivism Reduction Program; Behavioral:Business-as-usual,"[u'Western New Mexico Correctional Facility (WNMCF)', u'Central New Mexico Correctional Facility (CNMCF)', u'Penitentiary of New Mexico (PNM)', u'Springer Correctional Facility (SCF)']",19-May-11,18,9999,Male,FALSE,164NCT01169922,University of New Mexico,FALSE,NM,https://ClinicalTrials.gov/show/NCT01169922,FALSE,HIV Prevention With Adolescents: Neurocognitive Deficits and Treatment Response,Risk Reduction Behavior; Sexual Behavior; Health Behavior; Drinking Behavior; Adolescent Behavior,Behavioral:SEXUAL RISK REDUCTION + ALCOHOL RISK REDUCTION; Behavioral:INFORMATION-ONLY SEXUAL RISK REDUCTION,"[u'Diversion Meetings (Youth Services Center)', u'Youth Reporting Center (Youth Services Center)', u'Albuquerque Academy', u'Sandia Preparatory School']",5-Aug-11,14,18,Both,TRUE,207NCT01086605,Alliance for Clinical Trials in Oncology,FALSE,NM,https://ClinicalTrials.gov/show/NCT01086605,FALSE,Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer,Breast Cancer,Drug:pixantrone dimaleate,[],4-Aug-15,18,9999,Both,FALSE,1NCT01012297,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT01012297,FALSE,Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma,Recurrent Uterine Corpus Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Biological:Bevacizumab; Drug:Docetaxel; Biological:Filgrastim; Drug:Gemcitabine Hydrochloride; Biological:Pegfilgrastim; Other:Placebo,[],11-Nov-15,18,9999,Female,FALSE,9NCT00775645,Southwest Oncology Group,TRUE,NM,https://ClinicalTrials.gov/show/NCT00775645,FALSE,"S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy",Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity,Dietary Supplement:acetyl-L-carnitine hydrochloride; Other:placebo,[],13-Jan-14,18,9999,Female,FALSE,3NCT00741429,Mannkind Corporation,FALSE,NM,https://ClinicalTrials.gov/show/NCT00741429,FALSE,A 2-Month Safety Follow-Up Trial,Type 1 Diabetes; Type 2 Diabetes,Drug:Technosphere Insulin Inhalation Powder; Drug:Comparator,[],1-Dec-14,18,70,Both,FALSE,138NCT00644228,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT00644228,FALSE,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],12-Sep-14,18,9999,Both,FALSE,9NCT00637247,AmpliMed Corporation,TRUE,NM,https://ClinicalTrials.gov/show/NCT00637247,FALSE,A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer,Pancreatic Neoplasms,Drug:imexon in combination with gemcitabine; Drug:imexon placebo + gemcitabine,[],30-Nov-10,18,9999,Both,FALSE,21NCT00588770,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT00382070,NSABP Foundation Inc,TRUE,NM,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00337129,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT00337129,FALSE,S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer,Head and Neck Cancer,Drug:eribulin mesylate,[],11-Aug-15,18,9999,Both,FALSE,9NCT00331760,Radiation Therapy Oncology Group,TRUE,NM,https://ClinicalTrials.gov/show/NCT00331760,FALSE,Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery,Cervical Cancer; Endometrial Cancer,Drug:cisplatin; Radiation:intensity-modulated radiation therapy,[],13-Oct-15,18,9999,Female,FALSE,4NCT00303628,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT00303628,FALSE,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],20-May-14,18,9999,Both,FALSE,9NCT00276055,New Mexico Cancer Care Alliance,FALSE,NM,https://ClinicalTrials.gov/show/NCT00276055,FALSE,"Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma",Sarcoma,"Drug:Gemcitabine, Docetaxel and Bevacizumab","[u'Hematology Oncology Associates', u'University of New Mexico', u'St. Vincent Regional Medical Center', u'New Mexico Cancer Care Associates']",17-Jun-15,18,9999,Both,FALSE,153NCT00263588,GlaxoSmithKline,TRUE,NM,https://ClinicalTrials.gov/show/NCT00263588,FALSE,Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer,"Neoplasms, Breast",Drug:lapatinib,[],28-Jan-16,18,9999,Both,FALSE,8NCT00250822,New Mexico Cancer Care Alliance,FALSE,NM,https://ClinicalTrials.gov/show/NCT00250822,FALSE,"Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter",Liver Cancer,Drug:Gemcitabine and Oxaliplatin,"[u'Hematology Oncology Associates', u'Lovelace Sandia Health Systems Dept of Hematology', u'University of New Mexico', u'St. Vincent Regional Medical Center']",23-Sep-11,18,9999,Both,FALSE,153NCT00250029,New Mexico Cancer Care Alliance,FALSE,NM,https://ClinicalTrials.gov/show/NCT00250029,FALSE,Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen,Colonic Diseases; Cancer,Drug:Oxaliplatin,"[u'Hematology Oncology Associates', u'Lovelace Sandia Health Systems Dept of Hematology', u'University of New Mexico Cancer Center', u'New Mexico Veterans Administration Health Care System']",23-Sep-11,18,9999,Both,FALSE,153NCT00127933,Hoffmann-La Roche,FALSE,NM,https://ClinicalTrials.gov/show/NCT00127933,FALSE,XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer,Breast Cancer,Drug:capecitabine [Xeloda]; Drug:Taxotere; Drug:Herceptin (HER2-neu positive patients only); Drug:capecitabine [Xeloda]; Drug:Taxotere,[],13-Jul-11,18,9999,Female,FALSE,119NCT00108745,Gynecologic Oncology Group,FALSE,NM,https://ClinicalTrials.gov/show/NCT00108745,FALSE,Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer,Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Drug:Paclitaxel Poliglumex; Other:Clinical Observation; Drug:Paclitaxel,[],23-Dec-14,0,9999,Female,FALSE,14NCT00087178,NSABP Foundation Inc,FALSE,NM,https://ClinicalTrials.gov/show/NCT00087178,FALSE,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],5-Oct-15,18,9999,Female,FALSE,2NCT00070564,Southwest Oncology Group,TRUE,NM,https://ClinicalTrials.gov/show/NCT00070564,FALSE,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",Breast Cancer,Biological:pegfilgrastim; Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],15-Sep-15,18,9999,Both,FALSE,3NCT00041067,Southwest Oncology Group,TRUE,NM,https://ClinicalTrials.gov/show/NCT00041067,FALSE,"S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer",Breast Cancer,Biological:filgrastim; Biological:trastuzumab; Drug:docetaxel; Drug:vinorelbine,[],20-May-13,18,9999,Female,FALSE,3NCT01942668,TherapeuticsMD,FALSE,NM,https://ClinicalTrials.gov/show/NCT01942668,FALSE,A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms,Menopause,Drug:Estradiol; Drug:Progesterone; Drug:Placebo,[],13-Oct-15,40,65,Female,FALSE,190NCT01886872,National Cancer Institute (NCI),FALSE,NM,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01666444,VentiRx Pharmaceuticals Inc.,FALSE,NM,https://ClinicalTrials.gov/show/NCT01666444,FALSE,"VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer,Drug:pegylated liposomal doxorubicin (PLD); Drug:VTX-2337; Drug:Placebo,[],5-Jan-16,18,9999,Female,FALSE,217NCT01835158,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,NY,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01349322,Radiation Therapy Oncology Group,FALSE,NY,https://ClinicalTrials.gov/show/NCT01349322,FALSE,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],14-Nov-15,18,9999,Female,FALSE,4NCT01313676,GlaxoSmithKline,FALSE,NY,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT01275677,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01101438,NCIC Clinical Trials Group,TRUE,NY,https://ClinicalTrials.gov/show/NCT01101438,FALSE,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,Breast Cancer,Drug:metformin hydrochloride; Other:placebo,[],5-May-15,18,74,Both,FALSE,11NCT01070836,Biogen,FALSE,NY,https://ClinicalTrials.gov/show/NCT01070836,FALSE,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],14-Jan-16,0,9999,Both,FALSE,73NCT01015833,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00942357,Gynecologic Oncology Group,FALSE,NY,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00942331,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00658515,Hoffmann-La Roche,FALSE,NY,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00490139,GlaxoSmithKline,FALSE,NY,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT00454701,Astellas Pharma Inc,FALSE,NY,https://ClinicalTrials.gov/show/NCT00454701,FALSE,Assessment and Tracking of Long-term Alefacept Safety,Psoriasis,Drug:Alefacept exposure,[],10-Dec-13,18,9999,Both,FALSE,68NCT00433511,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00426660,ViiV Healthcare,FALSE,NY,https://ClinicalTrials.gov/show/NCT00426660,FALSE,Expanded Access Program for Maraviroc At Multiple Centers,Advanced HIV Infection,Drug:maraviroc,[],12-Sep-11,16,9999,Both,FALSE,219NCT00382070,NSABP Foundation Inc,TRUE,NY,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00373685,Pfizer,FALSE,NY,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00346216,Pfizer,FALSE,NY,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00326898,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00264901,Novo Nordisk A/S,FALSE,NY,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00262600,Boehringer Ingelheim,FALSE,NY,https://ClinicalTrials.gov/show/NCT00262600,FALSE,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation; Stroke,Drug:warfarin; Drug:Dabigatran dose 1; Drug:Dabigatran dose 2,[],5-Nov-14,18,9999,Both,FALSE,75NCT00239681,AstraZeneca,FALSE,NY,https://ClinicalTrials.gov/show/NCT00239681,FALSE,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],6-Feb-14,50,9999,Both,FALSE,13NCT00217737,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00111020,Bayer,FALSE,NY,https://ClinicalTrials.gov/show/NCT00111020,FALSE,Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma,"Carcinoma, Renal Cell","Drug:Sorafenib (Nexavar, BAY43-9006)",[],5-Aug-14,15,9999,Both,FALSE,23NCT00079274,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT00053898,NSABP Foundation Inc,TRUE,NY,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT00034879,AstraZeneca,FALSE,NY,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT00003906,NSABP Foundation Inc,TRUE,NY,https://ClinicalTrials.gov/show/NCT00003906,FALSE,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],5-Oct-15,35,9999,Female,FALSE,2NCT00002378,Hoffmann-La Roche,FALSE,NY,https://ClinicalTrials.gov/show/NCT00002378,FALSE,A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients,HIV Infections,Drug:Ritonavir; Drug:Nelfinavir mesylate; Drug:Saquinavir; Drug:Delavirdine mesylate; Drug:Lamivudine; Drug:Stavudine; Drug:Zidovudine,[],23-Jun-05,16,9999,Both,FALSE,119NCT00000814,National Institute of Allergy and Infectious Diseases (NIAID),TRUE,NY,https://ClinicalTrials.gov/show/NCT00000814,FALSE,A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease,HIV Infections,Drug:Nevirapine; Drug:Zidovudine; Drug:Didanosine,[],30-Mar-12,6,20,Both,FALSE,7NCT00000781,National Institute of Allergy and Infectious Diseases (NIAID),TRUE,NY,https://ClinicalTrials.gov/show/NCT00000781,FALSE,"A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)",HIV Infections,Drug:Nevirapine; Drug:Zidovudine; Drug:Zalcitabine; Drug:Didanosine,[],30-Mar-12,13,9999,Both,FALSE,7NCT00000638,National Institute of Allergy and Infectious Diseases (NIAID),TRUE,NY,https://ClinicalTrials.gov/show/NCT00000638,FALSE,Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection,HIV Infections; Tuberculosis,Drug:Isoniazid; Drug:Pyrazinamide; Drug:Pyridoxine hydrochloride; Drug:Rifampin,[],29-Mar-12,13,9999,Both,FALSE,7NCT00000637,National Institute of Allergy and Infectious Diseases (NIAID),TRUE,NY,https://ClinicalTrials.gov/show/NCT00000637,FALSE,"A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children",HIV Infections,Drug:Zidovudine; Drug:Didanosine,[],29-Mar-12,3,17,Both,FALSE,7NCT00000811,National Institute of Allergy and Infectious Diseases (NIAID),TRUE,NY,https://ClinicalTrials.gov/show/NCT00000811,FALSE,A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children,"Bacterial Infections; Pneumonia, Pneumocystis Carinii; HIV Infections",Drug:Azithromycin; Drug:Atovaquone; Drug:Sulfamethoxazole-Trimethoprim,[],2-Apr-12,3,18,Both,FALSE,7NCT00000796,National Institute of Allergy and Infectious Diseases (NIAID),TRUE,NY,https://ClinicalTrials.gov/show/NCT00000796,FALSE,A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.,HIV Infections; Tuberculosis,Drug:Cycloserine; Drug:Ethionamide; Drug:Capreomycin sulfate; Drug:Aminosalicylic acid; Drug:Streptomycin sulfate; Drug:Ethambutol hydrochloride; Drug:Amikacin sulfate; Drug:Isoniazid; Drug:Pyrazinamide; Drug:Pyridoxine hydrochloride; Drug:Levofloxacin; Drug:Rifampin; Drug:Clofazimine,"[u'Cook County Hosp', u'Henry Ford Hosp', u'Samaritan Village Inc / Bronx Municipal Hosp', u'Bronx Municipal Hosp Ctr/Jacobi Med Ctr', u'Comprehensive Health Care Ctr / Bronx Municipal Hosp', u'Montefiore Drug Treatment Ctr / Bronx Municipal Hosp', u'Montefiore Family Health Ctr / Bronx Municipal Hosp', u'Bronx Lebanon Hosp Ctr', u'Jack Weiler Hosp / Bronx Municipal Hosp', u'Montefiore Med Ctr / Bronx Municipal Hosp', u'North Central Bronx Hosp / Bronx Municipal Hosp', u'Interfaith Med Ctr', u'SUNY / Health Sciences Ctr at Brooklyn', u'Beth Israel Med Ctr', u'Harlem AIDS Treatment Group / Harlem Hosp Ctr', u'Bellevue Hosp / New York Univ Med Ctr', u""Saint Clare's Hosp and Health Ctr"", u'Cornell Univ Med Ctr', u'Mount Sinai Med Ctr', u'Columbia Presbyterian Med Ctr', u'Clinical Directors Network of Region II']",30-Mar-12,13,9999,Both,FALSE,7NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,NY,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT00803062,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT00803062,FALSE,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],22-May-15,18,9999,Female,FALSE,9NCT00557921,Cogentus Pharmaceuticals,FALSE,NY,https://ClinicalTrials.gov/show/NCT00557921,FALSE,Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1),Acute Coronary Syndrome; Myocardial Infarction; Coronary Artery Disease; Percutaneous Coronary Intervention,Drug:CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin; Drug:Plavix (clopidogrel 75 mg) and aspirin,[],27-Jan-09,21,9999,Both,FALSE,89NCT00303628,National Cancer Institute (NCI),FALSE,NY,https://ClinicalTrials.gov/show/NCT00303628,FALSE,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],20-May-14,18,9999,Both,FALSE,9NCT00103181,NSABP Foundation Inc,TRUE,NY,https://ClinicalTrials.gov/show/NCT00103181,FALSE,Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer,Breast Cancer,Radiation:3-dimensional conformal accelerated partial breast irradiation; Radiation:brachytherapy; Radiation:whole breast irradiation; Radiation:MammoSite or other single-entry intracavitary device,[],8-Oct-15,18,9999,Female,FALSE,2NCT00001083,National Institute of Allergy and Infectious Diseases (NIAID),TRUE,NY,https://ClinicalTrials.gov/show/NCT00001083,FALSE,Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs,HIV Infections,Drug:Indinavir sulfate; Drug:Ritonavir; Drug:Nevirapine; Drug:Lamivudine; Drug:Stavudine; Drug:Zidovudine,[],14-Feb-12,2,17,Both,FALSE,7NCT00001066,National Institute of Allergy and Infectious Diseases (NIAID),TRUE,NY,https://ClinicalTrials.gov/show/NCT00001066,FALSE,A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children,HIV Infections,Drug:Lamivudine; Drug:Zidovudine; Drug:Didanosine,[],1-Mar-11,3,15,Both,FALSE,7NCT00000841,National Institute of Allergy and Infectious Diseases (NIAID),TRUE,NY,https://ClinicalTrials.gov/show/NCT00000841,FALSE,A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months,HIV Infections,Drug:Indinavir sulfate; Drug:Lamivudine; Drug:Stavudine; Drug:Zidovudine,[],26-Jul-13,18,9999,Both,FALSE,7NCT01764633,Amgen,FALSE,NY,https://ClinicalTrials.gov/show/NCT01764633,FALSE,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],20-Jan-16,40,85,Both,FALSE,16NCT02465060,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,NC,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01508026,Forest Laboratories,FALSE,NC,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT01313676,GlaxoSmithKline,FALSE,NC,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT01275677,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01130272,"Furiex Pharmaceuticals, Inc",FALSE,NC,https://ClinicalTrials.gov/show/NCT01130272,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],11-Jun-12,18,65,Both,FALSE,112NCT01070836,Biogen,FALSE,NC,https://ClinicalTrials.gov/show/NCT01070836,FALSE,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],14-Jan-16,0,9999,Both,FALSE,73NCT01015833,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00942331,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00785291,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00433511,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00382070,NSABP Foundation Inc,TRUE,NC,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00373685,Pfizer,FALSE,NC,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00346216,Pfizer,FALSE,NC,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00324805,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,NC,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00264901,Novo Nordisk A/S,FALSE,NC,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00262847,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT00262847,FALSE,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],18-Aug-15,18,9999,Female,FALSE,9NCT00217737,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00041119,Alliance for Clinical Trials in Oncology,TRUE,NC,https://ClinicalTrials.gov/show/NCT00041119,FALSE,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],23-Jul-15,18,9999,Female,FALSE,1NCT00053898,NSABP Foundation Inc,TRUE,NC,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT00034879,AstraZeneca,FALSE,NC,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT01764633,Amgen,FALSE,NC,https://ClinicalTrials.gov/show/NCT01764633,FALSE,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],20-Jan-16,40,85,Both,FALSE,16NCT00067938,GlaxoSmithKline,FALSE,NC,https://ClinicalTrials.gov/show/NCT00067938,FALSE,Bipolar Study in Adults at Least 18 Years of Age,Bipolar Disorder,Drug:lamotrigine,[],11-Oct-12,18,9999,Both,FALSE,8NCT00003906,NSABP Foundation Inc,TRUE,NC,https://ClinicalTrials.gov/show/NCT00003906,FALSE,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],5-Oct-15,35,9999,Female,FALSE,2NCT01642914,Forest Laboratories,FALSE,NC,https://ClinicalTrials.gov/show/NCT01642914,FALSE,Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating,Chronic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Matching placebo,[],30-Sep-13,18,9999,Both,TRUE,110NCT00072046,Alliance for Clinical Trials in Oncology,TRUE,NC,https://ClinicalTrials.gov/show/NCT00072046,FALSE,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],23-Jun-15,18,9999,Both,FALSE,1NCT01498289,Southwest Oncology Group,FALSE,NC,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01126437,Boehringer Ingelheim,FALSE,NC,https://ClinicalTrials.gov/show/NCT01126437,FALSE,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:tiotropium 18 mcg; Drug:tiotropium 1.25 mcg (2 actuations/day); Drug:tiotropium 2.5 mcg (2 actuations/day),[],20-May-14,40,9999,Both,FALSE,75NCT00887536,NSABP Foundation Inc,FALSE,NC,https://ClinicalTrials.gov/show/NCT00887536,FALSE,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],24-Jun-15,18,70,Female,FALSE,2NCT01835158,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01642251,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT01642251,FALSE,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01000727,GlaxoSmithKline,FALSE,NC,https://ClinicalTrials.gov/show/NCT01000727,FALSE,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Drug:Darapladib 160 mg; Drug:Placebo; Other:Standard Therapy,[],3-Sep-15,18,9999,Both,FALSE,8NCT00861705,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT00861705,FALSE,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],28-Sep-15,18,9999,Both,FALSE,9NCT00838903,GlaxoSmithKline,FALSE,NC,https://ClinicalTrials.gov/show/NCT00838903,FALSE,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:sitagliptin; Drug:glimepiride; Drug:metformin; Biological:placebo albiglutide; Drug:placebo sitagliptin; Drug:placebo glimepiride,[],11-Aug-14,18,9999,Both,FALSE,8NCT00693992,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT00693992,FALSE,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],26-Jun-15,18,9999,Both,FALSE,9NCT00658515,Hoffmann-La Roche,FALSE,NC,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00639418,MedImmune LLC,TRUE,NC,https://ClinicalTrials.gov/show/NCT00639418,FALSE,A Study to Describe Pediatric Influenza Vaccine Coverage,Healthy,Biological:Influenza vaccination,[],12-Sep-14,6,9999,Both,TRUE,15NCT00588770,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT00373256,Pfizer,FALSE,NC,https://ClinicalTrials.gov/show/NCT00373256,FALSE,A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer,Breast Neoplasms,Drug:Sunitinib; Drug:paclitaxel; Drug:bevacizumab; Drug:paclitaxel,[],5-Sep-12,18,9999,Both,FALSE,10NCT00326898,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00079274,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT01959529,Novo Nordisk A/S,FALSE,NC,https://ClinicalTrials.gov/show/NCT01959529,FALSE,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],8-Jan-16,50,9999,Both,FALSE,158NCT01802333,National Cancer Institute (NCI),FALSE,NC,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT01553591,"Furiex Pharmaceuticals, Inc",FALSE,NC,https://ClinicalTrials.gov/show/NCT01553591,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],26-Apr-15,18,80,Both,FALSE,112NCT01041781,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT01041781,FALSE,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT00892177,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT00892177,FALSE,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],23-Nov-15,18,9999,Both,FALSE,1NCT00079274,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,ND,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01275677,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00205777,Pfizer,FALSE,ND,https://ClinicalTrials.gov/show/NCT00205777,FALSE,Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women,Osteoporosis,Drug:Bazedoxifene Acetate; Other:Placebo,[],28-Feb-13,55,80,Female,FALSE,10NCT00053898,NSABP Foundation Inc,TRUE,ND,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT00946712,Southwest Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00785291,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00433511,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00382070,NSABP Foundation Inc,TRUE,ND,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00324805,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00217737,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00134056,Southwest Oncology Group,TRUE,ND,https://ClinicalTrials.gov/show/NCT00134056,FALSE,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],6-May-15,18,9999,Male,FALSE,3NCT00075946,Eastern Cooperative Oncology Group,TRUE,ND,https://ClinicalTrials.gov/show/NCT00075946,FALSE,Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma,Lymphoma,Biological:rituximab,[],3-Jun-15,18,9999,Both,FALSE,17NCT00075764,Southwest Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT00075764,FALSE,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:fulvestrant,[],8-May-14,18,9999,Female,FALSE,3NCT00041119,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00041119,FALSE,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],23-Jul-15,18,9999,Female,FALSE,1NCT00003596,Radiation Therapy Oncology Group,TRUE,ND,https://ClinicalTrials.gov/show/NCT00003596,FALSE,Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer,Anal Cancer,Drug:cisplatin; Drug:fluorouracil; Drug:mitomycin C; Radiation:radiation therapy,[],18-Nov-13,18,9999,Both,FALSE,4NCT00003594,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00003594,FALSE,Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,Colorectal Cancer,Drug:irinotecan; Drug:fluorouracil; Drug:leucovorin calcium; Drug:oxaliplatin,[],9-Jul-15,18,9999,Both,FALSE,1NCT01886872,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01366183,Gynecologic Oncology Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01366183,FALSE,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],23-Dec-14,75,9999,Both,FALSE,14NCT01004887,North Central Cancer Treatment Group,FALSE,ND,https://ClinicalTrials.gov/show/NCT01004887,FALSE,Study of Tissue and Blood Samples From Patients With High-Grade Glioma,Brain and Central Nervous System Tumors,Genetic:DNA ploidy analysis; Genetic:fluorescence in situ hybridization; Genetic:microsatellite instability analysis; Genetic:mutation analysis; Genetic:polymerase chain reaction; Other:diagnostic laboratory biomarker analysis; Other:flow cytometry; Other:immunohistochemistry staining method,[],27-Jun-13,0,9999,Both,FALSE,18NCT00880191,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT00880191,FALSE,Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy,"Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:dexamethasone; Drug:gabapentin; Other:placebo,[],23-Nov-15,18,9999,Both,FALSE,1NCT00860041,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00860041,FALSE,Acute Pain Caused by Paclitaxel in Patients With Cancer,"Chemotherapeutic Agent Toxicity; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific",Behavioral:pain questionnaires,[],7-Jul-15,18,9999,Both,FALSE,1NCT00826540,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT00826540,FALSE,Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,Drug:sorafenib tosylate; Biological:bevacizumab,[],31-Jul-15,18,9999,Both,FALSE,1NCT00776100,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT00776100,FALSE,Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Other:clinical observation; Radiation:radiation therapy,[],8-Jul-15,18,9999,Both,FALSE,1NCT00719563,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00719563,FALSE,American Ginseng in Treating Patients With Fatigue Caused by Cancer,"Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific",Drug:American ginseng; Other:placebo,[],14-Jul-14,18,9999,Both,FALSE,1NCT00641706,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT00641706,FALSE,"Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme",Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor,Drug:vorinostat; Procedure:therapeutic conventional surgery; Drug:bortezomib,[],28-Apr-14,18,9999,Both,FALSE,9NCT00626405,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00626405,FALSE,Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery,Melanoma (Skin),Biological:bevacizumab; Drug:carboplatin; Drug:paclitaxel albumin-stabilized nanoparticle formulation; Drug:temozolomide,[],8-Jul-15,18,9999,Both,FALSE,1NCT00550836,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT00550836,FALSE,Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer,Pancreatic Cancer,Biological:panitumumab; Drug:erlotinib hydrochloride; Drug:gemcitabine hydrochloride,[],8-Jul-15,18,9999,Both,FALSE,1NCT00521001,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00521001,FALSE,Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery,Melanoma (Skin),Drug:everolimus; Drug:temozolomide,[],9-Jul-15,18,9999,Both,FALSE,1NCT00516503,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00516503,FALSE,Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer,"Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific",Drug:baclofen/amitriptyline/ketamine gel; Other:placebo,[],3-Jul-15,18,9999,Both,FALSE,1NCT00489411,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00489411,FALSE,Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer,"Neurotoxicity; Pain; Peripheral Neuropathy; Unspecified Adult Solid Tumor, Protocol Specific",Drug:duloxetine hydrochloride; Other:placebo,[],6-Jul-15,25,9999,Both,FALSE,1NCT00460109,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00460109,FALSE,Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma,Lymphoma,Biological:denileukin diftitox; Biological:rituximab,[],4-Jul-15,18,9999,Both,FALSE,1NCT00454194,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT00454194,FALSE,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Drug:pemetrexed disodium; Drug:sorafenib tosylate,[],6-Jul-15,18,9999,Both,FALSE,1NCT00376675,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00376675,FALSE,Methylphenidate in Treating Patients With Fatigue Caused by Cancer,"Fatigue; Unspecified Adult Solid Tumor, Protocol Specific",Drug:methylphenidate hydrochloride; Other:placebo,[],14-Sep-15,18,9999,Both,FALSE,1NCT00329719,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT00329719,FALSE,Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor,Drug:sorafenib tosylate; Drug:temsirolimus; Procedure:conventional surgery,[],29-May-15,18,9999,Both,FALSE,9NCT00326898,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00326599,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00326599,FALSE,Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:cediranib maleate; Drug:gemcitabine hydrochloride,[],9-Jul-15,18,9999,Both,FALSE,1NCT00316836,Alliance for Clinical Trials in Oncology,FALSE,ND,https://ClinicalTrials.gov/show/NCT00316836,FALSE,"Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole",Breast Cancer,Procedure:mammography,[],13-Jul-15,18,9999,Female,FALSE,1NCT00310180,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00303628,National Cancer Institute (NCI),FALSE,ND,https://ClinicalTrials.gov/show/NCT00303628,FALSE,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],20-May-14,18,9999,Both,FALSE,9NCT00296036,North Central Cancer Treatment Group,TRUE,ND,https://ClinicalTrials.gov/show/NCT00296036,FALSE,Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer,"Breast Cancer; Drug/Agent Toxicity by Tissue/Organ; Unspecified Adult Solid Tumor, Protocol Specific",Dietary Supplement:pyridoxine hydrochloride; Drug:urea/lactic acid-based topical cream; Other:placebo,[],17-Nov-10,18,9999,Both,FALSE,18NCT00268489,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00268489,FALSE,Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],9-Jul-15,18,9999,Both,FALSE,1NCT00227565,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00227565,FALSE,Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:pemetrexed disodium; Radiation:radiation,[],9-Jul-15,18,9999,Both,FALSE,1NCT00112528,Alliance for Clinical Trials in Oncology,TRUE,ND,https://ClinicalTrials.gov/show/NCT00112528,FALSE,"Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer",Pancreatic Cancer,Biological:bevacizumab; Drug:gemcitabine hydrochloride; Drug:oxaliplatin,[],9-Jul-15,18,9999,Both,FALSE,1NCT02465060,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02315430,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02315430,FALSE,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Female,FALSE,9NCT02311907,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02311907,FALSE,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],22-May-15,18,9999,Female,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02137837,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT02137837,FALSE,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",Breast Cancer,Drug:Fulvestrant; Drug:Anastrozole; Drug:Everolimus; Drug:Placebo - Anastrozole; Drug:Placebo - Everolimus,[],20-May-15,18,9999,Female,FALSE,3NCT02042443,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT02042443,FALSE,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],3-Feb-16,0,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01841736,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01841736,FALSE,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01824823,Eastern Cooperative Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01824823,FALSE,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],11-Sep-15,18,9999,Both,FALSE,17NCT01802333,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT01716715,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01716715,FALSE,"Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],12-Jan-16,18,9999,Female,FALSE,9NCT01708954,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01708954,FALSE,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],23-Oct-15,18,9999,Both,FALSE,9NCT01708941,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01708941,FALSE,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Recombinant Interferon Alfa-2b,[],11-Jan-16,18,9999,Both,FALSE,9NCT01688973,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01688973,FALSE,Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery,Childhood Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Tivantinib,[],11-Jan-16,0,9999,Both,FALSE,9NCT01658943,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01653028,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01653028,FALSE,Alisertib in Treating Patients With Advanced or Metastatic Sarcoma,Myxofibrosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Leiomyosarcoma; Recurrent Liposarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis,[],2-Feb-16,18,9999,Both,FALSE,9NCT01648348,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01648348,FALSE,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT01642251,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01642251,FALSE,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01609790,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01609790,FALSE,Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors,Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Placebo; Biological:Trebananib,[],31-Jul-15,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,OH,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01522976,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01522976,FALSE,Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia,Adult Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts,Drug:Azacitidine; Drug:Lenalidomide; Drug:Vorinostat,[],24-Jun-15,18,9999,Both,FALSE,9NCT01515800,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01515800,FALSE,S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer,Breast Cancer,Behavioral:Text message reminder,[],23-Oct-15,18,120,Female,FALSE,3NCT01508026,Forest Laboratories,FALSE,OH,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT01498289,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01439945,Alliance for Clinical Trials in Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT01439945,FALSE,Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer,Breast Cancer; Cancer Survivor; Hot Flashes,Drug:magnesium oxide; Other:placebo,[],31-Jul-15,18,9999,Female,FALSE,1NCT01412879,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01412879,FALSE,S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:cyclophosphamide; Drug:cytarabine; Drug:dexamethasone; Drug:doxorubicin hydrochloride; Drug:leucovorin calcium; Drug:methotrexate; Drug:vincristine sulfate,[],15-Sep-15,18,65,Both,FALSE,3NCT01385137,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01385137,FALSE,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],15-Oct-15,18,120,Female,FALSE,3NCT01376349,Alliance for Clinical Trials in Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT01376349,FALSE,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],24-Sep-15,18,9999,Female,FALSE,1NCT01366183,Gynecologic Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01366183,FALSE,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],23-Dec-14,75,9999,Both,FALSE,14NCT01349322,Radiation Therapy Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01349322,FALSE,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],14-Nov-15,18,9999,Female,FALSE,4NCT01313676,GlaxoSmithKline,FALSE,OH,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT01275677,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01260701,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01260701,FALSE,Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Diffuse Gastric Adenocarcinoma; Gastric Intestinal Type Adenocarcinoma; Gastric Mixed Adenocarcinoma; Recurrent Gastric Carcinoma,Drug:Akt Inhibitor MK2206,[],14-Dec-15,18,9999,Both,FALSE,9NCT01251861,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01251861,FALSE,Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer,Recurrent Prostate Carcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer,Drug:Akt Inhibitor MK2206; Drug:Bicalutamide; Other:Clinical Observation; Other:Laboratory Biomarker Analysis,[],18-Jan-16,18,9999,Male,FALSE,9NCT01229943,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01229943,FALSE,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],22-Apr-15,18,9999,Both,FALSE,9NCT01198158,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01198145,Alliance for Clinical Trials in Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT01198145,FALSE,Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy,"Diarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific",Drug:sulfasalazine; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01196390,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01189227,NSABP Foundation Inc,FALSE,OH,https://ClinicalTrials.gov/show/NCT01189227,FALSE,Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery,Colorectal Cancer; Metastatic Cancer,Procedure:Postoperative chemotherapy; Procedure:Perioperative chemotherapy,[],8-May-13,18,9999,Both,FALSE,2NCT01167712,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT01142388,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01142388,FALSE,Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Recurrent Esophageal Carcinoma; Stage IV Esophageal Cancer,Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Pharmacological Study,[],2-Jun-15,18,9999,Both,FALSE,9NCT01120275,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01120275,FALSE,Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma,Acral Lentiginous Malignant Melanoma; Lentigo Maligna Malignant Melanoma; Nodular Malignant Melanoma; Recurrent Melanoma; Solar Radiation-related Skin Melanoma; Stage IV Melanoma; Superficial Spreading Malignant Melanoma,Drug:gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other:laboratory biomarker analysis,[],9-Jun-14,18,9999,Both,FALSE,9NCT01099449,Alliance for Clinical Trials in Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT01099449,FALSE,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],4-Jul-15,18,9999,Both,FALSE,1NCT01097278,Southwest Oncology Group,FALSE,OH,https://ClinicalTrials.gov/show/NCT01097278,FALSE,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],7-Jan-15,18,50,Female,FALSE,3NCT01093222,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01093222,FALSE,"Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma",Extrahepatic Bile Duct Adenocarcinoma; Gallbladder Adenocarcinoma; Gallbladder Adenocarcinoma With Squamous Metaplasia; Hilar Cholangiocarcinoma; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Undifferentiated Gallbladder Carcinoma; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma,Drug:Erlotinib Hydrochloride; Drug:Sorafenib Tosylate,[],3-Jun-15,18,9999,Both,FALSE,9NCT01091454,Alliance for Clinical Trials in Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT01091454,FALSE,Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer,Triple-negative Breast Cancer,Drug:brostallicin; Drug:cisplatin,[],23-Jul-15,18,9999,Both,FALSE,1NCT01086605,Alliance for Clinical Trials in Oncology,FALSE,OH,https://ClinicalTrials.gov/show/NCT01086605,FALSE,Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer,Breast Cancer,Drug:pixantrone dimaleate,[],4-Aug-15,18,9999,Both,FALSE,1NCT01081262,National Cancer Institute (NCI),FALSE,OH,https://ClinicalTrials.gov/show/NCT01081262,FALSE,Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer,Borderline Ovarian Mucinous Tumor; Ovarian Mucinous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer,Biological:Bevacizumab; Drug:Capecitabine; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Oxaliplatin; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],12-Jan-16,18,9999,Female,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT01275677,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00264901,Novo Nordisk A/S,FALSE,OK,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00036270,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT00036270,FALSE,Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane,Breast Neoplasms,Drug:exemestane (Aromasin); Drug:tamoxifen + exemestane,[],6-Oct-15,50,9999,Female,FALSE,10NCT01287897,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT01287897,FALSE,A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy,Crohn's Disease,Drug:PF-04236921 SC injection; Drug:PF-04236921 SC injection; Drug:PF-04236921 SC injection,[],14-Dec-15,18,75,Both,FALSE,10NCT00946712,Southwest Oncology Group,FALSE,OK,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00857220,Sunovion,FALSE,OK,https://ClinicalTrials.gov/show/NCT00857220,FALSE,Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia,Insomnia; Attention Deficit Hyperactivity Disorder,Drug:eszopiclone; Drug:eszopiclone,[],18-Jun-13,6,17,Both,FALSE,180NCT00412984,Bristol-Myers Squibb,FALSE,OK,https://ClinicalTrials.gov/show/NCT00412984,FALSE,Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation,Atrial Fibrillation; Atrial Flutter,Drug:warfarin; Drug:apixaban,[],27-Sep-13,18,9999,Both,FALSE,80NCT00267748,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT00267748,FALSE,Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC),"Carcinoma, Renal Cell",Drug:Sunitinib Malate Continuous Daily Dosing; Drug:Sunitinib Malate Schedule 4/2,[],3-Aug-11,18,9999,Both,FALSE,10NCT00080340,Telik,FALSE,OK,https://ClinicalTrials.gov/show/NCT00080340,FALSE,Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Non Small Cell Lung Carcinoma,Drug:TLK286 (Telcyta) HCl for Injection; Drug:gefitinib (Iressa),[],10-Jan-08,18,9999,Both,FALSE,185NCT01835158,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT00942331,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00809354,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT00809354,FALSE,Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip,Osteoarthritis; Arthritis,Drug:NSAID; Biological:tanezumab; Biological:tanezumab; Biological:tanezumab; Drug:NSAID; Biological:tanezumab; Drug:NSAID,[],4-Mar-15,18,9999,Both,FALSE,10NCT00785291,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00673049,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT00673049,FALSE,"Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer","Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Adenosquamous Cell","Drug:CP 751,871 (Figitumumab); Drug:Erlotinib; Drug:Erlotinib",[],22-Jul-13,18,9999,Both,FALSE,10NCT00609622,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT00609622,FALSE,Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer,Colorectal Neoplasms,Drug:sunitinib; Drug:mFOLFOX6; Drug:bevacizumab; Drug:mFOLFOX6,[],10-Sep-12,18,9999,Both,FALSE,10NCT00457392,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT00457392,FALSE,A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone,"Carcinoma, Non-Small Cell Lung",Drug:erlotinib; Drug:sunitinib; Drug:erlotinib; Drug:placebo,[],24-Sep-13,18,9999,Both,FALSE,10NCT00433511,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00373685,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00346216,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00324805,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00130897,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT00130897,FALSE,Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma,"Carcinoma, Renal Cell",Drug:Sutent,[],8-Mar-12,18,9999,Both,FALSE,10NCT00003906,NSABP Foundation Inc,TRUE,OK,https://ClinicalTrials.gov/show/NCT00003906,FALSE,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],5-Oct-15,35,9999,Female,FALSE,2NCT01366183,Gynecologic Oncology Group,FALSE,OK,https://ClinicalTrials.gov/show/NCT01366183,FALSE,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],23-Dec-14,75,9999,Both,FALSE,14NCT01035255,Novartis Pharmaceuticals,FALSE,OK,https://ClinicalTrials.gov/show/NCT01035255,FALSE,This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure,Heart Failure With Reduced Ejection Fraction,Drug:LCZ696 200 mg BID; Drug:Enalapril 10 mg BID,[],9-Sep-15,18,9999,Both,FALSE,156NCT00856973,Sunovion,FALSE,OK,https://ClinicalTrials.gov/show/NCT00856973,FALSE,Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia,Insomnia; Attention Deficit Hyperactivity Disorder,Drug:eszopiclone; Drug:eszopiclone; Drug:Placebo,[],7-Jun-13,6,17,Both,FALSE,180NCT00658515,Hoffmann-La Roche,FALSE,OK,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00310180,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00217737,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00205777,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT00205777,FALSE,Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women,Osteoporosis,Drug:Bazedoxifene Acetate; Other:Placebo,[],28-Feb-13,55,80,Female,FALSE,10NCT00067938,GlaxoSmithKline,FALSE,OK,https://ClinicalTrials.gov/show/NCT00067938,FALSE,Bipolar Study in Adults at Least 18 Years of Age,Bipolar Disorder,Drug:lamotrigine,[],11-Oct-12,18,9999,Both,FALSE,8NCT00034879,AstraZeneca,FALSE,OK,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT02045732,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT02045732,FALSE,A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS),Multiple Sclerosis,Biological:PF-06342674 0.25 mg/kg; Biological:Placebo; Biological:PF-06342674 1.5 mg/kg; Biological:PF-06342674 6.0 mg/kg,"[u'Albany Advanced Imaging', u'Fallon Wellness Pharmacy', u'Northeast Eye Center', u'The MS Center of Northeastern New York', u'Cleveland Clinic', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Retina Vitreous Center', u'Lynn Health Science Institute', u'Pfizer Investigational Site', u'Radiology Associates (X-ray facility only)']",12-Jan-16,18,55,Both,FALSE,10NCT02031640,"Teva Branded Pharmaceutical Products, R&D Inc.",FALSE,OK,https://ClinicalTrials.gov/show/NCT02031640,FALSE,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma,Asthma,Drug:Beclomethasone dipropionate; Drug:Placebo; Drug:Albuterol/salbutamol,[],21-May-15,12,9999,Both,FALSE,186NCT01886872,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01855789,Hoffmann-La Roche,FALSE,OK,https://ClinicalTrials.gov/show/NCT01855789,FALSE,A Study on the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous RoActemra/Actemra (Tocilizumab) With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:methotrexate; Drug:placebo; Drug:tocilizumab [RoActemra/Actemra],[],1-Feb-16,18,9999,Both,FALSE,119NCT01789957,AstraZeneca,FALSE,OK,https://ClinicalTrials.gov/show/NCT01789957,FALSE,Extension Study for 2993-112,Type 2 Diabetes Mellitus,Drug:AC2993,[],23-Feb-15,16,75,Both,FALSE,13NCT01658943,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01609790,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT01609790,FALSE,Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors,Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Placebo; Biological:Trebananib,[],31-Jul-15,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,OK,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01543178,"Valeant Pharmaceuticals International, Inc.",FALSE,OK,https://ClinicalTrials.gov/show/NCT01543178,FALSE,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],15-Jun-15,18,9999,Both,FALSE,47NCT01508026,Forest Laboratories,FALSE,OK,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT01498289,Southwest Oncology Group,FALSE,OK,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01345318,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT01345318,FALSE,B0151005 Open-Label Extension Study,Crohn's Disease,Biological:PF-04236921; Biological:PF-04236921,[],19-Jan-16,18,75,Both,FALSE,10NCT01262677,Pfizer,FALSE,OK,https://ClinicalTrials.gov/show/NCT01262677,FALSE,Once-A-Day Pregabalin For Partial Seizures,"Partial Seizures; Epilepsies, Partial",Drug:pregabalin; Drug:pregabalin; Drug:pregabalin; Drug:pregabalin; Drug:pregabalin; Drug:pregabalin; Drug:placebo,[],13-Sep-13,18,9999,Both,FALSE,10NCT01198158,National Cancer Institute (NCI),FALSE,OK,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01130272,"Furiex Pharmaceuticals, Inc",FALSE,OK,https://ClinicalTrials.gov/show/NCT01130272,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],11-Jun-12,18,65,Both,FALSE,112NCT01100684,Tioga Pharmaceuticals,FALSE,OK,https://ClinicalTrials.gov/show/NCT01100684,FALSE,Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS),Diarrhea Predominant Irritable Bowel Syndrome,Drug:Asimadoline; Drug:Placebo,[],17-Dec-13,18,79,Both,FALSE,192NCT01076764,Sanofi,FALSE,OK,https://ClinicalTrials.gov/show/NCT01076764,FALSE,Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy,Acute Coronary Syndrome,Drug:Otamixaban (XRP0673); Drug:Otamixaban matching placebo; Drug:Unfractionated Heparin; Drug:Unfractionated Heparin matching placebo; Drug:Eptifibatide; Drug:Eptifibatide matching placebo,[],16-May-13,18,9999,Both,FALSE,12NCT00942357,Gynecologic Oncology Group,FALSE,OK,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00769379,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00433511,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00878709,"Puma Biotechnology, Inc.",FALSE,OR,https://ClinicalTrials.gov/show/NCT00878709,FALSE,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Breast Cancer,Drug:neratinib; Other:placebo,[],20-Aug-15,18,9999,Female,FALSE,166NCT00382070,NSABP Foundation Inc,TRUE,OR,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00326898,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,OR,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01275677,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00785291,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT01198158,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01000558,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT01000558,FALSE,SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma,Lymphoma,Other:biologic sample preservation procedure,[],17-May-13,18,9999,Both,FALSE,3NCT00946712,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00103181,NSABP Foundation Inc,TRUE,OR,https://ClinicalTrials.gov/show/NCT00103181,FALSE,Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer,Breast Cancer,Radiation:3-dimensional conformal accelerated partial breast irradiation; Radiation:brachytherapy; Radiation:whole breast irradiation; Radiation:MammoSite or other single-entry intracavitary device,[],8-Oct-15,18,9999,Female,FALSE,2NCT00075764,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT00075764,FALSE,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:fulvestrant,[],8-May-14,18,9999,Female,FALSE,3NCT00874211,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT00874211,FALSE,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],4-Mar-15,0,9999,Both,FALSE,3NCT00775645,Southwest Oncology Group,TRUE,OR,https://ClinicalTrials.gov/show/NCT00775645,FALSE,"S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy",Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity,Dietary Supplement:acetyl-L-carnitine hydrochloride; Other:placebo,[],13-Jan-14,18,9999,Female,FALSE,3NCT00644228,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT00644228,FALSE,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],12-Sep-14,18,9999,Both,FALSE,9NCT00265941,Radiation Therapy Oncology Group,TRUE,OR,https://ClinicalTrials.gov/show/NCT00265941,FALSE,Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Drug:cisplatin,[],11-Nov-15,18,9999,Both,FALSE,4NCT00079274,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT01385137,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT01385137,FALSE,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],15-Oct-15,18,120,Female,FALSE,3NCT00920010,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT00920010,FALSE,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],5-Feb-15,0,9999,Both,FALSE,3NCT00919425,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT00919425,FALSE,"S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer",Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms,Other:biologic sample preservation procedure,[],5-Mar-15,0,9999,Both,FALSE,3NCT00490139,GlaxoSmithKline,FALSE,OR,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT00041119,Alliance for Clinical Trials in Oncology,TRUE,OR,https://ClinicalTrials.gov/show/NCT00041119,FALSE,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],23-Jul-15,18,9999,Female,FALSE,1NCT01886872,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,OR,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT00382018,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT00382018,FALSE,S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy,Breast Cancer,Drug:chemotherapy,[],15-Sep-15,18,9999,Female,FALSE,3NCT00053898,NSABP Foundation Inc,TRUE,OR,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT00003857,Radiation Therapy Oncology Group,TRUE,OR,https://ClinicalTrials.gov/show/NCT00003857,FALSE,Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ,Breast Cancer,Drug:tamoxifen citrate; Procedure:adjuvant therapy; Radiation:radiation therapy,[],14-Nov-15,26,120,Female,FALSE,4NCT01802333,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT01097278,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT01097278,FALSE,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],7-Jan-15,18,50,Female,FALSE,3NCT00822120,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT00822120,FALSE,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,Lymphoma; Nonneoplastic Condition,Biological:bleomycin sulfate; Biological:filgrastim; Drug:ABVD regimen; Drug:BEACOPP regimen; Drug:cyclophosphamide; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:prednisone; Drug:procarbazine hydrochloride; Drug:vinblastine sulfate; Drug:vincristine sulfate,[],8-May-15,18,60,Both,FALSE,3NCT00337129,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT00337129,FALSE,S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer,Head and Neck Cancer,Drug:eribulin mesylate,[],11-Aug-15,18,9999,Both,FALSE,9NCT00304031,Radiation Therapy Oncology Group,TRUE,OR,https://ClinicalTrials.gov/show/NCT00304031,FALSE,Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,Brain and Central Nervous System Tumors,Drug:Concurrent temozolomide; Radiation:Concurrent radiation therapy; Drug:100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle; Drug:75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle,[],13-Oct-15,18,120,Both,FALSE,4NCT00109850,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT00109850,FALSE,"S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer",Esophageal Cancer,Biological:cetuximab; Drug:cisplatin; Drug:irinotecan hydrochloride; Radiation:radiation therapy,[],16-Nov-15,18,9999,Both,FALSE,3NCT00057746,Radiation Therapy Oncology Group,TRUE,OR,https://ClinicalTrials.gov/show/NCT00057746,FALSE,Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer,Lung Cancer,Radiation:Prophylactic Cranial Irradiation (PCI),[],15-Jan-14,0,9999,Both,FALSE,4NCT00003641,Eastern Cooperative Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT00003641,FALSE,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,Melanoma (Skin),Biological:recombinant interferon alfa; Other:clinical observation,[],11-Jul-12,18,9999,Both,FALSE,17NCT00003596,Radiation Therapy Oncology Group,TRUE,OR,https://ClinicalTrials.gov/show/NCT00003596,FALSE,Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer,Anal Cancer,Drug:cisplatin; Drug:fluorouracil; Drug:mitomycin C; Radiation:radiation therapy,[],18-Nov-13,18,9999,Both,FALSE,4NCT01011478,NSABP Foundation Inc,TRUE,OR,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT00919139,Southwest Oncology Group,FALSE,OR,https://ClinicalTrials.gov/show/NCT00919139,FALSE,"S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.",Multiple Myeloma; Smoldering Myeloma; Waldenstrom's Macroglobulinemia; Monoclonal Gammopathy of Undetermined Significance; Amyloidosis,Other:biologic sample preservation procedure,[],1-Apr-15,0,9999,Both,FALSE,3NCT00887536,NSABP Foundation Inc,FALSE,OR,https://ClinicalTrials.gov/show/NCT00887536,FALSE,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],24-Jun-15,18,70,Female,FALSE,2NCT00828139,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT00828139,FALSE,Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Biological:ziv-aflibercept; Drug:topotecan hydrochloride,[],9-Apr-14,18,9999,Both,FALSE,9NCT00693992,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT00693992,FALSE,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],26-Jun-15,18,9999,Both,FALSE,9NCT00640042,Pfizer,TRUE,OR,https://ClinicalTrials.gov/show/NCT00640042,FALSE,"Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",Pain,Drug:morphine sulfate extended release capsules,[],6-Jun-12,21,9999,Both,FALSE,10NCT00601900,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT00601900,FALSE,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],23-Apr-15,18,9999,Female,FALSE,9NCT00569127,National Cancer Institute (NCI),FALSE,OR,https://ClinicalTrials.gov/show/NCT00569127,FALSE,"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor",Neuroendocrine Carcinoma,Biological:Recombinant Interferon Alfa-2b; Drug:Octreotide Acetate; Biological:Bevacizumab,[],5-Jan-15,0,9999,Both,FALSE,9NCT00346216,Pfizer,FALSE,OR,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,OR,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT02465060,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01642251,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT01642251,FALSE,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01609790,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT01609790,FALSE,Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors,Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Placebo; Biological:Trebananib,[],31-Jul-15,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,PA,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01475721,GlaxoSmithKline,FALSE,PA,https://ClinicalTrials.gov/show/NCT01475721,FALSE,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],10-Dec-15,12,9999,Both,FALSE,8NCT01349322,Radiation Therapy Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT01349322,FALSE,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],14-Nov-15,18,9999,Female,FALSE,4NCT01313676,GlaxoSmithKline,FALSE,PA,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT01275677,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01198158,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01196390,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01167712,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT01070836,Biogen,FALSE,PA,https://ClinicalTrials.gov/show/NCT01070836,FALSE,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],14-Jan-16,0,9999,Both,FALSE,73NCT01042704,"Robert Redner, MD",TRUE,PA,https://ClinicalTrials.gov/show/NCT01042704,FALSE,Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma,Myeloma,Drug:Bendamustine; Drug:Lenalidomide; Drug:Dexamethasone; Drug:Aspirin; Drug:Prophylaxis; Drug:Antibiotic; Other:Biweekly Follow Up; Other:Cyclical Follow Up; Other:Restaging; Other:Post-Treatment Follow Up,"[u'Karmanos Cancer Institute', u'UPMC Cancer Centers - Teramana Cancer Center', u'UPMC Cancer Centers - Beaver', u'UPMC Cancer Centers - Jefferson', u'UPMC Cancer Centers - Arnold Palmer at Mountain View', u'UPMC Cancer Centers - Arnold Palmer at Oakbrook', u'UPMC Cancer Centers - Indiana', u'UPMC Cancer Centers - Johnstown', u'Hematology-Oncology Associates of UPCI', u'Hematology/Oncology - Private Practice', u'UPMC Cancer Centers - Monroeville', u'UPMC Cancer Centers - Arnold Palmer at Mt. Pleasant', u'UPMC Cancer Centers - New Castle', u""UPMC Cancer Centers - St. Margaret's"", u'UPMC Cancer Centers - Hillman Cancer Center', u'UPMC Cancer Centers - Drake', u'VA Healthcare System - 646', u'UPMC Cancer Centers - Passavant', u'UPMC Cancer Centers - Uniontown', u'UPMC Cancer Centers - Washington', u'UPMC Cancer Centers - North Hills', u'UPMC Cancer Centers - Windber']",13-Jan-16,18,9999,Both,FALSE,37NCT01011478,NSABP Foundation Inc,TRUE,PA,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT01000727,GlaxoSmithKline,FALSE,PA,https://ClinicalTrials.gov/show/NCT01000727,FALSE,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Drug:Darapladib 160 mg; Drug:Placebo; Other:Standard Therapy,[],3-Sep-15,18,9999,Both,FALSE,8NCT00984217,University of Pittsburgh,FALSE,PA,https://ClinicalTrials.gov/show/NCT00984217,FALSE,Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies,"Adenoma, Pleomorphic; Mixed Salivary Gland Tumor; Salivary Gland Tumor, Mixed; Syringoma, Chondroid",Radiation:Radiation; Drug:Panitumumab,"[u'UPMC Cancer Center - Teramana Cancer Center - Steubenville', u'UPMC Cancer Center - Beaver', u'UPMC Cancer Center - Clairton', u'UPMC Cancer Center -Arnold Palmer Pavilion', u'UPMC Cancer Center - Oakbrook Commons - Greensburg', u'UPMC Cancer Center - Oakbrook Commons', u'UPMC Cancer Center - Arnold Palmer Pavilion - Greensburg', u'UPMC Cancer Center - Indiana', u'UPMC Cancer Center - John P. Murtha Pavilion - Johnstown', u'UPMC Cancer Center - McKeesport', u'UPMC Cancer Center - Monroeville', u'UPMC Cancer Center - Sewickley Medical Oncology/Hematology Group', u'UPMC Cancer Center -Mt. Pleasant', u'UPMC Cancer Center - New Castle', u'UPMC Cancer Centers', u""UPMC Cancer Center - St. Margaret's"", u'UPMC Cancer Center -Delafield Rd.', u'Hillman Cancer Center: University of Pittsburgh Cancer Institute / UPMC Department of Radiology', u'UPMC Cancer Center -UPMC Shadyside', u'UPMC Cancer Center - Passavant', u'UPMC Cancer Center - Upper St. Clair', u'UPMC Cancer Center -Drake', u'UPMC Presbyterian -Radiation Oncology', u'UPMC Cancer Center -UPMC Northwest', u'UPMC Cancer Center - Uniontown', u'UPMC Cancer Center - Washington', u'UPMC Cancer Center - North Hills']",6-Jan-16,18,9999,Both,FALSE,208NCT00954174,Gynecologic Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT00954174,FALSE,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00946712,Southwest Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00942357,Gynecologic Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00887159,National Cancer Institute (NCI),TRUE,PA,https://ClinicalTrials.gov/show/NCT00887159,FALSE,Cisplatin and Etoposide With or Without Vismodegib or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Biological:cixutumumab; Drug:vismodegib; Drug:cisplatin; Drug:etoposide,[],1-Jul-15,18,9999,Both,FALSE,9NCT00884741,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT00884741,FALSE,Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Cognitive Side Effects of Cancer Therapy,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Procedure:Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Procedure:Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Temozolomide,[],29-Jul-15,18,9999,Both,FALSE,9NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,PA,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT00785291,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00781391,Daiichi Sankyo Inc.,FALSE,PA,https://ClinicalTrials.gov/show/NCT00781391,FALSE,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke; Atrial Fibrillation; Embolism,Drug:warfarin tablets; Drug:Edoxaban tablets (high dose regimen-60mg); Drug:Edoxaban tablets (low dose regimen-30mg); Drug:placebo warfarin; Drug:placebo edoxaban,[],12-Mar-15,21,9999,Both,FALSE,95NCT00769379,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00658515,Hoffmann-La Roche,FALSE,PA,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00640042,Pfizer,TRUE,PA,https://ClinicalTrials.gov/show/NCT00640042,FALSE,"Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",Pain,Drug:morphine sulfate extended release capsules,[],6-Jun-12,21,9999,Both,FALSE,10NCT00625898,NSABP Foundation Inc,FALSE,PA,https://ClinicalTrials.gov/show/NCT00625898,FALSE,BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab,Breast Cancer,Drug:Docetaxel; Drug:Trastuzumab; Drug:Carboplatin; Drug:Bevacizumab; Drug:5-Fluorouracil; Drug:Epirubicin; Drug:Cyclophosphamide,[],7-Jul-14,18,9999,Female,FALSE,2NCT00588770,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT00581360,University of Pittsburgh,FALSE,PA,https://ClinicalTrials.gov/show/NCT00581360,FALSE,Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck,Adenoid Cystic Carcinoma,Drug:doxorubicin and bortezomib,"[u'UPMC Cancer Center - Teramana Cancer Center - Steubenville', u'UPMC Cancer Center - Beaver', u'UPMC Cancer Center - Clairton', u'UPMC Cancer Center - Arnold Palmer Pavilion - Greensburg', u'UPMC Cancer Center - Oakbrook Commons - Greensburg', u'UPMC Cancer Center - Indiana', u'UPMC Cancer Center - John P. Murtha Pavilion - Johnstown', u'UPMC Cancer Center - McKeesport', u'UPMC Cancer Center -Haymaker Rd.', u'UPMC Cancer Center -Mosside Blvd.', u'UPMC Cancer Center - Sewickley Medical Oncology/Hematology Group', u'UPMC Cancer Center -Mt. Pleasant', u'UPMC Cancer Center -New Castle', u'UPMC Cancer Center - Mercy', u'University of Pittsburgh Cancer Institute-Hillman Cancer Center', u'UPMC Cancer Center - Passavant', u'UPMC Cancer Center -Drake', u'UPMC Cancer Center -Delafield Rd.', u'UPMC Cancer Center - Uniontown', u'UPMC Cancer Center - Washington', u'UPMC Cancer Center -Wexford']",9-Jan-14,18,9999,Both,FALSE,208NCT00567580,Radiation Therapy Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT00567580,FALSE,Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:flutamide; Radiation:radiation therapy,[],31-Mar-15,18,9999,Male,FALSE,4NCT00566852,Radiation Therapy Oncology Group,FALSE,PA,https://ClinicalTrials.gov/show/NCT00566852,FALSE,Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors,"Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Unspecified Adult Solid Tumor, Protocol Specific",Drug:memantine hydrochloride; Other:placebo; Radiation:radiation therapy,[],26-Mar-15,18,9999,Both,FALSE,4NCT00557921,Cogentus Pharmaceuticals,FALSE,PA,https://ClinicalTrials.gov/show/NCT00557921,FALSE,Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1),Acute Coronary Syndrome; Myocardial Infarction; Coronary Artery Disease; Percutaneous Coronary Intervention,Drug:CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin; Drug:Plavix (clopidogrel 75 mg) and aspirin,[],27-Jan-09,21,9999,Both,FALSE,89NCT00492206,University of Pittsburgh,FALSE,PA,https://ClinicalTrials.gov/show/NCT00492206,FALSE,Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC,Non Small Cell Lung Cancer (NSCLC),Drug:Cetuximab,"[u'Sylvester Comprehensive Cancer Center, University of Miami', u'Emory Winship Cancer Institute', u'Sidney Kimmel Comprehensive Cancer Center at John Hopkins', u'UPMC Cancer Center -Teramana Cancer Center', u'UPMC Cancer Center -Beaver', u'UPMC Cancer Center - Clairton', u'UPMC Cancer Center - Oakbrook Commons', u'UPMC Cancer Center -Arnold Palmer Pavilion', u'Penn State Cancer Institute, Penn State Milton S. Hershey Medical Center', u'UPMC Cancer Center -Indiana', u'UPMC Cancer Center -John P. Murtha Pavilion', u'UPMC Cancer Center -McKeesport', u'UPMC Cancer Center -Haymaker Rd.', u'UPMC Cancer Center -Mosside Blvd.', u'UPMC Cancer Center -Sewickley Medical Center', u'UPMC Cancer Center -Mt. Pleasant', u'UPMC Cancer Center -Jameson', u'UPMC Cancer Center -New Castle', u'UPMC Cancer Center -St. Clair', u'UPMC Cancer Center -Delafield Rd.', u'UPMC Cancer Center -St. Margaret', u'Universtity of Pittsburgh Cancer Institute -Hillman Cancer Center', u'UPMC Presbyterian -Radiation Oncology', u'UPMC Cancer Center -Passavant', u'UPMC Cancer Center -Drake', u'UPMC Cancer Center -UPMC Shadyside', u'UPMC Cancer Center -UPMC Northwest', u'UPMC Cancer Center -Robert Eberly Pavilion', u'UPMC Cancer Center -Uniontown', u'UPMC Cancer Center -Washington', u'UPMC Cancer Center -Wexford']",16-Jan-13,18,9999,Both,FALSE,208NCT00490139,GlaxoSmithKline,FALSE,PA,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT00433511,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00408694,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT00408694,FALSE,"Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer",Stage II Squamous Cell Carcinoma of the Nasopharynx; Stage III Lymphoepithelioma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy; Biological:bevacizumab; Drug:cisplatin; Drug:fluorouracil,[],21-Apr-14,18,9999,Both,FALSE,9NCT00403767,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",FALSE,PA,https://ClinicalTrials.gov/show/NCT00403767,FALSE,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation; Stroke; Embolism,Drug:Rivaroxaban; Drug:Warfarin; Drug:Matching placebo for Rivaroxaban arm (Warfarin placebo); Drug:Matching placebo for Warfarin arm (Rivaroxaban placebo),[],10-Apr-14,18,9999,Both,FALSE,136NCT00382070,NSABP Foundation Inc,TRUE,PA,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00373685,Pfizer,FALSE,PA,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00365105,Radiation Therapy Oncology Group,TRUE,PA,https://ClinicalTrials.gov/show/NCT00365105,FALSE,"Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer",Breast Cancer; Lung Cancer; Metastatic Cancer; Pain; Prostate Cancer,Dietary Supplement:Calcium; Dietary Supplement:Vitamin D; Drug:zoledronic acid; Drug:Sm-153; Radiation:Sr-89,[],20-Mar-15,18,9999,Both,FALSE,4NCT00346216,Pfizer,FALSE,PA,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00326898,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00304031,Radiation Therapy Oncology Group,TRUE,PA,https://ClinicalTrials.gov/show/NCT00304031,FALSE,Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,Brain and Central Nervous System Tumors,Drug:Concurrent temozolomide; Radiation:Concurrent radiation therapy; Drug:100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle; Drug:75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle,[],13-Oct-15,18,120,Both,FALSE,4NCT00303628,National Cancer Institute (NCI),FALSE,PA,https://ClinicalTrials.gov/show/NCT00303628,FALSE,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],20-May-14,18,9999,Both,FALSE,9NCT00288080,Radiation Therapy Oncology Group,TRUE,PA,https://ClinicalTrials.gov/show/NCT00288080,FALSE,Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:docetaxel; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:prednisone; Drug:triptorelin; Radiation:radiation therapy,[],20-Mar-15,18,9999,Male,FALSE,4NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,PA,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00310180,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00346216,Pfizer,FALSE,RI,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00324805,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00053898,NSABP Foundation Inc,TRUE,RI,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT02465060,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT01827761,Brown University,FALSE,RI,https://ClinicalTrials.gov/show/NCT01827761,FALSE,Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258,Cancer,Behavioral:Questionnaire,"[u'Memorial Hospital', u'Rhode Island Hospital (including Newport)', u'The Miriam Hospital', u'Roger Williams Medical Center']",9-May-14,18,9999,Both,FALSE,81NCT01764633,Amgen,FALSE,RI,https://ClinicalTrials.gov/show/NCT01764633,FALSE,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],20-Jan-16,40,85,Both,FALSE,16NCT01547741,NSABP Foundation Inc,FALSE,RI,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01275677,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00862368,The Miriam Hospital,TRUE,RI,https://ClinicalTrials.gov/show/NCT00862368,FALSE,Sustaining Smoking Cessation in Smokers With Kids With Asthma,Asthma; Smoking Cessation,Behavioral:PAM; Behavioral:PAM-Enhanced/Asthma Counseling Phone Calls; Behavioral:Follow-Up Phone Calls - Child Wellness Topic,"[u""St. Anne's Hospital"", u'Memorial Hospital of RI', u""Hasbro Children's Hospital"", u'The Miriam Hospital', u'Kent County Hospital']",24-Apr-12,18,9999,Both,TRUE,41NCT00861705,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT00861705,FALSE,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],28-Sep-15,18,9999,Both,FALSE,9NCT00705406,BioCryst Pharmaceuticals,FALSE,RI,https://ClinicalTrials.gov/show/NCT00705406,FALSE,"A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza","Acute, Uncomplicated Human Influenza",Drug:Peramivir; Drug:Placebo,[],12-Feb-15,18,9999,Both,FALSE,72NCT00607256,Pfizer,FALSE,RI,https://ClinicalTrials.gov/show/NCT00607256,FALSE,"Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia",Fibromyalgia,"Drug:[S,S]-reboxetine",[],15-Feb-11,18,9999,Both,FALSE,10NCT00490139,GlaxoSmithKline,FALSE,RI,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT00433511,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00373685,Pfizer,FALSE,RI,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00326898,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00264901,Novo Nordisk A/S,FALSE,RI,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00240383,Bristol-Myers Squibb,FALSE,RI,https://ClinicalTrials.gov/show/NCT00240383,FALSE,"Dose Ranging Study With LT, Monotherapy, PPAR",Diabetes Mellitus II,Drug:Muraglitazar,[],10-Sep-10,18,70,Both,FALSE,80NCT00239681,AstraZeneca,FALSE,RI,https://ClinicalTrials.gov/show/NCT00239681,FALSE,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],6-Feb-14,50,9999,Both,FALSE,13NCT00079274,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT00041119,Alliance for Clinical Trials in Oncology,TRUE,RI,https://ClinicalTrials.gov/show/NCT00041119,FALSE,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],23-Jul-15,18,9999,Female,FALSE,1NCT00034879,AstraZeneca,FALSE,RI,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT00003797,Brown University,FALSE,RI,https://ClinicalTrials.gov/show/NCT00003797,FALSE,Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas,Pancreatic Cancer,Biological:trastuzumab; Drug:gemcitabine hydrochloride,"[u""Rush-Presbyterian-St. Luke's Medical Center"", u'New England Medical Center Hospital', u""St. Elizabeth's Medical Center"", u'Cancer Institute of New Jersey', u'Memorial Sloan-Kettering Cancer Center', u'Mount Sinai Medical Center, NY', u'University of Pittsburgh Cancer Institute', u'Memorial Hospital of Rhode Island', u'Rhode Island Hospital', u'Roger Williams Medical Center/BUSM', u'Brown University Oncology Group', u'University of Texas - MD Anderson Cancer Center']",18-Dec-13,18,9999,Both,FALSE,81NCT01900665,Eli Lilly and Company,FALSE,RI,https://ClinicalTrials.gov/show/NCT01900665,FALSE,Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo,Alzheimer's Disease,Drug:Solanezumab; Drug:Placebo,[],29-Apr-15,55,90,Both,FALSE,104NCT01757925,UnitedHealth Group,FALSE,RI,https://ClinicalTrials.gov/show/NCT01757925,FALSE,Evaluation of a Commercial Gaming Impact in a Childhood Obesity Intervention,Childhood Obesity,Behavioral:weight managment program; Other:Active Gaming,"[u'YMCA Andvore', u'YMCA Lawrence', u'YMCA Merrimack Valley of MAss', u'YMCA Boroughs', u'Barrinton YMCA', u'Newman YMCA', u'YMCA Kent', u'Jones Elementary', u'Barabara Jordan Elementary', u'Oyster Creek Elementary', u'Townwest Elementary']",28-Dec-12,6,12,Both,TRUE,196NCT01744353,Brown University,FALSE,RI,https://ClinicalTrials.gov/show/NCT01744353,FALSE,BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study,Metastatic Pancreatic Cancer,Drug:FOLFOX-A,"[u'Memorial Hospital', u'Rhode Island Hospital (including Newport and East Greenwich locations)', u'The Miriam Hospital']",3-Apr-15,18,9999,Both,FALSE,81NCT01744340,howard safran,FALSE,RI,https://ClinicalTrials.gov/show/NCT01744340,FALSE,A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer,Head and Neck Cancer; Colon Cancer,Drug:Head and neck; Drug:Colon- Closed as of May 2014,"[u'Montefiore', u'Memorial Hospital', u'Rhode Island Hospital', u'The Miriam Hospital']",27-Mar-15,18,9999,Both,FALSE,121NCT01507545,Morphotek,FALSE,RI,https://ClinicalTrials.gov/show/NCT01507545,FALSE,Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO),Metastatic Colorectal Cancer; Colorectal Cancer,Drug:MORAb-004; Drug:Placebo,[],4-Sep-15,18,9999,Both,FALSE,149NCT01479621,Teva Pharmaceutical Industries,FALSE,RI,https://ClinicalTrials.gov/show/NCT01479621,FALSE,A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids,Asthma,Drug:Placebo; Drug:Flovent Diskus; Drug:Fluticasone propionate DPI Dose 1; Drug:Fluticasone propionate DPI Dose 2; Drug:Fluticasone propionate DPI Dose 3; Drug:Fluticasone propionate DPI Dose 4,[],19-Mar-15,12,9999,Both,FALSE,187NCT01475721,GlaxoSmithKline,FALSE,RI,https://ClinicalTrials.gov/show/NCT01475721,FALSE,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],10-Dec-15,12,9999,Both,FALSE,8NCT01365130,howard safran,FALSE,RI,https://ClinicalTrials.gov/show/NCT01365130,FALSE,Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen,Esophageal; Gastrooesophageal Cancer; Gastric Cancer,Drug:jevtana,"[u'Memorial Hospital', u'Brown University Oncology Research Group', u'Roger Williams']",12-Jun-14,18,9999,Both,FALSE,121NCT01363843,William Sikov,FALSE,RI,https://ClinicalTrials.gov/show/NCT01363843,FALSE,Complete Neoadjuvant Treatment for REctal Cancer (CONTRE),Colon Cancer; Rectal Cancer,Drug:FOLFOX6; Radiation:RT with concurrent chemotherapy; Procedure:Surgery,"[u'Memorial Hospital', u'The Miriam Hospital', u'Rhode Island Hospital']",25-Jul-14,18,9999,Both,FALSE,223NCT01351389,Brown University,FALSE,RI,https://ClinicalTrials.gov/show/NCT01351389,FALSE,Brief Interventions in the Emergency Department for Alcohol and HIV/Sexual Risk,Alcohol Consumption; Unsafe Sex,Behavioral:Brief Motivational Intervention (BMI); Behavioral:Brief Advice,"[u'Memorial Hospital of Rhode Island', u'Brown University Center for Alcohol and Addiction Studies', u'Kent Hospital']",12-Sep-14,18,65,Both,FALSE,81NCT01327846,Novartis Pharmaceuticals,FALSE,RI,https://ClinicalTrials.gov/show/NCT01327846,FALSE,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),Atherosclerosis,Drug:Canakinumab; Drug:Placebo,[],19-May-15,18,9999,Both,FALSE,156NCT01313676,GlaxoSmithKline,FALSE,RI,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT01302067,Pfizer,FALSE,RI,https://ClinicalTrials.gov/show/NCT01302067,FALSE,A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine,Overactive Bladder,Drug:Fesoterodine 8mg; Drug:Fesoterodine 4mg; Drug:Placebo,[],25-Feb-14,18,9999,Both,FALSE,10NCT01302054,Pfizer,FALSE,RI,https://ClinicalTrials.gov/show/NCT01302054,FALSE,"A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.","Urinary Bladder, Overactive",Drug:Fesoterodine 8 mg; Drug:Placebo,[],22-Mar-13,18,9999,Both,FALSE,10NCT01276509,Pfizer,FALSE,RI,https://ClinicalTrials.gov/show/NCT01276509,FALSE,Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease,Crohn's Disease,Drug:PF-00547659 SC injection; Drug:PF-00547659 SC injection; Drug:PF-00547659 SC injection; Drug:PF-00547659 SC injection,[],7-Dec-15,18,75,Both,FALSE,10NCT01224795,BioCryst Pharmaceuticals,FALSE,RI,https://ClinicalTrials.gov/show/NCT01224795,FALSE,A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.,Influenza,Drug:Peramivir; Drug:Placebo Comparator,[],15-Dec-14,12,9999,Both,FALSE,72NCT01196390,National Cancer Institute (NCI),FALSE,RI,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01175226,Biota Scientific Management Pty Ltd,FALSE,RI,https://ClinicalTrials.gov/show/NCT01175226,FALSE,A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection,Rhinovirus,Drug:BTA798; Drug:Placebo,[],12-Sep-13,18,70,Both,FALSE,74NCT01130272,"Furiex Pharmaceuticals, Inc",FALSE,RI,https://ClinicalTrials.gov/show/NCT01130272,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],11-Jun-12,18,65,Both,FALSE,112NCT01101438,NCIC Clinical Trials Group,TRUE,RI,https://ClinicalTrials.gov/show/NCT01101438,FALSE,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,Breast Cancer,Drug:metformin hydrochloride; Other:placebo,[],5-May-15,18,74,Both,FALSE,11NCT01057693,Pfizer,FALSE,RI,https://ClinicalTrials.gov/show/NCT01057693,FALSE,Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy,"Diabetic Neuropathy, Painful",Drug:pregabalin (Lyrica); Drug:Placebo,[],18-Jan-13,18,9999,Both,FALSE,10NCT01042769,Hoffmann-La Roche,FALSE,RI,https://ClinicalTrials.gov/show/NCT01042769,FALSE,A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Aleglitazar; Drug:Placebo,[],1-Feb-16,18,9999,Both,FALSE,119NCT00937352,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",FALSE,RI,https://ClinicalTrials.gov/show/NCT00937352,FALSE,A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease,Alzheimer's Disease,Drug:Bapineuzumab,[],26-Nov-13,51,9999,Both,FALSE,131NCT00911937,Pfizer,FALSE,RI,https://ClinicalTrials.gov/show/NCT00911937,FALSE,A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency,Overactive Bladder,Drug:Fesoterodine; Drug:Placebo,[],9-Jul-12,18,9999,Both,FALSE,10NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,RI,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT02465060,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01498289,Southwest Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01275677,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01097278,Southwest Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT01097278,FALSE,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],7-Jan-15,18,50,Female,FALSE,3NCT00942331,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00785291,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00373685,Pfizer,FALSE,SC,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00346216,Pfizer,FALSE,SC,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00264901,Novo Nordisk A/S,FALSE,SC,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00946712,Southwest Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00803062,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00803062,FALSE,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],22-May-15,18,9999,Female,FALSE,9NCT02042443,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT02042443,FALSE,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],3-Feb-16,0,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,SC,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01313676,GlaxoSmithKline,FALSE,SC,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT01015833,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00954174,Gynecologic Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT00954174,FALSE,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00324805,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01099449,Alliance for Clinical Trials in Oncology,FALSE,SC,https://ClinicalTrials.gov/show/NCT01099449,FALSE,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],4-Jul-15,18,9999,Both,FALSE,1NCT00874211,Southwest Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT00874211,FALSE,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],4-Mar-15,0,9999,Both,FALSE,3NCT00499369,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00499369,FALSE,Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Biological:bevacizumab,[],25-Jul-14,18,9999,Both,FALSE,9NCT00326898,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00217737,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT00951496,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00951496,FALSE,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00450281,Southwest Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT00450281,FALSE,"S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",Lung Cancer,Genetic:chromogenic in situ hybridization; Genetic:gene expression analysis; Genetic:mutation analysis; Genetic:polymerase chain reaction; Genetic:polymorphism analysis; Other:fluorescent antibody technique; Other:immunohistochemistry staining method; Other:laboratory biomarker analysis; Other:matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other:study of socioeconomic and demographic variables; Procedure:study of high risk factors,[],23-Oct-15,18,120,Both,FALSE,3NCT01385137,Southwest Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT01385137,FALSE,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],15-Oct-15,18,120,Female,FALSE,3NCT01011478,NSABP Foundation Inc,TRUE,SC,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT00861705,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00861705,FALSE,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],28-Sep-15,18,9999,Both,FALSE,9NCT00792701,Southwest Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT00792701,FALSE,S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer,Lung Cancer,Drug:cisplatin; Drug:gemcitabine hydrochloride; Other:active surveillance,[],5-Feb-15,18,9999,Both,FALSE,3NCT02276222,Sunovion Respiratory Development Inc.,FALSE,SC,https://ClinicalTrials.gov/show/NCT02276222,FALSE,A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD,Chronic Obstructive Pulmonary Disease (COPD),Drug:Glycopyrrolate (SUN-101 ); Drug:tiotropium (Spiriva),[],25-Aug-15,40,9999,Both,FALSE,181NCT01642251,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT01642251,FALSE,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01508026,Forest Laboratories,FALSE,SC,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT01196390,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT00775645,Southwest Oncology Group,TRUE,SC,https://ClinicalTrials.gov/show/NCT00775645,FALSE,"S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy",Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity,Dietary Supplement:acetyl-L-carnitine hydrochloride; Other:placebo,[],13-Jan-14,18,9999,Female,FALSE,3NCT00602459,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00602459,FALSE,Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,[],22-Apr-15,18,9999,Both,FALSE,9NCT00569127,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00569127,FALSE,"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor",Neuroendocrine Carcinoma,Biological:Recombinant Interferon Alfa-2b; Drug:Octreotide Acetate; Biological:Bevacizumab,[],5-Jan-15,0,9999,Both,FALSE,9NCT00567580,Radiation Therapy Oncology Group,FALSE,SC,https://ClinicalTrials.gov/show/NCT00567580,FALSE,Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:flutamide; Radiation:radiation therapy,[],31-Mar-15,18,9999,Male,FALSE,4NCT02500797,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT02500797,FALSE,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],11-Jan-16,18,9999,Both,FALSE,9NCT02311907,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT02311907,FALSE,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],22-May-15,18,9999,Female,FALSE,9NCT01712516,Novartis Pharmaceuticals,FALSE,SC,https://ClinicalTrials.gov/show/NCT01712516,FALSE,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:QAB149; Drug:NVA237; Drug:Placebo,[],13-Jul-15,40,9999,Both,FALSE,156NCT01709864,Novartis Pharmaceuticals,FALSE,SC,https://ClinicalTrials.gov/show/NCT01709864,FALSE,NVA237 Versus Placebo 12-week Efficacy Study,Chronic Obstructive Pulmonary Disease,Drug:NVA237; Drug:Placebo,[],12-Feb-15,40,9999,Both,FALSE,156NCT01126437,Boehringer Ingelheim,FALSE,SC,https://ClinicalTrials.gov/show/NCT01126437,FALSE,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:tiotropium 18 mcg; Drug:tiotropium 1.25 mcg (2 actuations/day); Drug:tiotropium 2.5 mcg (2 actuations/day),[],20-May-14,40,9999,Both,FALSE,75NCT01004640,Alliance for Clinical Trials in Oncology,FALSE,SC,https://ClinicalTrials.gov/show/NCT01004640,FALSE,Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial,Leukemia,Genetic:DNA analysis; Genetic:Southern blotting; Genetic:cytogenetic analysis; Genetic:polymerase chain reaction,[],23-Jul-15,0,9999,Both,FALSE,1NCT00937937,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00937937,FALSE,Dinaciclib in Treating Patients With Stage IV Melanoma,Acral Lentiginous Malignant Melanoma; Lentigo Maligna Malignant Melanoma; Mucosal Melanoma; Nodular Malignant Melanoma; Recurrent Melanoma; Stage IV Melanoma; Superficial Spreading Malignant Melanoma,Drug:dinaciclib,[],9-Jun-14,18,9999,Both,FALSE,9NCT00892177,Alliance for Clinical Trials in Oncology,FALSE,SC,https://ClinicalTrials.gov/show/NCT00892177,FALSE,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],23-Nov-15,18,9999,Both,FALSE,1NCT00887536,NSABP Foundation Inc,FALSE,SC,https://ClinicalTrials.gov/show/NCT00887536,FALSE,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],24-Jun-15,18,70,Female,FALSE,2NCT00770809,National Cancer Institute (NCI),FALSE,SC,https://ClinicalTrials.gov/show/NCT00770809,FALSE,Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,HER2/Neu Positive; Male Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Lapatinib Ditosylate; Biological:Trastuzumab; Drug:Paclitaxel; Other:Laboratory Biomarker Analysis,[],7-May-15,18,9999,Both,FALSE,9NCT00601900,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00601900,FALSE,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],23-Apr-15,18,9999,Female,FALSE,9NCT00433511,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00079274,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT01275677,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00326898,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT02465060,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,SD,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT00946712,Southwest Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00942357,Gynecologic Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00887159,National Cancer Institute (NCI),TRUE,SD,https://ClinicalTrials.gov/show/NCT00887159,FALSE,Cisplatin and Etoposide With or Without Vismodegib or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Biological:cixutumumab; Drug:vismodegib; Drug:cisplatin; Drug:etoposide,[],1-Jul-15,18,9999,Both,FALSE,9NCT00861705,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00861705,FALSE,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],28-Sep-15,18,9999,Both,FALSE,9NCT00803062,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00803062,FALSE,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],22-May-15,18,9999,Female,FALSE,9NCT00785291,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00588770,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT00569127,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00569127,FALSE,"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor",Neuroendocrine Carcinoma,Biological:Recombinant Interferon Alfa-2b; Drug:Octreotide Acetate; Biological:Bevacizumab,[],5-Jan-15,0,9999,Both,FALSE,9NCT00490139,GlaxoSmithKline,FALSE,SD,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT00217737,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00134056,Southwest Oncology Group,TRUE,SD,https://ClinicalTrials.gov/show/NCT00134056,FALSE,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],6-May-15,18,9999,Male,FALSE,3NCT00087178,NSABP Foundation Inc,FALSE,SD,https://ClinicalTrials.gov/show/NCT00087178,FALSE,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],5-Oct-15,18,9999,Female,FALSE,2NCT00075946,Eastern Cooperative Oncology Group,TRUE,SD,https://ClinicalTrials.gov/show/NCT00075946,FALSE,Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma,Lymphoma,Biological:rituximab,[],3-Jun-15,18,9999,Both,FALSE,17NCT00003594,Alliance for Clinical Trials in Oncology,TRUE,SD,https://ClinicalTrials.gov/show/NCT00003594,FALSE,Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,Colorectal Cancer,Drug:irinotecan; Drug:fluorouracil; Drug:leucovorin calcium; Drug:oxaliplatin,[],9-Jul-15,18,9999,Both,FALSE,1NCT02311907,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT02311907,FALSE,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],22-May-15,18,9999,Female,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01720173,Gynecologic Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT01720173,FALSE,"Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Biological:Dalantercept; Other:Laboratory Biomarker Analysis,[],23-Dec-14,18,9999,Female,FALSE,14NCT01498289,Southwest Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01167712,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT01011478,NSABP Foundation Inc,TRUE,SD,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT00954174,Gynecologic Oncology Group,FALSE,SD,https://ClinicalTrials.gov/show/NCT00954174,FALSE,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00951496,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00951496,FALSE,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00942331,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00892177,Alliance for Clinical Trials in Oncology,FALSE,SD,https://ClinicalTrials.gov/show/NCT00892177,FALSE,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],23-Nov-15,18,9999,Both,FALSE,1NCT00891878,Alliance for Clinical Trials in Oncology,FALSE,SD,https://ClinicalTrials.gov/show/NCT00891878,FALSE,Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer,Drug:capecitabine; Drug:sunitinib malate,[],8-Jul-15,18,9999,Both,FALSE,1NCT00808132,Pfizer,FALSE,SD,https://ClinicalTrials.gov/show/NCT00808132,FALSE,Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis,Menopause; Osteoporosis,Drug:bazedoxifene 20 mg/ conjugated estrogens 0.45 mg; Drug:bazedoxifene 20 mg/ conjugated estrogens 0.625 mg; Drug:bazedoxifene 20 mg; Drug:conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg; Drug:Placebo,[],10-Mar-14,40,64,Female,FALSE,10NCT00798603,Alliance for Clinical Trials in Oncology,FALSE,SD,https://ClinicalTrials.gov/show/NCT00798603,FALSE,"Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",Lung Cancer,Biological:bevacizumab; Drug:carboplatin; Drug:pemetrexed disodium,[],3-Jul-15,70,9999,Both,FALSE,1NCT00702949,Alliance for Clinical Trials in Oncology,TRUE,SD,https://ClinicalTrials.gov/show/NCT00702949,FALSE,Pregabalin in Treating Women With Hot Flashes,Breast Cancer; Hot Flashes,Drug:pregabalin; Other:placebo,[],23-Nov-15,18,9999,Female,TRUE,1NCT00693992,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00693992,FALSE,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],26-Jun-15,18,9999,Both,FALSE,9NCT00644228,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00644228,FALSE,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],12-Sep-14,18,9999,Both,FALSE,9NCT00602641,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00602641,FALSE,"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma",Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:melphalan; Drug:prednisone; Drug:thalidomide; Drug:lenalidomide,[],9-Jun-15,18,9999,Both,FALSE,9NCT00531817,Hoffmann-La Roche,FALSE,SD,https://ClinicalTrials.gov/show/NCT00531817,FALSE,A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Tocilizumab; Drug:Placebo; Drug:Permitted DMARDs,[],13-Aug-12,18,9999,Both,FALSE,119NCT00521001,Alliance for Clinical Trials in Oncology,TRUE,SD,https://ClinicalTrials.gov/show/NCT00521001,FALSE,Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery,Melanoma (Skin),Drug:everolimus; Drug:temozolomide,[],9-Jul-15,18,9999,Both,FALSE,1NCT00516698,Alliance for Clinical Trials in Oncology,FALSE,SD,https://ClinicalTrials.gov/show/NCT00516698,FALSE,Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer,Breast Cancer,Genetic:polymorphism analysis; Other:high performance liquid chromatography; Other:laboratory biomarker analysis; Procedure:radiomammography,[],5-Jul-15,18,9999,Female,FALSE,1NCT00516503,Alliance for Clinical Trials in Oncology,TRUE,SD,https://ClinicalTrials.gov/show/NCT00516503,FALSE,Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer,"Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific",Drug:baclofen/amitriptyline/ketamine gel; Other:placebo,[],3-Jul-15,18,9999,Both,FALSE,1NCT00438659,North Central Cancer Treatment Group,TRUE,SD,https://ClinicalTrials.gov/show/NCT00438659,FALSE,Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ,Breast Cancer; Dermatologic Complications; Radiation Toxicity; Skin Reactions Secondary to Radiation Therapy,Drug:mometasone furoate; Other:placebo,[],11-Feb-15,18,9999,Both,FALSE,18NCT00404235,Alliance for Clinical Trials in Oncology,TRUE,SD,https://ClinicalTrials.gov/show/NCT00404235,FALSE,Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,Melanoma (Skin),Drug:carboplatin; Drug:paclitaxel albumin-stabilized nanoparticle formulation,[],7-Jul-15,18,9999,Both,FALSE,1NCT00382070,NSABP Foundation Inc,TRUE,SD,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT00378703,National Cancer Institute (NCI),FALSE,SD,https://ClinicalTrials.gov/show/NCT00378703,FALSE,"Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer",Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Sorafenib; Drug:temsirolimus; Biological:bevacizumab,[],14-Apr-15,18,9999,Both,FALSE,9NCT00376675,Alliance for Clinical Trials in Oncology,TRUE,SD,https://ClinicalTrials.gov/show/NCT00376675,FALSE,Methylphenidate in Treating Patients With Fatigue Caused by Cancer,"Fatigue; Unspecified Adult Solid Tumor, Protocol Specific",Drug:methylphenidate hydrochloride; Other:placebo,[],14-Sep-15,18,9999,Both,FALSE,1NCT00310180,National Cancer Institute (NCI),FALSE,TN,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00264901,Novo Nordisk A/S,FALSE,TN,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT00080340,Telik,FALSE,TN,https://ClinicalTrials.gov/show/NCT00080340,FALSE,Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Non Small Cell Lung Carcinoma,Drug:TLK286 (Telcyta) HCl for Injection; Drug:gefitinib (Iressa),[],10-Jan-08,18,9999,Both,FALSE,185NCT01740427,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT01740427,FALSE,A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2),Breast Neoplasms,Drug:PD-0332991; Drug:Letrozole; Drug:Placebo; Drug:Letrozole,[],4-Feb-16,18,9999,Female,FALSE,10NCT00678392,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00678392,FALSE,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,Kidney Neoplasms,Drug:Axitinib (AG-013736); Drug:Sorafenib,[],10-Dec-15,18,9999,Both,FALSE,10NCT00615056,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00615056,FALSE,A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen,Colorectal Neoplasms,"Drug:Bevacizumab (avastin); Drug:FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]); Drug:AG-013736 (axitinib); Drug:FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]); Drug:AG-013736 (axitinib); Drug:FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]); Drug:Bevacizumab (avastin); Drug:FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])",[],12-Apr-13,18,9999,Both,FALSE,10NCT00057720,Telik,FALSE,TN,https://ClinicalTrials.gov/show/NCT00057720,FALSE,TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer,Ovarian Neoplasms,Drug:TLK286 HCl for injection; Drug:topotecan hydrochloride for injection; Drug:doxorubicin HCl liposome injection,[],21-Jul-11,18,9999,Female,FALSE,185NCT00932451,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00932451,FALSE,"An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene","Carcinoma, Non-Small-Cell Lung",Drug:PF-02341066,[],23-Nov-15,18,9999,Both,FALSE,10NCT00887536,NSABP Foundation Inc,FALSE,TN,https://ClinicalTrials.gov/show/NCT00887536,FALSE,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],24-Jun-15,18,70,Female,FALSE,2NCT00373685,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00346216,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT01154140,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT01154140,FALSE,A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung,Non Squamous Lung Cancer,Drug:treatment; Drug:treatment,[],30-Nov-15,18,9999,Both,FALSE,10NCT00932893,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00932893,FALSE,"An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene","Carcinoma, Non-Small-Cell Lung",Drug:PF-02341066; Drug:Pemetrexed; Drug:Docetaxel,[],3-Dec-15,18,9999,Both,FALSE,10NCT00640042,Pfizer,TRUE,TN,https://ClinicalTrials.gov/show/NCT00640042,FALSE,"Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",Pain,Drug:morphine sulfate extended release capsules,[],6-Jun-12,21,9999,Both,FALSE,10NCT00968708,Takeda,FALSE,TN,https://ClinicalTrials.gov/show/NCT00968708,FALSE,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,"Diabetes Mellitus, Type 2; Acute Coronary Syndrome",Drug:Alogliptin; Drug:Placebo,[],15-Apr-14,18,9999,Both,FALSE,5NCT00878709,"Puma Biotechnology, Inc.",FALSE,TN,https://ClinicalTrials.gov/show/NCT00878709,FALSE,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Breast Cancer,Drug:neratinib; Other:placebo,[],20-Aug-15,18,9999,Female,FALSE,166NCT00137436,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00137436,FALSE,Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer,Prostatic Neoplasms,Drug:Docetaxel; Drug:Prednisone; Drug:SU011248,"[u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site']",25-Aug-11,18,9999,Male,FALSE,10NCT00849056,GlaxoSmithKline,FALSE,TN,https://ClinicalTrials.gov/show/NCT00849056,FALSE,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:placebo,[],29-May-14,18,9999,Both,FALSE,8NCT00798889,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00798889,FALSE,Rollover Protocol for Prior SU011248 Protocols,Solid Tumors,Drug:Sunitinib,[],13-Dec-12,18,9999,Both,FALSE,10NCT00699374,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00699374,FALSE,Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer,"Carcinoma, Hepatocellular",Drug:sunitinib malate; Drug:sorafenib,[],7-Dec-12,18,9999,Both,FALSE,10NCT00839527,GlaxoSmithKline,FALSE,TN,https://ClinicalTrials.gov/show/NCT00839527,FALSE,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:placebo to match albiglutide; Biological:albiglutide; Drug:metformin; Drug:glimepiride; Drug:pioglitazone; Drug:placebo to match pioglitazone,[],29-May-14,18,9999,Both,FALSE,8NCT00838903,GlaxoSmithKline,FALSE,TN,https://ClinicalTrials.gov/show/NCT00838903,FALSE,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:sitagliptin; Drug:glimepiride; Drug:metformin; Biological:placebo albiglutide; Drug:placebo sitagliptin; Drug:placebo glimepiride,[],11-Aug-14,18,9999,Both,FALSE,8NCT00490139,GlaxoSmithKline,FALSE,TN,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT00435409,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00435409,FALSE,A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer,Breast Neoplasms,Drug:Sunitinib + Capecitabine; Drug:Capecitabine,[],15-Jun-12,18,9999,Both,FALSE,10NCT00433511,National Cancer Institute (NCI),FALSE,TN,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00403767,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",FALSE,TN,https://ClinicalTrials.gov/show/NCT00403767,FALSE,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation; Stroke; Embolism,Drug:Rivaroxaban; Drug:Warfarin; Drug:Matching placebo for Rivaroxaban arm (Warfarin placebo); Drug:Matching placebo for Warfarin arm (Rivaroxaban placebo),[],10-Apr-14,18,9999,Both,FALSE,136NCT00324805,National Cancer Institute (NCI),FALSE,TN,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00239681,AstraZeneca,FALSE,TN,https://ClinicalTrials.gov/show/NCT00239681,FALSE,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],6-Feb-14,50,9999,Both,FALSE,13NCT00113516,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00113516,FALSE,A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer,Drug:carboplatin; Drug:paclitaxel; Drug:sunitinib,[],14-May-10,18,9999,Both,FALSE,10NCT00072852,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00072852,FALSE,"Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine",Breast Neoplasms,Drug:Irinotecan,[],15-Oct-08,18,9999,Female,FALSE,10NCT01275677,National Cancer Institute (NCI),FALSE,TN,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01136967,Eisai Inc.,FALSE,TN,https://ClinicalTrials.gov/show/NCT01136967,FALSE,"An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma",Unresectable Stage III; Stage IV Melanoma,Drug:E7080; Drug:E7080,[],1-Apr-14,18,9999,Both,FALSE,102NCT01015833,National Cancer Institute (NCI),FALSE,TN,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00471276,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00471276,FALSE,Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer,Breast Neoplasms,Drug:sunitinib,[],21-Jul-11,18,9999,Female,FALSE,10NCT00460603,Pfizer,FALSE,TN,https://ClinicalTrials.gov/show/NCT00460603,FALSE,Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer,Colorectal Neoplasms,Drug:bevacizumab; Drug:AG-013726; Drug:AG-013736 (axitinib),[],7-Nov-13,18,9999,Both,FALSE,10NCT00217737,National Cancer Institute (NCI),FALSE,TN,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00088556,Telik,FALSE,TN,https://ClinicalTrials.gov/show/NCT00088556,FALSE,"Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung",Drug:TLK286; Drug:carboplatin; Drug:paclitaxel,[],30-May-12,18,9999,Both,FALSE,185NCT00067938,GlaxoSmithKline,FALSE,TN,https://ClinicalTrials.gov/show/NCT00067938,FALSE,Bipolar Study in Adults at Least 18 Years of Age,Bipolar Disorder,Drug:lamotrigine,[],11-Oct-12,18,9999,Both,FALSE,8NCT00006104,Vanderbilt-Ingram Cancer Center,FALSE,TN,https://ClinicalTrials.gov/show/NCT00006104,FALSE,Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer,Breast Cancer,Biological:trastuzumab; Drug:docetaxel,"[u'Providence Hospital', u'Robert H. Lurie Comprehensive Cancer Center, Northwestern University', u'Evanston Hospital', u'Owensboro Medical Health System', u'Fox Chase Cancer Center', u'Erlanger Health Systems', u'Memorial Health Care System', u'Williamson Medical Center', u'Jackson-Madison County Hospital', u'Methodist/Thompson Oncology Research', u'Tennessee Cancer Specialists', u'Boston Baskin Cancer Group', u'St. Thomas Health Services', u'Vanderbilt-Ingram Cancer Center', u'Methodist Medical Center of Oak Ridge']",10-Aug-12,18,9999,Female,FALSE,215NCT01959529,Novo Nordisk A/S,FALSE,TN,https://ClinicalTrials.gov/show/NCT01959529,FALSE,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],8-Jan-16,50,9999,Both,FALSE,158NCT01508026,Forest Laboratories,FALSE,TN,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT01130272,"Furiex Pharmaceuticals, Inc",FALSE,TN,https://ClinicalTrials.gov/show/NCT01130272,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],11-Jun-12,18,65,Both,FALSE,112NCT01100684,Tioga Pharmaceuticals,FALSE,TN,https://ClinicalTrials.gov/show/NCT01100684,FALSE,Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS),Diarrhea Predominant Irritable Bowel Syndrome,Drug:Asimadoline; Drug:Placebo,[],17-Dec-13,18,79,Both,FALSE,192NCT01070836,Biogen,FALSE,TN,https://ClinicalTrials.gov/show/NCT01070836,FALSE,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],14-Jan-16,0,9999,Both,FALSE,73NCT00838916,GlaxoSmithKline,FALSE,TN,https://ClinicalTrials.gov/show/NCT00838916,FALSE,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:insulin glargine,[],22-May-14,18,9999,Both,FALSE,8NCT00769379,National Cancer Institute (NCI),FALSE,TN,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00699998,Eli Lilly and Company,FALSE,TN,https://ClinicalTrials.gov/show/NCT00699998,FALSE,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,Acute Coronary Syndrome,Drug:Clopidogrel; Drug:Prasugrel; Drug:Commercially-available Aspirin,[],21-Mar-13,18,9999,Both,FALSE,104NCT00666211,Vanderbilt-Ingram Cancer Center,FALSE,TN,https://ClinicalTrials.gov/show/NCT00666211,FALSE,Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain,"Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Pain; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific",Other:educational intervention; Other:Titrated pain management; Other:questionnaire administration,"[u'Jennie Stuart Medical Center', u'Mitchell Memorial Cancer Center at Owensboro Medical Health System', u'Erlanger Health System', u'Tennessee Plateau Oncology', u'Center for Biomedical Research', u'The Jones Clinic', u'Vanderbilt-Ingram Cancer Center - Cool Springs', u'Vanderbilt-Ingram Cancer Center at Franklin', u'Meharry Medical College', u'Veterans Affairs Medical Center - Nashville', u'Vanderbilt-Ingram Cancer Center']",4-Aug-12,21,9999,Both,FALSE,215NCT02122471,Synergy Pharmaceuticals Inc.,FALSE,TX,https://ClinicalTrials.gov/show/NCT02122471,FALSE,12-Week Study of Plecanatide for CIC (The National CIC3 Study),Chronic Idiopathic Constipation,Drug:Plecanatide; Drug:Placebo,[],29-Jan-15,18,80,Both,FALSE,183NCT02030600,Novo Nordisk A/S,FALSE,TX,https://ClinicalTrials.gov/show/NCT02030600,FALSE,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes","Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],8-Dec-15,18,9999,Both,FALSE,158NCT01959529,Novo Nordisk A/S,FALSE,TX,https://ClinicalTrials.gov/show/NCT01959529,FALSE,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],8-Jan-16,50,9999,Both,FALSE,158NCT01547741,NSABP Foundation Inc,FALSE,TX,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01543178,"Valeant Pharmaceuticals International, Inc.",FALSE,TX,https://ClinicalTrials.gov/show/NCT01543178,FALSE,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],15-Jun-15,18,9999,Both,FALSE,47NCT01508026,Forest Laboratories,FALSE,TX,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT01475721,GlaxoSmithKline,FALSE,TX,https://ClinicalTrials.gov/show/NCT01475721,FALSE,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],10-Dec-15,12,9999,Both,FALSE,8NCT01462344,GlaxoSmithKline,FALSE,TX,https://ClinicalTrials.gov/show/NCT01462344,FALSE,6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg,[],1-Oct-15,4,11,Both,FALSE,8NCT01458275,Sunovion,FALSE,TX,https://ClinicalTrials.gov/show/NCT01458275,FALSE,A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis,Drug:Ciclesonide nasal aerosol 37 mcg; Drug:ciclesonide nasal aerosol 74 mcg; Drug:Placebo,[],16-Apr-14,6,11,Both,FALSE,180NCT01427270,Purdue Pharma LP,FALSE,TX,https://ClinicalTrials.gov/show/NCT01427270,FALSE,Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain,Low Back Pain,Drug:Oxycodone/Naloxone controlled-release; Drug:Oxycodone HCl controlled-release; Drug:Placebo,[],6-Nov-14,18,9999,Both,FALSE,36NCT01349322,Radiation Therapy Oncology Group,FALSE,TX,https://ClinicalTrials.gov/show/NCT01349322,FALSE,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],14-Nov-15,18,9999,Female,FALSE,4NCT01327846,Novartis Pharmaceuticals,FALSE,TX,https://ClinicalTrials.gov/show/NCT01327846,FALSE,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),Atherosclerosis,Drug:Canakinumab; Drug:Placebo,[],19-May-15,18,9999,Both,FALSE,156NCT01313676,GlaxoSmithKline,FALSE,TX,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT01306890,Dendreon,FALSE,TX,https://ClinicalTrials.gov/show/NCT01306890,FALSE,A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer,Advanced Prostate Cancer; Prostatic Neoplasms,Biological:sipuleucel-T,[],5-Oct-15,18,9999,Male,FALSE,97NCT01275677,National Cancer Institute (NCI),FALSE,TX,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01195662,AstraZeneca,FALSE,TX,https://ClinicalTrials.gov/show/NCT01195662,FALSE,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication,Type 2 Diabetes,Drug:Dapagliflozin; Drug:Placebo matching Dapagliflozin,[],2-Dec-15,18,89,Both,FALSE,13NCT01183780,Eli Lilly and Company,FALSE,TX,https://ClinicalTrials.gov/show/NCT01183780,FALSE,A Study in Second Line Metastatic Colorectal Cancer,Colorectal Cancer,Biological:Ramucirumab; Biological:Placebo; Drug:Irinotecan; Drug:Folinic Acid; Drug:5-Fluorouracil,[],14-Sep-15,18,9999,Both,FALSE,104NCT01168973,Eli Lilly and Company,FALSE,TX,https://ClinicalTrials.gov/show/NCT01168973,FALSE,A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy,Non-Small Cell Lung Cancer,Biological:Ramucirumab; Drug:Placebo (for Ramucirumab); Drug:Docetaxel,[],20-Aug-15,18,9999,Both,FALSE,104NCT01130272,"Furiex Pharmaceuticals, Inc",FALSE,TX,https://ClinicalTrials.gov/show/NCT01130272,FALSE,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],11-Jun-12,18,65,Both,FALSE,112NCT01107886,AstraZeneca,FALSE,TX,https://ClinicalTrials.gov/show/NCT01107886,FALSE,Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications,Type 2 Diabetes Mellitus,Drug:Saxagliptin; Drug:Placebo,[],9-Jul-14,40,9999,Both,FALSE,13NCT01098539,GlaxoSmithKline,FALSE,TX,https://ClinicalTrials.gov/show/NCT01098539,FALSE,A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:sitagliptin,[],24-Jul-14,18,9999,Both,FALSE,8NCT01075100,US Oncology Research,FALSE,TX,https://ClinicalTrials.gov/show/NCT01075100,FALSE,Ixabepilone + Carboplatin Metastatic Breast Cancer,Metastatic Breast Cancer,Drug:Ixabepilone; Drug:Carboplatin,[],19-May-14,18,9999,Both,FALSE,214NCT01068912,"MDVI, LLC",FALSE,TX,https://ClinicalTrials.gov/show/NCT01068912,FALSE,Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza,Influenza,Drug:Favipiravir; Drug:Favipiravir; Drug:Placebo comparator,[],20-Oct-15,20,80,Both,FALSE,143NCT01042769,Hoffmann-La Roche,FALSE,TX,https://ClinicalTrials.gov/show/NCT01042769,FALSE,A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Aleglitazar; Drug:Placebo,[],1-Feb-16,18,9999,Both,FALSE,119NCT01035255,Novartis Pharmaceuticals,FALSE,TX,https://ClinicalTrials.gov/show/NCT01035255,FALSE,This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure,Heart Failure With Reduced Ejection Fraction,Drug:LCZ696 200 mg BID; Drug:Enalapril 10 mg BID,[],9-Sep-15,18,9999,Both,FALSE,156NCT01000727,GlaxoSmithKline,FALSE,TX,https://ClinicalTrials.gov/show/NCT01000727,FALSE,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Drug:Darapladib 160 mg; Drug:Placebo; Other:Standard Therapy,[],3-Sep-15,18,9999,Both,FALSE,8NCT00976391,GlaxoSmithKline,FALSE,TX,https://ClinicalTrials.gov/show/NCT00976391,FALSE,A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine,"Diabetes Mellitus, Type 2",Biological:albiglutide + insulin glargine; Drug:insulin glargine + preprandial lispro insulin,[],31-Jul-14,18,75,Both,FALSE,8NCT00946712,Southwest Oncology Group,FALSE,TX,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00887536,NSABP Foundation Inc,FALSE,TX,https://ClinicalTrials.gov/show/NCT00887536,FALSE,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],24-Jun-15,18,70,Female,FALSE,2NCT00878709,"Puma Biotechnology, Inc.",FALSE,TX,https://ClinicalTrials.gov/show/NCT00878709,FALSE,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Breast Cancer,Drug:neratinib; Other:placebo,[],20-Aug-15,18,9999,Female,FALSE,166NCT00849056,GlaxoSmithKline,FALSE,TX,https://ClinicalTrials.gov/show/NCT00849056,FALSE,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:placebo,[],29-May-14,18,9999,Both,FALSE,8NCT00849017,GlaxoSmithKline,FALSE,TX,https://ClinicalTrials.gov/show/NCT00849017,FALSE,Safety and Efficacy Study of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Biological:albiglutide uptitration; Biological:placebo,[],29-May-14,18,9999,Both,FALSE,8NCT00839527,GlaxoSmithKline,FALSE,TX,https://ClinicalTrials.gov/show/NCT00839527,FALSE,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:placebo to match albiglutide; Biological:albiglutide; Drug:metformin; Drug:glimepiride; Drug:pioglitazone; Drug:placebo to match pioglitazone,[],29-May-14,18,9999,Both,FALSE,8NCT00838916,GlaxoSmithKline,FALSE,TX,https://ClinicalTrials.gov/show/NCT00838916,FALSE,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:insulin glargine,[],22-May-14,18,9999,Both,FALSE,8NCT00838903,GlaxoSmithKline,FALSE,TX,https://ClinicalTrials.gov/show/NCT00838903,FALSE,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:sitagliptin; Drug:glimepiride; Drug:metformin; Biological:placebo albiglutide; Drug:placebo sitagliptin; Drug:placebo glimepiride,[],11-Aug-14,18,9999,Both,FALSE,8NCT00821327,US Oncology Research,FALSE,TX,https://ClinicalTrials.gov/show/NCT00821327,FALSE,"Gemzar, Cisp, Sunitinib Urothelial Ca",Urothelial Cancer,"Drug:Gemcitabine, Cisplatin, Sunitinib",[],20-May-14,18,9999,Both,FALSE,214NCT00769379,National Cancer Institute (NCI),FALSE,TX,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00678392,Pfizer,FALSE,TX,https://ClinicalTrials.gov/show/NCT00678392,FALSE,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,Kidney Neoplasms,Drug:Axitinib (AG-013736); Drug:Sorafenib,[],10-Dec-15,18,9999,Both,FALSE,10NCT00658515,Hoffmann-La Roche,FALSE,TX,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00642603,Hoffmann-La Roche,FALSE,TX,https://ClinicalTrials.gov/show/NCT00642603,FALSE,A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Drug:capecitabine [Xeloda]; Drug:capecitabine [Xeloda]; Drug:bevacizumab [Avastin]; Drug:oxaliplatin; Drug:irinotecan,[],31-May-11,18,9999,Both,FALSE,119NCT00616772,"AbbVie (prior sponsor, Abbott)",FALSE,TX,https://ClinicalTrials.gov/show/NCT00616772,FALSE,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Coronary Artery Disease; Coronary Heart Disease; Dyslipidemia,Drug:ABT-335; Drug:Placebo; Other:Atorvastatin,[],3-Dec-13,45,9999,Both,FALSE,52NCT00599313,US Oncology Research,FALSE,TX,https://ClinicalTrials.gov/show/NCT00599313,FALSE,Phase II Sunitinib Prog Met AIPC,Metastatic Prostate Cancer,Drug:Sunitinib,[],21-May-14,18,9999,Male,FALSE,214NCT00593827,Bristol-Myers Squibb,FALSE,TX,https://ClinicalTrials.gov/show/NCT00593827,FALSE,Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer,Metastatic Breast Cancer,Drug:Ixabepilone; Drug:Ixabepilone,[],25-Apr-12,18,9999,Female,FALSE,80NCT00557921,Cogentus Pharmaceuticals,FALSE,TX,https://ClinicalTrials.gov/show/NCT00557921,FALSE,Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1),Acute Coronary Syndrome; Myocardial Infarction; Coronary Artery Disease; Percutaneous Coronary Intervention,Drug:CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin; Drug:Plavix (clopidogrel 75 mg) and aspirin,[],27-Jan-09,21,9999,Both,FALSE,89NCT00527111,US Oncology Research,FALSE,TX,https://ClinicalTrials.gov/show/NCT00527111,FALSE,Pre-op Rectal ChemoRad +/- Cetuximab,Rectal Cancer,Drug:Cetuximab; Drug:5-fluorouracil; Radiation:Pelvic irradiation,[],7-Nov-15,18,9999,Both,FALSE,214NCT00518115,GlaxoSmithKline,TRUE,TX,https://ClinicalTrials.gov/show/NCT00518115,FALSE,Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only,"Diabetes Mellitus, Type 2",Drug:Albiglutide (GSK716155) or exenatide,[],19-Jun-14,18,75,Both,FALSE,8NCT00517829,US Oncology Research,FALSE,TX,https://ClinicalTrials.gov/show/NCT00517829,FALSE,Docetaxel+Oxali+/-Cetux Met Gastric/GEJ,Gastric Cancer Adenocarcinoma Metastatic,Drug:Docetaxel + oxaliplatin; Drug:Docetaxel + oxaliplatin + cetuximab,[],19-May-14,18,9999,Both,FALSE,214NCT00507416,"Millennium Pharmaceuticals, Inc.",FALSE,TX,https://ClinicalTrials.gov/show/NCT00507416,FALSE,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",Multiple Myeloma,Drug:Bortezomib; Drug:Dexamethasone; Drug:Melphalan; Drug:Prednisone; Drug:Thalidomide,[],28-Mar-14,18,9999,Both,FALSE,146NCT01546844,HealthInsight,FALSE,UT,https://ClinicalTrials.gov/show/NCT01546844,FALSE,Mobile Health Technology as an Intervention for Diabetes Self-Management,Type II Diabetes Mellitus,Other:Participation in Care4Life,"[u'Coalville Health Center', u'Pioneer Comprehensive Medical', u'Holladay Family Practice', u'Olympus Clinic', u'Exodus Healthcare - Main Office - Magna', u'Community Health Centers Inc. - 72nd Street Clinic', u'Park City Healthcare, Inc.', u'Riverton Family Health Center', u'Granger Medical-Riverton', u'Stephen D. Ratcliffe Community Health Center', u'Alpine Internal Medicine', u'HealthInsight', u'Central City Community Health Center Health First Family Medicine', u'Evolutionary Healthcare, Llc', u'Health Clinic Of Utah - SLC', u'Wasatch Internal Medicine', u'Jordan Ridge Family Medicine', u""Utah Healthcare Institute - St. Mark's Family Medicine"", u'Wasatch Homeless Health Care - 4th Street Clinic', u""Utah Physicians Care Centers - St Mark's Internal Medicine"", u'Barbara E. Rizzardi, M.D.', u'Copperview Medical Center, Llc', u'Community Health Centers Inc. - Oquirrh View', u'Valley Family Medicine', u'Advanced Practice Medical Clinic', u'Granger Medical - Jordan Medical Arts', u'Jordan Meadows Medical Center', u'West Valley Family And Preventive Medicine', u'Granger Medical Clinic Inc. - Main Office', u'Kathryn Allen, MD']",4-Sep-12,18,9999,Both,FALSE,118NCT02199691,"Sanofi Pasteur, a Sanofi Company",FALSE,UT,https://ClinicalTrials.gov/show/NCT02199691,FALSE,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents,Meningitis; Meningococcal Meningitis; Meningococcal Infections,"Biological:Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine; Biological:Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197Conjugate Vaccine; Biological:Adacel: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Biological:GARDASIL: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant; Biological:Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine; Biological:Adacel: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Biological:GARDASIL: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant",[],5-Nov-15,10,17,Both,TRUE,38NCT01508026,Forest Laboratories,FALSE,UT,https://ClinicalTrials.gov/show/NCT01508026,FALSE,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],28-Mar-14,18,9999,Both,FALSE,110NCT00806195,Novartis,FALSE,UT,https://ClinicalTrials.gov/show/NCT00806195,FALSE,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis; Meningococcal Infection,"Biological:MenACWY-CRM197; Biological:DTaP (Diptheria, Tetanus, Pertussis) Vaccine; Biological:Hib (Haemophilus influenza b) Vaccine; Biological:IPV (Inactivated Polio Vaccine) Vaccine; Biological:Pneumococcal conjugate Vaccine; Biological:MMR (Measles, Mumps, and Rubella) Vaccine; Biological:Varicella Vaccine; Biological:Hepatitis A Virus",[],13-May-13,55,89,Both,TRUE,155NCT00423735,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00423735,FALSE,Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Neoplasm,Drug:Dasatinib; Other:Pharmacological Study,[],5-Jan-16,18,9999,Both,FALSE,9NCT00390455,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00390455,FALSE,Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive,Estrogen Receptor Positive; HER2 Positive Breast Carcinoma; HER2/Neu Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Lapatinib Ditosylate; Drug:Fulvestrant; Other:Placebo; Other:Laboratory Biomarker Analysis,[],1-Jun-15,18,9999,Female,FALSE,9NCT00369122,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00369122,FALSE,"Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer,Radiation:external beam radiation therapy; Radiation:brachytherapy; Biological:bevacizumab; Drug:cisplatin,[],22-Sep-14,0,9999,Female,FALSE,9NCT00326898,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00303628,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00303628,FALSE,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],20-May-14,18,9999,Both,FALSE,9NCT00262847,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00262847,FALSE,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],18-Aug-15,18,9999,Female,FALSE,9NCT00217737,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT02184572,GlaxoSmithKline,FALSE,UT,https://ClinicalTrials.gov/show/NCT02184572,FALSE,"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age",Measles; Mumps; Rubella,"Biological:GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762); Biological:Merck & Co., Inc.'s M-M-RII (also called M-M-R Vax Pro), combined measles-mumps-rubella virus vaccine; Biological:Varivax (Merck & Co., Inc.); Biological:Havrix; Biological:Prevnar 13 (Pfizer Inc.)",[],4-Feb-16,12,15,Both,TRUE,8NCT01167712,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT00803062,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00803062,FALSE,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],22-May-15,18,9999,Female,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00303953,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00303953,FALSE,PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma,Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma,Drug:belinostat,[],23-Apr-14,18,9999,Both,FALSE,9NCT02465060,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01802333,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,UT,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01275677,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00942357,Gynecologic Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00920010,Southwest Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT00920010,FALSE,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],5-Feb-15,0,9999,Both,FALSE,3NCT00874211,Southwest Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT00874211,FALSE,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],4-Mar-15,0,9999,Both,FALSE,3NCT00861705,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00861705,FALSE,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],28-Sep-15,18,9999,Both,FALSE,9NCT00792948,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00792948,FALSE,Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia,Adult Acute Lymphoblastic Leukemia in Remission; Adult B Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Adult L1 Acute Lymphoblastic Leukemia; Adult L2 Acute Lymphoblastic Leukemia; Adult T Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dasatinib; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Biological:Filgrastim; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Methotrexate; Drug:Methylprednisolone; Procedure:Peripheral Blood Stem Cell Transplantation; Drug:Prednisone; Drug:Sirolimus; Drug:Tacrolimus; Radiation:Total-Body Irradiation; Drug:Vincristine Sulfate,[],12-Jan-16,18,60,Both,FALSE,9NCT00683137,Pfizer,FALSE,UT,https://ClinicalTrials.gov/show/NCT00683137,FALSE,Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery,Pain; Hallux Valgus,Drug:valdecoxib; Drug:valdecoxib; Drug:valdecoxib/placebo,[],22-May-08,18,9999,Both,FALSE,10NCT00617708,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00617708,FALSE,S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery,Stage IV Pancreatic Cancer,Biological:cixutumumab; Drug:erlotinib hydrochloride; Drug:gemcitabine hydrochloride,[],25-Jul-14,18,9999,Both,FALSE,9NCT00450281,Southwest Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT00450281,FALSE,"S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",Lung Cancer,Genetic:chromogenic in situ hybridization; Genetic:gene expression analysis; Genetic:mutation analysis; Genetic:polymerase chain reaction; Genetic:polymorphism analysis; Other:fluorescent antibody technique; Other:immunohistochemistry staining method; Other:laboratory biomarker analysis; Other:matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other:study of socioeconomic and demographic variables; Procedure:study of high risk factors,[],23-Oct-15,18,120,Both,FALSE,3NCT00433381,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00433381,FALSE,Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma,Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor,Drug:irinotecan hydrochloride; Biological:bevacizumab; Drug:temozolomide,[],7-May-14,18,9999,Both,FALSE,9NCT00376961,Southwest Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT00376961,FALSE,"S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",Lymphoma,Biological:rituximab; Drug:bortezomib; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate,[],8-May-15,18,9999,Both,FALSE,3NCT00337129,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00337129,FALSE,S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer,Head and Neck Cancer,Drug:eribulin mesylate,[],11-Aug-15,18,9999,Both,FALSE,9NCT00305864,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT00305864,FALSE,"Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma,Radiation:3-dimensional conformal radiation therapy; Drug:temozolomide; Drug:motexafin gadolinium,[],29-Apr-14,18,9999,Both,FALSE,9NCT00134056,Southwest Oncology Group,TRUE,UT,https://ClinicalTrials.gov/show/NCT00134056,FALSE,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],6-May-15,18,9999,Male,FALSE,3NCT00124579,Southwest Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT00124579,FALSE,"S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",Multiple Myeloma,Drug:bortezomib; Drug:dexamethasone; Drug:thalidomide,[],5-Mar-15,18,9999,Both,FALSE,3NCT00107276,Southwest Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT00107276,FALSE,S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer,Breast Cancer,Drug:capecitabine; Drug:cyclophosphamide,[],3-Jul-13,18,9999,Female,FALSE,3NCT00089323,NSABP Foundation Inc,FALSE,UT,https://ClinicalTrials.gov/show/NCT00089323,FALSE,"Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer",Breast Cancer,Procedure:Bone Marrow Aspiration,[],19-Jan-16,18,9999,Both,FALSE,2NCT00079001,Alliance for Clinical Trials in Oncology,TRUE,UT,https://ClinicalTrials.gov/show/NCT00079001,FALSE,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer; Prostate Cancer,Drug:zoledronic acid; Other:placebo; Drug:androgen deprivation therapy; Drug:GnRH agonist; Dietary Supplement:Calcium supplement; Dietary Supplement:Vitamin D,[],23-Nov-15,18,9999,Male,FALSE,1NCT00075764,Southwest Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT00075764,FALSE,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:fulvestrant,[],8-May-14,18,9999,Female,FALSE,3NCT00062439,Southwest Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT00062439,FALSE,S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors,Lung Cancer,Drug:cisplatin; Drug:docetaxel; Drug:etoposide; Procedure:conventional surgery; Radiation:radiation therapy,[],30-Oct-13,0,9999,Both,FALSE,3NCT00003641,Eastern Cooperative Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT00003641,FALSE,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,Melanoma (Skin),Biological:recombinant interferon alfa; Other:clinical observation,[],11-Jul-12,18,9999,Both,FALSE,17NCT01964989,Novartis Vaccines,FALSE,UT,https://ClinicalTrials.gov/show/NCT01964989,FALSE,"Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.",Influenza Virus,Biological:Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV); Biological:Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV),[],7-Dec-15,6,72,Both,TRUE,157NCT01841736,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT01841736,FALSE,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Both,FALSE,9NCT01609790,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT01609790,FALSE,Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors,Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Placebo; Biological:Trebananib,[],31-Jul-15,18,9999,Both,FALSE,9NCT01385137,Southwest Oncology Group,FALSE,UT,https://ClinicalTrials.gov/show/NCT01385137,FALSE,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],15-Oct-15,18,120,Female,FALSE,3NCT01240746,"Sanofi Pasteur, a Sanofi Company",TRUE,UT,https://ClinicalTrials.gov/show/NCT01240746,FALSE,Study of Quadrivalent Influenza Vaccine Among Children,Influenza,"Biological:Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative; Biological:Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative; Biological:Quadrivalent Influenza Vaccine, No Preservative",[],16-Jun-15,6,8,Both,TRUE,38NCT01196390,National Cancer Institute (NCI),FALSE,UT,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01143259,"Intermountain Health Care, Inc.",FALSE,UT,https://ClinicalTrials.gov/show/NCT01143259,FALSE,Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use,Ileus,Drug:Alvimopam; Drug:300 mg Polyethylene,"[u'American Fork Hospital', u'Valley View Hospital', u'Logan Regional Hospital', u'Intermoutain Medical Center', u'McKay-Dee Hospital', u'Utah Valley', u'LDS Hospital', u'Alta View Hospital', u'Dixie Regional']",25-Aug-14,18,9999,Both,FALSE,129NCT01011478,NSABP Foundation Inc,TRUE,UT,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT01004640,Alliance for Clinical Trials in Oncology,FALSE,VT,https://ClinicalTrials.gov/show/NCT01004640,FALSE,Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial,Leukemia,Genetic:DNA analysis; Genetic:Southern blotting; Genetic:cytogenetic analysis; Genetic:polymerase chain reaction,[],23-Jul-15,0,9999,Both,FALSE,1NCT00372996,Pfizer,FALSE,VT,https://ClinicalTrials.gov/show/NCT00372996,FALSE,"Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer",Breast Neoplasms,"Drug:CP-751,871; Drug:exemestane; Drug:exemestane; Drug:Fulvestrant",[],6-Oct-15,18,9999,Female,FALSE,10NCT00053898,NSABP Foundation Inc,TRUE,VT,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT01275677,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00003906,NSABP Foundation Inc,TRUE,VT,https://ClinicalTrials.gov/show/NCT00003906,FALSE,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],5-Oct-15,35,9999,Female,FALSE,2NCT00003389,Eastern Cooperative Oncology Group,TRUE,VT,https://ClinicalTrials.gov/show/NCT00003389,FALSE,Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma,Lymphoma,Drug:Doxorubicin; Drug:Bleomycin; Drug:Vinblastine; Drug:Dacarbazine; Drug:Vincristine; Drug:Mechlorethamine; Drug:Etoposide; Drug:Prednisone; Drug:Cyclophosphamide; Radiation:Radiotherapy,[],25-Sep-15,16,9999,Both,FALSE,17NCT01886872,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01457391,Dartmouth-Hitchcock Medical Center,FALSE,VT,https://ClinicalTrials.gov/show/NCT01457391,FALSE,Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment,"Stress Disorders, Post-Traumatic; Substance-Related Disorders",Behavioral:Cognitive Behavioral Therapy; Behavioral:Individual Addiction Counseling; Behavioral:Treatment-as-usual,"[u'Central Vermont Substance Abuse Services', u'Brattleboro Retreat', u'Howard Center', u'Evergreen - Rutland Mental Health']",12-Feb-15,18,9999,Both,FALSE,26NCT00769379,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00310180,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00023751,Alliance for Clinical Trials in Oncology,FALSE,VT,https://ClinicalTrials.gov/show/NCT00023751,FALSE,Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer,Colorectal Cancer,Drug:fluorouracil; Drug:leucovorin calcium; Procedure:conventional surgery; Radiation:radiation therapy,[],13-Jul-15,18,9999,Both,FALSE,1NCT00022087,Alliance for Clinical Trials in Oncology,TRUE,VT,https://ClinicalTrials.gov/show/NCT00022087,FALSE,"Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer",Breast Cancer; Osteoporosis,Dietary Supplement:calcium salts; Dietary Supplement:cholecalciferol; Drug:zoledronic acid,[],26-Sep-13,40,9999,Female,FALSE,1NCT00003312,Radiation Therapy Oncology Group,TRUE,VT,https://ClinicalTrials.gov/show/NCT00003312,FALSE,Brachytherapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:iodine I 125,[],23-Jan-14,0,9999,Male,FALSE,4NCT00002596,Memorial Sloan Kettering Cancer Center,TRUE,VT,https://ClinicalTrials.gov/show/NCT00002596,FALSE,Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors,Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Testicular Germ Cell Tumor,Biological:bleomycin sulfate; Biological:filgrastim; Drug:carboplatin; Drug:cisplatin; Drug:cyclophosphamide; Drug:etoposide; Procedure:autologous bone marrow transplantation; Procedure:bone marrow ablation with stem cell support; Procedure:conventional surgery; Procedure:peripheral blood stem cell transplantation; Radiation:radiation therapy,[],25-Jun-13,12,9999,Male,FALSE,32NCT00002545,Radiation Therapy Oncology Group,TRUE,VT,https://ClinicalTrials.gov/show/NCT00002545,FALSE,Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme,Brain and Central Nervous System Tumors,Drug:carmustine; Radiation:low-LET photon therapy,[],9-Aug-13,18,9999,Both,FALSE,4NCT01547741,NSABP Foundation Inc,FALSE,VT,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01198158,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01015833,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00942331,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00693992,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT00693992,FALSE,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],26-Jun-15,18,9999,Both,FALSE,9NCT00602459,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT00602459,FALSE,Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,[],22-Apr-15,18,9999,Both,FALSE,9NCT00490139,GlaxoSmithKline,FALSE,VT,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT00433511,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00423735,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT00423735,FALSE,Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Neoplasm,Drug:Dasatinib; Other:Pharmacological Study,[],5-Jan-16,18,9999,Both,FALSE,9NCT00331773,Radiation Therapy Oncology Group,TRUE,VT,https://ClinicalTrials.gov/show/NCT00331773,FALSE,Radiation Therapy in Treating Patients With Stage II Prostate Cancer,Prostate Cancer,Radiation:3-dimensional conformal radiation therapy (3D-CRT); Radiation:hypofractionated radiation therapy; Radiation:Intensity-modulated radiation therapy (IMRT),[],20-Mar-15,18,9999,Male,FALSE,4NCT00326898,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00257608,"Genentech, Inc.",FALSE,VT,https://ClinicalTrials.gov/show/NCT00257608,FALSE,A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS),Non-Small Cell Lung Cancer,Drug:bevacizumab; Drug:placebo; Drug:erlotinib HCl,[],30-Sep-15,18,9999,Both,FALSE,113NCT00099125,Radiation Therapy Oncology Group,TRUE,VT,https://ClinicalTrials.gov/show/NCT00099125,FALSE,"Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Brain and Central Nervous System Tumors,Drug:irinotecan hydrochloride; Drug:temozolomide; Procedure:adjuvant therapy; Radiation:radiation therapy,[],23-Jan-14,18,9999,Both,FALSE,4NCT00052845,Alliance for Clinical Trials in Oncology,TRUE,VT,https://ClinicalTrials.gov/show/NCT00052845,FALSE,"Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy",Prostate Cancer,Drug:docetaxel; Drug:estramustine phosphate sodium; Drug:exisulind,[],27-Sep-13,18,9999,Male,FALSE,1NCT00048971,Alliance for Clinical Trials in Oncology,FALSE,VT,https://ClinicalTrials.gov/show/NCT00048971,FALSE,Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy,Colorectal Cancer; Diarrhea; Neutropenia,Genetic:mutation analysis; Genetic:polymorphic microsatellite marker analysis,[],14-Jul-15,18,9999,Both,FALSE,1NCT00042965,Alliance for Clinical Trials in Oncology,TRUE,VT,https://ClinicalTrials.gov/show/NCT00042965,FALSE,Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer,Kidney Cancer,Drug:capecitabine; Drug:gemcitabine hydrochloride,[],7-Jul-15,18,9999,Both,FALSE,1NCT00041054,Alliance for Clinical Trials in Oncology,TRUE,VT,https://ClinicalTrials.gov/show/NCT00041054,FALSE,Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:etoposide; Drug:exisulind,[],13-Jul-15,18,9999,Both,FALSE,1NCT00033696,Alliance for Clinical Trials in Oncology,TRUE,VT,https://ClinicalTrials.gov/show/NCT00033696,FALSE,Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer,Lung Cancer,Biological:filgrastim; Drug:carboplatin; Drug:etoposide; Drug:paclitaxel; Drug:topotecan hydrochloride; Radiation:radiation therapy,[],25-Sep-13,18,9999,Both,FALSE,1NCT00032084,Southwest Oncology Group,FALSE,VT,https://ClinicalTrials.gov/show/NCT00032084,FALSE,S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery,Lung Cancer,Behavioral:smoking cessation intervention; Drug:bupropion hydrochloride; Drug:nicotine; Procedure:psychosocial assessment and care,[],8-Mar-13,18,9999,Both,FALSE,3NCT00026195,Alliance for Clinical Trials in Oncology,FALSE,VT,https://ClinicalTrials.gov/show/NCT00026195,FALSE,Irinotecan in Treating Aging Patients With Solid Tumors,"Unspecified Adult Solid Tumor, Protocol Specific",Drug:irinotecan hydrochloride,[],13-Jul-15,18,9999,Both,FALSE,1NCT00012220,Cancer and Leukemia Group B,TRUE,VT,https://ClinicalTrials.gov/show/NCT00012220,FALSE,Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas,Pancreatic Cancer,Drug:cisplatin; Drug:docetaxel; Drug:gemcitabine hydrochloride; Drug:irinotecan hydrochloride,[],8-Oct-13,18,9999,Both,FALSE,24NCT00010218,Alliance for Clinical Trials in Oncology,TRUE,VT,https://ClinicalTrials.gov/show/NCT00010218,FALSE,Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer,Lung Cancer,Drug:karenitecin,[],25-Sep-13,18,9999,Both,FALSE,1NCT00009906,National Cancer Institute (NCI),FALSE,VT,https://ClinicalTrials.gov/show/NCT00009906,FALSE,Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor,Gastrointestinal Stromal Tumor,Drug:Imatinib Mesylate,[],19-Dec-14,15,9999,Both,FALSE,9NCT00006265,Alliance for Clinical Trials in Oncology,TRUE,VT,https://ClinicalTrials.gov/show/NCT00006265,FALSE,Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,Leukemia,Drug:ara-C; Biological:gemtuzumab ozogamicin,[],27-Sep-13,17,9999,Both,FALSE,1NCT00006223,Eastern Cooperative Oncology Group,FALSE,VT,https://ClinicalTrials.gov/show/NCT00006223,FALSE,flt3L in Treating Patients With Acute Myeloid Leukemia,Leukemia,Biological:recombinant flt3 ligand,[],20-Jun-13,18,9999,Both,FALSE,17NCT00006125,Alliance for Clinical Trials in Oncology,TRUE,VT,https://ClinicalTrials.gov/show/NCT00006125,FALSE,Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma,Lymphoma,Drug:doxorubicin hydrochloride; Drug:topotecan hydrochloride,[],7-Jul-15,0,9999,Both,FALSE,1NCT00006029,Alliance for Clinical Trials in Oncology,TRUE,VT,https://ClinicalTrials.gov/show/NCT00006029,FALSE,Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma,Lymphoma,Drug:gemcitabine hydrochloride; Drug:pegylated liposomal doxorubicin hydrochloride; Drug:vinorelbine tartrate,[],7-Jul-15,0,9999,Both,FALSE,1NCT00006015,National Cancer Institute (NCI),TRUE,VT,https://ClinicalTrials.gov/show/NCT00006015,FALSE,"Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer",Colorectal Cancer,Biological:trastuzumab; Drug:fluorouracil; Drug:leucovorin calcium; Drug:oxaliplatin,[],1-May-13,18,9999,Both,FALSE,9NCT00005972,Alliance for Clinical Trials in Oncology,TRUE,VT,https://ClinicalTrials.gov/show/NCT00005972,FALSE,Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer,Lung Cancer,Drug:gemcitabine hydrochloride; Drug:irinotecan hydrochloride,[],27-Sep-13,18,9999,Both,FALSE,1NCT00005964,Alliance for Clinical Trials in Oncology,FALSE,VT,https://ClinicalTrials.gov/show/NCT00005964,FALSE,"Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",Lymphoma,Biological:filgrastim; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:prednisone; Drug:vincristine sulfate,[],6-Jul-15,0,9999,Both,FALSE,1NCT00005820,Alliance for Clinical Trials in Oncology,TRUE,VT,https://ClinicalTrials.gov/show/NCT00005820,FALSE,Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy,Prostate Cancer,Drug:nitrocamptothecin,[],7-Jul-15,0,9999,Male,FALSE,1NCT00005090,Southwest Oncology Group,FALSE,VT,https://ClinicalTrials.gov/show/NCT00005090,FALSE,S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease,Lymphoma,Biological:bleomycin sulfate; Drug:carmustine; Drug:cyclophosphamide; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:vinblastine; Procedure:peripheral blood stem cell transplantation,[],22-Jan-13,15,65,Both,FALSE,3NCT00005022,Radiation Therapy Oncology Group,TRUE,VT,https://ClinicalTrials.gov/show/NCT00005022,FALSE,Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer,Lung Cancer,Drug:cisplatin; Drug:etoposide; Radiation:radiation therapy,[],31-Oct-13,18,80,Both,FALSE,4NCT00004933,Alliance for Clinical Trials in Oncology,FALSE,VT,https://ClinicalTrials.gov/show/NCT00004933,FALSE,Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa,Leukemia,Drug:hydroxyurea; Drug:Homoharringtonine,[],23-Jun-15,16,9999,Both,FALSE,1NCT01547741,NSABP Foundation Inc,FALSE,VA,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01275677,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00887536,NSABP Foundation Inc,FALSE,VA,https://ClinicalTrials.gov/show/NCT00887536,FALSE,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],24-Jun-15,18,70,Female,FALSE,2NCT00769379,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00658515,Hoffmann-La Roche,FALSE,VA,https://ClinicalTrials.gov/show/NCT00658515,FALSE,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],1-Feb-16,45,9999,Both,FALSE,119NCT00346216,Pfizer,FALSE,VA,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00264901,Novo Nordisk A/S,FALSE,VA,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT01070836,Biogen,FALSE,VA,https://ClinicalTrials.gov/show/NCT01070836,FALSE,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],14-Jan-16,0,9999,Both,FALSE,73NCT00034879,AstraZeneca,FALSE,VA,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT00310180,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT01663727,Hoffmann-La Roche,FALSE,VA,https://ClinicalTrials.gov/show/NCT01663727,FALSE,"Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer",Metastatic Breast Cancer,Drug:Bevacizumab [Avastin]; Drug:Paclitaxel; Drug:Placebo,[],2-Nov-15,18,9999,Both,FALSE,119NCT00239681,AstraZeneca,FALSE,VA,https://ClinicalTrials.gov/show/NCT00239681,FALSE,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],6-Feb-14,50,9999,Both,FALSE,13NCT00067938,GlaxoSmithKline,FALSE,VA,https://ClinicalTrials.gov/show/NCT00067938,FALSE,Bipolar Study in Adults at Least 18 Years of Age,Bipolar Disorder,Drug:lamotrigine,[],11-Oct-12,18,9999,Both,FALSE,8NCT00373685,Pfizer,FALSE,VA,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00053898,NSABP Foundation Inc,TRUE,VA,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT01313676,GlaxoSmithKline,FALSE,VA,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT00036270,Pfizer,FALSE,VA,https://ClinicalTrials.gov/show/NCT00036270,FALSE,Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane,Breast Neoplasms,Drug:exemestane (Aromasin); Drug:tamoxifen + exemestane,[],6-Oct-15,50,9999,Female,FALSE,10NCT00262600,Boehringer Ingelheim,FALSE,VA,https://ClinicalTrials.gov/show/NCT00262600,FALSE,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation; Stroke,Drug:warfarin; Drug:Dabigatran dose 1; Drug:Dabigatran dose 2,[],5-Nov-14,18,9999,Both,FALSE,75NCT02465060,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01475721,GlaxoSmithKline,FALSE,VA,https://ClinicalTrials.gov/show/NCT01475721,FALSE,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],10-Dec-15,12,9999,Both,FALSE,8NCT01349322,Radiation Therapy Oncology Group,FALSE,VA,https://ClinicalTrials.gov/show/NCT01349322,FALSE,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],14-Nov-15,18,9999,Female,FALSE,4NCT00324805,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01104155,Eisai Inc.,FALSE,VA,https://ClinicalTrials.gov/show/NCT01104155,FALSE,"Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer",Non-small Cell Lung Cancer,Drug:eribulin mesylate + erlotinib; Drug:eribulin mesylate + erlotinib,[],17-Sep-14,18,9999,Both,FALSE,102NCT00041925,"Anesiva, Inc.",FALSE,VA,https://ClinicalTrials.gov/show/NCT00041925,FALSE,Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures,"Peripheral Vascular Diseases; Arterial Occlusive Diseases; Ischemia; Graft Occlusion, Vascular; Hyperplasia",Drug:CGT003 (E2F Duplex Decoy),[],14-Jul-05,18,9999,Both,FALSE,22NCT00785291,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00134056,Southwest Oncology Group,TRUE,VA,https://ClinicalTrials.gov/show/NCT00134056,FALSE,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],6-May-15,18,9999,Male,FALSE,3NCT00111020,Bayer,FALSE,VA,https://ClinicalTrials.gov/show/NCT00111020,FALSE,Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma,"Carcinoma, Renal Cell","Drug:Sorafenib (Nexavar, BAY43-9006)",[],5-Aug-14,15,9999,Both,FALSE,23NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,VA,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00433511,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00217737,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00079274,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT00968968,GlaxoSmithKline,FALSE,VA,https://ClinicalTrials.gov/show/NCT00968968,FALSE,Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone,Cancer,Drug:Lapatinib; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,8NCT02139046,Takeda,FALSE,VA,https://ClinicalTrials.gov/show/NCT02139046,FALSE,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Drug:Febuxostat IR; Drug:Febuxostat XR; Drug:Febuxostat placebo; Drug:Colchicine; Drug:Naproxen; Drug:Lansoprazole,[],13-Nov-15,18,9999,Both,FALSE,5NCT01740427,Pfizer,FALSE,VA,https://ClinicalTrials.gov/show/NCT01740427,FALSE,A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2),Breast Neoplasms,Drug:PD-0332991; Drug:Letrozole; Drug:Placebo; Drug:Letrozole,[],4-Feb-16,18,9999,Female,FALSE,10NCT00373256,Pfizer,FALSE,VA,https://ClinicalTrials.gov/show/NCT00373256,FALSE,A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer,Breast Neoplasms,Drug:Sunitinib; Drug:paclitaxel; Drug:bevacizumab; Drug:paclitaxel,[],5-Sep-12,18,9999,Both,FALSE,10NCT00693992,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT00693992,FALSE,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],26-Jun-15,18,9999,Both,FALSE,9NCT00326898,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00087178,NSABP Foundation Inc,FALSE,VA,https://ClinicalTrials.gov/show/NCT00087178,FALSE,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],5-Oct-15,18,9999,Female,FALSE,2NCT00382070,NSABP Foundation Inc,TRUE,VA,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT01167712,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT01126437,Boehringer Ingelheim,FALSE,VA,https://ClinicalTrials.gov/show/NCT01126437,FALSE,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:tiotropium 18 mcg; Drug:tiotropium 1.25 mcg (2 actuations/day); Drug:tiotropium 2.5 mcg (2 actuations/day),[],20-May-14,40,9999,Both,FALSE,75NCT00968708,Takeda,FALSE,VA,https://ClinicalTrials.gov/show/NCT00968708,FALSE,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,"Diabetes Mellitus, Type 2; Acute Coronary Syndrome",Drug:Alogliptin; Drug:Placebo,[],15-Apr-14,18,9999,Both,FALSE,5NCT00678392,Pfizer,FALSE,VA,https://ClinicalTrials.gov/show/NCT00678392,FALSE,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,Kidney Neoplasms,Drug:Axitinib (AG-013736); Drug:Sorafenib,[],10-Dec-15,18,9999,Both,FALSE,10NCT00596830,Pfizer,FALSE,VA,https://ClinicalTrials.gov/show/NCT00596830,FALSE,"Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology","Carcinoma, Squamous Cell; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung","Drug:CP-751,871 (Figitumumab); Drug:Carboplatin; Drug:Paclitaxel; Drug:Carboplatin; Drug:Paclitaxel",[],11-Dec-13,18,9999,Both,FALSE,10NCT00403767,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",FALSE,VA,https://ClinicalTrials.gov/show/NCT00403767,FALSE,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation; Stroke; Embolism,Drug:Rivaroxaban; Drug:Warfarin; Drug:Matching placebo for Rivaroxaban arm (Warfarin placebo); Drug:Matching placebo for Warfarin arm (Rivaroxaban placebo),[],10-Apr-14,18,9999,Both,FALSE,136NCT00262847,National Cancer Institute (NCI),FALSE,VA,https://ClinicalTrials.gov/show/NCT00262847,FALSE,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],18-Aug-15,18,9999,Female,FALSE,9NCT00063999,Gynecologic Oncology Group,FALSE,VA,https://ClinicalTrials.gov/show/NCT00063999,FALSE,"Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",Endometrial Cancer,Biological:filgrastim; Drug:carboplatin; Drug:cisplatin; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],23-Apr-09,18,9999,Female,FALSE,14NCT02465060,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02315430,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT02315430,FALSE,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Female,FALSE,9NCT02257528,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT02257528,FALSE,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],3-Feb-16,18,9999,Female,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02137837,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT02137837,FALSE,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",Breast Cancer,Drug:Fulvestrant; Drug:Anastrozole; Drug:Everolimus; Drug:Placebo - Anastrozole; Drug:Placebo - Everolimus,[],20-May-15,18,9999,Female,FALSE,3NCT01886872,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01802333,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT01716715,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01716715,FALSE,"Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],12-Jan-16,18,9999,Female,FALSE,9NCT01658943,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,WA,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01540565,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01540565,FALSE,"Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Veliparib,[],5-Jan-16,18,9999,Female,FALSE,9NCT01515800,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01515800,FALSE,S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer,Breast Cancer,Behavioral:Text message reminder,[],23-Oct-15,18,120,Female,FALSE,3NCT01498289,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01468909,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01468909,FALSE,"Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],12-Jan-16,18,9999,Female,FALSE,9NCT01412879,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01412879,FALSE,S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:cyclophosphamide; Drug:cytarabine; Drug:dexamethasone; Drug:doxorubicin hydrochloride; Drug:leucovorin calcium; Drug:methotrexate; Drug:vincristine sulfate,[],15-Sep-15,18,65,Both,FALSE,3NCT01385137,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01385137,FALSE,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],15-Oct-15,18,120,Female,FALSE,3NCT01275677,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01266447,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01266447,FALSE,"Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Small Cell Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage III Cervical Cancer; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Biological:Filgrastim; Other:Laboratory Biomarker Analysis; Biological:Pegfilgrastim; Drug:Topotecan Hydrochloride; Drug:Veliparib,[],5-Jan-16,18,9999,Female,FALSE,9NCT01260701,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01260701,FALSE,Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Diffuse Gastric Adenocarcinoma; Gastric Intestinal Type Adenocarcinoma; Gastric Mixed Adenocarcinoma; Recurrent Gastric Carcinoma,Drug:Akt Inhibitor MK2206,[],14-Dec-15,18,9999,Both,FALSE,9NCT01229943,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01229943,FALSE,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],22-Apr-15,18,9999,Both,FALSE,9NCT01196429,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01196429,FALSE,"Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer",Ovarian Clear Cell Cystadenocarcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer,Drug:Carboplatin; Drug:Docetaxel; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Temsirolimus,[],20-Nov-15,18,9999,Female,FALSE,9NCT01196390,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01189266,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01189266,FALSE,Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma,Childhood Glioblastoma; Untreated Childhood Anaplastic Astrocytoma; Untreated Childhood Anaplastic Oligoastrocytoma; Untreated Childhood Brain Stem Glioma; Untreated Childhood Giant Cell Glioblastoma; Untreated Childhood Gliosarcoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],11-Jan-16,37,21,Both,FALSE,9NCT01167712,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT01132820,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01132820,FALSE,Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer,Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Cediranib Maleate; Other:Laboratory Biomarker Analysis,[],5-Jan-16,18,9999,Female,FALSE,9NCT01120275,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01120275,FALSE,Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma,Acral Lentiginous Malignant Melanoma; Lentigo Maligna Malignant Melanoma; Nodular Malignant Melanoma; Recurrent Melanoma; Solar Radiation-related Skin Melanoma; Stage IV Melanoma; Superficial Spreading Malignant Melanoma,Drug:gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other:laboratory biomarker analysis,[],9-Jun-14,18,9999,Both,FALSE,9NCT01120236,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01120236,FALSE,Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer,Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer,Drug:Bicalutamide; Biological:Cixutumumab; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Drug:Leuprolide Acetate; Other:Pharmacological Study,[],25-Jun-15,18,9999,Male,FALSE,9NCT01078454,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01078454,FALSE,Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis,Light Chain Deposition Disease; Primary Systemic Amyloidosis,Drug:melphalan; Drug:dexamethasone; Drug:bortezomib,[],20-Nov-14,18,9999,Both,FALSE,9NCT01041781,Alliance for Clinical Trials in Oncology,FALSE,WA,https://ClinicalTrials.gov/show/NCT01041781,FALSE,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01015833,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT01015833,FALSE,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01011478,NSABP Foundation Inc,TRUE,WA,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT01000558,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT01000558,FALSE,SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma,Lymphoma,Other:biologic sample preservation procedure,[],17-May-13,18,9999,Both,FALSE,3NCT00996047,Southwest Oncology Group,TRUE,WA,https://ClinicalTrials.gov/show/NCT00996047,FALSE,"S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers",Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms,Genetic:cytogenetic analysis; Genetic:fluorescence in situ hybridization,[],5-Mar-15,0,9999,Both,FALSE,3NCT00977574,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT00977574,FALSE,"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Biological:Bevacizumab; Drug:Carboplatin; Drug:Ixabepilone; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Temsirolimus,[],3-Feb-16,18,9999,Female,FALSE,9NCT00972478,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT00972478,FALSE,"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",Stage II Contiguous Adult Diffuse Large Cell Lymphoma; Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate; Drug:Vorinostat,[],30-Dec-15,18,9999,Both,FALSE,9NCT00951496,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT00951496,FALSE,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00946712,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00942357,Gynecologic Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00942331,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00920010,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT00920010,FALSE,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],5-Feb-15,0,9999,Both,FALSE,3NCT00919425,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT00919425,FALSE,"S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer",Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms,Other:biologic sample preservation procedure,[],5-Mar-15,0,9999,Both,FALSE,3NCT00919139,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT00919139,FALSE,"S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.",Multiple Myeloma; Smoldering Myeloma; Waldenstrom's Macroglobulinemia; Monoclonal Gammopathy of Undetermined Significance; Amyloidosis,Other:biologic sample preservation procedure,[],1-Apr-15,0,9999,Both,FALSE,3NCT00900484,Southwest Oncology Group,TRUE,WA,https://ClinicalTrials.gov/show/NCT00900484,FALSE,"SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma",Lymphoma,Other:biologic sample preservation procedure; Other:immunohistochemistry staining method; Other:laboratory biomarker analysis,[],17-May-13,16,9999,Both,FALSE,3NCT00874211,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT00874211,FALSE,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],4-Mar-15,0,9999,Both,FALSE,3NCT00861705,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT00861705,FALSE,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],28-Sep-15,18,9999,Both,FALSE,9NCT00856492,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT00856492,FALSE,"S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer",Breast Cancer,Biological:bevacizumab; Biological:pegfilgrastim; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel albumin-stabilized nanoparticle formulation,[],8-May-15,18,9999,Female,FALSE,3NCT00828139,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT00828139,FALSE,Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Biological:ziv-aflibercept; Drug:topotecan hydrochloride,[],9-Apr-14,18,9999,Both,FALSE,9NCT00822120,Southwest Oncology Group,FALSE,WA,https://ClinicalTrials.gov/show/NCT00822120,FALSE,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,Lymphoma; Nonneoplastic Condition,Biological:bleomycin sulfate; Biological:filgrastim; Drug:ABVD regimen; Drug:BEACOPP regimen; Drug:cyclophosphamide; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:prednisone; Drug:procarbazine hydrochloride; Drug:vinblastine sulfate; Drug:vincristine sulfate,[],8-May-15,18,60,Both,FALSE,3NCT00792948,National Cancer Institute (NCI),FALSE,WA,https://ClinicalTrials.gov/show/NCT00792948,FALSE,Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia,Adult Acute Lymphoblastic Leukemia in Remission; Adult B Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Adult L1 Acute Lymphoblastic Leukemia; Adult L2 Acute Lymphoblastic Leukemia; Adult T Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dasatinib; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Biological:Filgrastim; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Methotrexate; Drug:Methylprednisolone; Procedure:Peripheral Blood Stem Cell Transplantation; Drug:Prednisone; Drug:Sirolimus; Drug:Tacrolimus; Radiation:Total-Body Irradiation; Drug:Vincristine Sulfate,[],12-Jan-16,18,60,Both,FALSE,9NCT00264901,Novo Nordisk A/S,FALSE,WV,https://ClinicalTrials.gov/show/NCT00264901,FALSE,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],25-Nov-14,18,9999,Both,FALSE,158NCT01961037,West Virginia University,FALSE,WV,https://ClinicalTrials.gov/show/NCT01961037,FALSE,Translation of an Evidence-Based Fall-Prevention Program Into Rural West Virginia Churches,Accidental Falls,Other:Tai Chi: Moving for Better Balance,"[u'Hughes River Presbyterian Church', u'Wesley United Methodist Church', u'Harper Memorial Church', u'First Baptist Church', u'First Assembly of God', u'Cisco Community Church', u'First Baptist Church', u'Memorial United Methodist Church', u'Spencer Presbyterian Church']",22-Dec-15,55,9999,Both,TRUE,222NCT01275677,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00382070,NSABP Foundation Inc,TRUE,WV,https://ClinicalTrials.gov/show/NCT00382070,FALSE,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],4-Nov-14,18,9999,Female,FALSE,2NCT02465060,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT01886872,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,WV,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT00310180,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT00310180,FALSE,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],4-Feb-16,18,75,Female,FALSE,9NCT00887536,NSABP Foundation Inc,FALSE,WV,https://ClinicalTrials.gov/show/NCT00887536,FALSE,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],24-Jun-15,18,70,Female,FALSE,2NCT00433511,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT00433511,FALSE,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT00346216,Pfizer,FALSE,WV,https://ClinicalTrials.gov/show/NCT00346216,FALSE,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],11-Jan-16,18,9999,Both,FALSE,10NCT00326898,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT00326898,FALSE,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00217737,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT00217737,FALSE,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],4-Feb-16,18,9999,Both,FALSE,9NCT00087178,NSABP Foundation Inc,FALSE,WV,https://ClinicalTrials.gov/show/NCT00087178,FALSE,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],5-Oct-15,18,9999,Female,FALSE,2NCT00079274,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT00079274,FALSE,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],23-Jan-15,18,9999,Both,FALSE,9NCT00053898,NSABP Foundation Inc,TRUE,WV,https://ClinicalTrials.gov/show/NCT00053898,FALSE,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],9-Mar-15,0,9999,Female,FALSE,2NCT00034879,AstraZeneca,FALSE,WV,https://ClinicalTrials.gov/show/NCT00034879,FALSE,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],3-Jan-13,18,9999,Both,FALSE,13NCT00003641,Eastern Cooperative Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT00003641,FALSE,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,Melanoma (Skin),Biological:recombinant interferon alfa; Other:clinical observation,[],11-Jul-12,18,9999,Both,FALSE,17NCT01302067,Pfizer,FALSE,WV,https://ClinicalTrials.gov/show/NCT01302067,FALSE,A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine,Overactive Bladder,Drug:Fesoterodine 8mg; Drug:Fesoterodine 4mg; Drug:Placebo,[],25-Feb-14,18,9999,Both,FALSE,10NCT00588770,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT00324805,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT00324805,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],4-Feb-16,18,9999,Both,FALSE,9NCT00265850,Alliance for Clinical Trials in Oncology,TRUE,WV,https://ClinicalTrials.gov/show/NCT00265850,FALSE,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],16-Oct-14,18,9999,Both,FALSE,1NCT00110019,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT00110019,FALSE,Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,Mucosal Melanoma; Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Pharmacological Study; Other:Placebo; Drug:Sorafenib Tosylate,[],28-Sep-15,18,9999,Both,FALSE,9NCT00072046,Alliance for Clinical Trials in Oncology,TRUE,WV,https://ClinicalTrials.gov/show/NCT00072046,FALSE,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],23-Jun-15,18,9999,Both,FALSE,1NCT00052910,Alliance for Clinical Trials in Oncology,TRUE,WV,https://ClinicalTrials.gov/show/NCT00052910,FALSE,Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer,Esophageal Cancer; Gastric Cancer,Drug:cisplatin; Drug:epirubicin hydrochloride; Drug:fluorouracil; Drug:leucovorin calcium; Radiation:radiation therapy,[],23-Jun-15,18,9999,Both,FALSE,1NCT01708954,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT01708954,FALSE,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],23-Oct-15,18,9999,Both,FALSE,9NCT01349322,Radiation Therapy Oncology Group,FALSE,WV,https://ClinicalTrials.gov/show/NCT01349322,FALSE,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],14-Nov-15,18,9999,Female,FALSE,4NCT01313676,GlaxoSmithKline,FALSE,WV,https://ClinicalTrials.gov/show/NCT01313676,FALSE,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],14-Jan-16,40,80,Both,FALSE,8NCT01101438,NCIC Clinical Trials Group,TRUE,WV,https://ClinicalTrials.gov/show/NCT01101438,FALSE,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,Breast Cancer,Drug:metformin hydrochloride; Other:placebo,[],5-May-15,18,74,Both,FALSE,11NCT01011478,NSABP Foundation Inc,TRUE,WV,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT00693992,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT00693992,FALSE,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],26-Jun-15,18,9999,Both,FALSE,9NCT00602641,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT00602641,FALSE,"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma",Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:melphalan; Drug:prednisone; Drug:thalidomide; Drug:lenalidomide,[],9-Jun-15,18,9999,Both,FALSE,9NCT00601900,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT00601900,FALSE,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],23-Apr-15,18,9999,Female,FALSE,9NCT00520975,National Cancer Institute (NCI),FALSE,WV,https://ClinicalTrials.gov/show/NCT00520975,FALSE,First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU,HER2/Neu Positive; Male Breast Carcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],17-Dec-15,18,9999,Both,FALSE,9NCT00490139,GlaxoSmithKline,FALSE,WV,https://ClinicalTrials.gov/show/NCT00490139,FALSE,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],5-Nov-15,18,9999,Both,FALSE,8NCT00486668,NSABP Foundation Inc,TRUE,WV,https://ClinicalTrials.gov/show/NCT00486668,FALSE,A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer,Invasive Breast Cancer,Drug:doxorubicin; Drug:cyclophosphamide; Drug:paclitaxel; Drug:trastuzumab; Drug:lapatinib,[],11-Aug-15,18,9999,Female,FALSE,2NCT00408408,NSABP Foundation Inc,TRUE,WV,https://ClinicalTrials.gov/show/NCT00408408,FALSE,"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery",Breast Cancer,Biological:bevacizumab; Drug:capecitabine; Drug:cyclophosphamide; Drug:docetaxel; Drug:doxorubicin hydrochloride (Adriamycin); Drug:gemcitabine hydrochloride,[],9-Feb-15,18,9999,Female,FALSE,2NCT00373685,Pfizer,FALSE,WV,https://ClinicalTrials.gov/show/NCT00373685,FALSE,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],2-Feb-12,55,9999,Both,FALSE,10NCT00262600,Boehringer Ingelheim,FALSE,WV,https://ClinicalTrials.gov/show/NCT00262600,FALSE,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation; Stroke,Drug:warfarin; Drug:Dabigatran dose 1; Drug:Dabigatran dose 2,[],5-Nov-14,18,9999,Both,FALSE,75NCT00238264,Children's Oncology Group,TRUE,WV,https://ClinicalTrials.gov/show/NCT00238264,FALSE,Radiation Therapy in Treating Young Patients With Gliomas,Brain Tumor; Central Nervous System Tumor,Radiation:radiation therapy,[],4-Mar-15,3,20,Both,FALSE,17NCT00134056,Southwest Oncology Group,TRUE,WV,https://ClinicalTrials.gov/show/NCT00134056,FALSE,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],6-May-15,18,9999,Male,FALSE,3NCT00111020,Bayer,FALSE,WV,https://ClinicalTrials.gov/show/NCT00111020,FALSE,Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma,"Carcinoma, Renal Cell","Drug:Sorafenib (Nexavar, BAY43-9006)",[],5-Aug-14,15,9999,Both,FALSE,23NCT00103181,NSABP Foundation Inc,TRUE,WV,https://ClinicalTrials.gov/show/NCT00103181,FALSE,Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer,Breast Cancer,Radiation:3-dimensional conformal accelerated partial breast irradiation; Radiation:brachytherapy; Radiation:whole breast irradiation; Radiation:MammoSite or other single-entry intracavitary device,[],8-Oct-15,18,9999,Female,FALSE,2NCT00089323,NSABP Foundation Inc,FALSE,WV,https://ClinicalTrials.gov/show/NCT00089323,FALSE,"Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer",Breast Cancer,Procedure:Bone Marrow Aspiration,[],19-Jan-16,18,9999,Both,FALSE,2NCT00075725,Children's Oncology Group,TRUE,WV,https://ClinicalTrials.gov/show/NCT00075725,FALSE,Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,Leukemia,Drug:cyclophosphamide; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:dexamethasone; Drug:doxorubicin hydrochloride; Drug:leucovorin calcium; Drug:mercaptopurine; Drug:methotrexate; Drug:pegaspargase; Drug:prednisone; Drug:thioguanine; Drug:vincristine sulfate; Radiation:radiation therapy,[],10-Jul-15,1,30,Both,FALSE,17NCT02465060,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02315430,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT02315430,FALSE,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Female,FALSE,9NCT02311907,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT02311907,FALSE,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],22-May-15,18,9999,Female,FALSE,9NCT02116530,Alliance for Clinical Trials in Oncology,FALSE,WI,https://ClinicalTrials.gov/show/NCT02116530,FALSE,Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy,"Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:Olanzapine; Drug:Chemotherapy (cisplatin or cyclophosphamide and doxorubicin); Drug:Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant); Other:Placebo,[],15-Jun-15,18,9999,Both,FALSE,1NCT01886872,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01841736,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01841736,FALSE,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT01802333,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT01708954,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01708954,FALSE,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],23-Oct-15,18,9999,Both,FALSE,9NCT01708941,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01708941,FALSE,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Recombinant Interferon Alfa-2b,[],11-Jan-16,18,9999,Both,FALSE,9NCT01658943,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01642251,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01642251,FALSE,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,WI,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01522976,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01522976,FALSE,Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia,Adult Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts,Drug:Azacitidine; Drug:Lenalidomide; Drug:Vorinostat,[],24-Jun-15,18,9999,Both,FALSE,9NCT01498289,Southwest Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01366183,Gynecologic Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01366183,FALSE,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],23-Dec-14,75,9999,Both,FALSE,14NCT01349322,Radiation Therapy Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT01349322,FALSE,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],14-Nov-15,18,9999,Female,FALSE,4NCT01275677,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT01198158,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01198145,Alliance for Clinical Trials in Oncology,FALSE,WI,https://ClinicalTrials.gov/show/NCT01198145,FALSE,Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy,"Diarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific",Drug:sulfasalazine; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01196390,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01167712,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT01134614,National Cancer Institute (NCI),TRUE,WI,https://ClinicalTrials.gov/show/NCT01134614,FALSE,Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,Recurrent Melanoma; Stage III Melanoma; Stage IV Melanoma,Biological:ipilimumab; Biological:sargramostim,[],23-Mar-15,18,9999,Both,FALSE,9NCT01099449,Alliance for Clinical Trials in Oncology,FALSE,WI,https://ClinicalTrials.gov/show/NCT01099449,FALSE,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],4-Jul-15,18,9999,Both,FALSE,1NCT01078454,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT01078454,FALSE,Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis,Light Chain Deposition Disease; Primary Systemic Amyloidosis,Drug:melphalan; Drug:dexamethasone; Drug:bortezomib,[],20-Nov-14,18,9999,Both,FALSE,9NCT01041781,Alliance for Clinical Trials in Oncology,FALSE,WI,https://ClinicalTrials.gov/show/NCT01041781,FALSE,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01011478,NSABP Foundation Inc,TRUE,WI,https://ClinicalTrials.gov/show/NCT01011478,FALSE,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],9-Mar-15,18,9999,Both,FALSE,2NCT00986674,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00986674,FALSE,Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:cixutumumab; Drug:carboplatin; Drug:paclitaxel; Biological:cetuximab,[],19-Sep-14,18,9999,Both,FALSE,9NCT00976573,Alliance for Clinical Trials in Oncology,FALSE,WI,https://ClinicalTrials.gov/show/NCT00976573,FALSE,"Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",Melanoma (Skin),Biological:bevacizumab; Drug:carboplatin; Drug:everolimus; Drug:paclitaxel,[],18-Sep-15,18,9999,Both,FALSE,1NCT00951496,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00951496,FALSE,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00946712,Southwest Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00942357,Gynecologic Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00942331,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00884741,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00884741,FALSE,Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Cognitive Side Effects of Cancer Therapy,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Procedure:Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Procedure:Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Temozolomide,[],29-Jul-15,18,9999,Both,FALSE,9NCT00869206,Alliance for Clinical Trials in Oncology,FALSE,WI,https://ClinicalTrials.gov/show/NCT00869206,FALSE,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],23-Jul-15,18,9999,Both,FALSE,1NCT00861705,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00861705,FALSE,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],28-Sep-15,18,9999,Both,FALSE,9NCT00822120,Southwest Oncology Group,FALSE,WI,https://ClinicalTrials.gov/show/NCT00822120,FALSE,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,Lymphoma; Nonneoplastic Condition,Biological:bleomycin sulfate; Biological:filgrastim; Drug:ABVD regimen; Drug:BEACOPP regimen; Drug:cyclophosphamide; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:prednisone; Drug:procarbazine hydrochloride; Drug:vinblastine sulfate; Drug:vincristine sulfate,[],8-May-15,18,60,Both,FALSE,3NCT00803062,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00803062,FALSE,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],22-May-15,18,9999,Female,FALSE,9NCT00785291,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00785291,FALSE,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],5-Jun-15,18,9999,Both,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00719563,Alliance for Clinical Trials in Oncology,TRUE,WI,https://ClinicalTrials.gov/show/NCT00719563,FALSE,American Ginseng in Treating Patients With Fatigue Caused by Cancer,"Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific",Drug:American ginseng; Other:placebo,[],14-Jul-14,18,9999,Both,FALSE,1NCT00693992,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00693992,FALSE,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],26-Jun-15,18,9999,Both,FALSE,9NCT00651261,Alliance for Clinical Trials in Oncology,TRUE,WI,https://ClinicalTrials.gov/show/NCT00651261,FALSE,"Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",Leukemia,Drug:cytarabine; Drug:daunorubicin; Drug:midostaurin; Other:placebo; Drug:dexamethasone acetate,[],15-Sep-15,18,59,Both,FALSE,1NCT00644228,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00644228,FALSE,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],12-Sep-14,18,9999,Both,FALSE,9NCT00602641,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00602641,FALSE,"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma",Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:melphalan; Drug:prednisone; Drug:thalidomide; Drug:lenalidomide,[],9-Jun-15,18,9999,Both,FALSE,9NCT00602459,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00602459,FALSE,Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,[],22-Apr-15,18,9999,Both,FALSE,9NCT00601900,National Cancer Institute (NCI),FALSE,WI,https://ClinicalTrials.gov/show/NCT00601900,FALSE,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],23-Apr-15,18,9999,Female,FALSE,9NCT00601627,Alliance for Clinical Trials in Oncology,FALSE,WI,https://ClinicalTrials.gov/show/NCT00601627,FALSE,"Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery",Pancreatic Cancer,Biological:panitumumab; Drug:capecitabine; Drug:fluorouracil; Drug:gemcitabine hydrochloride; Radiation:radiation therapy,[],1-Jul-15,18,9999,Both,FALSE,1NCT01886872,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01886872,FALSE,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],4-Feb-16,65,9999,Both,FALSE,9NCT01835158,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01835158,FALSE,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],2-Feb-16,18,9999,Both,FALSE,9NCT02500797,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02500797,FALSE,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],11-Jan-16,18,9999,Both,FALSE,9NCT02465060,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02465060,FALSE,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],4-Feb-16,18,9999,Both,FALSE,9NCT02196181,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02196181,FALSE,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],4-Feb-16,18,9999,Both,FALSE,9NCT02042443,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02042443,FALSE,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],3-Feb-16,0,9999,Both,FALSE,9NCT01824823,Eastern Cooperative Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01824823,FALSE,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],11-Sep-15,18,9999,Both,FALSE,17NCT01802333,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01802333,FALSE,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],29-Jan-16,18,60,Both,FALSE,9NCT01648348,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01648348,FALSE,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],4-Feb-16,18,9999,Both,FALSE,9NCT02315430,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02315430,FALSE,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Female,FALSE,9NCT01642251,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01642251,FALSE,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],4-Feb-16,18,9999,Both,FALSE,9NCT01275677,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01275677,FALSE,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],4-Feb-16,18,9999,Female,FALSE,9NCT00942331,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT00942331,FALSE,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],4-Feb-16,18,9999,Both,FALSE,9NCT00769379,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT00769379,FALSE,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],4-Feb-16,18,9999,Female,FALSE,9NCT00588770,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT00588770,FALSE,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],4-Feb-16,18,9999,Both,FALSE,9NCT02311907,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT02311907,FALSE,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],22-May-15,18,9999,Female,FALSE,9NCT02137837,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT02137837,FALSE,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",Breast Cancer,Drug:Fulvestrant; Drug:Anastrozole; Drug:Everolimus; Drug:Placebo - Anastrozole; Drug:Placebo - Everolimus,[],20-May-15,18,9999,Female,FALSE,3NCT01841736,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01841736,FALSE,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Both,FALSE,9NCT01658943,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01658943,FALSE,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],20-Nov-15,18,9999,Both,FALSE,9NCT01653028,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01653028,FALSE,Alisertib in Treating Patients With Advanced or Metastatic Sarcoma,Myxofibrosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Leiomyosarcoma; Recurrent Liposarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis,[],2-Feb-16,18,9999,Both,FALSE,9NCT01547741,NSABP Foundation Inc,FALSE,WY,https://ClinicalTrials.gov/show/NCT01547741,FALSE,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],21-Oct-15,18,9999,Female,FALSE,2NCT01498289,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01498289,FALSE,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],22-Apr-15,18,9999,Both,FALSE,3NCT01466881,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01466881,FALSE,Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma,Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-Cell Lymphoma; Hepatosplenic T-Cell Lymphoma; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Adult T-Cell Leukemia/Lymphoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],26-Jun-15,18,9999,Both,FALSE,9NCT01376349,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT01376349,FALSE,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],24-Sep-15,18,9999,Female,FALSE,1NCT01366183,Gynecologic Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01366183,FALSE,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],23-Dec-14,75,9999,Both,FALSE,14NCT01260701,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01260701,FALSE,Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Diffuse Gastric Adenocarcinoma; Gastric Intestinal Type Adenocarcinoma; Gastric Mixed Adenocarcinoma; Recurrent Gastric Carcinoma,Drug:Akt Inhibitor MK2206,[],14-Dec-15,18,9999,Both,FALSE,9NCT01238172,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT01238172,FALSE,Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance,Prostate Cancer,Other:dietary education and counseling; Other:prostate cancer foundation booklet,[],20-Aug-15,50,80,Male,FALSE,1NCT01229943,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01229943,FALSE,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],22-Apr-15,18,9999,Both,FALSE,9NCT01198158,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01198158,FALSE,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],4-Feb-16,18,9999,Both,FALSE,9NCT01196390,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01196390,FALSE,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],4-Feb-16,18,9999,Both,FALSE,9NCT01167712,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01167712,FALSE,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],21-Dec-15,18,9999,Female,FALSE,9NCT01120275,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01120275,FALSE,Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma,Acral Lentiginous Malignant Melanoma; Lentigo Maligna Malignant Melanoma; Nodular Malignant Melanoma; Recurrent Melanoma; Solar Radiation-related Skin Melanoma; Stage IV Melanoma; Superficial Spreading Malignant Melanoma,Drug:gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other:laboratory biomarker analysis,[],9-Jun-14,18,9999,Both,FALSE,9NCT01120236,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01120236,FALSE,Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer,Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer,Drug:Bicalutamide; Biological:Cixutumumab; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Drug:Leuprolide Acetate; Other:Pharmacological Study,[],25-Jun-15,18,9999,Male,FALSE,9NCT01097278,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01097278,FALSE,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],7-Jan-15,18,50,Female,FALSE,3NCT01093222,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01093222,FALSE,"Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma",Extrahepatic Bile Duct Adenocarcinoma; Gallbladder Adenocarcinoma; Gallbladder Adenocarcinoma With Squamous Metaplasia; Hilar Cholangiocarcinoma; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Undifferentiated Gallbladder Carcinoma; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma,Drug:Erlotinib Hydrochloride; Drug:Sorafenib Tosylate,[],3-Jun-15,18,9999,Both,FALSE,9NCT01086605,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT01086605,FALSE,Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer,Breast Cancer,Drug:pixantrone dimaleate,[],4-Aug-15,18,9999,Both,FALSE,1NCT01081262,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01081262,FALSE,Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer,Borderline Ovarian Mucinous Tumor; Ovarian Mucinous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer,Biological:Bevacizumab; Drug:Capecitabine; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Oxaliplatin; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],12-Jan-16,18,9999,Female,FALSE,9NCT01078454,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01078454,FALSE,Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis,Light Chain Deposition Disease; Primary Systemic Amyloidosis,Drug:melphalan; Drug:dexamethasone; Drug:bortezomib,[],20-Nov-14,18,9999,Both,FALSE,9NCT01041781,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT01041781,FALSE,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01017601,Alliance for Clinical Trials in Oncology,FALSE,WY,https://ClinicalTrials.gov/show/NCT01017601,FALSE,Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Biological:Seneca Valley virus-001; Other:placebo,[],31-Jul-15,18,9999,Both,FALSE,1NCT01004978,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT01004978,FALSE,Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,Hepatocellular Carcinoma; Non-Resectable Hepatocellular Carcinoma,Drug:Cisplatin; Drug:Doxorubicin Hydrochloride; Drug:Doxorubicin-Eluting Beads; Other:Laboratory Biomarker Analysis; Drug:Mitomycin; Other:Pharmacological Study; Other:Placebo; Drug:Sorafenib Tosylate,[],4-Feb-16,18,9999,Both,FALSE,9NCT01000558,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT01000558,FALSE,SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma,Lymphoma,Other:biologic sample preservation procedure,[],17-May-13,18,9999,Both,FALSE,3NCT00972478,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT00972478,FALSE,"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",Stage II Contiguous Adult Diffuse Large Cell Lymphoma; Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate; Drug:Vorinostat,[],30-Dec-15,18,9999,Both,FALSE,9NCT00956670,Gynecologic Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT00956670,FALSE,"Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer",Lymphedema; Stage IA Cervical Cancer; Stage IA Uterine Corpus Cancer; Stage IA Vulvar Cancer; Stage IB Cervical Cancer; Stage IB Uterine Corpus Cancer; Stage IB Vulvar Cancer; Stage II Uterine Corpus Cancer; Stage II Vulvar Cancer; Stage IIA Cervical Cancer; Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVB Vulvar Cancer,Procedure:Therapeutic Lymphadenectomy; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Laparoscopic Surgery; Procedure:Study of High Risk Factors; Other:Questionnaire Administration; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00954174,Gynecologic Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT00954174,FALSE,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00951496,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT00951496,FALSE,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],3-Feb-16,18,9999,Female,FALSE,9NCT00946712,Southwest Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT00946712,FALSE,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],1-Sep-15,18,9999,Both,FALSE,3NCT00942357,Gynecologic Oncology Group,FALSE,WY,https://ClinicalTrials.gov/show/NCT00942357,FALSE,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],23-Dec-14,18,9999,Female,FALSE,14NCT00937937,National Cancer Institute (NCI),FALSE,WY,https://ClinicalTrials.gov/show/NCT00937937,FALSE,Dinaciclib in Treating Patients With Stage IV Melanoma,Acral Lentiginous Malignant Melanoma; Lentigo Maligna Malignant Melanoma; Mucosal Melanoma; Nodular Malignant Melanoma; Recurrent Melanoma; Stage IV Melanoma; Superficial Spreading Malignant Melanoma,Drug:dinaciclib,[],9-Jun-14,18,9999,Both,FALSE,9